assay_id,assay_tissue,doc_id,tissue_id,assay_organism,assay_category,cell_id,assay_tax_id,assay_subcellular_fraction,curated_by,assay_strain,description,assay_type,assay_test_type,assay_cell_type,tid,relationship_type
1,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,12052,H
2,,684,,,,,,,Autocuration,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,22226,U
3,,15453,,,,,,,Autocuration,,,B,,,22226,U
4,,17841,,Bos taurus,,,9913.0,,Autocuration,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,104729,H
5,,17430,,Homo sapiens,,163.0,9606.0,,Intermediate,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,143B,80001,N
6,,17430,,Homo sapiens,,163.0,9606.0,,Intermediate,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,143B,80001,N
7,,13799,,Mus musculus,,163.0,10090.0,,Intermediate,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,143B,80001,N
8,,17774,,Homo sapiens,,163.0,9606.0,,Expert,,In vitro cell cytotoxicity was determined against 143B cell line,F,,143B,80001,N
9,,3801,,Homo sapiens,,163.0,9606.0,,Intermediate,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,143B,80001,N
10,,17430,,Homo sapiens,,163.0,9606.0,,Intermediate,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,143B,80001,N
11,,17430,,Homo sapiens,,163.0,9606.0,,Intermediate,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,143B,80001,N
12,,17774,,Homo sapiens,,163.0,9606.0,,Expert,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,143B,80001,N
13,,11324,,Staphylococcus aureus,,,1280.0,,Intermediate,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,50185,N
14,,11324,,Staphylococcus aureus,,,1280.0,,Intermediate,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,50185,N
15,,11324,,Staphylococcus aureus,,,1280.0,,Intermediate,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,50185,N
16,,11324,,Staphylococcus aureus,,,1280.0,,Intermediate,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,50185,N
17,,11347,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,100122,D
18,,16474,,,,,,,Autocuration,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,12054,H
19,,10091,,,,,,,Autocuration,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,12054,H
20,,16474,,,,,,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,12054,H
21,,16474,,,,,,,Autocuration,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,12054,H
22,,16474,,,,,,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,12054,H
23,,16474,,,,,,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,12054,H
24,,16474,,,,,,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,12054,H
25,,14352,,,,,,,Autocuration,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,22226,U
26,,5646,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,12054,H
27,,5646,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,12054,H
28,,10997,,,,,,,Autocuration,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,12426,H
29,,6309,,soya bean,,,3847.0,,Autocuration,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,12054,H
30,,167,,Glycine max,,,3847.0,,Autocuration,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,12054,H
31,,167,,Glycine max,,,3847.0,,Autocuration,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,12054,H
32,,11087,,Glycine max,,,3847.0,,Autocuration,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,12054,H
33,,11087,,Glycine max,,,3847.0,,Autocuration,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,12054,H
34,,13622,,Glycine max,,,3847.0,,Autocuration,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,12054,H
35,,13622,,Glycine max,,,3847.0,,Autocuration,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,12054,H
36,,11347,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,22226,U
37,,5926,,Escherichia coli,,,562.0,,Autocuration,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,22226,U
38,,4567,,,,,,,Autocuration,,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,22226,U
39,,3782,,,,,,,Intermediate,,Dissociation constant towards 16S rRNA construct A,B,,,22222,M
40,,3782,,,,,,,Intermediate,,Dissociation constant towards 16S rRNA construct B,B,,,22222,M
41,,4466,,Escherichia coli,,,562.0,,Expert,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,100263,M
42,,6592,,Escherichia coli,,,562.0,,Expert,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,100263,M
43,,898,,,,,,,Autocuration,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,13053,H
44,,898,,,,,,,Autocuration,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,13053,H
45,,13163,,Homo sapiens,,,9606.0,,Autocuration,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,20001,H
46,,13163,,Homo sapiens,,,9606.0,,Autocuration,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,20001,H
47,,10691,,Rattus norvegicus,,,10116.0,,Expert,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,12971,D
48,,10691,,Rattus norvegicus,,,10116.0,,Expert,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,12971,D
49,,10691,,Rattus norvegicus,,,10116.0,,Expert,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,12971,D
50,,10691,,Rattus norvegicus,,,10116.0,,Expert,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,12971,D
51,,898,,,,,,,Autocuration,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,13053,H
52,,912,,,,,,,Autocuration,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,11512,H
53,,912,,,,,,,Autocuration,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,11512,H
54,,912,,,,,,,Autocuration,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,11512,H
55,,15103,,Rattus norvegicus,,,10116.0,Membranes,Autocuration,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,104740,D
56,,5116,,Homo sapiens,,506.0,9606.0,,Intermediate,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,1A9,80002,N
57,,14578,,Rattus norvegicus,,,10116.0,,Autocuration,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,Oocytes,104835,D
58,,14578,,Rattus norvegicus,,,10116.0,,Autocuration,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,Oocytes,104821,D
59,,14578,,Rattus norvegicus,,,10116.0,,Autocuration,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,Oocytes,104848,D
60,,4787,,Homo sapiens,,506.0,9606.0,,Expert,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,1A9,80002,N
61,,4787,,Homo sapiens,,506.0,9606.0,,Intermediate,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,1A9,80002,N
62,,3547,,Homo sapiens,,506.0,9606.0,,Intermediate,,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,1A9,80002,N
63,,3547,,Homo sapiens,,506.0,9606.0,,Intermediate,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,1A9,80002,N
64,,6726,,Homo sapiens,,506.0,9606.0,,Intermediate,,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,1A9,80002,N
65,,3455,,Homo sapiens,,506.0,9606.0,,Expert,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,1A9,80002,N
66,,5726,,Homo sapiens,,506.0,9606.0,,Intermediate,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,1A9,80002,N
67,,5726,,Homo sapiens,,506.0,9606.0,,Intermediate,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,1A9,80002,N
68,,5726,,Homo sapiens,,506.0,9606.0,,Intermediate,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,1A9,80002,N
69,,3395,,Homo sapiens,,506.0,9606.0,,Intermediate,,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,1A9,80002,N
70,,3415,,Homo sapiens,,506.0,9606.0,,Expert,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,1A9,80002,N
71,,3415,,Homo sapiens,,506.0,9606.0,,Expert,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,1A9,80002,N
72,,17099,,Homo sapiens,,506.0,9606.0,,Expert,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,1A9,80002,N
73,,17099,,Homo sapiens,,506.0,9606.0,,Intermediate,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,1A9,80002,N
74,,17099,,Homo sapiens,,506.0,9606.0,,Intermediate,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,1A9,80002,N
75,,17099,,Homo sapiens,,506.0,9606.0,,Intermediate,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,1A9,80002,N
76,,17721,,Homo sapiens,,503.0,9606.0,,Intermediate,,Inhibitory concentration against Jurkat cells,F,,Jurkat,81072,N
77,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,22226,U
78,,11347,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,100121,D
79,,17117,,,,,,,Expert,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,11231,H
80,,17117,,,,,,,Expert,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,11231,H
81,,17117,,,,,,,Expert,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,11231,H
82,,11375,,Candida albicans,,,5476.0,Microsomes,Autocuration,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,11231,H
83,,11375,,Candida albicans,,,5476.0,Microsomes,Autocuration,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,11231,H
84,,11375,,Saccharomyces cerevisiae,,,4932.0,Microsomes,Autocuration,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,11231,H
85,,11375,,Saccharomyces cerevisiae,,,4932.0,Microsomes,Autocuration,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,11231,H
86,Liver,11375,2107.0,Sus scrofa,,,9823.0,Microsomes,Autocuration,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,12083,H
87,,791,,Rattus norvegicus,,,10116.0,,Autocuration,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,11231,H
88,,791,,Rattus norvegicus,,,10116.0,,Autocuration,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,11231,H
89,,791,,Rattus norvegicus,,,10116.0,,Autocuration,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,11231,H
90,Liver,11375,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,12083,D
91,Liver,11375,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,12083,D
92,Liver,153,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,12083,D
93,,8269,,,,,,,Expert,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,11377,H
94,,8269,,,,,,,Expert,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,11377,H
95,,17653,,Homo sapiens,,726.0,9606.0,,Expert,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,HepG2,81020,N
96,,14277,,Homo sapiens,,726.0,9606.0,,Intermediate,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,HepG2,81020,N
97,,1717,,Homo sapiens,,726.0,9606.0,,Intermediate,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,HepG2,81020,N
98,,14091,,Homo sapiens,,726.0,9606.0,,Intermediate,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,HepG2,81020,N
99,,14091,,Homo sapiens,,726.0,9606.0,,Intermediate,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,HepG2,81020,N
100,,17653,,Hepatitis B virus,,,10407.0,,Expert,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,50606,N
101,,13105,,Homo sapiens,,726.0,9606.0,,Intermediate,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,HepG2,81020,N
102,,1717,,Homo sapiens,,726.0,9606.0,,Intermediate,,Concentration required to inhibit 50% of 2.2.15 cell line,F,,HepG2,81020,N
103,,13105,,Homo sapiens,,726.0,9606.0,,Intermediate,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,HepG2,81020,N
104,,13600,,Homo sapiens,,,9606.0,,Intermediate,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,2.2.15,50587,N
105,,13467,,Homo sapiens,,,9606.0,,Intermediate,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,2.2.15,50587,N
106,,17477,,Hepatitis B virus,,,10407.0,,Expert,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,2.2.15,50606,N
107,,1593,,Homo sapiens,,,9606.0,,Intermediate,,In vitro anti-HBV activity in 2.2.15 cells,F,,2.2.15,50587,N
108,,1593,,Homo sapiens,,,9606.0,,Intermediate,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,2.2.15,50587,N
109,,15089,,Homo sapiens,,,9606.0,,Intermediate,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,2.2.15,50587,N
110,,15089,,Homo sapiens,,,9606.0,,Intermediate,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,2.2.15,50587,N
111,,1593,,Homo sapiens,,,9606.0,,Intermediate,,Cytotoxicity in 2.2.15 cells,F,,2.2.15,50587,N
112,,1593,,Homo sapiens,,,9606.0,,Intermediate,,Cytotoxicity in 2.2.15 cells; Not determined,F,,2.2.15,50587,N
113,,13600,,Homo sapiens,,,9606.0,,Intermediate,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,2.2.15,50587,N
114,,13467,,Homo sapiens,,,9606.0,,Intermediate,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,2.2.15,50587,N
115,,13467,,Homo sapiens,,,9606.0,,Intermediate,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,2.2.15,50587,N
116,,14764,,Homo sapiens,,726.0,9606.0,,Intermediate,,Antiviral activity against HBV was determined in 2.215 cell line,F,,HepG2,81020,N
117,,6531,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,22226,U
118,,17322,,,,,,,Autocuration,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,22226,U
119,,17072,,Homo sapiens,,388.0,9606.0,,Intermediate,,Inhibitory concentration against 2008 (ovarian) cells,F,,2008,80612,N
120,,16936,,Homo sapiens,,388.0,9606.0,,Intermediate,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,2008,80612,N
121,,16936,,Homo sapiens,,388.0,9606.0,,Intermediate,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,2008,80612,N
122,,17146,,Homo sapiens,,388.0,9606.0,,Intermediate,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,2008,80612,N
123,,17146,,Homo sapiens,,388.0,9606.0,,Intermediate,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,2008,80612,N
124,,10797,,Homo sapiens,,561.0,9606.0,,Intermediate,,In vitro inhibition of 2008/R ovarian cancer cell line,F,,2008/R,80613,N
125,,10797,,Homo sapiens,,561.0,9606.0,,Intermediate,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,2008/R,80613,N
126,,10797,,Homo sapiens,,389.0,9606.0,,Intermediate,,In vitro inhibition of 2008/S ovarian cancer cell line,F,,2008/S,80614,N
127,,10797,,Homo sapiens,,389.0,9606.0,,Intermediate,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,2008/S,80614,N
128,,4823,,Homo sapiens,,,9606.0,,Expert,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,100256,S
129,,12912,,Homo sapiens,,,9606.0,,Intermediate,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,100256,S
130,,2957,,,,,,,Expert,,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,100256,S
131,,2957,,,,,,,Expert,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,100256,S
132,,3260,,,,,,,Intermediate,,Inhibitory activity against 20S proteosome,B,,,100256,S
133,,3451,,Homo sapiens,,,9606.0,,Autocuration,,Compound was tested for inhibitory activity against tryptase,B,,,22226,U
134,,13885,,Homo sapiens,,726.0,9606.0,,Intermediate,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,HepG2,81020,N
135,,13885,,Homo sapiens,,726.0,9606.0,,Intermediate,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,HepG2,81020,N
136,,3676,,,,,,,Autocuration,,Compound was tested for the inhibition of Alpha-glucosidase,B,,,22226,U
137,,6043,,,,,,,Autocuration,,Inhibitory concentration against human neutrophil elastase (HNE),B,,,235,H
138,Heart,11140,948.0,Rattus norvegicus,,,10116.0,,Autocuration,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,22226,U
139,,10543,,,,,,,Autocuration,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,19640,H
140,,10543,,,,,,,Expert,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,19640,H
141,,10543,,,,,,,Autocuration,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,19640,H
142,,10543,,,,,,,Expert,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,19640,H
143,,11365,,Mus musculus,,524.0,10090.0,,Intermediate,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,P338,80360,N
144,,11365,,Mus musculus,,524.0,10090.0,,Intermediate,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,P338,80360,N
145,,11803,,Homo sapiens,,554.0,9606.0,,Intermediate,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,PBL,80384,N
146,,11803,,Ovis aries,,,9940.0,,Autocuration,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,22226,U
147,,11803,,Ovis aries,,,9940.0,,Autocuration,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,22226,U
148,,12278,,,,,,,Autocuration,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,191,H
149,,8249,,Homo sapiens,,,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,22226,U
150,,8249,,Homo sapiens,,,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,22226,U
151,,8249,,Homo sapiens,,635.0,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,CCRF-CEM,22226,U
152,,8249,,Homo sapiens,,635.0,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,CCRF-CEM,22226,U
153,,8249,,Homo sapiens,,635.0,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,CCRF-CEM,22226,U
154,,8249,,Homo sapiens,,635.0,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,CCRF-CEM,22226,U
155,,8249,,Homo sapiens,,,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,22226,U
156,,8249,,Homo sapiens,,,9606.0,,Autocuration,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,22226,U
157,,16992,,,,,,,Autocuration,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,104290,H
158,,10543,,Streptococcus pyogenes,,,1314.0,,Intermediate,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,50264,N
159,,17833,,Human herpesvirus 3,,,10335.0,,Intermediate,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,50527,N
160,,17290,,vericilla zoster virus,,468.0,10335.0,,Expert,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,HEL,50527,N
161,,17290,,vericilla zoster virus,,,10335.0,,Intermediate,,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,50527,N
162,,17290,,vericilla zoster virus,,,10335.0,,Intermediate,,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,50527,N
163,,10932,,escherichia cloac,,,561.0,,Intermediate,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,50145,N
164,,9707,,,,,,,Autocuration,,Ratio of Ki at A2 to Ki at A1 receptors,B,,,22226,U
165,,2346,,Candida albicans,,,5476.0,,Expert,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,11143,H
166,,2205,,Candida glabrata CBS 138,,,284593.0,,Expert,,"Inhibition of 1,3-beta-glucan synthase",B,,,18077,H
167,,11900,,Homo sapiens,,832.0,9606.0,,Intermediate,,Inhibition of growth of 1-87 human tumor cell line,F,,1-87 tumor cell line,80609,N
168,,14864,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,12166,D
169,,16474,,Glycine max,,,3847.0,,Autocuration,,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,100171,D
170,,16474,,Glycine max,,,3847.0,,Autocuration,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,100171,D
171,,16474,,Glycine max,,,3847.0,,Autocuration,,% inhibition against soybean 1-lipoxygenase (SLO),B,,,100171,D
172,,16474,,Glycine max,,,3847.0,,Autocuration,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,100171,D
173,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,100171,D
174,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,100171,D
175,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,100171,D
176,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,100171,D
177,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,100171,D
178,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,100171,D
179,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,100171,D
180,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,100171,D
181,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,100171,D
182,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,100171,D
183,,3094,,Glycine max,,,3847.0,,Autocuration,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,100171,D
184,,10413,,Mus musculus,,,10090.0,,Autocuration,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,22226,U
185,,16929,,Mus musculus,,294.0,10090.0,,Intermediate,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,C3H 10T1/2,80049,N
186,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,22226,U
187,,16587,,,,,,,Autocuration,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,11489,H
188,,16587,,,,,,,Autocuration,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,11862,H
189,,16587,,,,,,,Autocuration,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,11862,H
190,,16587,,,,,,,Autocuration,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,11489,H
191,,16587,,,,,,,Autocuration,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,11862,H
192,,8058,,Bos taurus,,,9913.0,,Expert,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,12347,D
193,,9065,,Rattus norvegicus,,,10116.0,,Expert,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,100120,D
194,Adrenal gland,8865,2369.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,100120,D
195,,9066,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,100120,D
196,,8394,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,100120,D
197,,8394,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,100120,D
198,,6431,,,,,,,Autocuration,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,10328,H
199,,6431,,,,,,,Autocuration,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,11490,H
200,,6431,,,,,,,Autocuration,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,11490,H
201,,9295,,,,,,,Autocuration,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,11134,H
202,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,12052,H
203,,13622,,,,,,,Autocuration,,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,11134,H
204,,12079,,,,,,,Autocuration,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,11134,H
205,,13622,,,,,,,Autocuration,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,11134,H
206,,12079,,Homo sapiens,,,9606.0,,Autocuration,,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,11134,D
207,,13500,,,,,,,Expert,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,11835,H
208,,13723,,,,,,,Expert,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,11601,H
209,,16474,,,,,,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,11134,H
210,,1630,,,,,,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase,B,,,11134,H
211,,167,,,,,,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,11134,H
212,,16474,,,,,,,Autocuration,,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,11134,H
213,,167,,,,,,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,11134,H
214,,16474,,,,,,,Autocuration,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,11134,H
215,,10091,,,,,,,Autocuration,,Inhibitory activity towards porcine 12-lipoxygenase,B,,,11601,H
216,,11966,,,,,,,Autocuration,,Tested for inhibition against porcine 12-LO,B,,,11601,H
217,,951,,,,,,,Autocuration,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,12052,H
218,,10997,,,,,,,Autocuration,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,12052,H
219,,10193,,,,,,,Expert,,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,12052,H
220,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,12052,H
221,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,12052,H
222,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,12052,H
223,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,12052,H
224,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,12052,H
225,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,12052,H
226,,15569,,Homo sapiens,,621.0,9606.0,,Intermediate,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,41M,80007,N
227,,12989,,Homo sapiens,,621.0,9606.0,,Expert,,In vitro antitumor activity against 41M cell line.,F,,41M,80007,N
228,,16745,,Homo sapiens,,621.0,9606.0,,Intermediate,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,41M,80007,N
229,,15569,,Homo sapiens,,621.0,9606.0,,Intermediate,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,41M,80007,N
230,,12989,,Homo sapiens,,621.0,9606.0,,Expert,,In vitro antitumor activity against 41McisR cell line.,F,,41M,80007,N
231,,12989,,Homo sapiens,,621.0,9606.0,,Expert,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,41M,80007,N
232,,16745,,Homo sapiens,,621.0,9606.0,,Intermediate,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,41M,80007,N
233,,6210,,Homo sapiens,,,9606.0,,Expert,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,84,D
234,,6210,,Homo sapiens,,,9606.0,,Expert,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,68,D
235,,6226,,,,,,,Expert,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,68,H
236,,17855,,,,,,,Expert,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,10201,H
237,,17855,,,,,,,Expert,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,10201,H
238,,17855,,,,,,,Expert,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,10201,H
239,,10413,,,,,,,Autocuration,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,12220,H
240,,10413,,Escherichia coli,,,562.0,,Autocuration,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,11303,H
241,,10413,,Escherichia coli,,,562.0,,Autocuration,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,11303,H
242,,10413,,Escherichia coli,,,562.0,,Autocuration,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,11303,H
243,,10413,,,,,,,Autocuration,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,12220,H
244,,10413,,,,,,,Autocuration,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,12220,H
245,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,11303,H
246,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,11303,H
247,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,11303,H
248,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,11303,H
249,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,11303,H
250,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,11303,H
251,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,11303,H
252,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,11303,H
253,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,11303,H
254,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,11303,H
255,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,11303,H
256,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,11303,H
257,,7323,,,,,,,Autocuration,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,11303,H
258,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,22226,U
259,,7587,,Sus scrofa,,,9823.0,,Autocuration,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,22226,U
260,,13750,,Saccharomyces cerevisiae,,,4932.0,,Expert,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,100249,H
261,,7662,,Rattus norvegicus,,,10116.0,,Autocuration,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,22226,U
262,,7662,,Rattus norvegicus,,,10116.0,,Autocuration,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,22226,U
263,,7662,,Rattus norvegicus,,,10116.0,,Autocuration,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,22226,U
264,,12211,,,,,,,Autocuration,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,104698,H
265,,12211,,,,,,,Autocuration,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,104698,H
266,Ileum,12211,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,20033,D
267,,12211,,,,,,,Expert,,Stimulatory activity of intragastric pressure was tested in the rat,F,,,10623,H
268,,15453,,,,,,,Autocuration,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,121,H
269,,11884,,Rattus norvegicus,,,10116.0,,Autocuration,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,22226,U
270,,7185,,,,,,,Autocuration,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,12688,H
271,,6876,,Homo sapiens,,,9606.0,,Expert,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,121,D
272,,6876,,Homo sapiens,,,9606.0,,Expert,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,121,D
273,,11863,,,,,,,Autocuration,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,12198,H
274,,11863,,,,,,,Autocuration,,Inhibition constant of high-affinity 5-HT uptake,B,,,12198,H
275,,11863,,,,,,,Autocuration,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,12198,H
276,,11863,,,,,,,Autocuration,,Maximum rate was determined for high affinity transport of 5-HT,F,,,12198,H
277,,4639,,,,,,,Autocuration,,Compound was tested for agonistic activity against 5-HT uptake,F,,,104714,H
278,,15796,,,,,,,Expert,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,10577,H
279,,15796,,Bos taurus,,,9913.0,,Expert,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,105,H
280,,12801,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,104744,D
281,,12801,,,,,,,Autocuration,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,104744,H
282,,12120,,,,,,Membranes,Autocuration,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,104744,H
283,,12120,,,,,,Membranes,Autocuration,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,104744,H
284,,11963,,,,,,,Autocuration,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,104744,H
285,,11701,,,,,,,Autocuration,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,51,H
286,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
287,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,51,H
288,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
289,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,10576,H
290,,11574,,Cavia porcellus,,,10141.0,,Intermediate,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,105570,D
291,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,279,H
292,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,107,H
293,,15363,,Rattus norvegicus,,,10116.0,,Expert,,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,12687,D
294,,15329,,,,,,,Expert,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,12687,H
295,,15329,,,,,,,Expert,,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,12687,H
296,,15329,,,,,,,Expert,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,12687,H
297,,15329,,,,,,,Expert,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,12687,H
298,,15329,,,,,,,Autocuration,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,12687,H
299,,15329,,,,,,,Expert,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,12687,H
300,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,20033,D
301,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,20033,D
302,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,20033,D
303,,12092,,,,,,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,10623,H
304,,1317,,Rattus norvegicus,,,10116.0,,Expert,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,10623,D
305,,12409,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,168,H
306,,11126,,Gallus gallus,,,9031.0,,Autocuration,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,22226,U
307,,11126,,Homo sapiens,,,9606.0,,Autocuration,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,22226,U
308,,11126,,Homo sapiens,,,9606.0,,Autocuration,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,22226,U
309,,11126,,Homo sapiens,,649.0,9606.0,,Autocuration,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,HL-60,80156,N
310,,11126,,Homo sapiens,,,9606.0,,Autocuration,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,22226,U
311,,11126,,Homo sapiens,,,9606.0,,Autocuration,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,22226,U
312,,17807,,Homo sapiens,,,9606.0,,Autocuration,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,Oocytes,104703,D
313,,16575,,,,,,,Intermediate,,Chymotryptic inhibitory activity against 26S proteasome,F,,,100256,S
314,,15407,,,,,,,Intermediate,,Inhibitory activity against 26S proteasome degradation of IkB,B,,,100256,S
315,,10797,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,A2780,81034,N
316,,10797,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro inhibition of 2780/S ovarian cancer cell line,F,,A2780,81034,N
317,,3469,,Homo sapiens,,,9606.0,,Autocuration,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,22226,U
318,,16037,,,,,,,Intermediate,,Association constant for binding to AATT 28-mer AATT hairpin,B,,,22222,M
319,,16037,,,,,,,Intermediate,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,22222,M
320,,16037,,,,,,,Intermediate,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,22222,M
321,,16037,,,,,,,Intermediate,,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,22222,M
322,,16524,,Homo sapiens,,,9606.0,,Autocuration,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,22226,U
323,,16524,,Homo sapiens,,,9606.0,,Autocuration,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,22226,U
324,,16524,,Homo sapiens,,,9606.0,,Autocuration,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,22226,U
325,,16758,,Cricetulus griseus,,,10029.0,,Autocuration,,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,22226,U
326,,16758,,Cricetulus griseus,,,10029.0,,Autocuration,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,22226,U
327,,16758,,Cricetulus griseus,,,10029.0,,Autocuration,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,22226,U
328,,14360,,,,,,,Autocuration,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,241,H
329,,14360,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,241,D
330,,9964,,Rattus norvegicus,,,10116.0,,Autocuration,,Selectivity ratio of ID50 in liver and heart,B,,,22226,U
331,,9964,,,,,,,Autocuration,,"Selectivity, ratio of relative ID50 in liver and heart",B,,,12132,H
332,,9964,,,,,,,Autocuration,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,12132,H
333,,9964,,,,,,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,12132,H
334,,9964,,,,,,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,12132,H
335,,9964,,,,,,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,12132,H
336,,9964,,,,,,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,12132,H
337,,9964,,,,,,,Autocuration,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,22226,U
338,,9964,,,,,,,Autocuration,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,12132,H
339,,9964,,Homo sapiens,,,9606.0,,Autocuration,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,22226,U
340,,9964,,,,,,,Autocuration,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,12132,H
341,,9964,,,,,,,Autocuration,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,12132,H
342,,9964,,,,,,,Autocuration,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,12132,H
343,,9964,,Rattus norvegicus,,,10116.0,,Autocuration,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,22226,U
344,,9964,,,,,,,Autocuration,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,12132,H
345,,9964,,,,,,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,12132,H
346,,9964,,Rattus norvegicus,,,10116.0,,Autocuration,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,22226,U
347,,9964,,,,,,,Autocuration,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,12132,H
348,,9964,,,,,,,Autocuration,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,12132,H
349,,3796,,Rattus norvegicus,,,10116.0,,Autocuration,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,22226,U
350,,4251,,Escherichia coli,,,562.0,,Autocuration,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,19690,H
351,,4251,,Escherichia coli,,,562.0,,Autocuration,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,19690,H
352,,4251,,Escherichia coli,,,562.0,,Autocuration,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,19690,H
353,,4251,,Escherichia coli,,,562.0,,Autocuration,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,19690,H
354,,166,,,,,,,Autocuration,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,19690,H
355,,17861,,,,,,,Autocuration,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,19690,H
356,,166,,,,,,,Autocuration,,Inhibition constant against 3-dehydroquinate synthase,B,,,19690,H
357,,166,,,,,,,Autocuration,,Association rate constant against 3-dehydroquinate synthase,B,,,19690,H
358,,166,,,,,,,Autocuration,,Rate constant against 3-dehydroquinate synthase,B,,,19690,H
359,,3548,,,,,,,Autocuration,,Inhibitory activity against fuc-TVII,B,,,22226,U
360,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,12236,D
361,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,12236,D
362,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,12236,D
363,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,12236,D
364,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,12236,D
365,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,12236,D
366,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,12236,D
367,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,12236,D
368,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,12236,D
369,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,12236,D
370,Liver,9877,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,12236,D
371,,3003,,,,,,,Autocuration,,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,104832,H
372,,3003,,,,,,,Autocuration,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,104832,H
373,,3003,,,,,,,Autocuration,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,104832,H
374,,17185,,Homo sapiens,,,9606.0,,Expert,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,10612,D
375,,6072,,Homo sapiens,,844.0,9606.0,,Intermediate,,Cytotoxicity on 3677 melanoma cells,F,,3677 melanoma cell line,80616,N
376,,6072,,Homo sapiens,,844.0,9606.0,,Intermediate,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,3677 melanoma cell line,80616,N
377,,5018,,Mus musculus,,700.0,10090.0,,Intermediate,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,MC-38,80617,N
378,,2852,,Homo sapiens,,,9606.0,,Intermediate,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,22226,U
379,,8663,,,,798.0,,,Autocuration,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,B16,22226,U
380,,8663,,,,798.0,,,Autocuration,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,B16,22226,U
381,,3245,,Human rhinovirus 14,,,12131.0,,Expert,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,12464,D
382,,3245,,Human rhinovirus sp.,,,169066.0,,Intermediate,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,50085,N
383,,3877,,human rhinovirus type 14,,,169066.0,,Intermediate,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,50679,N
384,,3877,,human rhinovirus type 14,,,169066.0,,Intermediate,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,50679,N
385,,5861,,Human rhinovirus 14,,,12131.0,,Expert,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,12464,D
386,,5861,,Human rhinovirus 14,,,12131.0,,Expert,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,12464,D
387,,5861,,Human rhinovirus 14,,,12131.0,,Expert,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,12464,D
388,,5861,,Human rhinovirus 14,,,12131.0,,Expert,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,12464,D
389,,13748,,Enterovirus,,,12059.0,,Intermediate,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,50665,N
390,,13748,,Enterovirus,,,12059.0,,Intermediate,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,50665,N
391,,13748,,Enterovirus,,,12059.0,,Intermediate,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,50665,N
392,,13748,,Enterovirus,,,12059.0,,Intermediate,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,50665,N
393,,13748,,Human rhinovirus B,,,147712.0,,Expert,,Inhibition of human rhinovirus 3C protease,B,,,12464,H
394,,17699,,Homo sapiens,,,9606.0,,Autocuration,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,22226,U
395,,7145,,Mus musculus,,833.0,10090.0,,Intermediate,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,3EM 37,80619,N
396,,7145,,Mus musculus,,833.0,10090.0,,Intermediate,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,3EM 37,80619,N
397,,7145,,Mus musculus,,833.0,10090.0,,Intermediate,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,3EM 37,80619,N
398,,7145,,Mus musculus,,833.0,10090.0,,Intermediate,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,3EM 37,80619,N
399,,7145,,Mus musculus,,833.0,10090.0,,Intermediate,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,3EM 37,80619,N
400,,7145,,Mus musculus,,833.0,10090.0,,Intermediate,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,3EM 37,80619,N
401,,5325,,Mus musculus,,847.0,10090.0,,Intermediate,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,3LL cell line,80620,N
402,,5325,,Mus musculus,,847.0,10090.0,,Intermediate,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,3LL cell line,80620,N
403,,5325,,Mus musculus,,847.0,10090.0,,Expert,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,3LL cell line,80620,N
404,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,3LL cell line,80620,N
405,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,3LL cell line,80620,N
406,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,3LL cell line,80620,N
407,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,3LL cell line,80620,N
408,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,3LL cell line,80620,N
409,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,3LL cell line,80620,N
410,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,3LL cell line,80620,N
411,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,3LL cell line,80620,N
412,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,3LL cell line,80620,N
413,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,3LL cell line,80620,N
414,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,3LL cell line,80620,N
415,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,3LL cell line,80620,N
416,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,3LL cell line,80620,N
417,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,3LL cell line,80620,N
418,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,3LL cell line,80620,N
419,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,3LL cell line,80620,N
420,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,3LL cell line,80620,N
421,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,3LL cell line,80620,N
422,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,3LL cell line,80620,N
423,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,3LL cell line,80620,N
424,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,3LL cell line,80620,N
425,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,3LL cell line,80620,N
426,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,3LL cell line,80620,N
427,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,3LL cell line,80620,N
428,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,3LL cell line,80620,N
429,,16169,,Mus musculus,,847.0,10090.0,,Intermediate,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,3LL cell line,80620,N
430,,15547,,Homo sapiens,,971.0,9606.0,,Intermediate,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,3LLD122,80621,N
431,,8663,,,,,,,Autocuration,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,22226,U
432,,8663,,,,,,,Autocuration,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,22226,U
433,,8663,,,,,,,Autocuration,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,22226,U
434,,8663,,,,,,,Autocuration,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,22226,U
435,,4504,,Mus musculus,,723.0,10090.0,,Intermediate,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,NIH3T3,80951,N
436,,4504,,Mus musculus,,723.0,10090.0,,Intermediate,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,NIH3T3,80951,N
437,,12695,,,,723.0,,,Expert,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,NIH3T3,11169,H
438,,12695,,Mus musculus,,723.0,10090.0,,Intermediate,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,NIH3T3,80951,N
439,,12695,,Mus musculus,,723.0,10090.0,,Intermediate,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,NIH3T3,80951,N
440,,17642,,Mus musculus,,723.0,10090.0,,Expert,,Effective dose against murine 3T3 fibroblasts cells,F,,NIH3T3,80951,N
441,,17642,,Mus musculus,,723.0,10090.0,,Expert,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,NIH3T3,80951,N
442,,12340,,Mus musculus,,723.0,10090.0,,Expert,,Cytotoxic effect on 3T3 cells,F,,NIH3T3,80951,N
443,,12340,,Mus musculus,,723.0,10090.0,,Expert,,Cytotoxic effect on 3T3 cells,F,,NIH3T3,80951,N
444,,12716,,Mus musculus,,723.0,10090.0,,Intermediate,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,NIH3T3,80951,N
445,,6277,,Mus musculus,,723.0,10090.0,,Intermediate,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,NIH3T3,80951,N
446,,6277,,Mus musculus,,723.0,10090.0,,Intermediate,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,NIH3T3,80951,N
447,,6277,,Mus musculus,,723.0,10090.0,,Expert,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,NIH3T3,80951,N
448,,6277,,Mus musculus,,723.0,10090.0,,Expert,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,NIH3T3,80951,N
449,,6277,,Mus musculus,,723.0,10090.0,,Intermediate,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,NIH3T3,80951,N
450,,6277,,Mus musculus,,723.0,10090.0,,Expert,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,NIH3T3,80951,N
451,,6277,,Mus musculus,,723.0,10090.0,,Expert,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,NIH3T3,80951,N
452,,6277,,Mus musculus,,723.0,10090.0,,Intermediate,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,NIH3T3,80951,N
453,,17780,,Mus musculus,,723.0,10090.0,,Expert,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,NIH3T3,80951,N
454,,12751,,Mus musculus,,,10090.0,,Autocuration,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,104860,D
455,,12380,,Mus musculus,,723.0,10090.0,,Expert,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,NIH3T3,80951,N
456,,14892,,Mus musculus,,723.0,10090.0,,Intermediate,,Inhibitory activity against 3T3 cell line,F,,NIH3T3,80951,N
457,,12695,,Mus musculus,,723.0,10090.0,,Intermediate,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,NIH3T3,80951,N
458,,12695,,,,,,,Expert,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,11169,H
459,,12695,,Mus musculus,,723.0,10090.0,,Intermediate,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,NIH3T3,80951,N
460,,12695,,Mus musculus,,723.0,10090.0,,Intermediate,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,NIH3T3,80951,N
461,,12695,,,,,,,Expert,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,11169,H
462,,12695,,,,,,,Expert,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,11169,H
463,,6277,,Mus musculus,,723.0,10090.0,,Intermediate,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,NIH3T3,80951,N
464,,6277,,Mus musculus,,723.0,10090.0,,Expert,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,NIH3T3,80951,N
465,,4959,,Homo sapiens,,723.0,9606.0,,Expert,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,NIH3T3,9,D
466,,4959,,Homo sapiens,,723.0,9606.0,,Expert,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,NIH3T3,9,D
467,,4959,,Homo sapiens,,723.0,9606.0,,Expert,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,NIH3T3,188,D
468,,4959,,Homo sapiens,,723.0,9606.0,,Expert,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,NIH3T3,188,D
469,,12082,,Mus musculus,,723.0,10090.0,,Intermediate,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,NIH3T3,80951,N
470,,12082,,Mus musculus,,723.0,10090.0,,Intermediate,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,NIH3T3,80951,N
471,,12082,,Mus musculus,,723.0,10090.0,,Intermediate,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,NIH3T3,80951,N
472,,12082,,Mus musculus,,723.0,10090.0,,Intermediate,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,NIH3T3,80951,N
473,,2643,,Mus musculus,,723.0,10090.0,,Intermediate,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,NIH3T3,80951,N
474,,11926,,Mus musculus,,723.0,10090.0,,Expert,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,NIH3T3,80951,N
475,,15204,,Mus musculus,,723.0,10090.0,,Intermediate,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,NIH3T3,80951,N
476,,15992,,Mus musculus,,723.0,10090.0,,Expert,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,NIH3T3,80951,N
477,,16279,,Mus musculus,,723.0,10090.0,,Intermediate,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,NIH3T3,80951,N
478,,16279,,Mus musculus,,723.0,10090.0,,Intermediate,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,80951,N
479,,16279,,Mus musculus,,723.0,10090.0,,Intermediate,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,80951,N
480,,16279,,Mus musculus,,723.0,10090.0,,Intermediate,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,80951,N
481,,16279,,Mus musculus,,723.0,10090.0,,Intermediate,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,80951,N
482,,16279,,Mus musculus,,723.0,10090.0,,Intermediate,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,NIH3T3,80951,N
483,,12831,,Mus musculus,,723.0,10090.0,,Expert,,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,NIH3T3,80951,N
484,,13497,,Mus musculus,,723.0,10090.0,,Intermediate,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,NIH3T3,80951,N
485,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,3T3-L1,80006,N
486,,13618,,Mus musculus,,620.0,10090.0,,Intermediate,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,3T3-L1,80006,N
487,,11902,,Mus musculus,,620.0,10090.0,,Intermediate,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,3T3-L1,80006,N
488,,11902,,Mus musculus,,620.0,10090.0,,Intermediate,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,3T3-L1,80006,N
489,,11902,,Mus musculus,,620.0,10090.0,,Intermediate,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,3T3-L1,80006,N
490,,14840,,Mus musculus,,620.0,10090.0,,Intermediate,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,3T3-L1,80006,N
491,,14840,,Mus musculus,,620.0,10090.0,,Intermediate,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,3T3-L1,80006,N
492,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,3T3-L1,80006,N
493,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,3T3-L1,80006,N
494,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,3T3-L1,80006,N
495,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,3T3-L1,80006,N
496,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,3T3-L1,80006,N
497,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,3T3-L1,80006,N
498,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,3T3-L1,80006,N
499,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,3T3-L1,80006,N
500,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,3T3-L1,80006,N
501,,13715,,,,620.0,,,Expert,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,3T3-L1,80006,N
502,,13715,,,,620.0,,,Expert,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,3T3-L1,80006,N
503,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,3T3-L1,80006,N
504,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,3T3-L1,80006,N
505,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,3T3-L1,80006,N
506,,13715,,,,620.0,,,Expert,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,3T3-L1,80006,N
507,,13715,,,,620.0,,,Expert,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,3T3-L1,80006,N
508,,13715,,,,620.0,,,Expert,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,3T3-L1,80006,N
509,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,3T3-L1,80006,N
510,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,3T3-L1,80006,N
511,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,3T3-L1,80006,N
512,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,3T3-L1,80006,N
513,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,3T3-L1,80006,N
514,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,3T3-L1,80006,N
515,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,3T3-L1,80006,N
516,,13715,,,,620.0,,,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,3T3-L1,80006,N
517,,6411,,,,620.0,,,Expert,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,3T3-L1,11214,H
518,,6411,,Mus musculus,,620.0,10090.0,,Intermediate,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,3T3-L1,80006,N
519,,6411,,,,620.0,,,Expert,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,3T3-L1,11214,H
520,,3966,,Mus musculus,,620.0,10090.0,,Expert,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,3T3-L1,80006,N
521,,3966,,Mus musculus,,620.0,10090.0,,Intermediate,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,3T3-L1,80006,N
522,,15556,,Mus musculus,,620.0,10090.0,,Expert,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,3T3-L1,80006,N
523,,5845,,Mus musculus,,620.0,10090.0,,Expert,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,3T3-L1,80006,N
524,,14422,,Mus musculus,,620.0,10090.0,,Expert,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,3T3-L1,80006,N
525,,5845,,Mus musculus,,620.0,10090.0,,Expert,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,3T3-L1,80006,N
526,,14508,,Mus musculus,,620.0,10090.0,,Expert,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,3T3-L1,80006,N
527,,14508,,Mus musculus,,620.0,10090.0,,Expert,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,3T3-L1,80006,N
528,,14508,,Mus musculus,,620.0,10090.0,,Expert,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,3T3-L1,80006,N
529,,6349,,Rattus norvegicus,,1118.0,10116.0,,Intermediate,,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,3Y1 cell line,80622,N
530,,15899,,Rattus norvegicus,,1118.0,10116.0,,Expert,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,3Y1 cell line,80622,N
531,,15899,,Rattus norvegicus,,1118.0,10116.0,,Expert,,Cytotoxicity in 3Y1 cells.,F,,3Y1 cell line,80622,N
532,,15899,,Rattus norvegicus,,1118.0,10116.0,,Expert,,Cytostatic effect in 3Y1 cells.,F,,3Y1 cell line,80622,N
533,,15899,,Rattus norvegicus,,1118.0,10116.0,,Intermediate,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,3Y1 cell line,80622,N
534,,17038,,Rattus norvegicus,,1118.0,10116.0,,Expert,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,3Y1 cell line,80622,N
535,,12421,,,,,,,Autocuration,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,22226,U
536,,12947,,,,,,,Autocuration,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,22226,U
537,,12947,,,,,,,Autocuration,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,22226,U
538,,4896,,Sus scrofa,,,9823.0,,Expert,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,11607,D
539,,6148,,,,,,,Autocuration,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,11607,H
540,,16432,,,,,,,Autocuration,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,11607,H
541,,4978,,,,,,,Expert,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,11607,H
542,,4978,,,,,,,Expert,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,11607,H
543,,3723,,,,,,,Autocuration,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,11607,H
544,,3518,,,,,,,Autocuration,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,11607,H
545,,4164,,,,,,,Autocuration,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,11607,H
546,,3518,,,,,,,Autocuration,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,11607,H
547,,4164,,Sus scrofa,,,9823.0,,Expert,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,11607,D
548,,3518,,,,,,,Autocuration,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,11607,H
549,,3518,,,,,,,Autocuration,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,11607,H
550,,4978,,,,,,,Autocuration,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,11607,H
551,,4978,,,,,,,Autocuration,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,11607,H
552,,6455,,,,,,,Autocuration,,Binding affinity against melatonin (MT1) receptor (pC1),B,,,104733,H
553,,2222,,,,,,,Autocuration,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,22226,U
554,,13020,,,,,,,Autocuration,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,22226,U
555,,13021,,,,,,,Autocuration,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,22226,U
556,,14532,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,10619,H
557,,14118,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,10619,H
558,Hippocampus,11884,10000000.0,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,51,H
559,,13969,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,51,H
560,,13392,,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,51,H
561,,14430,,,,,,,Expert,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,51,H
562,Hippocampus,12248,10000000.0,,,,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,51,H
563,Hippocampus,12249,10000000.0,,,,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,51,H
564,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,51,H
565,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
566,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,51,H
567,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,51,H
568,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
569,Hippocampus,12249,10000000.0,,,,,,Autocuration,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,51,H
570,Hippocampus,11799,10000000.0,,,,,,Autocuration,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,51,H
571,,14331,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,10576,D
572,Hippocampus,11884,10000000.0,Bos taurus,,,9913.0,,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,51,H
573,Hippocampus,14331,10000000.0,,,,,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,51,H
574,Hippocampus,11701,10000000.0,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,51,H
575,Hippocampus,11701,10000000.0,,,,,,Expert,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,51,H
576,Hippocampus,12248,10000000.0,,,,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,51,H
577,,12248,,,,449.0,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,CHO,51,H
578,Hippocampus,12248,10000000.0,,,,,,Expert,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,51,H
579,Hippocampus,12249,10000000.0,,,,,,Expert,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,51,H
580,,12248,,,,449.0,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,51,H
581,Hippocampus,11799,10000000.0,,,,,,Expert,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,51,H
582,,634,,,,,,,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,51,H
583,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,51,H
584,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
585,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,51,H
586,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
587,Hippocampus,9995,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,51,H
588,Hippocampus,12210,10000000.0,,,,,,Expert,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,51,H
589,Hippocampus,13311,10000000.0,,,,,,Expert,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
590,,2331,,Homo sapiens,,449.0,9606.0,,Expert,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,CHO,51,D
591,,1375,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,51,H
592,,1375,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,51,H
593,Hippocampus,11574,10000000.0,Cavia porcellus,,,10141.0,,Autocuration,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,51,H
594,Ileum,12867,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,51,H
595,Ileum,12867,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,51,H
596,Ileum,12867,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,51,H
597,Ileum,12867,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,51,H
598,Ileum,12867,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,51,H
599,Ileum,12867,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,51,H
600,,11574,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,51,H
601,,13114,,Cavia porcellus,,,10141.0,,Autocuration,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,51,H
602,,13181,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,51,H
603,Hippocampus,10639,10000000.0,Cavia porcellus,,,10141.0,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,106,H
604,Hippocampus,10639,10000000.0,Cavia porcellus,,,10141.0,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,106,H
605,,11883,,Cricetulus griseus,,449.0,10029.0,,Autocuration,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,CHO,11863,H
606,,17785,,,,,,,Autocuration,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,51,H
607,,1558,,,,308.0,,,Autocuration,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,HeLa,51,H
608,,1558,,,,308.0,,,Autocuration,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,HeLa,51,H
609,,15740,,,,,,,Autocuration,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,51,H
610,,17624,,,,449.0,,,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,CHO,51,H
611,,17624,,,,449.0,,,Expert,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,CHO,51,H
612,,17624,,,,449.0,,,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,CHO,51,H
613,,17624,,,,449.0,,,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,CHO,51,H
614,,17624,,,,449.0,,,Expert,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,51,H
615,,17624,,,,449.0,,,Expert,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,51,H
616,,17624,,,,449.0,,,Autocuration,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,CHO,51,H
617,,14256,,,,,,,Autocuration,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,51,H
618,,3445,,Homo sapiens,,308.0,9606.0,,Expert,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,HeLa,51,D
619,,3445,,Homo sapiens,,308.0,9606.0,,Expert,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,HeLa,51,D
620,,17200,,Homo sapiens,,449.0,9606.0,,Expert,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,CHO,51,D
621,,17200,,Homo sapiens,,449.0,9606.0,,Expert,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,CHO,51,D
622,,15180,,,,,,,Autocuration,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,51,H
623,,15180,,,,,,,Autocuration,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,51,H
624,,16026,,,,,,,Autocuration,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,51,H
625,,2759,,,,449.0,,,Autocuration,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,CHO,51,H
626,,2759,,Homo sapiens,,449.0,9606.0,,Expert,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,CHO,51,D
627,,2759,,,,449.0,,,Autocuration,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,CHO,51,H
628,,2759,,Homo sapiens,,449.0,9606.0,,Expert,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,CHO,51,D
629,,2759,,,,449.0,,,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,CHO,51,H
630,,2759,,,,449.0,,,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,CHO,51,H
631,,2759,,Homo sapiens,,449.0,9606.0,,Expert,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,CHO,51,D
632,,2759,,,,449.0,,,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,CHO,51,H
633,,2759,,Homo sapiens,,449.0,9606.0,,Expert,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,CHO,51,D
634,,3445,,Homo sapiens,,,9606.0,,Expert,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,51,D
635,,5272,,Homo sapiens,,,9606.0,,Expert,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,51,D
636,,5272,,Homo sapiens,,,9606.0,,Expert,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,51,D
637,,5272,,Homo sapiens,,,9606.0,,Expert,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,51,D
638,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,CHO,51,H
639,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,CHO,51,H
640,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,CHO,51,H
641,,17624,,,,449.0,,,Expert,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,CHO,51,H
642,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,CHO,51,H
643,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,CHO,51,H
644,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,CHO,51,H
645,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,CHO,51,H
646,,17624,,,,449.0,,,Expert,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,CHO,51,H
647,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,CHO,51,H
648,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,CHO,51,H
649,,17624,,,,449.0,,,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,CHO,51,H
650,,6563,,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,51,H
651,,6563,,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,51,H
652,,6563,,,,,,,Autocuration,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,51,H
653,,17296,,,,722.0,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,51,H
654,,6876,,Homo sapiens,,,9606.0,,Expert,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,51,D
655,,6876,,,,,,,Expert,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,51,H
656,,5272,,Homo sapiens,,,9606.0,,Expert,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,51,D
657,,5272,,Homo sapiens,,,9606.0,,Expert,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,51,D
658,,5548,,,,,,,Autocuration,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,51,H
659,,5548,,,,,,,Expert,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,51,H
660,,5548,,,,,,,Autocuration,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,51,H
661,,5548,,,,,,,Autocuration,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,51,H
662,,5929,,,,,,,Expert,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,51,H
663,,5929,,Homo sapiens,,,9606.0,,Expert,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,51,D
664,,5929,,Homo sapiens,,,9606.0,,Expert,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,51,D
665,,16245,,,,,,,Autocuration,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,51,H
666,,5640,,,,,,,Expert,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,51,H
667,,5640,,,,,,,Autocuration,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,51,H
668,,14509,,,,449.0,,,Autocuration,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,CHO,51,H
669,,14509,,,,449.0,,,Expert,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,CHO,51,H
670,,15331,,,,,,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,51,H
671,,15331,,,,,,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,51,H
672,,6563,,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,51,H
673,,6563,,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,51,H
674,,6563,,,,,,,Autocuration,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,51,H
675,,6563,,Homo sapiens,,,9606.0,,Expert,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,51,D
676,,6563,,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,51,H
677,,5272,,Homo sapiens,,,9606.0,,Expert,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,51,D
678,,5272,,Homo sapiens,,,9606.0,,Expert,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,51,D
679,,5272,,Homo sapiens,,,9606.0,,Expert,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,51,D
680,,5272,,Homo sapiens,,,9606.0,,Expert,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,51,D
681,,5272,,Homo sapiens,,,9606.0,,Expert,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,51,D
682,,5272,,Homo sapiens,,,9606.0,,Expert,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,51,D
683,,5272,,Homo sapiens,,,9606.0,,Expert,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,51,D
684,,5272,,Homo sapiens,,,9606.0,,Expert,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,51,D
685,,16146,,Homo sapiens,,,9606.0,,Expert,,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,51,D
686,,17624,,,,449.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,51,H
687,,13706,,,,722.0,,,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,HEK293,105,D
688,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,CHO,51,H
689,,17624,,,,449.0,,,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,CHO,51,H
690,,6861,,,,,,,Expert,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,51,H
691,,17200,,Homo sapiens,,,9606.0,,Expert,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,51,D
692,,17624,,,,449.0,,,Autocuration,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,51,H
693,,17624,,,,449.0,,,Autocuration,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,51,H
694,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,22226,U
695,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,22226,U
696,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,22226,U
697,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,22226,U
698,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,22226,U
699,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,22226,U
700,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,22226,U
701,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,22226,U
702,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,22226,U
703,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,22226,U
704,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,22226,U
705,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,22226,U
706,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,22226,U
707,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,22226,U
708,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,22226,U
709,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,22226,U
710,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,22226,U
711,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,22226,U
712,,12058,,Rattus norvegicus,,,10116.0,,Autocuration,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,22226,U
713,,11440,,,,,,,Autocuration,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,105093,H
714,Hypothalamus,6238,1898.0,,,,,,Autocuration,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,11923,H
715,,10046,,,,,,,Autocuration,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,10577,H
716,,10046,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,10577,H
717,,10046,,,,,,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,10577,H
718,,167,,,,,,,Autocuration,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,55,H
719,,167,,,,,,,Autocuration,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,55,H
720,,11520,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,12166,H
721,,11520,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,12166,H
722,,11520,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,12166,H
723,,11520,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,12166,H
724,,135,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,55,H
725,,135,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,55,H
726,,11311,,Cavia porcellus,,,10141.0,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,55,H
727,,10193,,Cavia porcellus,,,10141.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,55,H
728,,12281,,Homo sapiens,,,9606.0,,Expert,,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,55,D
729,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,55,H
730,,12576,,,,,,,Autocuration,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,17087,H
731,,12281,,,,,,,Autocuration,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,17087,H
732,,12576,,,,,,,Autocuration,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,17087,H
733,,11089,,Sus scrofa,,,9823.0,,Expert,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,55,H
734,,11006,,,,,,,Expert,,In vitro inhibition of rat 5-Lipoxygenase,B,,,12166,H
735,,11481,,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory activity against 5-Lipoxygenase,B,,,12166,D
736,,10864,,,,702.0,,,Expert,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,RBL-1,12166,H
737,,3595,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,RBL-1,12166,H
738,,11311,,,,702.0,,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,RBL-1,12166,H
739,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,12166,H
740,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,12166,H
741,,11006,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,12166,H
742,,3595,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,RBL-1,12166,H
743,,11311,,,,,,,Autocuration,,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,12166,H
744,,11481,,Rattus norvegicus,,,10116.0,,Autocuration,,Ratio of IC50 against 5-LO and COX,B,,,22226,U
745,,11006,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,12166,H
746,,11006,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,12166,H
747,,11311,,,,,,,Autocuration,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,12166,H
748,,11006,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,12166,H
749,Prostate gland,4288,2367.0,,,,,,Autocuration,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,120,H
750,,7587,,Columba livia,,,8932.0,,Autocuration,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,22226,U
751,,7587,,Columba livia,,,8932.0,,Autocuration,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,22226,U
752,,7587,,Columba livia,,,8932.0,,Autocuration,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,22226,U
753,,11249,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,10732,H
754,,8003,,Rattus norvegicus,,,10116.0,,Expert,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,12198,D
755,,8003,,Rattus norvegicus,,,10116.0,,Expert,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,12198,D
756,,8003,,Rattus norvegicus,,,10116.0,,Expert,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,12198,D
757,Hippocampus,12416,10000000.0,,,,,,Expert,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,10576,H
758,,16293,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,51,H
759,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,22226,U
760,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,22226,U
761,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,22226,U
762,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,22226,U
763,Hippocampus,10085,10000000.0,,,,,,Autocuration,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,104744,H
764,Hippocampus,10085,10000000.0,,,,,,Autocuration,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,104744,H
765,Hippocampus,10085,10000000.0,,,,,,Autocuration,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,104744,H
766,,9841,,,,,,Membranes,Autocuration,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,104744,H
767,,8822,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,104744,D
768,,9806,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,104744,D
769,,9806,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,104744,D
770,,8868,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,104744,H
771,Hippocampus,9036,10000000.0,,,,,,Autocuration,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,104744,H
772,Hippocampus,11374,10000000.0,,,,,,Autocuration,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,104744,H
773,,10881,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,104744,H
774,,8822,,,,,,,Autocuration,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,104744,H
775,,9806,,Rattus norvegicus,,,10116.0,,Autocuration,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,104744,D
776,,15463,,,,,,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,104744,H
777,,15463,,,,,,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,104744,H
778,Brain,14542,955.0,,,,,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,104744,H
779,Brain,14542,955.0,,,,,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,104744,H
780,,8569,,,,,,,Autocuration,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,104744,H
781,,10062,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,104744,D
782,,4771,,,,,,,Autocuration,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,104744,H
783,,10062,,,,,,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,104744,H
784,,10062,,,,,,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,104744,H
785,,10062,,,,,,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,104744,H
786,,15463,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,104744,H
787,,15463,,,,,,,Autocuration,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,104744,H
788,,9098,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,104744,H
789,,3070,,Rattus norvegicus,,,10116.0,,Autocuration,,Affinity for 5-hydroxytryptamine 1 receptor,B,,,22226,U
790,Brain,14542,955.0,,,,,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,104744,H
791,Brain,14542,955.0,,,,,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,104744,H
792,,6398,,,,,,,Autocuration,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,104744,H
793,Brain,1344,955.0,,,,,,Autocuration,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,104744,H
794,,11963,,,,,,,Autocuration,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,104744,H
795,,8908,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,22226,U
796,,9098,,,,,,,Autocuration,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,104744,H
797,,8841,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,104744,D
798,,8814,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,22226,U
799,,11752,,,,,,,Autocuration,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,104744,H
800,Brain,11642,955.0,,,,,,Autocuration,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,104744,H
801,,11642,,,,,,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,104744,H
802,Brain,9231,955.0,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,104744,H
803,Brain,11351,955.0,,,,,,Autocuration,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,104744,H
804,,4639,,,,,,,Autocuration,,Compound was tested for binding affinity against 5-HT1 receptor,B,,,22226,U
805,,1205,,,,,,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,22226,U
806,,10025,,,,,,,Expert,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,10576,H
807,,13241,,,,,,,Autocuration,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,10576,H
808,,16245,,,,,,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,10576,H
809,,16245,,,,,,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,10576,H
810,,12438,,,,,,,Autocuration,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,10576,H
811,,16245,,,,,,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,10576,H
812,,16245,,,,,,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,10576,H
813,,15740,,,,,,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,10576,H
814,,15535,,,,,,,Autocuration,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,10576,H
815,,15535,,,,,,,Expert,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,51,H
816,,15535,,,,,,,Autocuration,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,10576,H
817,,9888,,,,,,,Expert,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,10576,H
818,Hippocampus,10085,10000000.0,,,,,,Autocuration,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,10576,H
819,Hippocampus,10085,10000000.0,,,,,,Autocuration,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,10576,H
820,,17331,,,,,,Membranes,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,10576,H
821,Hippocampus,10845,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,10576,D
822,Hippocampus,10845,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,10576,D
823,Hippocampus,10845,10000000.0,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,10576,H
824,Hippocampus,10845,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,10576,D
825,Hippocampus,10845,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,10576,D
826,,13730,,,,,,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,10576,H
827,,13508,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,10576,H
828,Hippocampus,13508,10000000.0,,,,,,Expert,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,10576,H
829,Hippocampus,12073,10000000.0,,,,,,Expert,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
830,Hippocampus,4671,10000000.0,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,10576,H
831,Hippocampus,13631,10000000.0,,,,,,Expert,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,10576,H
832,,12438,,,,,,,Autocuration,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,10576,H
833,,10483,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,10576,H
834,Hippocampus,10483,10000000.0,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,10576,H
835,,12352,,,,,,,Intermediate,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,10576,H
836,Hippocampus,14732,10000000.0,,,,,,Autocuration,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,10576,H
837,,11049,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,10576,D
838,,11049,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,10576,D
839,,13657,,,,,,,Expert,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,10576,H
840,,11473,,,,,,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,10576,H
841,,2014,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,10576,H
842,Hippocampus,3086,10000000.0,,,,,,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
843,,15854,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,10576,H
844,Hippocampus,10922,10000000.0,,,,,,Expert,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,10576,H
845,Hippocampus,13346,10000000.0,,,,,,Expert,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,10576,H
846,,15311,,,,,,,Expert,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,10576,H
847,Hippocampus,10922,10000000.0,,,,,,Autocuration,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,10576,H
848,,10025,,,,,,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,10576,H
849,,10025,,,,,,,Expert,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,10576,H
850,,9742,,,,,,,Autocuration,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,10576,H
851,,9742,,,,,,,Autocuration,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,10576,H
852,,12304,,,,,,,Expert,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,10576,H
853,Hippocampus,15789,10000000.0,,,,,,Autocuration,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,10576,H
854,,9912,,,,,,,Autocuration,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,10576,H
855,,9912,,,,,,,Autocuration,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,10576,H
856,,9912,,,,,,,Autocuration,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,10576,H
857,,16693,,,,,,,Expert,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,10576,H
858,,13276,,,,,,,Expert,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,10576,H
859,Hippocampus,12678,10000000.0,,,,,,Autocuration,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,10576,H
860,,11825,,,,,,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,10576,H
861,,12443,,,,,,,Expert,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,10576,H
862,,13830,,,,,,,Expert,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,10576,H
863,Hippocampus,14286,10000000.0,,,,,,Expert,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,10576,H
864,Hippocampus,14356,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,10576,D
865,,15306,,,,,,,Autocuration,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,10576,H
866,,15306,,,,,,,Expert,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,10576,H
867,,16616,,Rattus norvegicus,,,10116.0,,Expert,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,10576,D
868,Hippocampus,3651,10000000.0,,,,,,Autocuration,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,10576,H
869,Hippocampus,14331,10000000.0,,,,,,Autocuration,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,10576,H
870,Hippocampus,14331,10000000.0,,,,,,Autocuration,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,10576,H
871,,14178,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,10576,D
872,,10639,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,10576,D
873,Hippocampus,12306,10000000.0,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,10576,H
874,,1348,,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,10576,D
875,Hippocampus,13605,10000000.0,,,,,,Autocuration,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,10576,H
876,,17624,,,,449.0,,,Autocuration,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,CHO,51,H
877,,17624,,,,449.0,,,Autocuration,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,CHO,51,H
878,,17624,,,,449.0,,,Autocuration,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,CHO,51,H
879,,15267,,,,,,,Autocuration,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,51,H
880,,16532,,,,,,,Autocuration,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,51,H
881,,6563,,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,51,H
882,,4751,,,,449.0,,,Autocuration,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,CHO,51,H
883,,15463,,,,,,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,51,H
884,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,51,H
885,,5640,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
886,,6563,,,,,,,Autocuration,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,51,H
887,,5548,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,51,H
888,,6347,,,,,,,Autocuration,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,51,H
889,,17296,,,,722.0,,,Autocuration,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,51,H
890,,13047,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,51,H
891,,15740,,,,,,,Autocuration,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,51,H
892,,5640,,,,,,,Expert,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,51,H
893,,5640,,,,,,,Autocuration,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,51,H
894,,17211,,,,308.0,,,Expert,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,HeLa,51,H
895,,4751,,,,449.0,,,Autocuration,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,CHO,51,H
896,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,51,D
897,,4707,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,51,H
898,,13910,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,51,D
899,,16190,,,,308.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,HeLa,51,H
900,,16633,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
901,,11898,,,,449.0,,,Autocuration,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,CHO,51,H
902,,11898,,,,449.0,,,Autocuration,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,51,H
903,,14331,,,,,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,51,H
904,,17624,,,,449.0,,,Expert,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,CHO,51,H
905,,17624,,,,449.0,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,CHO,51,H
906,,3307,,,,,,,Autocuration,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,51,H
907,,6563,,Homo sapiens,,449.0,9606.0,,Expert,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,CHO,51,D
908,,14165,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,51,H
909,,5732,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,51,H
910,,13366,,,,,,,Expert,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,51,H
911,,17626,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,51,H
912,,6588,,,,308.0,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,HeLa,51,H
913,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,51,H
914,,15463,,,,,,,Autocuration,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,51,H
915,,15463,,,,,,,Autocuration,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,51,H
916,,14770,,,,,,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,51,H
917,,16245,,,,1167.0,,,Autocuration,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,Cell line,51,H
918,,16245,,,,,,,Autocuration,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,51,H
919,,5548,,,,,,,Autocuration,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
920,,5548,,,,,,,Expert,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
921,,5548,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
922,,6876,,,,,,,Expert,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,51,H
923,,2598,,,,,,,Autocuration,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
924,,17785,,,,,,,Expert,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,51,H
925,,6013,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,51,H
926,,5929,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,51,H
927,,16633,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
928,,1558,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,51,H
929,,16026,,,,,,,Expert,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
930,,12469,,,,,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,51,H
931,,15874,,Homo sapiens,,,9606.0,,Expert,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,51,D
932,,15874,,,,,,,Autocuration,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,51,H
933,,3935,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,51,H
934,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,51,H
935,,13706,,,,485.0,,,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,CHO-K1,51,H
936,,13729,,,,485.0,,,Expert,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,CHO-K1,51,H
937,,15413,,,,,,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,51,H
938,,15413,,,,,,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,51,H
939,,15413,,,,,,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,51,H
940,,15413,,,,,,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,51,H
941,,3445,,Homo sapiens,,308.0,9606.0,,Expert,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,HeLa,51,D
942,,15740,,,,,,,Autocuration,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,51,H
943,,15740,,,,,,,Autocuration,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,51,H
944,,17626,,,,,,,Autocuration,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,51,H
945,,4234,,Homo sapiens,,,9606.0,,Expert,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,51,D
946,,5640,,,,,,,Expert,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,51,H
947,,5272,,Rattus norvegicus,,,10116.0,,Expert,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,51,H
948,,4622,,,,449.0,,,Autocuration,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,CHO,51,H
949,,17085,,,,,,,Expert,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,51,H
950,,3025,,,,,,,Autocuration,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,51,H
951,,15315,,,,,,,Expert,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,51,H
952,,15267,,,,,,,Autocuration,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,51,H
953,,17158,,,,308.0,,,Autocuration,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,HeLa,51,H
954,,14214,,Homo sapiens,,308.0,9606.0,,Expert,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,HeLa,51,D
955,,17133,,,,,,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
956,,16532,,,,,,,Autocuration,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,51,H
957,,2391,,Homo sapiens,,,9606.0,,Expert,,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,51,D
958,,14447,,,,,,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,51,H
959,,14447,,,,,,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,51,H
960,,15086,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,51,H
961,,13051,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,51,D
962,,16026,,,,,,,Autocuration,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,51,H
963,,17085,,,,,,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,51,H
964,,17133,,,,,,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,51,H
965,,17133,,,,,,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,51,H
966,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,HeLa,51,H
967,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,HeLa,51,H
968,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,HeLa,51,H
969,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,HeLa,51,H
970,,16394,,,,,,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,51,H
971,,16394,,,,,,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,51,H
972,,16394,,,,,,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,51,H
973,,16394,,,,,,,Autocuration,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,51,H
974,,16394,,,,,,,Autocuration,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,51,H
975,,15740,,,,,,,Autocuration,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,51,H
976,,15740,,,,,,,Autocuration,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,51,H
977,,15740,,,,,,,Autocuration,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,51,H
978,,17296,,,,722.0,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,51,H
979,,5640,,,,,,,Expert,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,51,H
980,,5640,,,,,,,Autocuration,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,51,H
981,,5640,,,,,,,Autocuration,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,51,H
982,,5640,,,,,,,Autocuration,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,51,H
983,,2759,,,,449.0,,,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,CHO,51,H
984,,16394,,,,,,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,51,H
985,,16394,,Homo sapiens,,,9606.0,,Expert,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,51,D
986,,3445,,Homo sapiens,,,9606.0,,Expert,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,51,D
987,,4316,,,,449.0,,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,CHO,51,H
988,,4316,,,,,,,Expert,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,51,H
989,,15180,,Homo sapiens,,,9606.0,,Expert,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,51,D
990,,15180,,Homo sapiens,,,9606.0,,Expert,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,51,D
991,,15042,,,,,,,Autocuration,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,51,H
992,,15042,,,,,,,Autocuration,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,51,H
993,,15042,,,,,,,Autocuration,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,51,H
994,,15042,,,,,,,Autocuration,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,51,H
995,,15042,,,,,,,Autocuration,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,51,H
996,,15042,,,,,,,Autocuration,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,51,H
997,,15042,,,,,,,Autocuration,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,51,H
998,,15180,,Homo sapiens,,308.0,9606.0,,Expert,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,HeLa,51,D
999,,15180,,Homo sapiens,,308.0,9606.0,,Expert,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,HeLa,51,D
1000,,15180,,Homo sapiens,,308.0,9606.0,,Expert,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,HeLa,51,D
1001,,16245,,,,,,,Autocuration,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,51,H
1002,,16026,,,,,,,Autocuration,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,51,H
1003,,17296,,,,722.0,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,HEK293,51,H
1004,,2759,,,,449.0,,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,CHO,51,H
1005,,2759,,,,449.0,,,Autocuration,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,CHO,51,H
1006,,2759,,Homo sapiens,,449.0,9606.0,,Expert,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,CHO,51,D
1007,,2759,,,,449.0,,,Autocuration,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,CHO,51,H
1008,,15419,,,,,,,Expert,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,51,H
1009,,15419,,,,,,,Autocuration,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,51,H
1010,,16026,,,,,,,Autocuration,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,51,H
1011,,1414,,,,,,,Expert,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,51,H
1012,,1414,,,,,,,Expert,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,51,H
1013,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,51,H
1014,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,51,H
1015,,5104,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,51,H
1016,,5105,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,51,H
1017,,16312,,,,,,,Autocuration,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,51,H
1018,,15180,,Homo sapiens,,,9606.0,,Expert,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,51,D
1019,,5033,,,,,,,Autocuration,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,51,H
1020,,16909,,Homo sapiens,,449.0,9606.0,,Expert,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,CHO,51,D
1021,,2590,,,,,,,Autocuration,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,51,H
1022,,2590,,,,,,,Autocuration,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,51,H
1023,,16394,,,,,,,Expert,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,51,H
1024,,4540,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,HEK293,51,D
1025,,17296,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,HEK293,51,H
1026,,17296,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,HEK293,51,H
1027,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,HEK293,51,H
1028,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,HEK293,51,H
1029,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,HEK293,51,H
1030,,6166,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,51,H
1031,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,HEK293,51,H
1032,,4199,,,,722.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,HEK293,51,H
1033,,15316,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,51,H
1034,,14875,,,,,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,51,H
1035,,14727,,,,308.0,,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,HeLa,51,H
1036,,14727,,,,,,,Expert,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,51,H
1037,,15146,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,HEK293,51,H
1038,,5213,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,HEK293,51,H
1039,,16429,,,,,,,Autocuration,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,51,H
1040,,15042,,Homo sapiens,,308.0,9606.0,,Expert,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,HeLa,51,D
1041,,14818,,,,722.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,HEK293,51,H
1042,,4829,,,,722.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,HEK293,51,H
1043,,17200,,,,,,,Expert,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,51,D
1044,,13051,,Homo sapiens,,,9606.0,,Autocuration,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,51,D
1045,,5486,,,,,,,Autocuration,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,106,H
1046,,5254,,,,,,,Autocuration,,Binding affinity against 5-HT1D receptor,B,,,105,H
1047,,5254,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,105,H
1048,,15331,,,,,,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,107,H
1049,,13506,,Homo sapiens,,,9606.0,,Autocuration,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,10576,H
1050,,15267,,,,,,,Autocuration,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,51,H
1051,,16616,,,,,,,Autocuration,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,11863,H
1052,,16616,,,,,,,Autocuration,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,11863,H
1053,,16616,,,,,,,Autocuration,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,11863,H
1054,,16616,,Mus musculus,,,10090.0,,Expert,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,11863,D
1055,,16616,,Mus musculus,,,10090.0,,Expert,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,11863,D
1056,,16616,,Mus musculus,,,10090.0,,Expert,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,11863,D
1057,,16616,,Mus musculus,,,10090.0,,Expert,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,11863,D
1058,,16616,,Mus musculus,,,10090.0,,Expert,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,11863,D
1059,,16616,,Mus musculus,,,10090.0,,Expert,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,11863,D
1060,Hippocampus,10297,10000000.0,,,,,,Autocuration,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,11863,H
1061,,13704,,,,,,,Expert,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,11863,H
1062,Hippocampus,10297,10000000.0,Mus musculus,,,10090.0,,Expert,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,11863,D
1063,Hippocampus,10297,10000000.0,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,11863,H
1064,Hippocampus,10297,10000000.0,Mus musculus,,,10090.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,11863,D
1065,Hippocampus,10297,10000000.0,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,11863,H
1066,,217,,,,,,,Autocuration,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,11863,H
1067,Hippocampus,10297,10000000.0,Mus musculus,,,10090.0,,Expert,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,11863,D
1068,,4921,,Sus scrofa,,,9823.0,,Autocuration,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,51,H
1069,,4921,,Sus scrofa,,,9823.0,,Autocuration,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,51,H
1070,,4996,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,51,H
1071,,12918,,Sus scrofa,,,9823.0,,Autocuration,,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,51,H
1072,,5333,,Sus scrofa,,,9823.0,,Autocuration,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,51,H
1073,,4437,,Sus scrofa,,,9823.0,,Autocuration,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,51,H
1074,,1742,,Sus scrofa,,,9823.0,,Autocuration,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,51,H
1075,,16688,,Sus scrofa,,,9823.0,,Expert,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,51,H
1076,,12861,,Sus scrofa,,,9823.0,,Autocuration,,Binding activity radioligand.,B,,,51,H
1077,,12861,,Sus scrofa,,,9823.0,,Expert,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,51,H
1078,,12861,,Sus scrofa,,,9823.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,51,H
1079,,12490,,,,,,,Expert,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,10624,H
1080,,11828,,Sus scrofa,,,9823.0,,Expert,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,51,H
1081,Hippocampus,11866,10000000.0,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,51,H
1082,,12827,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,51,H
1083,,12918,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,51,H
1084,,12919,,Sus scrofa,,,9823.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,51,H
1085,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,51,H
1086,,15796,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,10576,D
1087,Hippocampus,3651,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,10576,D
1088,,188,,,,,,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,10576,H
1089,,16616,,Rattus norvegicus,,,10116.0,Membranes,Expert,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,10576,D
1090,Hippocampus,16616,10000000.0,Rattus norvegicus,,,10116.0,Membranes,Expert,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,10576,D
1091,Hippocampus,12306,10000000.0,,,,,,Autocuration,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,10576,H
1092,Hippocampus,17167,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,10576,D
1093,,14776,,,,,,,Autocuration,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,10576,H
1094,,12158,,,,,,,Expert,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,10576,H
1095,,13481,,,,,,,Autocuration,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,10576,H
1096,,13427,,,,,,,Autocuration,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,10576,H
1097,,10210,,,,,,,Autocuration,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,10576,H
1098,,10205,,,,,,Membranes,Autocuration,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,10576,H
1099,,10205,,,,,,Membranes,Autocuration,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,10576,H
1100,,10205,,,,,,Membranes,Expert,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,10576,H
1101,,12280,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,10576,D
1102,,17386,,,,,,,Expert,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,10576,H
1103,,13654,,,,,,,Expert,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,10576,H
1104,Hippocampus,14423,10000000.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,10576,H
1105,Hippocampus,15412,10000000.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,10576,H
1106,Hippocampus,12073,10000000.0,,,,,,Autocuration,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
1107,,4101,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,10576,D
1108,,10062,,,,,,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,10576,H
1109,,6238,,,,,,,Autocuration,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1110,,16273,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,10576,H
1111,,11139,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,10576,H
1112,,16796,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,10576,H
1113,Brain,9548,955.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,10576,D
1114,Brain,10381,955.0,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,10576,H
1115,,13408,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1116,Hippocampus,13825,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,10576,D
1117,Hippocampus,11147,10000000.0,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,10576,H
1118,,10552,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1119,Striatum,10552,2435.0,,,,,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,10576,H
1120,,17136,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,10576,D
1121,,5778,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,10576,D
1122,Hippocampus,13481,10000000.0,,,,,,Autocuration,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1123,Hippocampus,13481,10000000.0,,,,,,Autocuration,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,10576,H
1124,Hippocampus,13630,10000000.0,,,,,,Intermediate,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1125,,16245,,,,,,,Expert,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,10576,H
1126,Hippocampus,14509,10000000.0,,,,,,Autocuration,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1127,Hippocampus,14509,10000000.0,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,10576,H
1128,Hippocampus,14509,10000000.0,,,,,,Autocuration,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,10576,H
1129,Hippocampus,14509,10000000.0,,,,,,Autocuration,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,10576,H
1130,,14256,,,,,,,Expert,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,10576,H
1131,,11139,,,,,,,Autocuration,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,10576,H
1132,,11047,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,10576,D
1133,,11047,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,10576,D
1134,,11047,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,10576,D
1135,,2395,,Rattus norvegicus,,485.0,10116.0,,Expert,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,CHO-K1,10576,D
1136,,9699,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,10576,H
1137,Hippocampus,12028,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,10576,D
1138,Hippocampus,12028,10000000.0,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,10576,H
1139,,5815,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,10576,H
1140,,16616,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,10576,H
1141,,5815,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,10576,H
1142,Hippocampus,2761,10000000.0,,,,,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,10576,H
1143,,13133,,,,,,,Expert,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,10576,H
1144,,10444,,,,,,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,10576,H
1145,,13278,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,10576,D
1146,,15874,,,,,,,Autocuration,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,10576,H
1147,Striatum,10552,2435.0,,,,,Membranes,Autocuration,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,10576,H
1148,,11130,,,,,,,Autocuration,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,10576,H
1149,,11130,,,,,,,Autocuration,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,10576,H
1150,Brain,14542,955.0,,,,,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,10576,H
1151,,13670,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,10576,D
1152,,9888,,,,,,,Expert,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,10576,H
1153,,3678,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,10576,D
1154,Hippocampus,11332,10000000.0,,,,,,Autocuration,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1155,Hippocampus,11332,10000000.0,,,,,,Autocuration,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1156,,1185,,,,,,,Expert,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,10576,H
1157,,2014,,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,10576,H
1158,,1185,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,10576,H
1159,,14429,,,,,,,Expert,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,10576,H
1160,,16288,,,,,,,Expert,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,10576,H
1161,,5432,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,10576,D
1162,,14429,,,,,,,Autocuration,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,10576,H
1163,,13672,,,,,,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,10576,H
1164,Hippocampus,11296,10000000.0,,,,,,Expert,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,10576,H
1165,,11296,,,,,,,Autocuration,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,10576,H
1166,,14749,,,,449.0,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,CHO,10576,H
1167,,15086,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,10576,H
1168,Hippocampus,13462,10000000.0,,,,,,Autocuration,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,10576,H
1169,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,10576,H
1170,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,10576,H
1171,,10796,,,,,,,Autocuration,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,10576,H
1172,Brain,12816,955.0,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1173,Hippocampus,13542,10000000.0,,,,,,Expert,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,10576,H
1174,,13308,,,,,,,Expert,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,10576,H
1175,Hippocampus,13541,10000000.0,,,,,,Expert,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,10576,H
1176,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,10576,H
1177,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,10576,H
1178,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,10576,H
1179,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,10576,H
1180,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,10576,H
1181,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,10576,H
1182,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,10576,H
1183,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,10576,H
1184,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,10576,H
1185,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,10576,H
1186,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,10576,H
1187,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,10576,H
1188,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,10576,H
1189,Hippocampus,10058,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,10576,D
1190,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,10576,H
1191,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,10576,H
1192,,12879,,,,,,,Expert,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,10576,H
1193,,11964,,,,,,,Expert,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,10576,H
1194,,11964,,,,,,,Autocuration,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,10576,H
1195,,11964,,,,,,,Autocuration,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,10576,H
1196,Brain,9548,955.0,,,,,,Expert,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,10576,H
1197,,9098,,,,,,,Expert,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,10576,H
1198,,9098,,,,,,,Autocuration,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,10576,H
1199,,9098,,,,,,,Autocuration,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,10576,H
1200,,13248,,,,449.0,,,Expert,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,CHO,10576,H
1201,,3147,,,,,,,Expert,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,10576,H
1202,,13949,,,,,,,Expert,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,10576,H
1203,,11883,,,,449.0,,,Autocuration,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,CHO,10576,H
1204,,11883,,,,,,,Autocuration,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,10576,H
1205,,11883,,Rattus norvegicus,,,10116.0,,Expert,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,10576,D
1206,,15535,,,,,,Membranes,Expert,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,10576,H
1207,,15535,,,,,,,Autocuration,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,10576,H
1208,,15535,,,,,,,Autocuration,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,10576,H
1209,,16372,,Homo sapiens,,449.0,9606.0,,Expert,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,CHO,51,D
1210,,14608,,,,,,,Expert,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,10576,H
1211,Hippocampus,4795,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,10576,D
1212,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1213,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,10576,H
1214,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,10576,H
1215,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,10576,H
1216,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,10576,H
1217,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,10576,H
1218,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,10576,H
1219,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,10576,H
1220,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,10576,H
1221,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,10576,H
1222,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,10576,H
1223,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,10576,H
1224,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,10576,H
1225,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,10576,H
1226,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,10576,H
1227,,9742,,,,,,,Autocuration,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,10576,H
1228,,12073,,,,,,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,10576,H
1229,,4101,,,,,,,Autocuration,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,10576,H
1230,,15360,,,,,,,Autocuration,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,10576,H
1231,Hippocampus,11576,10000000.0,,,,,,Autocuration,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,10576,H
1232,,5834,,,,,,,Expert,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,10576,H
1233,,2395,,Rattus norvegicus,,485.0,10116.0,,Expert,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,CHO-K1,10576,D
1234,,1375,,,,,,,Autocuration,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,10576,H
1235,,1375,,,,,,,Autocuration,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,10576,H
1236,,3967,,,,,,,Autocuration,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,10576,H
1237,,12884,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,10576,H
1238,,2343,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,10576,H
1239,,11511,,,,,,,Autocuration,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,10576,H
1240,,11511,,Rattus norvegicus,,,10116.0,,Expert,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,10576,D
1241,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,10576,H
1242,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,10576,H
1243,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,10576,H
1244,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,10576,H
1245,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,10576,H
1246,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,10576,H
1247,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,10576,H
1248,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,10576,H
1249,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,10576,H
1250,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,10576,H
1251,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,10576,H
1252,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,10576,H
1253,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,10576,H
1254,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,10576,H
1255,,16394,,,,,,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,10576,H
1256,,16616,,Rattus norvegicus,,,10116.0,Membranes,Expert,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,10576,D
1257,,16796,,,,,,,Autocuration,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,10576,H
1258,,16796,,,,,,,Autocuration,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,10576,H
1259,,15629,,,,,,,Autocuration,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,10576,H
1260,,13241,,,,,,,Autocuration,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,10576,H
1261,Hippocampus,12073,10000000.0,,,,,,Expert,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
1262,Hippocampus,14286,10000000.0,,,,,,Autocuration,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,10576,H
1263,Brain,14542,955.0,,,,,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,10576,H
1264,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,10576,H
1265,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,10576,H
1266,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,10576,H
1267,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,10576,H
1268,,13630,,,,,,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,10576,H
1269,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,10576,H
1270,,13630,,Rattus norvegicus,,,10116.0,,Expert,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,10576,D
1271,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,10576,H
1272,,13630,,,,,,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,10576,H
1273,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,10576,H
1274,,13630,,,,,,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,10576,H
1275,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,10576,H
1276,,13630,,,,,,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,10576,H
1277,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,10576,H
1278,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,10576,H
1279,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,10576,H
1280,,13630,,,,,,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,10576,H
1281,,13630,,,,,,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,10576,H
1282,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,10576,H
1283,,13630,,,,,,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,10576,H
1284,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,10576,H
1285,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,10576,H
1286,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,10576,H
1287,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,10576,H
1288,Hippocampus,9783,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,10576,H
1289,Hippocampus,9783,10000000.0,,,,,,Expert,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,10576,H
1290,,14331,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,10576,D
1291,Hippocampus,15260,10000000.0,,,,,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,10576,H
1292,Hippocampus,15260,10000000.0,,,,,,Autocuration,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,10576,H
1293,Hippocampus,15260,10000000.0,,,,,,Autocuration,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,10576,H
1294,,16616,,Rattus norvegicus,,,10116.0,,Expert,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,10576,D
1295,,15629,,,,,,,Autocuration,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,10576,H
1296,,15086,,,,,,,Autocuration,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,10576,H
1297,,5717,,,,,,,Expert,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,10576,H
1298,,12652,,,,,,,Autocuration,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,10576,H
1299,Hippocampus,14608,10000000.0,,,,,,Autocuration,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,10576,H
1300,Hippocampus,12306,10000000.0,,,,,,Autocuration,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,10576,H
1301,Hippocampus,12306,10000000.0,,,,,,Autocuration,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,10576,H
1302,,15247,,Rattus norvegicus,,,10116.0,,Expert,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,10576,D
1303,Hippocampus,17529,10000000.0,,,,,,Expert,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,10576,H
1304,Hippocampus,14826,10000000.0,,,,,,Autocuration,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
1305,Hippocampus,14826,10000000.0,,,,,,Autocuration,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
1306,Hippocampus,13241,10000000.0,,,,,,Autocuration,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,10576,H
1307,Hippocampus,14093,10000000.0,,,,,,Autocuration,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,10576,H
1308,Hippocampus,14093,10000000.0,,,,,,Autocuration,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,10576,H
1309,Brain,14442,955.0,,,,,,Autocuration,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,10576,H
1310,,9919,,,,,,,Autocuration,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,10576,H
1311,,9919,,,,,,,Autocuration,,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,10576,H
1312,Hippocampus,11440,10000000.0,,,,,,Autocuration,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,10576,H
1313,,11257,,,,,,,Autocuration,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,10576,H
1314,,10330,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,10576,H
1315,Hippocampus,17331,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,10576,D
1316,,16567,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,10576,H
1317,,12058,,Rattus norvegicus,,,10116.0,,Expert,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,10576,D
1318,Hippocampus,9699,10000000.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,10576,H
1319,,9547,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,10576,H
1320,,10330,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,10576,H
1321,,14331,,,,,,,Autocuration,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,10576,H
1322,,14060,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,10576,D
1323,Hippocampus,14744,10000000.0,,,,,,Autocuration,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,10576,H
1324,,13506,,,,,,,Autocuration,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,10576,H
1325,Brain,10862,955.0,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,10576,H
1326,Brain,10862,955.0,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,10576,H
1327,,10062,,,,,,,Expert,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,10576,H
1328,,12073,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,10576,H
1329,,14875,,,,,,,Autocuration,,GTPgammaS radioligand binding assay,B,,,106,H
1330,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,106,H
1331,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,106,H
1332,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,106,H
1333,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,106,H
1334,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,106,H
1335,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,106,H
1336,,17211,,,,308.0,,,Expert,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,HeLa,106,H
1337,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,HeLa,106,H
1338,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,106,D
1339,,16190,,,,449.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,106,H
1340,,14165,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,106,H
1341,,14165,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,106,H
1342,,4234,,Homo sapiens,,,9606.0,,Expert,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,106,D
1343,,6328,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,106,H
1344,,14770,,,,,,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,106,H
1345,,2598,,,,,,,Autocuration,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,106,H
1346,,6897,,,,,,,Expert,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,106,H
1347,,6897,,,,,,,Autocuration,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,106,H
1348,,6013,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,106,H
1349,,5843,,,,,,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,106,H
1350,,14454,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,106,H
1351,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,106,H
1352,,3935,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,106,H
1353,,13729,,,,485.0,,,Expert,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,CHO-K1,106,H
1354,,14251,,,,,,,Expert,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,106,H
1355,,17085,,,,,,,Expert,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,106,H
1356,,3025,,,,,,,Autocuration,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,106,H
1357,,15315,,,,,,,Expert,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,106,H
1358,,14214,,Homo sapiens,,,9606.0,,Expert,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,106,D
1359,,3804,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,106,D
1360,,2391,,Homo sapiens,,,9606.0,,Expert,,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,106,D
1361,,4175,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,106,D
1362,,17296,,,,449.0,,,Autocuration,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,CHO,106,H
1363,,17085,,,,,,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,106,H
1364,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,HeLa,106,H
1365,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,HeLa,106,H
1366,,17211,,,,308.0,,,Autocuration,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,HeLa,106,H
1367,,15926,,Homo sapiens,,,9606.0,,Expert,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,106,D
1368,,16312,,,,485.0,,,Autocuration,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,CHO-K1,106,H
1369,,5843,,,,,,,Expert,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,106,H
1370,,5843,,,,,,,Autocuration,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,106,H
1371,,16312,,,,485.0,,,Expert,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,CHO-K1,106,H
1372,,15926,,Homo sapiens,,,9606.0,,Expert,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,106,D
1373,,15926,,Homo sapiens,,,9606.0,,Expert,,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,106,D
1374,,4540,,Homo sapiens,,449.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,106,D
1375,,6166,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,106,H
1376,,17296,,,,449.0,,,Autocuration,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,CHO,106,H
1377,,17296,,,,449.0,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,CHO,106,H
1378,,17296,,,,449.0,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,CHO,106,H
1379,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,CHO,106,H
1380,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,CHO,106,H
1381,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,CHO,106,H
1382,,4199,,,,449.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,CHO,106,H
1383,,14875,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,106,D
1384,,15146,,,,449.0,,,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,CHO,106,H
1385,,5213,,,,,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,106,H
1386,,14818,,,,449.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,CHO,106,H
1387,,4829,,,,449.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,106,H
1388,,14454,,,,,,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,106,H
1389,,14454,,,,,,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,106,H
1390,,14875,,,,449.0,,,Autocuration,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,CHO,106,H
1391,,14875,,,,449.0,,,Autocuration,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,CHO,106,H
1392,,15250,,,,,,,Autocuration,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,105,H
1393,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,CHO,105,H
1394,,15086,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,17105,H
1395,,3025,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,106,H
1396,,14998,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,106,H
1397,,14998,,Oryctolagus cuniculus,,,9986.0,,Intermediate,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,106,H
1398,,14998,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,106,H
1399,,13969,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,10577,H
1400,,13392,,,,,,,Intermediate,,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,10577,D
1401,Striatum,3651,2435.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,10577,D
1402,,10025,,,,,,,Expert,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,10577,H
1403,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,10576,H
1404,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,10576,H
1405,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,10576,H
1406,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,10576,H
1407,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,10576,H
1408,,13863,,,,,,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,10576,H
1409,Hippocampus,4622,10000000.0,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,10576,H
1410,,14911,,,,,,,Intermediate,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1411,Hippocampus,12678,10000000.0,,,,,,Autocuration,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,10576,H
1412,Hippocampus,12678,10000000.0,,,,,,Expert,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,10576,H
1413,Hippocampus,14235,10000000.0,,,,,,Expert,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1414,Hippocampus,14949,10000000.0,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,10576,H
1415,Hippocampus,14949,10000000.0,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,10576,H
1416,Hippocampus,14949,10000000.0,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,10576,H
1417,Hippocampus,14949,10000000.0,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,10576,H
1418,Hippocampus,14949,10000000.0,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,10576,H
1419,,16118,,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,10576,H
1420,,3268,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,10576,H
1421,,3268,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,10576,H
1422,,16117,,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,10576,H
1423,Hippocampus,9783,10000000.0,,,,,,Expert,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,10576,H
1424,Hippocampus,9783,10000000.0,,,,,,Autocuration,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,10576,H
1425,Hippocampus,14356,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,10576,D
1426,,15740,,,,,,,Autocuration,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,10576,H
1427,Hippocampus,12306,10000000.0,,,,,,Autocuration,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,10576,H
1428,Hippocampus,13348,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,10576,D
1429,,10394,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,10576,H
1430,Hippocampus,15260,10000000.0,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,10576,H
1431,Hippocampus,10046,10000000.0,,,,,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,10576,H
1432,Hippocampus,15260,10000000.0,,,,,,Intermediate,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,10576,H
1433,,12851,,,,,,,Autocuration,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,10576,H
1434,Hippocampus,2148,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,10576,D
1435,,13134,,,,,,,Expert,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,10576,H
1436,,12462,,,,,,,Autocuration,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,10576,H
1437,,12462,,,,,,,Expert,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,10576,H
1438,,12462,,,,449.0,,,Autocuration,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,CHO,10576,H
1439,,11933,,,,,,,Expert,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1440,,11933,,,,,,,Autocuration,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,10576,H
1441,Hippocampus,403,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,10576,D
1442,Hippocampus,15538,10000000.0,,,,,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
1443,Hippocampus,15538,10000000.0,,,,,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,10576,H
1444,Hippocampus,15538,10000000.0,,,,,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,10576,H
1445,,12464,,,,,,,Intermediate,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,10576,H
1446,,1455,,,,,,,Expert,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,10576,H
1447,,12652,,,,,,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,10576,H
1448,Hippocampus,12639,10000000.0,,,,,,Autocuration,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,10576,H
1449,,13949,,,,,,,Expert,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,10576,H
1450,,12463,,Rattus norvegicus,,,10116.0,,Expert,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,10576,D
1451,Hippocampus,14829,10000000.0,,,,,,Expert,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,10576,H
1452,Hippocampus,14829,10000000.0,,,,,,Autocuration,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,10576,H
1453,,12092,,,,,,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,10576,H
1454,,403,,,,,,,Autocuration,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,10576,H
1455,,403,,,,,,,Autocuration,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,10576,H
1456,,3967,,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,10576,H
1457,,12771,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,10576,D
1458,,15086,,,,,,,Autocuration,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,10576,H
1459,Hippocampus,14909,10000000.0,,,,,,Autocuration,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
1460,Hippocampus,14949,10000000.0,,,,,,Expert,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,10576,H
1461,Hippocampus,2309,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,10576,D
1462,,4170,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,10576,H
1463,Hippocampus,11642,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,10576,D
1464,Hippocampus,11642,10000000.0,,,,,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,10576,H
1465,Hippocampus,12953,10000000.0,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,10576,H
1466,Hippocampus,12953,10000000.0,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,10576,H
1467,Hippocampus,12953,10000000.0,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,10576,H
1468,,12903,,,,449.0,,,Expert,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,CHO,10576,H
1469,,12536,,,,,,,Expert,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,10576,H
1470,,10058,,,,,,,Autocuration,,The inhibition activity of 5-HT1A at 1 uM,B,,,10576,H
1471,,12902,,,,485.0,,,Expert,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,CHO-K1,10576,H
1472,,14057,,,,,,,Expert,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,10576,H
1473,,11296,,,,,,,Autocuration,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,10576,H
1474,Hippocampus,11296,10000000.0,,,,,,Autocuration,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,10576,H
1475,Hippocampus,11296,10000000.0,,,,,,Expert,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,10576,H
1476,,16616,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,10576,D
1477,Hippocampus,16616,10000000.0,Rattus norvegicus,,,10116.0,Membranes,Expert,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,10576,D
1478,,16567,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,10576,H
1479,,16567,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,10576,H
1480,,16567,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,10576,H
1481,,16567,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,10576,H
1482,,17136,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,10576,H
1483,,17136,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,10576,H
1484,,16616,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,10576,D
1485,Hippocampus,17331,10000000.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,10576,H
1486,Hippocampus,17331,10000000.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,10576,H
1487,Hippocampus,17167,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,10576,D
1488,,15740,,,,,,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,10576,H
1489,,15740,,,,,,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,10576,H
1490,,4671,,,,,,,Autocuration,,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,10576,H
1491,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,10576,H
1492,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,10576,H
1493,Hippocampus,10058,10000000.0,,,,,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,10576,H
1494,,12073,,,,,,,Autocuration,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,10576,H
1495,,2759,,,,,,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,10576,H
1496,,2759,,,,,,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,10576,H
1497,,2759,,,,,,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,10576,H
1498,,2759,,,,,,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,10576,H
1499,,2759,,,,,,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,10576,H
1500,Brain,9737,955.0,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,10576,H
1501,,9737,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,10576,H
1502,,5717,,,,,,,Expert,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,10576,H
1503,Hippocampus,12253,10000000.0,,,,,,Autocuration,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,10576,H
1504,,14025,,,,,,,Autocuration,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,10576,H
1505,,10425,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,10576,H
1506,,14998,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,10576,H
1507,Hippocampus,13694,10000000.0,,,,,,Autocuration,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,10576,H
1508,Hippocampus,13694,10000000.0,,,,,,Autocuration,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,10576,H
1509,,4342,,,,,,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,10576,H
1510,,12936,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,10576,D
1511,,13144,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,10576,D
1512,,13343,,,,,,,Expert,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,10576,H
1513,,12132,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,10576,H
1514,,15419,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,10576,H
1515,Hippocampus,1479,10000000.0,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,10576,H
1516,,14287,,,,,,,Expert,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,10576,H
1517,,13116,,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,10576,H
1518,,2759,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,10576,D
1519,,2759,,,,,,,Autocuration,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,10576,H
1520,,14748,,,,,,,Expert,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,10576,H
1521,,12304,,,,,,,Autocuration,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,10576,H
1522,Hippocampus,12409,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,10576,D
1523,Hippocampus,12409,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,10576,D
1524,Hippocampus,13267,10000000.0,,,,,,Autocuration,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,10576,H
1525,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,10576,H
1526,,14256,,,,,,,Expert,,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,10576,H
1527,,16567,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,10576,H
1528,,15740,,,,,,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,10576,H
1529,,13278,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,12687,D
1530,,1970,,,,,,Membranes,Expert,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,10626,H
1531,Brain,10034,955.0,,,,,,Autocuration,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,10576,H
1532,,13348,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,51,H
1533,,13630,,,,,,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,10576,H
1534,Brain,10862,955.0,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,10576,H
1535,,12058,,,,,,,Autocuration,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,10576,H
1536,,4639,,,,,,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,51,H
1537,,15453,,,,,,,Expert,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,51,H
1538,,4820,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,51,H
1539,,1089,,,,,,,Autocuration,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,51,H
1540,,386,,,,,,Brain membranes,Autocuration,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,51,H
1541,,6011,,,,,,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,51,H
1542,,5014,,,,,,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,51,H
1543,,4402,,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,51,H
1544,,17066,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,51,H
1545,,17515,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,51,H
1546,,2474,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,51,H
1547,,4775,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,51,H
1548,,14294,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,51,D
1549,,14294,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,51,D
1550,,12249,,,,449.0,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,51,H
1551,,11376,,,,,,,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,51,H
1552,,2474,,,,,,,Autocuration,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,51,H
1553,Hippocampus,13311,10000000.0,,,,,,Autocuration,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,51,H
1554,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,51,H
1555,,1633,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,51,H
1556,,11866,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,51,H
1557,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,51,H
1558,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,51,H
1559,,16946,,,,,,,Autocuration,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,11863,H
1560,,13291,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,11863,H
1561,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,11863,H
1562,,10812,,,,,,,Autocuration,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,11863,H
1563,,3032,,Mus musculus,,449.0,10090.0,,Expert,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,CHO,11863,D
1564,,16655,,,,,,,Autocuration,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,11863,H
1565,,14532,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,11863,H
1566,,13944,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,11863,H
1567,,13033,,,,,,,Autocuration,,Binding affinity against serotonergic 5-HT1a receptor,B,,,11863,H
1568,,10321,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,11863,H
1569,,2968,,Mus musculus,,,10090.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,11863,D
1570,,13964,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,11863,H
1571,,15527,,,,,,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,11863,H
1572,,12248,,,,449.0,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,11863,H
1573,,12249,,,,449.0,,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,CHO,11863,H
1574,,15120,,,,,,,Autocuration,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,11863,H
1575,,13313,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,11863,H
1576,,2613,,,,,,,Autocuration,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,11863,H
1577,,16700,,,,,,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,11863,H
1578,,2201,,,,,,,Autocuration,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,11863,H
1579,,1274,,Mus musculus,,,10090.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,11863,D
1580,,1317,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,11863,H
1581,,12146,,,,,,,Autocuration,,Tested against 5-hydroxytryptamine 1A receptor,B,,,11863,H
1582,,14059,,,,,,,Autocuration,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,11863,H
1583,,14025,,Oryctolagus cuniculus,,,9986.0,,Expert,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,106,H
1584,,14025,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,106,H
1585,,14447,,Gorilla gorilla,,722.0,9593.0,,Intermediate,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,HEK293,105571,D
1586,,3025,,Cavia porcellus,,,10141.0,,Autocuration,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,106,H
1587,,3025,,Cavia porcellus,,,10141.0,,Autocuration,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,106,H
1588,,15329,,Cavia porcellus,,,10141.0,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,106,H
1589,,15329,,Cavia porcellus,,,10141.0,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,106,H
1590,,15847,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,106,H
1591,,15847,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,106,H
1592,,14165,,,,,,,Autocuration,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,106,H
1593,,14214,,,,,,,Autocuration,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,106,H
1594,,14214,,,,,,,Autocuration,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,106,H
1595,,14214,,Homo sapiens,,,9606.0,,Expert,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,106,D
1596,,13729,,Homo sapiens,,485.0,9606.0,,Expert,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,CHO-K1,106,D
1597,,3025,,,,449.0,,,Autocuration,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,CHO,106,H
1598,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,106,H
1599,,2391,,,,,,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,106,H
1600,,14956,,,,449.0,,,Expert,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,CHO,106,H
1601,,2598,,,,449.0,,,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,CHO,106,H
1602,,2598,,,,449.0,,,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,CHO,106,H
1603,,2598,,,,449.0,,,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,CHO,106,H
1604,,2598,,,,449.0,,,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,CHO,106,H
1605,,14956,,,,,,,Expert,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,106,H
1606,,14956,,,,,,,Autocuration,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,106,H
1607,,14214,,Homo sapiens,,,9606.0,,Expert,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,106,D
1608,,3463,,,,449.0,,,Expert,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,CHO,106,H
1609,,15331,,,,,,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,106,H
1610,,16146,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,106,D
1611,,14159,,Homo sapiens,,449.0,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,CHO,106,D
1612,,14158,,,,449.0,,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,CHO,106,H
1613,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,106,H
1614,,15250,,,,449.0,,,Expert,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,CHO,106,H
1615,,15250,,,,449.0,,,Expert,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,CHO,106,H
1616,,15331,,,,449.0,,,Expert,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,CHO,106,H
1617,,15332,,,,449.0,,,Expert,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,CHO,106,H
1618,,14956,,,,449.0,,,Expert,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,CHO,106,H
1619,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,106,H
1620,,14875,,,,,,,Autocuration,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,106,H
1621,,14454,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,105,H
1622,,14454,,Oryctolagus cuniculus,,,9986.0,,Expert,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,105,H
1623,,16288,,,,,,,Autocuration,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,105,H
1624,,16288,,,,,,,Autocuration,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,105,H
1625,,16312,,,,,,,Autocuration,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,105,H
1626,,1348,,Bos taurus,,,9913.0,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,105,H
1627,,5834,,Bos taurus,,,9913.0,,Autocuration,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,105,H
1628,Striatum,13366,2435.0,Bos taurus,,,9913.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,105,H
1629,,1414,,Bos taurus,,,9913.0,,Expert,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,105,H
1630,,14998,,Bos taurus,,,9913.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,105,H
1631,,11473,,Bos taurus,,,9913.0,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,105,H
1632,,11473,,Bos taurus,,,9913.0,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,105,H
1633,,10639,,Bos taurus,,,9913.0,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,105,H
1634,,10639,,Bos taurus,,,9913.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,105,H
1635,,1375,,Bos taurus,,,9913.0,,Autocuration,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,105,H
1636,,1375,,Bos taurus,,,9913.0,,Autocuration,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,105,H
1637,,16532,,Bos taurus,,,9913.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,105,H
1638,,11147,,Bos taurus,,,9913.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,105,H
1639,Striatum,13366,2435.0,Bos taurus,,,9913.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,105,H
1640,,10444,,Bos taurus,,,9913.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,105,H
1641,,16532,,Bos taurus,,,9913.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,105,H
1642,,16532,,Bos taurus,,,9913.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,105,H
1643,,12827,,Bos taurus,,,9913.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,105,H
1644,,12827,,Bos taurus,,,9913.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,105,H
1645,,12919,,Bos taurus,,,9913.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,105,H
1646,,14025,,Bos taurus,,,9913.0,,Autocuration,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,105,H
1647,,12919,,Bos taurus,,,9913.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,105,H
1648,,12919,,Bos taurus,,,9913.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,105,H
1649,,12919,,Bos taurus,,,9913.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,105,H
1650,,14447,,Gorilla gorilla,,722.0,9593.0,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,HEK293,105,H
1651,,1375,,Cavia porcellus,,,10141.0,,Intermediate,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,105570,D
1652,,1375,,Cavia porcellus,,,10141.0,,Intermediate,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,105570,D
1653,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,105570,D
1654,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,105570,D
1655,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,105570,D
1656,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,105570,D
1657,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,105570,D
1658,,11574,,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,105570,D
1659,,1558,,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,105570,D
1660,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,105570,D
1661,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,105570,D
1662,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,105570,D
1663,,12409,,Cavia porcellus,,,10141.0,,Intermediate,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,105570,D
1664,,12253,,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,105570,D
1665,,12936,,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,105570,D
1666,,13181,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,105,H
1667,Striatum,12409,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,105570,D
1668,,10639,,Cavia porcellus,,,10141.0,,Intermediate,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,105570,D
1669,,5254,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,51,H
1670,,13051,,,,,,,Autocuration,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,106,H
1671,,3463,,,,,,,Expert,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,105,H
1672,,15315,,,,,,,Autocuration,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,105,H
1673,,6011,,,,,,,Autocuration,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,105,H
1674,,14159,,Homo sapiens,,449.0,9606.0,,Expert,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,CHO,105,D
1675,,14159,,,,449.0,,,Autocuration,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,CHO,105,H
1676,,15250,,,,449.0,,,Expert,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,CHO,105,H
1677,,15250,,,,449.0,,,Autocuration,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,CHO,105,H
1678,,15331,,,,449.0,,,Expert,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,CHO,105,H
1679,,15332,,Homo sapiens,,449.0,9606.0,,Expert,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,CHO,105,D
1680,,15332,,,,449.0,,,Expert,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,CHO,105,H
1681,,3294,,,,449.0,,,Autocuration,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,CHO,105,H
1682,,14158,,,,449.0,,,Expert,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,CHO,105,H
1683,,14956,,,,449.0,,,Expert,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,CHO,105,H
1684,,12469,,,,,,,Autocuration,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,105,H
1685,,3463,,,,449.0,,,Expert,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,CHO,105,H
1686,,15250,,Homo sapiens,,449.0,9606.0,,Expert,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,CHO,105,D
1687,,15250,,Homo sapiens,,449.0,9606.0,,Expert,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,CHO,105,D
1688,,14956,,,,,,,Expert,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,105,H
1689,,14159,,,,,,,Autocuration,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,105,H
1690,,14159,,Homo sapiens,,,9606.0,,Expert,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,105,D
1691,,14499,,Homo sapiens,,449.0,9606.0,,Expert,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,CHO,105,D
1692,,15315,,,,,,,Autocuration,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,105,H
1693,,3294,,,,,,,Autocuration,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,105,H
1694,,3463,,,,449.0,,,Expert,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,CHO,105,H
1695,,15331,,,,,,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,105,H
1696,,14159,,Homo sapiens,,449.0,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,105,D
1697,,14158,,,,449.0,,,Expert,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,CHO,105,H
1698,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,105,H
1699,,15250,,,,449.0,,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,CHO,105,H
1700,,15250,,,,449.0,,,Expert,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,CHO,105,H
1701,,15331,,,,449.0,,,Expert,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,CHO,105,H
1702,,15332,,Homo sapiens,,449.0,9606.0,,Expert,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,105,D
1703,,14499,,Homo sapiens,,449.0,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,105,D
1704,,15332,,,,449.0,,,Expert,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,CHO,105,H
1705,,14956,,,,449.0,,,Expert,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,CHO,105,H
1706,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,105,H
1707,,6011,,Homo sapiens,,449.0,9606.0,,Expert,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,CHO,105,D
1708,,16190,,,,449.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,105,H
1709,,14165,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,105,H
1710,,4234,,Homo sapiens,,,9606.0,,Expert,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,105,D
1711,,15527,,,,,,,Autocuration,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,105,H
1712,,6328,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,105,H
1713,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,105,H
1714,,14770,,,,,,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,105,H
1715,,2598,,,,,,,Autocuration,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,105,H
1716,,6897,,,,,,,Expert,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,105,H
1717,,6013,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,105,H
1718,,5843,,,,,,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,105,H
1719,,14454,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,105,H
1720,,14454,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,105,H
1721,,14454,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,105,H
1722,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,105,H
1723,,13729,,,,485.0,,,Expert,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,CHO-K1,105,H
1724,,6011,,Homo sapiens,,,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,105,D
1725,,4234,,Homo sapiens,,,9606.0,,Expert,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,105,D
1726,,17085,,,,,,,Expert,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,105,H
1727,,3025,,,,,,,Autocuration,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,105,H
1728,,15315,,,,,,,Expert,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,105,H
1729,,14214,,Homo sapiens,,,9606.0,,Expert,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,105,D
1730,,3804,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,105,D
1731,,16700,,,,,,,Autocuration,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,105,H
1732,,2391,,Homo sapiens,,,9606.0,,Expert,,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,105,D
1733,,4175,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,105,D
1734,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,105,H
1735,,17085,,,,,,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,105,H
1736,,15926,,Homo sapiens,,,9606.0,,Expert,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,105,D
1737,,16312,,,,485.0,,,Autocuration,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,CHO-K1,105,H
1738,,16312,,,,485.0,,,Autocuration,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,CHO-K1,105,H
1739,,14956,,,,449.0,,,Autocuration,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,CHO,104802,H
1740,,3294,,,,,,,Autocuration,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,105,H
1741,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,105,H
1742,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,105,H
1743,,16312,,,,485.0,,,Expert,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,CHO-K1,105,H
1744,,5104,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,105,H
1745,,5105,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,105,H
1746,,14499,,,,,,,Autocuration,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,105,H
1747,,15926,,Homo sapiens,,,9606.0,,Expert,,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,105,D
1748,,4540,,Homo sapiens,,449.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,105,D
1749,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,CHO,105,H
1750,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,105,H
1751,,6166,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,105,H
1752,,15779,,,,449.0,,,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,CHO,105,H
1753,,15779,,,,449.0,,,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,CHO,105,H
1754,,17451,,,,722.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,HEK293,105,H
1755,,17451,,,,722.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,HEK293,105,H
1756,,17451,,,,722.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,HEK293,105,H
1757,,4199,,,,449.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,CHO,105,H
1758,,14875,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,105,D
1759,,15146,,,,449.0,,,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,CHO,105,H
1760,,5213,,,,,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,105,H
1761,,14818,,,,449.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,CHO,105,H
1762,,4829,,,,449.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,105,H
1763,,14454,,,,,,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,105,H
1764,,14454,,,,,,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,105,H
1765,,5254,,,,,,,Autocuration,,Binding affinity against 5-HT2C receptor,B,,,108,H
1766,,5254,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,108,H
1767,,10639,,,,,,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,10577,H
1768,,10639,,,,,,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,10577,H
1769,,12352,,,,,,,Expert,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,10577,H
1770,,9098,,,,,,,Autocuration,,Binding affinity towards 5-HT1B was determined,B,,,10577,H
1771,,14430,,,,,,,Expert,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,10577,H
1772,,13657,,,,,,,Expert,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,10577,H
1773,,13657,,,,,,,Autocuration,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,10577,H
1774,,15854,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,10577,H
1775,,10639,,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,10577,D
1776,,10025,,,,,,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,10577,H
1777,,10025,,,,,,,Autocuration,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,10577,H
1778,,14286,,,,,,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,10577,H
1779,Striatum,3651,2435.0,,,,,,Autocuration,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,10577,H
1780,,14178,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,10577,D
1781,,10639,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,10577,H
1782,Striatum,13605,2435.0,,,,,,Autocuration,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,10577,H
1783,Striatum,5834,2435.0,,,,,,Autocuration,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,10577,H
1784,Striatum,10922,2435.0,,,,,,Autocuration,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,10577,H
1785,,14286,,,,,,,Autocuration,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,10577,H
1786,,11825,,,,,,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,10577,H
1787,Striatum,14826,2435.0,,,,,,Autocuration,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,10577,H
1788,Striatum,9699,2435.0,,,,,,Autocuration,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,10577,H
1789,,14423,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,10577,H
1790,,10062,,,,,,,Expert,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,10577,H
1791,,10062,,,,,,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,10577,H
1792,,12280,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,10577,D
1793,Striatum,15412,2435.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,10577,H
1794,Striatum,15412,2435.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,10577,H
1795,,10062,,,,,,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,10577,H
1796,,11147,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,10577,H
1797,,9547,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,10577,H
1798,,10444,,,,,,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,10577,H
1799,Striatum,12469,2435.0,,,,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,10577,H
1800,,9098,,,,,,,Expert,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,10577,H
1801,,9098,,,,,,,Autocuration,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,10577,H
1802,,9699,,,,,,,Autocuration,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,10577,H
1803,,10394,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,10577,H
1804,,12092,,,,,,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,10577,H
1805,,16700,,,,,,,Autocuration,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,10577,H
1806,,403,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,10577,D
1807,,12771,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,10577,D
1808,,11642,,,,,,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,10577,H
1809,,12953,,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,10577,H
1810,,12953,,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,10577,H
1811,Striatum,12953,2435.0,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,10577,H
1812,,12953,,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,10577,H
1813,Brain,9737,955.0,,,,,,Autocuration,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,10577,H
1814,,9737,,,,,,,Autocuration,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,10577,H
1815,Brain,9737,955.0,,,,,,Autocuration,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,10577,H
1816,,12827,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,10577,H
1817,,5033,,,,,,,Autocuration,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,10577,H
1818,,9786,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,10577,D
1819,,13116,,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,10577,H
1820,,16429,,,,,,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,10577,H
1821,,12409,,Rattus norvegicus,,,10116.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,10577,D
1822,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,10577,H
1823,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,10577,H
1824,,5486,,,,,,,Autocuration,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,104686,H
1825,,4639,,,,,,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,106,H
1826,,386,,,,,,Brain membranes,Autocuration,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,106,H
1827,,2474,,,,,,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,106,H
1828,,6011,,,,,,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,106,H
1829,,5014,,,,,,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,106,H
1830,,17515,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,106,H
1831,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,106,H
1832,,1633,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,106,H
1833,,1633,,,,,,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,106,H
1834,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,106,H
1835,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,106,H
1836,,11574,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,106,H
1837,,10321,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,106,H
1838,,15527,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,106,H
1839,,17200,,,,,,,Autocuration,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,106,H
1840,,14423,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,104802,H
1841,,5834,,Bos taurus,,,9913.0,,Autocuration,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,108,H
1842,,11473,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,108,H
1843,,11473,,Sus scrofa,,,9823.0,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,108,H
1844,,10639,,Sus scrofa,,,9823.0,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,108,H
1845,,10639,,Sus scrofa,,,9823.0,,Autocuration,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,108,H
1846,,14331,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,108,H
1847,,10796,,Sus scrofa,,,9823.0,,Autocuration,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,108,H
1848,,9098,,Sus scrofa,,,9823.0,,Expert,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,108,H
1849,,14331,,Sus scrofa,,,9823.0,,Expert,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,108,H
1850,,11828,,Sus scrofa,,,9823.0,,Expert,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,108,H
1851,,11866,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,108,H
1852,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,108,H
1853,,188,,Rattus norvegicus,,,10116.0,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,12689,D
1854,,11825,,Rattus norvegicus,,,10116.0,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,12689,D
1855,,11825,,Rattus norvegicus,,,10116.0,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,12689,D
1856,,11624,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,12689,D
1857,,11139,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,12689,D
1858,,11147,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,12689,D
1859,,10444,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,12689,D
1860,,11624,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,12689,D
1861,,11662,,Rattus norvegicus,,,10116.0,,Autocuration,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,12689,D
1862,,11662,,Rattus norvegicus,,,10116.0,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,12689,D
1863,,11662,,Rattus norvegicus,,,10116.0,,Expert,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,12689,D
1864,,11662,,Rattus norvegicus,,,10116.0,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,12689,D
1865,,9098,,Rattus norvegicus,,,10116.0,,Autocuration,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,12689,D
1866,,10394,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,12689,D
1867,,11933,,,,,,,Expert,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,12689,H
1868,,12092,,Rattus norvegicus,,,10116.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,12689,D
1869,,12253,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,12689,D
1870,,12253,,Rattus norvegicus,,722.0,10116.0,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,HEK293,12689,D
1871,,1558,,,,,,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,108,H
1872,,2474,,,,,,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,108,H
1873,,2474,,,,,,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,108,H
1874,,11574,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,12689,H
1875,,1558,,,,,,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,12689,H
1876,,13944,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,12689,H
1877,,13033,,,,,,,Autocuration,,Binding affinity against serotonergic 5-HT1c receptor,B,,,12689,H
1878,,10321,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,12689,H
1879,,11866,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,12689,H
1880,,14454,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,105,H
1881,,11574,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,104686,H
1882,,11574,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,104686,H
1883,,13631,,,,,,,Autocuration,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,104686,H
1884,,9630,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,104686,D
1885,,8822,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,104686,D
1886,Brain,9064,955.0,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,104686,D
1887,,8868,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,104686,H
1888,,9064,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,104686,H
1889,,9806,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,104686,H
1890,,9098,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,104686,H
1891,,8868,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,104686,H
1892,,12765,,,,,,,Autocuration,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,104686,H
1893,,11049,,,,,,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,104686,H
1894,,11049,,,,,,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,104686,H
1895,,11049,,,,,,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,104686,H
1896,,11049,,,,,,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,104686,H
1897,,11049,,,,,,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,104686,H
1898,,11473,,,,,,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,104686,H
1899,,11473,,,,,,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,104686,H
1900,,3086,,,,,,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,104686,H
1901,,11049,,,,,,,Autocuration,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,104686,H
1902,,11049,,,,,,,Autocuration,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,104686,H
1903,,10639,,,,,,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,104686,H
1904,,10922,,,,,,,Autocuration,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,104686,H
1905,Brain,9064,955.0,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,104686,D
1906,Brain,10748,955.0,,,,,,Autocuration,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,104686,H
1907,,11614,,,,,,Membranes,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,104686,H
1908,,11615,,,,,,Membranes,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,104686,H
1909,,11615,,,,,,,Autocuration,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,104686,H
1910,,11614,,,,,,Membranes,Autocuration,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,104686,H
1911,,11702,,,,,,,Autocuration,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,104686,H
1912,,11702,,,,,,,Autocuration,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,104686,H
1913,,11702,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,104686,D
1914,,11702,,,,,,,Autocuration,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,104686,H
1915,,13346,,,,,,,Autocuration,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,104686,H
1916,,10025,,,,,,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,104686,H
1917,,10025,,,,,,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,104686,H
1918,,10025,,,,,,,Autocuration,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,104686,H
1919,,9036,,,,,,,Autocuration,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,104686,H
1920,,9036,,,,,,,Autocuration,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,104686,H
1921,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,104686,H
1922,,12304,,,,,,,Autocuration,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,104686,H
1923,,13276,,,,,,,Autocuration,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,104686,H
1924,,11825,,,,,,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,104686,H
1925,,12443,,,,,,,Autocuration,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,104686,H
1926,,13830,,,,,,,Autocuration,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,104686,H
1927,,9592,,,,,,Membranes,Autocuration,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,104686,H
1928,,9592,,,,,,Membranes,Autocuration,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,104686,H
1929,,10881,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,104686,H
1930,,13605,,,,,,,Autocuration,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,104686,H
1931,,11624,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,104686,D
1932,,4101,,,,,,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,104686,H
1933,,4101,,,,,,,Autocuration,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,104686,H
1934,,15360,,,,,,,Autocuration,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,104686,H
1935,,11576,,,,,,,Autocuration,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,104686,H
1936,,5834,,,,,,,Autocuration,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,104686,H
1937,,2395,,Rattus norvegicus,,485.0,10116.0,,Autocuration,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,CHO-K1,104686,D
1938,,11965,,,,,,Membranes,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,104686,H
1939,,3967,,,,,,,Autocuration,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,104686,H
1940,,11130,,,,,,Brain membranes,Autocuration,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,104686,H
1941,,13427,,,,,,,Autocuration,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,104686,H
1942,,9443,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,104686,H
1943,,9443,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,104686,H
1944,,11825,,,,,,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,104686,H
1945,,12120,,,,,,Membranes,Autocuration,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,104686,H
1946,,12120,,,,,,Membranes,Autocuration,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,104686,H
1947,Thoracic aorta,11963,1515.0,,,,,,Autocuration,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,104686,H
1948,,9069,,,,,,,Autocuration,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,104686,H
1949,,8868,,,,,,,Autocuration,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,104686,H
1950,,17200,,,,,,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,10624,H
1951,,17200,,,,,,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,10624,H
1952,,13969,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,17106,H
1953,,13392,,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,17106,D
1954,,1742,,,,,,,Autocuration,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,17106,H
1955,,1742,,,,,,,Autocuration,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,17106,H
1956,Striatum,14331,2435.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,17106,H
1957,,12861,,,,,,,Autocuration,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,17106,H
1958,,12861,,,,,,,Expert,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,17106,H
1959,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,17106,H
1960,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,17106,H
1961,,12861,,,,,,,Expert,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,17106,H
1962,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,17106,H
1963,,675,,,,,,,Autocuration,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,17106,H
1964,,12490,,,,,,,Expert,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,17106,H
1965,,11828,,,,,,,Expert,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,17106,H
1966,,11866,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,17106,H
1967,,773,,Sus scrofa,,,9823.0,,Autocuration,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,105,H
1968,,13047,,Oryctolagus cuniculus,,,9986.0,,Expert,,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,105,H
1969,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,105,H
1970,,13047,,Oryctolagus cuniculus,,,9986.0,,Expert,,The compound was tested for binding affinity against 5-HT1D receptor,B,,,105,H
1971,,188,,,,,,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,10578,H
1972,,10639,,,,,,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,10578,H
1973,,12438,,,,,,,Autocuration,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,10578,H
1974,,12438,,,,,,,Autocuration,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,10578,H
1975,,15854,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,10578,H
1976,,10394,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,10578,H
1977,,12092,,,,,,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,10578,H
1978,,3389,,,,,,,Expert,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,10578,H
1979,,6011,,,,,,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,105,H
1980,,4639,,,,,,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,105,H
1981,,2474,,,,,,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,105,H
1982,,5014,,,,,,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,105,H
1983,,17515,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,105,H
1984,,11866,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,105,H
1985,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,105,H
1986,,12146,,,,,,,Autocuration,,Tested against 5-hydroxytryptamine 1D receptor,B,,,105,H
1987,,10321,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,105,H
1988,,13267,,,,722.0,,,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,HEK293,105,H
1989,,1274,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,105,D
1990,,15250,,,,,,,Autocuration,,,B,,,105,H
1991,,13706,,,,485.0,,,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,CHO-K1,106,H
1992,,13706,,,,485.0,,,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,CHO-K1,105,H
1993,,13706,,,,722.0,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,HEK293,105,H
1994,,13706,,,,722.0,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,HEK293,105,H
1995,,13047,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,105,H
1996,,13366,,,,,,,Autocuration,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,105,H
1997,,13366,,,,,,,Expert,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,105,H
1998,,1558,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,105,H
1999,,12902,,,,485.0,,,Expert,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,CHO-K1,105,H
2000,,13706,,,,485.0,,,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,CHO-K1,105,H
2001,,13706,,,,,,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,105,H
2002,,13706,,,,,,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,105,H
2003,,14251,,,,,,,Autocuration,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,105,H
2004,,14251,,,,,,,Autocuration,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,105,H
2005,,14251,,,,,,,Autocuration,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,105,H
2006,,13313,,,,,,,Autocuration,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,105,H
2007,,13313,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,105,H
2008,,13366,,,,,,,Autocuration,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,105,H
2009,,13051,,,,,,,Expert,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,105,H
2010,,12903,,,,449.0,,,Expert,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,CHO,105,H
2011,,12469,,Homo sapiens,,,9606.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,105,D
2012,,5619,,,,,,,Autocuration,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,17106,H
2013,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,105,H
2014,,16633,,,,,,,Autocuration,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,105,H
2015,,16633,,,,,,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,105,H
2016,,16633,,,,,,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,105,H
2017,,16633,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,105,H
2018,,3269,,,,,,,Autocuration,,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,105,H
2019,,12409,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,105,H
2020,,13706,,,,,,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,106,H
2021,,13706,,,,722.0,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,HEK293,106,H
2022,,13706,,,,722.0,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,HEK293,106,H
2023,,12903,,,,449.0,,,Autocuration,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,CHO,106,H
2024,,13047,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,106,H
2025,,13366,,,,,,,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,106,D
2026,,13366,,,,,,,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,106,D
2027,,13366,,,,,,,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,106,D
2028,,13366,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,106,H
2029,,13366,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,106,H
2030,,12469,,,,449.0,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,CHO,106,H
2031,,13706,,,,485.0,,,Autocuration,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,CHO-K1,106,H
2032,,13706,,,,485.0,,,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,CHO-K1,106,H
2033,,13706,,,,,,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,106,H
2034,,12902,,,,485.0,,,Expert,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,CHO-K1,106,H
2035,,13051,,,,,,,Expert,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,105,H
2036,,12903,,,,449.0,,,Expert,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,CHO,106,H
2037,,1558,,,,485.0,,,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,CHO-K1,105,H
2038,,1558,,,,485.0,,,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,CHO-K1,105,H
2039,,1558,,,,485.0,,,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,CHO-K1,105,H
2040,,1558,,,,485.0,,,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,CHO-K1,105,H
2041,,1558,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,105,H
2042,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,106,H
2043,,13313,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,105,H
2044,,13313,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,105,H
2045,,12409,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,105,H
2046,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,CHO,10618,H
2047,,1348,,Homo sapiens,,,9606.0,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,10618,D
2048,,1348,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,10618,H
2049,,4234,,Homo sapiens,,,9606.0,,Expert,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,10618,D
2050,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,10618,H
2051,,10444,,,,,,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,10618,H
2052,,3935,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,10618,H
2053,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,10618,H
2054,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,10618,H
2055,,12936,,Homo sapiens,,449.0,9606.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,CHO,10618,D
2056,,6166,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,10618,H
2057,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,10618,H
2058,,15779,,,,449.0,,,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,CHO,10618,H
2059,,15779,,,,449.0,,,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,CHO,10618,H
2060,,13181,,,,,,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,10618,H
2061,,4199,,,,449.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,CHO,10618,H
2062,,14875,,,,,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,10618,H
2063,,15146,,,,449.0,,,Autocuration,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,CHO,10618,H
2064,,5213,,,,,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,10618,H
2065,,12146,,,,,,,Autocuration,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,10618,H
2066,,13267,,,,449.0,,,Autocuration,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,CHO,10618,H
2067,,14818,,,,449.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,CHO,10618,H
2068,,4829,,,,449.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,10618,H
2069,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,10618,H
2070,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,10618,H
2071,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,10618,H
2072,,16633,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,10618,H
2073,,17085,,,,,,,Autocuration,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,279,H
2074,,17085,,,,,,,Expert,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,279,H
2075,,16209,,,,,,,Autocuration,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,279,H
2076,,16209,,,,,,,Autocuration,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,279,H
2077,,17085,,,,,,,Expert,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,279,H
2078,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,279,H
2079,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,CHO,279,H
2080,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,279,H
2081,,16190,,,,449.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,CHO,279,H
2082,,16190,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,279,H
2083,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,279,H
2084,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,279,H
2085,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,279,H
2086,,6866,,,,,,,Autocuration,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,279,H
2087,,17085,,,,,,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,279,H
2088,,16312,,,,,,,Autocuration,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,279,H
2089,,6166,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,279,H
2090,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,CHO,279,H
2091,,4199,,,,449.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,CHO,279,H
2092,,14875,,,,,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,279,H
2093,,15146,,,,449.0,,,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,CHO,279,H
2094,,5213,,,,,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,279,H
2095,,14818,,,,449.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,CHO,279,H
2096,,4829,,,,449.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,279,H
2097,,4829,,,,449.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,CHO,279,H
2098,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,279,H
2099,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,279,H
2100,,5014,,,,,,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,279,H
2101,,11662,,,,,,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,104686,H
2102,,11662,,,,,,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,104686,H
2103,,11662,,,,,,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,104686,H
2104,,14093,,,,,,,Autocuration,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,12687,H
2105,,11200,,,,,,,Autocuration,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,104686,H
2106,,11200,,,,,,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,104686,H
2107,,12352,,,,,,,Intermediate,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,17005,H
2108,,13657,,Bos taurus,,,9913.0,,Autocuration,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,22226,U
2109,,14331,,Bos taurus,,,9913.0,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,22226,U
2110,,14331,,Bos taurus,,,9913.0,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,22226,U
2111,,14331,,,,,,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,22226,U
2112,,12685,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,104784,H
2113,,14389,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,104784,H
2114,,14386,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,104784,H
2115,,5732,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,104784,H
2116,,16293,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,104784,H
2117,,2078,,,,,,,Autocuration,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,104784,H
2118,,5486,,,,,,,Autocuration,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,10209,H
2119,,11820,,,,,,,Autocuration,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,104826,H
2120,,10297,,,,,,,Autocuration,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,104826,H
2121,,13704,,,,,,,Autocuration,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,104826,H
2122,,10297,,Mus musculus,,,10090.0,,Autocuration,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,104826,D
2123,,11820,,,,,,,Autocuration,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,104826,H
2124,,10297,,Mus musculus,,,10090.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,104826,D
2125,,11555,,,,,,,Autocuration,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,104826,H
2126,,11555,,,,,,,Autocuration,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,104826,H
2127,,11555,,,,,,,Autocuration,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,104826,H
2128,,10297,,Mus musculus,,,10090.0,,Autocuration,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,104826,D
2129,,16688,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,104784,H
2130,,16688,,Sus scrofa,,,9823.0,,Autocuration,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,104784,H
2131,,5333,,,,,,,Autocuration,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,22226,U
2132,,4437,,,,,,,Autocuration,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,22226,U
2133,,5033,,Sus scrofa,,,9823.0,,Autocuration,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,17005,H
2134,,15267,,,,,,,Autocuration,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,104686,H
2135,,15267,,,,,,,Autocuration,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,104686,H
2136,,11820,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,104826,H
2137,,9069,,,,,,,Autocuration,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,104686,H
2138,,9162,,Rattus norvegicus,,,10116.0,,Autocuration,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,104686,D
2139,,9162,,,,,,,Autocuration,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,104686,H
2140,,9162,,,,,,,Autocuration,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,104686,H
2141,,10428,,,,,,,Autocuration,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,104686,H
2142,,9628,,,,,,,Autocuration,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,104686,H
2143,,12704,,,,,,,Autocuration,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,104686,H
2144,,15453,,Rattus norvegicus,,,10116.0,,Autocuration,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,104686,D
2145,,188,,,,,,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,104686,H
2146,,10349,,,,,,,Autocuration,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,104686,H
2147,,10349,,,,,,,Autocuration,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,104686,H
2148,,8868,,,,,,,Autocuration,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,104686,H
2149,,10025,,,,,,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,104686,H
2150,,10025,,,,,,,Autocuration,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,104686,H
2151,,11702,,,,,,,Autocuration,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,104686,H
2152,,11702,,,,,,,Autocuration,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,104686,H
2153,,11702,,,,,,,Autocuration,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,104686,H
2154,,11702,,,,,,,Autocuration,,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,104686,H
2155,,11702,,,,,,,Autocuration,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,104686,H
2156,Hippocampus,10085,10000000.0,,,,,,Autocuration,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,104686,H
2157,Hippocampus,10085,10000000.0,,,,,,Autocuration,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,104686,H
2158,Brain,9630,955.0,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,104686,D
2159,,11070,,,,,,,Autocuration,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,104686,H
2160,,9841,,,,,,Membranes,Autocuration,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,104686,H
2161,,9841,,,,,,Membranes,Autocuration,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,104686,H
2162,,13291,,,,,,,Autocuration,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,104686,H
2163,,10590,,,,,,,Autocuration,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,104686,H
2164,Brain,9064,955.0,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,104686,D
2165,,12268,,Rattus norvegicus,,,10116.0,Membranes,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,104686,D
2166,Brain,13508,955.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,104686,H
2167,,11279,,,,,,,Autocuration,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,104686,H
2168,,11200,,,,,,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,104686,H
2169,,11200,,,,,,,Autocuration,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,104686,H
2170,,11200,,,,,,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,104686,H
2171,,11200,,,,,,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,104686,H
2172,,11200,,,,,,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,104686,H
2173,Brain,9231,955.0,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,104686,H
2174,,9737,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,104686,H
2175,Brain,9737,955.0,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,104686,H
2176,,9737,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,104686,H
2177,,9737,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,104686,H
2178,,11828,,Rattus norvegicus,,,10116.0,,Autocuration,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,104686,D
2179,,12253,,,,,,,Autocuration,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,104686,H
2180,,12253,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,104686,H
2181,,11279,,,,,,,Autocuration,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,104686,H
2182,,11866,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,104686,H
2183,,14424,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,104686,D
2184,,15180,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,104686,D
2185,,15180,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,104686,D
2186,,9786,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,104686,D
2187,,12132,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,104686,H
2188,,5486,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,104686,H
2189,,15316,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,104686,H
2190,,16429,,,,,,,Autocuration,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,104686,H
2191,,14617,,,,,,,Autocuration,,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,104686,H
2192,Brain,11351,955.0,,,,,,Autocuration,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,104686,H
2193,,11279,,,,,,,Autocuration,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,104686,H
2194,,9523,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,105075,H
2195,,9523,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,105075,H
2196,,9523,,,,,,,Autocuration,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,105075,H
2197,,9523,,,,,,,Autocuration,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,105075,H
2198,,9523,,,,,,,Autocuration,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,105075,H
2199,,9523,,,,,,,Autocuration,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,105075,H
2200,,9523,,,,,,,Autocuration,,Hill coefficient of compound was determined,B,,,105075,H
2201,,4771,,,,,,,Autocuration,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,22226,U
2202,,5033,,Rattus norvegicus,,,10116.0,,Autocuration,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,104686,D
2203,,10845,,,,,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,12687,H
2204,,10845,,,,,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,12687,H
2205,,16288,,,,,,,Autocuration,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,12687,H
2206,,16288,,,,,,,Autocuration,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,12687,H
2207,,16190,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,12687,H
2208,,12463,,Rattus norvegicus,,,10116.0,,Autocuration,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,104686,D
2209,,9699,,,,,,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,104686,H
2210,,9699,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,104686,H
2211,,11662,,,,,,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,104686,H
2212,,1205,,,,,,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,104784,H
2213,,11376,,,,,,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,22226,U
2214,,11376,,,,,,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,104784,H
2215,,4639,,,,,,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,104784,H
2216,,2222,,,,,,,Autocuration,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,104784,H
2217,,1558,,,,,,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,104784,H
2218,,1089,,,,,,,Autocuration,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,104784,H
2219,,386,,,,,,Brain membranes,Autocuration,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,104784,H
2220,,2474,,,,,,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,104784,H
2221,,17066,,,,,,,Autocuration,,Binding affinity towards 5-HT2 receptor,B,,,104784,H
2222,,959,,,,,,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,104784,H
2223,,6398,,,,,,,Autocuration,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,104784,H
2224,,11889,,,,,,,Autocuration,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,104686,H
2225,,4221,,,,,,,Autocuration,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,104784,H
2226,,11026,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,104784,H
2227,,11866,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,104784,H
2228,,4221,,,,,,,Autocuration,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,104784,H
2229,,13950,,,,,,,Autocuration,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,22226,U
2230,,1263,,,,,,,Autocuration,,5-hydroxytryptamine 2 receptor binding affinity,B,,,104784,H
2231,,13291,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,17005,H
2232,,10812,,,,,,,Autocuration,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,17005,H
2233,,13020,,,,,,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,104784,H
2234,,13021,,,,,,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,104784,H
2235,,13020,,,,,,,Autocuration,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,104784,H
2236,,14532,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,17005,H
2237,,13944,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,17005,H
2238,,14331,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,17005,H
2239,,14118,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,17005,H
2240,,13033,,,,,,,Autocuration,,Binding affinity against serotonergic 5-HT2 receptor,B,,,17005,H
2241,,10321,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,17005,H
2242,,12918,,,,,,,Autocuration,,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,17005,H
2243,,15120,,,,,,,Autocuration,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,17005,H
2244,,2613,,,,,,,Autocuration,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,17005,H
2245,,13378,,Homo sapiens,,,9606.0,,Autocuration,,Inhibitory activity against cloned human 5-HT2 receptor,B,,,104784,D
2246,,2331,,Homo sapiens,,449.0,9606.0,,Autocuration,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,CHO,104784,D
2247,,2331,,Homo sapiens,,449.0,9606.0,,Autocuration,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,CHO,104784,D
2248,,2331,,Homo sapiens,,449.0,9606.0,,Autocuration,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,CHO,104784,D
2249,,2331,,Homo sapiens,,449.0,9606.0,,Autocuration,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,CHO,104784,D
2250,,4170,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,104784,H
2251,,15453,,,,,,,Autocuration,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,104784,H
2252,,1479,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,17005,H
2253,,11139,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,104686,H
2254,,13969,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,17005,H
2255,,13392,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,17005,H
2256,,14430,,,,,,,Expert,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,17005,H
2257,,13181,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,107,H
2258,,17200,,,,,,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,51,H
2259,,17200,,,,,,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,107,H
2260,,17200,,,,,,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,51,H
2261,,13463,,,,,,,Autocuration,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,107,H
2262,,6347,,,,449.0,,,Autocuration,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,CHO,107,H
2263,,6857,,Homo sapiens,,449.0,9606.0,,Expert,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,CHO,107,D
2264,,4176,,,,,,,Autocuration,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,107,H
2265,,4176,,,,,,,Autocuration,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,107,H
2266,,4176,,,,,,,Autocuration,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,107,H
2267,,6347,,,,449.0,,,Autocuration,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,CHO,107,H
2268,,6347,,,,449.0,,,Autocuration,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,CHO,107,H
2269,,15331,,,,,,,Autocuration,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,107,H
2270,,16146,,Homo sapiens,,,9606.0,,Expert,,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,107,D
2271,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,107,H
2272,,13631,,,,,,,Expert,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,107,H
2273,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,107,H
2274,,4011,,,,449.0,,,Autocuration,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,CHO,107,H
2275,,4012,,,,449.0,,,Expert,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,CHO,107,H
2276,,6366,,,,307.0,,,Expert,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,L929,107,H
2277,,15949,,,,449.0,,,Expert,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,107,H
2278,,14093,,,,,,,Autocuration,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,107,H
2279,,13481,,,,,,,Autocuration,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,107,H
2280,,6347,,,,449.0,,,Autocuration,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,CHO,107,H
2281,,6347,,,,449.0,,,Autocuration,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,CHO,107,H
2282,,14093,,,,,,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,107,H
2283,,14093,,,,,,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,107,H
2284,,13481,,,,,,,Autocuration,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,107,H
2285,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,107,H
2286,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,107,H
2287,,14755,,,,,,,Autocuration,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,107,H
2288,,16441,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,107,H
2289,,14744,,,,,,,Autocuration,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,107,H
2290,,16659,,,,449.0,,,Expert,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,107,H
2291,,3307,,,,,,,Autocuration,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,107,H
2292,,6857,,Homo sapiens,,,9606.0,,Expert,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,107,D
2293,,5635,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,107,H
2294,,4234,,Homo sapiens,,,9606.0,,Expert,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,107,D
2295,,15527,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,107,H
2296,,6588,,,,449.0,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,CHO,107,H
2297,,13631,,,,,,,Expert,,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,107,H
2298,,17723,,,,,,,Autocuration,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,107,H
2299,,14770,,,,,,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,107,H
2300,,16293,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,107,D
2301,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,107,H
2302,,12469,,,,,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,107,H
2303,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,107,H
2304,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,107,H
2305,,16441,,,,,,,Expert,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,107,H
2306,,8,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,107,H
2307,,4176,,,,722.0,,,Autocuration,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,HEK293,107,H
2308,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,107,H
2309,,17200,,,,,,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,107,H
2310,,17200,,Homo sapiens,,,9606.0,,Expert,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,107,D
2311,,4013,,Homo sapiens,,449.0,9606.0,,Expert,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,CHO,107,D
2312,,5088,,,,,,,Autocuration,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,107,H
2313,,5088,,Homo sapiens,,,9606.0,,Expert,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,107,D
2314,,5088,,,,,,,Autocuration,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,107,H
2315,,5088,,Homo sapiens,,,9606.0,,Expert,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,107,D
2316,,5088,,,,,,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,107,H
2317,,5088,,,,,,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,107,H
2318,,9786,,,,,,,Autocuration,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,104686,H
2319,,9205,,Rattus norvegicus,,,10116.0,,Autocuration,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,104686,D
2320,,11257,,,,,,,Autocuration,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,104686,H
2321,,9362,,,,,,,Autocuration,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,104686,H
2322,,9362,,,,,,,Autocuration,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,104686,H
2323,,10590,,,,,,,Autocuration,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,104686,H
2324,,10468,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,104686,H
2325,,13050,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,104686,H
2326,,11624,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,104686,H
2327,,10468,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,104686,H
2328,,10330,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,104686,H
2329,,10062,,,,,,,Autocuration,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,104686,H
2330,,11642,,,,,,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,104686,H
2331,,10062,,,,,,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,104686,H
2332,,13427,,,,,,,Autocuration,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,104686,H
2333,,12280,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,104686,D
2334,,4101,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,104686,D
2335,,10062,,,,,,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,104686,H
2336,,11147,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,104686,H
2337,,2395,,Rattus norvegicus,,485.0,10116.0,,Autocuration,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,CHO-K1,104686,D
2338,,2395,,Rattus norvegicus,,485.0,10116.0,,Autocuration,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,CHO-K1,104686,D
2339,,9098,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,104686,D
2340,,9098,,,,,,,Autocuration,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,104686,H
2341,,9098,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,104686,D
2342,,9443,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,104686,H
2343,,9443,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,104686,H
2344,,9699,,,,,,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,104686,H
2345,,9699,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,104686,H
2346,,9098,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,104686,H
2347,,3070,,Rattus norvegicus,,,10116.0,,Autocuration,,Affinity for 5-hydroxytryptamine 2 receptor,B,,,104686,D
2348,,9547,,,,,,,Autocuration,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,104686,H
2349,,10444,,,,,,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,104686,H
2350,,14617,,,,,,,Autocuration,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,104686,H
2351,,14617,,,,,,,Autocuration,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,104686,H
2352,,11130,,,,,,,Autocuration,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,104686,H
2353,,11130,,,,,,,Autocuration,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,104686,H
2354,Brain,14542,955.0,,,,,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,104686,H
2355,,2797,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,104686,H
2356,,11332,,,,,,,Autocuration,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,104686,H
2357,,11332,,,,,,,Autocuration,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,104686,H
2358,Frontal cortex,10752,1870.0,,,,,,Autocuration,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,104686,H
2359,,1185,,,,,,,Autocuration,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,104686,H
2360,,1185,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,104686,H
2361,,11624,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,104686,D
2362,,1344,,,,,,,Autocuration,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,104686,H
2363,Striatum,15453,2435.0,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,104686,D
2364,,11662,,,,,,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,104686,H
2365,,11662,,,,,,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,104686,H
2366,,10796,,,,,,,Autocuration,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,104686,H
2367,,9069,,,,,,,Autocuration,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,104686,H
2368,,8814,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,104686,D
2369,,8908,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,104686,D
2370,,9098,,,,,,,Autocuration,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,104686,H
2371,,9098,,,,,,,Autocuration,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,104686,H
2372,,9098,,,,,,,Autocuration,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,104686,H
2373,,9098,,,,,,,Autocuration,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,104686,H
2374,,9098,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,104686,H
2375,,9098,,,,,,,Autocuration,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,104686,H
2376,,9098,,,,,,,Autocuration,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,104686,H
2377,,9161,,,,,,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,104686,H
2378,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,104686,H
2379,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,104686,H
2380,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,104686,H
2381,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,104686,H
2382,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,104686,H
2383,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,104686,H
2384,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,104686,H
2385,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,104686,H
2386,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,104686,H
2387,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,104686,H
2388,,9161,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,104686,H
2389,,12094,,,,,,,Autocuration,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,104686,H
2390,,12018,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,104686,H
2391,,10394,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,104686,H
2392,,15260,,,,,,,Autocuration,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,104686,H
2393,,11624,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,104686,D
2394,,13654,,,,,,,Autocuration,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,104686,H
2395,,9541,,,,,,,Autocuration,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,104686,H
2396,,11933,,,,,,,Autocuration,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,104686,H
2397,,15538,,,,,,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,104686,H
2398,,15538,,,,,,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,104686,H
2399,,15538,,,,,,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,104686,H
2400,,8841,,,,,,,Autocuration,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,104686,D
2401,,1455,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,104686,H
2402,,1455,,,,,,,Autocuration,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,104686,H
2403,,11752,,,,,,,Autocuration,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,104686,H
2404,Brain,11642,955.0,,,,,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,104686,H
2405,,12092,,,,,,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,104686,H
2406,,3967,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,104686,H
2407,,12771,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,104686,D
2408,,11642,,,,,,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,104686,H
2409,,11628,,,,,,,Autocuration,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,104686,H
2410,,13654,,,,,,,Autocuration,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,104686,H
2411,,11200,,,,,,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,104686,H
2412,,11200,,,,,,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,104686,H
2413,,11200,,,,,,,Autocuration,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,104686,H
2414,,11200,,,,,,,Autocuration,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,104686,H
2415,,11200,,,,,,,Autocuration,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,104686,H
2416,,11200,,,,,,,Autocuration,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,104686,H
2417,Brain,15436,955.0,,,,,,Expert,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,12687,H
2418,,15436,,Rattus norvegicus,,,10116.0,,Expert,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,12687,D
2419,,14025,,,,,,,Autocuration,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,12687,H
2420,,4342,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,12687,H
2421,,13735,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,12687,D
2422,,5816,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,12687,D
2423,,14287,,,,,,,Expert,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,12687,H
2424,,15738,,,,,,,Autocuration,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,12687,H
2425,,15738,,Rattus norvegicus,,,10116.0,,Expert,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,12687,D
2426,,15026,,,,,,,Autocuration,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,12687,H
2427,,16647,,,,,,,Expert,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,12687,H
2428,,16647,,,,,,,Autocuration,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,12687,H
2429,,13345,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,12687,D
2430,,1543,,,,,,Membranes,Autocuration,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,12687,H
2431,,12444,,,,,,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,12687,H
2432,,16404,,,,,,,Expert,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,12687,H
2433,,16404,,,,449.0,,,Autocuration,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,CHO,12687,H
2434,,15577,,,,,,,Expert,,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,12687,H
2435,,15577,,,,,,,Autocuration,,Serotonergic activity of the compound.,B,,,12687,H
2436,,2495,,,,,,,Autocuration,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,12687,H
2437,,15042,,Rattus norvegicus,,,10116.0,,Expert,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,12687,D
2438,,15026,,,,,,,Expert,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,12687,H
2439,,12919,,Rattus norvegicus,,,10116.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,12687,D
2440,,12919,,Rattus norvegicus,,,10116.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,12687,D
2441,,12919,,Rattus norvegicus,,,10116.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,12687,D
2442,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,12687,H
2443,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,12687,H
2444,,4820,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,107,H
2445,,6736,,,,,,,Autocuration,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,107,H
2446,,5163,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,107,H
2447,,5163,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,107,H
2448,,6011,,,,,,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,107,H
2449,,14294,,Homo sapiens,,,9606.0,,Expert,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,107,D
2450,,5014,,,,,,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,107,H
2451,,17066,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,107,H
2452,,17515,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,107,H
2453,,6736,,,,,,,Expert,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,107,H
2454,,5163,,,,,,,Expert,,Affinity for 5-hydroxytryptamine 2A receptor,B,,,107,H
2455,,16911,,,,723.0,,,Expert,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,NIH3T3,107,H
2456,,6841,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,107,H
2457,,6119,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,107,H
2458,,3962,,,,,,,Autocuration,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,107,H
2459,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,107,H
2460,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,107,H
2461,,3962,,,,,,,Autocuration,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,107,H
2462,,1633,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,107,H
2463,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,107,H
2464,,6576,,,,,,,Expert,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,107,H
2465,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,107,H
2466,,16946,,,,,,,Autocuration,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,107,H
2467,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,107,H
2468,,3032,,Mus musculus,,449.0,10090.0,,Expert,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,CHO,107,H
2469,,16655,,,,,,,Autocuration,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,107,H
2470,,13964,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,107,H
2471,,16989,,,,,,,Expert,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,107,H
2472,,16117,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,107,H
2473,,16700,,,,,,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,107,H
2474,,3269,,,,,,,Autocuration,,Affinity against 5-hydroxytryptamine 2A receptor,B,,,107,H
2475,,1274,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,107,D
2476,,1317,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,107,H
2477,,12146,,,,,,,Autocuration,,Tested against 5-hydroxytryptamine 2A receptor,B,,,107,H
2478,,12652,,,,,,,Autocuration,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,105075,H
2479,,12652,,,,,,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,105075,H
2480,,12652,,,,,,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,105075,H
2481,,12652,,,,,,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,105075,H
2482,,16647,,,,,,,Autocuration,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,107,H
2483,,15851,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,HEK293,227,D
2484,,6857,,Homo sapiens,,449.0,9606.0,,Expert,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,CHO,227,D
2485,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,227,H
2486,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,227,D
2487,,14093,,,,,,,Autocuration,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,227,H
2488,,13481,,,,,,,Autocuration,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,227,H
2489,,14093,,,,,,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,227,H
2490,,14093,,,,,,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,227,H
2491,,14093,,,,,,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,227,H
2492,,13481,,,,,,,Autocuration,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,227,H
2493,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,227,H
2494,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,227,H
2495,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,227,H
2496,,12369,,,,,,,Autocuration,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,107,H
2497,,12369,,,,,,,Expert,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,107,H
2498,,12369,,,,,,,Expert,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,107,H
2499,,14447,,,,,,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,107,H
2500,,14447,,,,,,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,107,H
2501,,17451,,,,723.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,107,H
2502,,6857,,,,449.0,,,Autocuration,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,107,H
2503,,6857,,Homo sapiens,,449.0,9606.0,,Expert,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,107,D
2504,,5635,,,,,,,Autocuration,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,104817,H
2505,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,107,H
2506,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,107,H
2507,,5105,,,,307.0,,,Autocuration,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,L929,107,H
2508,,5104,,,,307.0,,,Expert,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,L929,107,H
2509,,5105,,,,307.0,,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,L929,107,H
2510,,5105,,,,307.0,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,L929,107,H
2511,,5254,,,,,,,Autocuration,,Binding affinity against 5-HT2A receptor,B,,,107,H
2512,,5254,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,107,H
2513,,13267,,,,722.0,,,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,HEK293,107,H
2514,,13267,,,,722.0,,,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,HEK293,107,H
2515,,14157,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,HEK293,107,D
2516,,12936,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,107,D
2517,,14068,,,,,,,Expert,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,107,H
2518,,12936,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,107,D
2519,,12936,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,107,D
2520,,4540,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,HEK293,107,D
2521,,6166,,,,,,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,107,H
2522,,17296,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,107,H
2523,,17296,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,107,H
2524,,17296,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,107,H
2525,,15779,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,HEK293,107,D
2526,,14391,,,,722.0,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,HEK293,107,H
2527,,15851,,,,722.0,,,Expert,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,HEK293,107,H
2528,,15851,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,HEK293,107,D
2529,,3832,,,,722.0,,,Expert,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,HEK293,107,H
2530,,3833,,,,722.0,,,Expert,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,HEK293,107,H
2531,,12936,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,HEK293,107,D
2532,,17451,,,,723.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,NIH3T3,107,H
2533,,17451,,,,723.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,107,H
2534,,17451,,,,723.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,107,H
2535,,4199,,,,722.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,HEK293,107,H
2536,,1883,,,,485.0,,,Autocuration,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,CHO-K1,107,H
2537,,1883,,,,485.0,,,Expert,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,CHO-K1,107,H
2538,,14875,,Homo sapiens,,,9606.0,,Expert,,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,107,D
2539,,15146,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,HEK293,107,H
2540,,5213,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,HEK293,107,H
2541,,16404,,Homo sapiens,,449.0,9606.0,,Expert,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,CHO,107,D
2542,,14818,,,,722.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,HEK293,107,H
2543,,4829,,,,722.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,HEK293,107,H
2544,,12652,,,,723.0,,,Autocuration,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,NIH3T3,10620,H
2545,,4682,,,,723.0,,,Expert,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,NIH3T3,107,H
2546,,12652,,,,,,,Autocuration,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,10620,H
2547,,4921,,,,,,,Autocuration,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,10621,H
2548,,4921,,,,,,,Autocuration,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,10621,H
2549,,16312,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,107,H
2550,,14998,,Oryctolagus cuniculus,,,9986.0,,Expert,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,107,H
2551,,14025,,Oryctolagus cuniculus,,,9986.0,,Expert,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,107,H
2552,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,107,H
2553,,13047,,Oryctolagus cuniculus,,,9986.0,,Expert,,The compound was tested for binding affinity against 5-HT2A receptor,B,,,107,H
2554,,1883,,,,485.0,,,Autocuration,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,CHO-K1,10576,H
2555,,13463,,,,,,,Autocuration,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,12687,H
2556,,13463,,,,,,,Autocuration,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,12687,H
2557,Stomach,13463,945.0,,,,,,Autocuration,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,12687,H
2558,Stomach,13463,945.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,12687,D
2559,,13463,,,,,,,Autocuration,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,12687,H
2560,,16326,,,,723.0,,,Expert,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,NIH3T3,12687,H
2561,,14093,,,,,,,Autocuration,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,12687,H
2562,,14093,,,,,,,Autocuration,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,12687,H
2563,,15740,,,,,,,Autocuration,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2564,,16633,,,,,,,Autocuration,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,12687,H
2565,,17200,,Rattus norvegicus,,,10116.0,,Expert,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,12687,D
2566,,17133,,,,,,,Autocuration,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2567,,17133,,,,,,,Autocuration,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2568,,17133,,,,,,,Autocuration,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2569,,17200,,,,,,,Autocuration,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,12687,H
2570,,15363,,,,,,,Autocuration,,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,12687,H
2571,,17200,,,,,,,Autocuration,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,12687,H
2572,,17200,,Rattus norvegicus,,,10116.0,,Expert,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,12687,D
2573,,17200,,Rattus norvegicus,,,10116.0,,Expert,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,12687,D
2574,,17200,,Rattus norvegicus,,,10116.0,,Expert,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,12687,D
2575,,17200,,,,,,,Autocuration,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,12687,H
2576,,17211,,,,,,,Autocuration,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2577,,17331,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,12687,H
2578,,13565,,,,,,,Expert,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,12687,H
2579,,13730,,,,,,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,12687,H
2580,,12416,,,,,,,Expert,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,12687,H
2581,,15295,,,,,,,Autocuration,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,12687,H
2582,,1742,,,,,,,Autocuration,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,12687,H
2583,,15295,,,,,,,Autocuration,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,12687,H
2584,,14970,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,12687,H
2585,,16693,,,,,,,Expert,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,12687,H
2586,,14776,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,12687,D
2587,,14286,,,,,,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,12687,H
2588,,17200,,Rattus norvegicus,,,10116.0,,Expert,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,12687,D
2589,,15306,,,,,,,Expert,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,12687,H
2590,,14178,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,12687,D
2591,,14229,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,12687,D
2592,,12884,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,12687,H
2593,,13149,,,,,,,Expert,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,12687,H
2594,,15295,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,12687,D
2595,,15740,,,,,,,Autocuration,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,12687,H
2596,,15185,,,,,,,Autocuration,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,12687,H
2597,,15185,,,,,,,Autocuration,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,12687,H
2598,,17529,,,,,,,Expert,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,12687,H
2599,,14826,,,,,,,Autocuration,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,12687,H
2600,,17211,,,,,,,Expert,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,12687,H
2601,,14826,,,,,,,Autocuration,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,12687,H
2602,,14093,,,,,,,Autocuration,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,12687,H
2603,,14093,,,,,,,Autocuration,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,12687,H
2604,,13246,,,,723.0,,,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,NIH3T3,12687,H
2605,,13246,,,,,,,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,12687,H
2606,,15436,,Rattus norvegicus,,,10116.0,,Expert,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,12687,D
2607,,15436,,Rattus norvegicus,,,10116.0,,Expert,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,12687,D
2608,Brain,14442,955.0,,,,,,Autocuration,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,12687,H
2609,,12457,,,,,,,Expert,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,12687,H
2610,,12457,,,,723.0,,,Expert,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,NIH3T3,12687,H
2611,,14755,,,,,,,Autocuration,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,12687,H
2612,,4707,,,,,,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,12687,H
2613,,13297,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,12687,H
2614,,17331,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,12687,H
2615,,4664,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,12687,H
2616,,16633,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,12687,H
2617,,4664,,Rattus norvegicus,,723.0,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,NIH3T3,12687,D
2618,,16133,,,,,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,12687,H
2619,,16133,,,,,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,12687,H
2620,,14060,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,12687,D
2621,,16326,,,,,,,Expert,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,12687,H
2622,,16659,,,,449.0,,,Expert,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,CHO,12687,H
2623,,14776,,,,,,,Autocuration,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,12687,H
2624,,13481,,,,,,,Autocuration,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,12687,H
2625,,17386,,,,,,,Autocuration,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,12687,H
2626,,6611,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,12687,D
2627,,14423,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,12687,H
2628,,15412,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,12687,H
2629,,15412,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,12687,H
2630,,6238,,,,,,,Autocuration,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,12687,H
2631,,6648,,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,12687,H
2632,,5667,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,12687,H
2633,,6611,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,12687,D
2634,,13481,,,,,,,Autocuration,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,12687,H
2635,,13481,,,,,,,Autocuration,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,12687,H
2636,,15558,,,,723.0,,,Expert,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,NIH3T3,12687,H
2637,,6013,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,12687,H
2638,,16633,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,12687,H
2639,,6013,,,,,,,Autocuration,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,12687,H
2640,,6013,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,12687,D
2641,,6013,,,,,,,Autocuration,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,12687,H
2642,,6013,,,,,,,Expert,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,12687,H
2643,,6013,,,,,,,Autocuration,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,12687,H
2644,,6013,,,,,,,Autocuration,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,12687,H
2645,,16293,,,,,,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2646,,17175,,,,723.0,,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,NIH3T3,12687,H
2647,,13278,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,12687,D
2648,Caudate-putamen,3682,5383.0,,,,,,Autocuration,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,12687,H
2649,,2014,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,12687,H
2650,,2014,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,12687,H
2651,,4932,,,,,,,Autocuration,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,12687,H
2652,,4932,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,12687,H
2653,,3935,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2654,Hippocampus,5432,10000000.0,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,12687,D
2655,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2656,,13672,,,,,,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,12687,H
2657,,13672,,,,,,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,12687,H
2658,,14749,,,,723.0,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,NIH3T3,12687,H
2659,,13462,,,,,,,Autocuration,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,12687,H
2660,,15740,,,,,,,Autocuration,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,12687,H
2661,,16647,,,,,,,Expert,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,12687,H
2662,Brain,13345,955.0,,,,,,Autocuration,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,12687,H
2663,,16740,,,,,,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,12687,H
2664,,16740,,,,,,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,12687,H
2665,,15535,,Rattus norvegicus,,,10116.0,,Expert,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,12687,D
2666,,16740,,,,,,,Expert,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,12687,H
2667,,16740,,,,,,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,12687,H
2668,,16740,,,,,,,Autocuration,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,12687,H
2669,,4795,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,12687,D
2670,,8,,,,,,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,12687,H
2671,,8,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,12687,H
2672,,17200,,Rattus norvegicus,,,10116.0,,Expert,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,12687,D
2673,,2148,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,12687,D
2674,,13345,,Rattus norvegicus,,,10116.0,,Expert,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,105102,D
2675,,5088,,,,,,,Autocuration,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,12687,H
2676,,5088,,,,,,,Autocuration,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,12687,H
2677,,17133,,,,,,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,12687,H
2678,,17133,,Rattus norvegicus,,,10116.0,,Expert,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,12687,D
2679,,16532,,,,,,,Autocuration,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,12687,H
2680,,15086,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,12687,H
2681,,2309,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,12687,D
2682,,12953,,,,,,,Expert,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,12687,H
2683,,12953,,,,,,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,12687,H
2684,,12953,,,,,,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,12687,H
2685,,16659,,,,449.0,,,Autocuration,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,CHO,12687,H
2686,,16740,,,,,,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,12687,H
2687,,16740,,,,,,,Autocuration,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,12687,H
2688,,17133,,,,,,,Autocuration,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,12687,H
2689,,17211,,,,,,,Autocuration,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,12687,H
2690,,17331,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,12687,H
2691,,16633,,,,,,,Autocuration,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,12687,H
2692,,16633,,,,,,,Autocuration,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,12687,H
2693,,16633,,,,,,,Autocuration,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,12687,H
2694,,15026,,,,,,,Expert,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,12687,H
2695,,15026,,,,,,,Expert,,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,12687,H
2696,,16404,,,,,,,Expert,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,105093,H
2697,,16404,,,,,,,Expert,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,105093,H
2698,,16404,,,,,,,Expert,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,105075,H
2699,,16404,,,,,,,Autocuration,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,12687,H
2700,,16326,,,,,,,Expert,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,12687,H
2701,,15847,,,,,,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,12687,H
2702,,15847,,,,,,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,12687,H
2703,,15329,,,,,,,Autocuration,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,12687,H
2704,Thoracic aorta,16404,1515.0,,,,,,Expert,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,12687,H
2705,Thoracic aorta,16404,1515.0,,,,,,Expert,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,12687,H
2706,Thoracic aorta,16404,1515.0,,,,,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,12687,H
2707,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,12687,H
2708,,12861,,,,,,,Expert,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,12687,H
2709,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,12687,H
2710,,12490,,,,,,,Expert,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,12687,H
2711,,12827,,,,339.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,N1E-115,12687,H
2712,,12827,,,,339.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,N1E-115,12687,H
2713,,12918,,,,,,,Autocuration,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,12687,H
2714,,12919,,Rattus norvegicus,,,10116.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,12687,D
2715,,17723,,,,,,,Autocuration,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,108,H
2716,,6013,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,108,H
2717,,16293,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,108,H
2718,,3857,,,,,,,Expert,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,108,H
2719,,3857,,,,,,,Expert,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,108,H
2720,,3857,,,,,,,Expert,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,108,H
2721,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,108,H
2722,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,108,H
2723,,16441,,,,,,,Expert,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,108,H
2724,,16441,,,,,,,Expert,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,108,H
2725,,4176,,,,722.0,,,Autocuration,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,HEK293,108,H
2726,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,108,H
2727,,17200,,Homo sapiens,,,9606.0,,Expert,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,108,D
2728,,5088,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,108,H
2729,,5088,,,,,,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,108,H
2730,,5088,,,,,,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,108,H
2731,,5088,,,,,,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,108,H
2732,,16659,,,,449.0,,,Autocuration,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,CHO,108,H
2733,,16659,,,,449.0,,,Autocuration,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,CHO,108,H
2734,,17451,,,,723.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,NIH3T3,108,H
2735,,6857,,Homo sapiens,,449.0,9606.0,,Expert,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,108,D
2736,,3857,,,,,,,Expert,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,108,H
2737,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,108,H
2738,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,108,H
2739,,5104,,,,449.0,,,Expert,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,CHO,108,H
2740,,5105,,,,449.0,,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,CHO,108,H
2741,,5105,,,,449.0,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,CHO,108,H
2742,,5254,,,,,,,Autocuration,,Binding affinity against 5-HT2C receptor,B,,,108,H
2743,,13267,,,,722.0,,,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,HEK293,108,H
2744,,14157,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,HEK293,108,D
2745,,12936,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,HEK293,108,D
2746,,14068,,,,,,,Expert,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,108,H
2747,,12936,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,HEK293,108,D
2748,,4540,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,HEK293,108,D
2749,,4540,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,HEK293,108,D
2750,,6166,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,108,H
2751,,17296,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,HEK293,108,H
2752,,17296,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,HEK293,108,H
2753,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,108,H
2754,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,108,H
2755,,14391,,,,722.0,,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,HEK293,108,H
2756,,15779,,,,722.0,,,Autocuration,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,HEK293,108,H
2757,,15851,,,,722.0,,,Expert,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,HEK293,108,H
2758,,15851,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,HEK293,108,D
2759,,15779,,,,722.0,,,Autocuration,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,HEK293,108,H
2760,,3832,,,,722.0,,,Expert,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,HEK293,108,H
2761,,3833,,,,722.0,,,Expert,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,HEK293,108,H
2762,,17451,,,,723.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,NIH3T3,108,H
2763,,4199,,,,722.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,HEK293,108,H
2764,,1883,,,,485.0,,,Expert,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,CHO-K1,108,H
2765,,4321,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,108,D
2766,,14875,,,,,,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,108,H
2767,,15146,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,HEK293,108,H
2768,,5213,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,HEK293,108,H
2769,,16404,,,,308.0,,,Autocuration,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,HeLa,108,H
2770,,13267,,,,,,,Autocuration,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,108,H
2771,Hippocampus,13267,10000000.0,,,,,,Autocuration,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,108,H
2772,,14818,,,,722.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,HEK293,108,H
2773,,4829,,,,722.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,HEK293,108,H
2774,,13463,,,,,,,Autocuration,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,11864,H
2775,Stomach,13463,945.0,,,,,,Autocuration,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,11864,H
2776,Stomach,13463,945.0,,,,,,Autocuration,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,11864,H
2777,,12652,,,,625.0,,,Autocuration,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,A9,11864,H
2778,,4682,,,,723.0,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,NIH3T3,11864,H
2779,,4682,,,,723.0,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,NIH3T3,11864,H
2780,,4682,,,,723.0,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,NIH3T3,11864,H
2781,,12652,,,,,,,Autocuration,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,11864,H
2782,Stomach,13463,945.0,Mus musculus,,,10090.0,,Autocuration,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,12689,H
2783,Stomach,13463,945.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,12689,D
2784,,13969,,,,,,,Expert,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,108,H
2785,,13392,,Sus scrofa,,,9823.0,,Expert,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,108,H
2786,,13392,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,108,H
2787,,14430,,,,,,,Expert,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,108,H
2788,,1742,,,,,,,Autocuration,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,108,H
2789,,14286,,,,,,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,108,H
2790,,5619,,,,,,,Autocuration,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,108,H
2791,,15086,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,108,H
2792,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,108,H
2793,,12861,,,,,,,Expert,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,108,H
2794,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,108,H
2795,,12827,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,108,H
2796,,12827,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,108,H
2797,,12919,,Sus scrofa,,,9823.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,108,H
2798,,12919,,Sus scrofa,,,9823.0,,Expert,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,108,H
2799,,16429,,Sus scrofa,,,9823.0,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,108,H
2800,,773,,Sus scrofa,,,9823.0,,Autocuration,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,108,H
2801,,5033,,Sus scrofa,,,9823.0,,Autocuration,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,108,H
2802,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,12687,H
2803,,14093,,,,,,,Autocuration,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,12689,H
2804,,14970,,,,,,,Expert,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,12689,H
2805,,14970,,,,,,,Autocuration,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,12689,H
2806,,14970,,,,,,,Autocuration,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,12689,H
2807,,14178,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,12689,D
2808,,14178,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,12689,D
2809,,14229,,Rattus norvegicus,,,10116.0,Brain membranes,Expert,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,12689,D
2810,,16532,,,,,,,Autocuration,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,12689,H
2811,,14826,,,,,,,Autocuration,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,12689,H
2812,,17211,,,,,,,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,12689,H
2813,,17211,,,,,,,Expert,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,12689,H
2814,,13246,,,,723.0,,,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,NIH3T3,12689,H
2815,,13246,,,,,,,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,12689,H
2816,,12457,,,,,,,Expert,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,12689,H
2817,,12457,,,,723.0,,,Expert,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,NIH3T3,12689,H
2818,,4707,,,,,,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,12689,H
2819,,13297,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,12689,H
2820,,16633,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,12689,H
2821,,16133,,,,,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,12689,H
2822,,16326,,,,,,,Expert,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,12689,H
2823,,14423,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,12689,H
2824,,15412,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,12689,H
2825,,15412,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,12689,H
2826,,15558,,,,625.0,,,Expert,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,A9,12689,H
2827,,16633,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,12689,H
2828,,6013,,,,,,,Expert,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,12689,H
2829,,17175,,,,,,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,12689,H
2830,,12469,,,,,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,12689,H
2831,Caudate-putamen,3682,5383.0,,,,,,Autocuration,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,12689,H
2832,,4932,,,,,,,Autocuration,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,12689,H
2833,,4932,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,12689,H
2834,,3935,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,12689,H
2835,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,12689,H
2836,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,12689,H
2837,,14749,,,,,,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,12689,H
2838,,15740,,,,,,,Autocuration,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,12689,H
2839,,17133,,Rattus norvegicus,,,10116.0,,Expert,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,12689,D
2840,,16532,,,,,,,Autocuration,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,12689,H
2841,,12369,,,,,,,Autocuration,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,12689,H
2842,,12369,,,,,,,Expert,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,12689,H
2843,,2309,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,12689,D
2844,,12953,,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,12689,H
2845,,12953,,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,12689,H
2846,,12953,,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,12689,H
2847,,12953,,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,12689,H
2848,,17133,,,,,,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,12689,H
2849,,17211,,,,,,,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,12689,H
2850,,17211,,,,,,,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,12689,H
2851,,14025,,,,,,,Autocuration,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,12689,H
2852,,14998,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,12689,H
2853,,4342,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,12689,H
2854,,13735,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,12689,D
2855,,13181,,,,,,,Autocuration,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,12689,H
2856,,1883,,,,485.0,,,Autocuration,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,CHO-K1,12689,H
2857,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,12689,H
2858,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,12689,H
2859,,14579,,,,,,,Autocuration,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,12689,H
2860,,4639,,,,,,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,108,H
2861,,4820,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,108,H
2862,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,227,H
2863,,14755,,,,,,,Autocuration,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,227,H
2864,,14744,,,,,,,Autocuration,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,227,H
2865,,6857,,Homo sapiens,,,9606.0,,Expert,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,227,D
2866,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,227,H
2867,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,227,H
2868,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,227,H
2869,,15363,,,,,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,227,H
2870,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,227,H
2871,,17200,,Homo sapiens,,,9606.0,,Expert,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,227,D
2872,,15851,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,HEK293,227,D
2873,,15851,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,HEK293,227,D
2874,,6857,,Homo sapiens,,449.0,9606.0,,Expert,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,227,D
2875,,6857,,Homo sapiens,,449.0,9606.0,,Expert,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,CHO,227,D
2876,,15779,,,,722.0,,,Autocuration,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,HEK293,227,H
2877,,15851,,,,722.0,,,Expert,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,HEK293,227,H
2878,,15779,,,,722.0,,,Autocuration,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,HEK293,227,H
2879,,14157,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,HEK293,227,D
2880,,4540,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,HEK293,227,D
2881,,6166,,,,,,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,227,H
2882,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,HEK293,227,H
2883,,14391,,,,722.0,,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,HEK293,227,H
2884,,3832,,,,722.0,,,Expert,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,HEK293,227,H
2885,,3833,,,,722.0,,,Expert,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,HEK293,227,H
2886,,15851,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,HEK293,227,D
2887,,15851,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,HEK293,227,D
2888,,4199,,,,722.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,HEK293,227,H
2889,,1883,,,,485.0,,,Expert,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,CHO-K1,227,H
2890,,4321,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,227,H
2891,,15146,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,HEK293,227,H
2892,,5213,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,HEK293,227,H
2893,,14818,,,,722.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,HEK293,227,H
2894,,4829,,,,722.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,HEK293,227,H
2895,,4829,,,,722.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,HEK293,227,H
2896,,14025,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,227,H
2897,Stomach,13463,945.0,,,,,,Expert,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,12688,H
2898,Stomach,7259,945.0,,,,,,Expert,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,12688,H
2899,Stomach,7259,945.0,,,,,,Autocuration,,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,12688,H
2900,Stomach,7185,945.0,Rattus norvegicus,,,10116.0,,Expert,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,12688,D
2901,,7185,,Rattus norvegicus,,,10116.0,,Expert,,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,12688,D
2902,Stomach,13267,945.0,,,,,,Autocuration,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,12688,H
2903,Stomach,13735,945.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,12688,D
2904,,15738,,,,,,,Autocuration,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,12688,H
2905,,15738,,,,,,,Autocuration,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,12688,H
2906,,15738,,,,,,,Autocuration,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,12688,H
2907,Stomach,12936,945.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,12688,D
2908,Stomach,12936,945.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,12688,D
2909,Stomach,12936,945.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,12688,D
2910,Stomach,12936,945.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,12688,D
2911,Stomach,16404,945.0,,,,,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,12688,H
2912,Stomach,16404,945.0,,,,,,Expert,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,12688,H
2913,Stomach,16404,945.0,,,,,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,12688,H
2914,Stomach,16404,945.0,,,,,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,12688,H
2915,Stomach,16404,945.0,Rattus norvegicus,,,10116.0,,Expert,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,12688,D
2916,Thoracic aorta,16404,1515.0,,,,,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,12688,H
2917,,7483,,,,,,,Autocuration,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,12688,H
2918,,7483,,,,,,,Expert,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,12688,H
2919,,7483,,,,,,,Autocuration,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,12688,H
2920,,7483,,,,,,,Autocuration,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,12688,H
2922,Stomach,16404,945.0,Rattus norvegicus,,,10116.0,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,12688,D
2923,,6347,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,227,H
2924,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,227,H
2925,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,227,H
2926,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,227,H
2927,,16946,,,,,,,Autocuration,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,227,H
2928,,16633,,,,,,,Autocuration,,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,227,H
2929,,16633,,,,,,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,227,H
2930,,16633,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,227,H
2931,,15026,,,,,,,Expert,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,108,H
2932,,15738,,Bos taurus,,,9913.0,,Autocuration,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,108,H
2933,,15738,,Bos taurus,,,9913.0,,Autocuration,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,108,H
2934,,15738,,Bos taurus,,,9913.0,,Autocuration,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,108,H
2935,,15738,,Bos taurus,,,9913.0,,Autocuration,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,108,H
2936,,16404,,Bos taurus,,,9913.0,,Expert,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,108,H
2937,,15026,,Bos taurus,,,9913.0,,Expert,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,108,H
2938,,15738,,Bos taurus,,,9913.0,,Autocuration,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,108,H
2939,,16312,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,108,H
2940,Striatum,5486,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,20033,D
2941,,5254,,,,,,,Autocuration,,Binding affinity against 5-HT1A receptor,B,,,51,H
2942,,3857,,,,449.0,,,Expert,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,CHO,108,H
2943,,6857,,Homo sapiens,,449.0,9606.0,,Expert,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,CHO,108,D
2944,,4176,,,,,,,Autocuration,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,108,H
2945,,6347,,,,449.0,,,Autocuration,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,CHO,108,H
2946,,6347,,,,449.0,,,Autocuration,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,CHO,108,H
2947,,16146,,Homo sapiens,,,9606.0,,Expert,,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,108,D
2948,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,108,H
2949,,3857,,,,,,,Autocuration,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,108,H
2950,,5635,,,,,,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,108,H
2951,,5635,,,,,,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,108,H
2952,,5635,,,,,,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,108,H
2953,,4012,,,,449.0,,,Expert,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,CHO,108,H
2954,,6366,,,,449.0,,,Expert,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,CHO,108,H
2955,,15949,,,,449.0,,,Expert,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,CHO,108,H
2956,,17211,,,,449.0,,,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,CHO,108,H
2957,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,108,D
2958,,14093,,,,,,,Autocuration,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,108,H
2959,,13481,,,,,,,Autocuration,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,108,H
2960,,6347,,Rattus norvegicus,,449.0,10116.0,,Expert,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,CHO,108,H
2961,,14093,,,,,,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,108,H
2962,,14093,,,,,,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,108,H
2963,,13481,,,,,,,Autocuration,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,108,H
2964,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,108,H
2965,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,108,H
2966,,14442,,,,,,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,108,H
2967,,14755,,,,,,,Autocuration,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,108,H
2968,,14744,,,,,,,Autocuration,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,108,H
2969,,16659,,,,449.0,,,Expert,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,CHO,108,H
2970,,6857,,Homo sapiens,,,9606.0,,Expert,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,108,D
2971,,5635,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,108,H
2972,,4234,,Homo sapiens,,,9606.0,,Expert,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,108,D
2973,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,108,H
2974,,5778,,Rattus norvegicus,,,10116.0,Membranes,Autocuration,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,104698,D
2975,,5094,,,,,,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,104698,H
2976,,809,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,104698,D
2977,,1578,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,104698,H
2978,,809,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,104698,H
2979,,12469,,,,,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,104698,H
2980,,14290,,,,,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,104698,H
2981,,14290,,,,,,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,104698,H
2982,,10609,,,,,,,Autocuration,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,104698,H
2983,,10609,,,,,,,Autocuration,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,104698,H
2984,,10609,,,,,,,Autocuration,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,104698,H
2985,,15253,,,,,,,Autocuration,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,104698,H
2986,,15253,,,,,,,Autocuration,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,104698,H
2987,,11683,,,,,,Membranes,Autocuration,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,104698,H
2988,,12092,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,104698,H
2989,,1946,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,104698,H
2990,,11623,,,,,,,Autocuration,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,104698,H
2991,,11623,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,104698,H
2992,,14788,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,104698,H
2993,,5432,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,104698,D
2994,,14826,,,,,,,Autocuration,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,104698,H
2995,,2222,,,,,,,Autocuration,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,104698,H
2996,,11963,,,,,,,Autocuration,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,104698,H
2997,,14145,,,,,,,Autocuration,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,104698,H
2998,,17819,,,,,,,Autocuration,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,104698,H
2999,,10394,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,104698,H
3000,,10394,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,104698,H
3001,,15034,,,,,,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,104698,H
3002,,691,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,104698,H
3003,,12092,,,,,,Membranes,Autocuration,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,104698,H
3004,,11752,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,104698,D
3005,Brain,11752,955.0,,,,,,Autocuration,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,104698,H
3006,,301,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,104698,H
3007,,16532,,,,,,,Autocuration,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,104698,H
3008,,16532,,,,,,,Autocuration,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,104698,H
3009,,12092,,,,,,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,104698,H
3010,,11684,,,,,,,Autocuration,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,104698,H
3011,,11684,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,104698,H
3012,,12953,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,104698,H
3013,,12953,,,,,,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,104698,H
3014,,12953,,,,,,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,104698,H
3015,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,104698,H
3016,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3017,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,104698,H
3018,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3019,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3020,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3021,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,104698,H
3022,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3023,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3024,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3025,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3026,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,104698,H
3027,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3028,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3029,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3030,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3031,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,104698,H
3032,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,104698,H
3033,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,104698,H
3034,,10609,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,104698,H
3035,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,104698,H
3036,,12861,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,104698,D
3037,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,104698,H
3038,,10728,,,,,,Brain membranes,Autocuration,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,104698,H
3039,,10728,,,,,,Brain membranes,Autocuration,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,104698,H
3040,,5163,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,108,H
3041,,5163,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,108,H
3042,,6011,,,,,,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,108,H
3043,,5014,,,,,,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,108,H
3044,,5635,,,,,,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,108,H
3045,,5163,,,,,,,Expert,,Affinity for 5-hydroxytryptamine 2C receptor,B,,,108,H
3046,,6841,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,108,H
3047,,6119,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,108,H
3048,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,108,H
3049,,1633,,,,,,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,108,H
3050,,1633,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,108,H
3051,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,108,H
3052,,6576,,,,,,,Expert,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,108,H
3053,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,108,H
3054,,12146,,,,,,,Autocuration,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,108,H
3055,,12146,,,,,,,Autocuration,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,108,H
3056,,16946,,,,,,,Autocuration,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,108,H
3057,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,108,H
3058,,16700,,,,,,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,108,H
3059,,3269,,,,,,,Autocuration,,Affinity against 5-hydroxytryptamine 2C receptor,B,,,108,H
3060,,1274,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,108,D
3061,,1317,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,108,H
3062,,5834,,Bos taurus,,,9913.0,,Autocuration,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,144,H
3063,,11147,,Bos taurus,,,9913.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,144,H
3064,,14145,,Cavia porcellus,,,10141.0,,Expert,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,104714,H
3065,Ileum,10561,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,104714,H
3066,,15847,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,104714,H
3067,,15847,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,104714,H
3068,Ileum,10561,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,104714,H
3069,Ileum,11454,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,104714,H
3070,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,104714,H
3071,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,104714,H
3072,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,104714,H
3073,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,104714,H
3074,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,104714,H
3075,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,104714,H
3076,Ileum,15253,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,104714,H
3077,Ileum,15253,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,104714,H
3078,Ileum,11963,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,104714,H
3079,Ileum,1946,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,104714,H
3080,Ileum,1946,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,104714,H
3081,,12045,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,104714,H
3082,Ileum,1559,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,104714,H
3083,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,104714,H
3084,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,104714,H
3085,Ileum,188,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,104714,H
3086,Ileum,12919,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,104714,H
3087,Ileum,12918,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,104714,H
3088,Ileum,1559,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,104714,H
3089,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,104714,H
3090,Ileum,1559,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,104714,H
3091,Ileum,1559,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,104714,H
3092,Ileum,1559,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,104714,H
3093,Ileum,14424,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,104714,H
3094,,13181,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,22226,U
3095,,5486,,,,,,,Autocuration,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,51,H
3096,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,104714,D
3097,,6013,,,,,,,Autocuration,,Binding affinity towards 5-HT3 receptor,B,,,104714,H
3098,,12861,,,,,,,Autocuration,,Binding activity radioligand.,B,,,104714,H
3099,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,104714,H
3100,,5104,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,104714,H
3101,,5105,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,104714,H
3102,,5104,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,104714,H
3103,,3935,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,22226,U
3104,,13657,,,,433.0,,,Expert,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,NG108-15,105030,H
3105,,10369,,,,,,,Autocuration,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,105030,H
3106,,10369,,,,,,,Autocuration,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,105030,H
3107,,12918,,,,,,,Autocuration,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,105030,H
3108,,12918,,,,,,,Autocuration,,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,105030,H
3109,,10369,,,,,,,Autocuration,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,105030,H
3110,,773,,,,,,,Autocuration,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,105030,H
3111,,12918,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,105030,H
3112,,10561,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,105030,H
3113,,12827,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,105030,H
3114,,12827,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,105030,H
3115,,12918,,,,,,,Autocuration,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,105030,H
3116,,273,,,,,,,Autocuration,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,105030,H
3117,,273,,,,,,,Autocuration,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,105030,H
3118,,10561,,,,,,,Autocuration,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,105030,H
3119,,5033,,,,,,,Autocuration,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,105030,H
3120,,16429,,,,339.0,,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,N1E-115,105030,H
3121,,10322,,,,,,,Autocuration,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,11765,H
3122,,14331,,,,,,,Autocuration,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,11765,H
3123,,13462,,Mus musculus,,,10090.0,,Autocuration,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,10630,D
3124,,12861,,,,,,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,17106,H
3125,,15086,,Sus scrofa,,,9823.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,144,H
3126,,12861,,Sus scrofa,,,9823.0,,Autocuration,,Binding activity radioligand.,B,,,144,H
3127,,10561,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,104714,H
3128,,10561,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,104714,H
3129,,10561,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,104714,H
3130,,10561,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,104714,H
3131,,273,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,104714,H
3132,,273,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,104714,H
3133,Ileum,273,2116.0,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,104714,H
3134,,273,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,104714,H
3135,,273,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,104714,H
3136,,273,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,104714,H
3137,,273,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,104714,H
3138,,13047,,Oryctolagus cuniculus,,449.0,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,CHO,104714,H
3139,,1650,,Rattus norvegicus,,,10116.0,,Autocuration,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,104698,D
3140,,16288,,,,,,,Autocuration,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,12020,H
3141,,16288,,,,,,,Autocuration,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,12020,H
3142,,10254,,Rattus norvegicus,,,10116.0,,Autocuration,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,104698,D
3143,,14532,,,,,,,Autocuration,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,104698,H
3144,Heart,13392,948.0,,,,,,Autocuration,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,104698,H
3145,Heart,13392,948.0,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,104698,H
3146,Heart,13392,948.0,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,104698,H
3147,Heart,13392,948.0,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,104698,H
3148,Heart,13392,948.0,,,,,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,104698,H
3149,,13392,,,,,,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,104698,H
3150,,13392,,,,,,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,104698,H
3151,,13392,,,,,,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,104698,H
3152,,13392,,,,,,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,104698,H
3153,,1089,,Rattus norvegicus,,,10116.0,,Autocuration,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,104698,D
3154,,1089,,,,,,,Autocuration,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,104698,H
3155,,11454,,Rattus norvegicus,,,10116.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,D
3156,,11454,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,104698,D
3157,,12205,,Rattus norvegicus,,,10116.0,,Autocuration,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,104698,D
3158,,1089,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,104698,D
3159,,5094,,,,,,,Autocuration,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,104698,H
3160,,2622,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,104698,D
3161,,245,,,,,,,Autocuration,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,104698,H
3162,,14788,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,104698,H
3163,,14788,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,104698,H
3164,,3020,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,104698,H
3165,,1742,,,,,,,Autocuration,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,104698,H
3166,Brain,17394,955.0,,,,,,Autocuration,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,104698,H
3167,Brain,17394,955.0,,,,,,Autocuration,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,104698,H
3168,,17394,,,,,,,Autocuration,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,104698,H
3169,,14286,,,,,,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,104698,H
3170,,14178,,,,,,,Autocuration,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,104698,H
3171,,14178,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,104698,D
3172,,14178,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,104698,D
3173,,14178,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,104698,D
3174,,15034,,,,,,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,104698,H
3175,,1089,,,,,,Membranes,Autocuration,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,104698,H
3176,,1089,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,104698,D
3177,,16532,,,,,,,Autocuration,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,104698,H
3178,,12801,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,104698,D
3179,,15194,,,,433.0,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,NG108-15,104698,H
3180,,15194,,,,433.0,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,NG108-15,104698,H
3181,,15194,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,104698,H
3182,,15194,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,104698,H
3183,,15194,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,104698,H
3184,,15194,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,104698,H
3185,,10610,,,,,,,Autocuration,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,104698,H
3186,,10355,,Rattus norvegicus,,,10116.0,,Autocuration,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,104698,D
3187,,691,,,,,,,Autocuration,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,104698,H
3188,,10611,,,,,,,Autocuration,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,104698,H
3189,,12801,,,,,,,Autocuration,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,104698,H
3190,,10609,,,,,,,Autocuration,,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,104698,H
3191,,11454,,,,,,,Autocuration,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3192,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3193,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,104698,H
3194,,11454,,Rattus norvegicus,,,10116.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,D
3195,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3196,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,104698,H
3197,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3198,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3199,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3200,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3201,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3202,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3203,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3204,,11454,,,,,,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3205,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3206,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3207,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3208,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,104698,H
3209,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,104698,H
3210,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,104698,H
3211,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,104698,H
3212,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,104698,H
3213,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3214,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3215,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3216,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3217,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3218,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3219,,11454,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,104698,H
3220,,670,,,,,,,Autocuration,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,104698,H
3221,,670,,,,,,,Autocuration,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,104698,H
3222,,10321,,,,,,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,104698,H
3223,,10321,,,,,,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,104698,H
3224,,10321,,,,,,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,104698,H
3225,,10321,,,,,,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,104698,H
3226,,10321,,,,,,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,104698,H
3227,,10322,,,,,,,Autocuration,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,104698,H
3228,,15412,,,,,,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,104698,H
3229,,15412,,,,,,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,104698,H
3230,,15412,,Rattus norvegicus,,,10116.0,,Autocuration,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,104698,D
3231,,15412,,,,,,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,104698,H
3232,Hippocampus,15412,10000000.0,,,,,,Intermediate,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,104698,D
3233,,15412,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,104698,D
3234,,17394,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,104698,D
3235,,12457,,,,,,,Autocuration,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,104698,H
3236,,12457,,,,,,,Autocuration,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,104698,H
3237,,12205,,,,,,,Autocuration,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,104698,H
3238,,14532,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,104698,H
3239,,1122,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,104698,H
3240,,5094,,,,,,,Autocuration,,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,104698,H
3241,Ileum,809,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,20033,D
3242,Ileum,809,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,20033,D
3243,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,20033,D
3244,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,20033,D
3245,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,20033,D
3246,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,20033,D
3247,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,20033,D
3248,Ileum,13961,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,20033,D
3249,Ileum,13961,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,20033,D
3250,Ileum,809,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,20033,D
3251,Ileum,809,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,20033,D
3252,Ileum,809,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,20033,D
3253,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,20033,D
3254,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,20033,D
3255,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,20033,D
3256,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,20033,D
3257,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,20033,D
3258,Ileum,14290,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,20033,D
3259,,15034,,Cavia porcellus,,,10141.0,,Intermediate,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,20033,D
3260,Striatum,5094,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,20033,D
3261,Striatum,5094,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,20033,D
3262,Striatum,5399,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,20033,D
3263,Striatum,17394,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,20033,D
3264,Striatum,17394,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,20033,D
3265,Striatum,17394,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,20033,D
3266,Ileum,13961,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,20033,D
3267,Ileum,13961,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,20033,D
3268,Ileum,13961,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,20033,D
3269,,16946,,Cavia porcellus,,,10141.0,,Intermediate,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,20033,D
3270,,16946,,Cavia porcellus,,,10141.0,,Intermediate,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,20033,D
3271,,15034,,Cavia porcellus,,,10141.0,,Intermediate,,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,20033,D
3272,,15034,,Cavia porcellus,,,10141.0,,Intermediate,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,20033,D
3273,,12918,,Cavia porcellus,,,10141.0,,Intermediate,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,20033,D
3274,,16946,,Cavia porcellus,,,10141.0,,Intermediate,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,20033,D
3275,Striatum,17394,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,20033,D
3276,Striatum,15034,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,20033,D
3277,Striatum,5094,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,20033,D
3278,Striatum,5094,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,20033,D
3279,Ileum,17358,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,20033,D
3280,,12953,,Cavia porcellus,,,10141.0,,Expert,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,20033,D
3281,,12953,,Cavia porcellus,,,10141.0,,Intermediate,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,20033,D
3282,,12953,,Cavia porcellus,,,10141.0,,Intermediate,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,20033,D
3283,,12953,,Cavia porcellus,,,10141.0,,Intermediate,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,20033,D
3284,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,20033,D
3285,Ileum,12918,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,20033,D
3286,Ileum,12919,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,20033,D
3287,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,20033,D
3288,Ileum,273,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,20033,D
3289,,13181,,Cavia porcellus,,,10141.0,,Intermediate,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,20033,D
3290,,13181,,Cavia porcellus,,,10141.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,168,H
3291,,15034,,Cavia porcellus,,,10141.0,,Intermediate,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,20033,D
3292,,5033,,Cavia porcellus,,,10141.0,,Intermediate,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,20033,D
3293,,1980,,Cavia porcellus,,,10141.0,,Intermediate,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,20033,D
3294,,13181,,Cavia porcellus,,722.0,10141.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,HEK293,168,H
3295,,14287,,Cavia porcellus,,,10141.0,,Intermediate,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,20033,D
3296,,1317,,Cavia porcellus,,,10141.0,,Intermediate,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,20033,D
3297,,15316,,Cavia porcellus,,,10141.0,,Intermediate,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,20033,D
3298,Striatum,16429,2435.0,Cavia porcellus,,,10141.0,,Intermediate,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,20033,D
3299,Hippocampus,14818,10000000.0,Cavia porcellus,,,10141.0,,Intermediate,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,20033,D
3300,,15194,,Cavia porcellus,,,10141.0,,Intermediate,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,20033,D
3301,,15194,,Cavia porcellus,,,10141.0,,Intermediate,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,20033,D
3302,Ileum,13961,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,20033,D
3303,,5486,,,,,,,Autocuration,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,108,H
3304,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,168,H
3305,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,168,H
3306,,4199,,,,308.0,,,Autocuration,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,HeLa,168,H
3307,,15146,,,,,,,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,168,H
3308,,5213,,,,,,,Autocuration,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,168,H
3309,,4829,,,,308.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,HeLa,168,H
3310,,17358,,,,,,,Autocuration,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,10622,H
3311,,17358,,,,,,,Autocuration,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,10622,H
3312,,16946,,,,,,,Autocuration,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,10622,H
3313,,17358,,,,,,,Autocuration,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,10622,H
3314,Cardiac atrium,268,2081.0,,,,,,Autocuration,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,11249,H
3315,Cardiac atrium,268,2081.0,,,,,,Autocuration,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,11249,H
3316,,15086,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,11249,H
3317,Hippocampus,14875,10000000.0,,,,,,Autocuration,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,11249,H
3318,Hippocampus,13267,10000000.0,Sus scrofa,,,9823.0,,Autocuration,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,168,H
3319,,13047,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,168,H
3320,,1650,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,10623,D
3321,,567,,,,,,,Autocuration,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,10623,H
3322,,17358,,,,,,,Autocuration,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,10623,H
3323,,188,,,,,,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,10623,H
3324,,670,,,,,,,Autocuration,,lntrinsic activity relative to 5-HT receptor,F,,,10623,H
3325,,204,,,,,,,Autocuration,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,10623,H
3326,,1946,,,,,,,Expert,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,10623,H
3327,,6398,,,,,,,Autocuration,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,10623,H
3328,,6398,,,,,,,Autocuration,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,10623,H
3329,,17358,,,,,,,Autocuration,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,10623,H
3330,,6398,,,,,,,Autocuration,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,10623,H
3331,,11752,,,,,,,Expert,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,10623,H
3332,,809,,,,,,,Autocuration,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,10623,H
3333,,14178,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,10623,D
3334,,567,,,,,,,Autocuration,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,10623,H
3335,,1946,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,10623,H
3336,,1946,,,,,,,Autocuration,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,10623,H
3337,,13961,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,10623,D
3338,Striatum,6238,2435.0,,,,,,Autocuration,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,10623,H
3339,,14290,,,,,,,Autocuration,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,10623,H
3340,,14290,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,10623,H
3341,Striatum,809,2435.0,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,10623,D
3342,Striatum,1578,2435.0,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,10623,H
3343,Striatum,16709,2435.0,,,,,,Expert,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,10623,H
3344,Striatum,1946,2435.0,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,10623,H
3345,Striatum,15253,2435.0,,,,,,Expert,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,10623,H
3346,Striatum,4535,2435.0,,,,,,Expert,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,10623,H
3347,,13961,,,,,,,Expert,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,10623,H
3348,Brain,17358,955.0,,,,,,Autocuration,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,10623,H
3349,,15847,,,,,,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,10623,H
3350,,15847,,,,,,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,10623,H
3351,,670,,,,,,,Autocuration,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,10623,H
3352,,670,,,,,,,Autocuration,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,10623,H
3353,,1317,,,,,,,Autocuration,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,10623,H
3354,,12936,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,10623,D
3355,Striatum,4535,2435.0,,,,,,Expert,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,10623,H
3356,,14424,,Rattus norvegicus,,,10116.0,,Expert,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,10623,D
3357,,14424,,,,,,,Expert,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,10623,H
3358,,14424,,,,,,,Expert,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,10623,H
3359,,14424,,Rattus norvegicus,,,10116.0,,Expert,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,10623,D
3360,,14424,,,,,,,Autocuration,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,10623,H
3361,,14424,,,,,,,Expert,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,10623,H
3362,,14424,,,,,,,Expert,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,10623,H
3363,,14424,,,,,,,Autocuration,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,10623,H
3364,,1980,,Rattus norvegicus,,,10116.0,,Autocuration,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,168,H
3365,,4639,,,,,,,Autocuration,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,168,H
3366,,17358,,,,,,,Autocuration,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,168,H
3367,,17358,,,,,,,Autocuration,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,168,H
3368,,17358,,,,,,,Autocuration,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,168,H
3369,,1558,,,,,,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,168,H
3370,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,168,H
3371,,16117,,,,,,,Autocuration,,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,168,H
3372,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,168,H
3373,,17358,,,,,,,Autocuration,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,168,H
3374,,17358,,,,,,,Autocuration,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,168,H
3375,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,168,H
3376,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,168,H
3377,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,168,H
3378,,1274,,,,,,,Expert,,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,168,H
3379,,10728,,,,,,Brain membranes,Autocuration,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,104698,H
3380,,11695,,,,,,Brain membranes,Autocuration,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,104698,H
3381,,11695,,,,,,Brain membranes,Autocuration,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,104698,H
3382,,12490,,,,,,,Autocuration,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,104698,H
3383,,11828,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,104698,D
3384,Hippocampus,12253,10000000.0,,,,,,Autocuration,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,104698,H
3385,,10561,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,104698,H
3386,,10561,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,104698,H
3387,,14432,,,,,,,Autocuration,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,104698,H
3388,,12936,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,104698,D
3389,,1274,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,104698,D
3390,,1980,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,104698,H
3391,,670,,,,,,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,104698,H
3392,,968,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,104698,D
3393,,14287,,,,,,,Autocuration,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,104698,H
3394,,567,,,,,,,Autocuration,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,104698,H
3395,,13267,,,,,,,Autocuration,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,104698,H
3396,,14826,,,,,,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,104698,H
3397,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,104698,H
3398,,15194,,,,,,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,104698,H
3399,,10394,,Rattus norvegicus,,,10116.0,,Autocuration,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,104698,D
3400,,13657,,,,,,,Expert,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,10576,D
3401,Brain,1879,955.0,,,,,,Autocuration,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,12020,H
3402,,1879,,,,,,,Autocuration,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,12020,H
3403,,1879,,,,,,,Autocuration,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,12020,H
3404,,204,,,,,,,Autocuration,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,12020,H
3405,,1879,,,,,,,Autocuration,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,12020,H
3406,,1879,,,,,,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,12020,H
3407,,1879,,,,,,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,12020,H
3408,,1879,,,,,,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,12020,H
3409,,10641,,,,,,,Autocuration,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,104698,H
3410,,773,,,,,,,Autocuration,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,12020,H
3411,,11952,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,104698,H
3412,,14145,,Rattus norvegicus,,,10116.0,,Autocuration,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,12020,D
3413,,17066,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,144,H
3414,,6398,,,,,,,Autocuration,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,104714,H
3415,,10321,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,22226,U
3416,,511,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,104714,H
3417,,4639,,,,,,,Autocuration,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,104714,H
3418,,4639,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,104714,H
3419,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,104714,H
3420,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,104714,H
3421,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,104714,H
3422,,1558,,,,,,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,104714,H
3423,,268,,,,,,,Autocuration,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,104714,H
3424,,2474,,,,,,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,104714,H
3425,,5067,,,,,,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,104714,H
3426,,5067,,,,,,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,104714,H
3427,,5067,,,,,,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,104714,H
3428,,5067,,,,,,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,104714,H
3429,,5067,,,,,,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,104714,H
3430,,5067,,,,,,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,104714,H
3431,,5067,,,,,,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,104714,H
3432,,5067,,,,,,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,104714,H
3433,,5067,,,,,,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,104714,H
3434,,5067,,,,,,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,104714,H
3435,,5067,,,,,,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,104714,H
3436,,5067,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,104714,H
3437,,14331,,,,,,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,104714,H
3438,,5067,,,,,,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,104714,H
3439,,6179,,,,433.0,,,Autocuration,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,NG108-15,104714,H
3440,,4265,,,,,,,Autocuration,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,104714,H
3441,,4265,,,,433.0,,,Autocuration,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,NG108-15,104714,H
3442,,17358,,,,,,,Autocuration,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,104714,H
3443,,17358,,,,,,,Autocuration,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,104714,H
3444,,13628,,,,,,,Autocuration,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,104714,H
3445,,4612,,,,,,,Autocuration,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,104714,H
3446,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,104714,H
3447,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,104714,H
3448,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,104714,H
3449,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,104714,H
3450,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,104714,H
3451,,511,,,,,,,Autocuration,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,104714,H
3452,,1479,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,104714,H
3453,,1317,,,,,,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,104714,H
3454,,12146,,,,,,,Autocuration,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,104714,H
3455,,12146,,,,,,,Autocuration,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,104714,H
3456,,13969,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,104714,H
3457,,13392,,,,,,,Expert,,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,108,H
3458,,13392,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,104698,H
3459,,14159,,,,,,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,144,H
3460,,1558,,,,,,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,144,H
3461,,16655,,,,,,,Autocuration,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,144,H
3462,,13020,,,,,,,Autocuration,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,104714,H
3463,,13021,,,,,,,Autocuration,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,104714,H
3464,,13020,,,,,,,Autocuration,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,104714,H
3465,,10321,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,144,H
3466,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,144,H
3467,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,144,H
3468,,17358,,,,,,,Autocuration,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,144,H
3469,,2222,,,,,,,Autocuration,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,144,H
3470,,10322,,,,,,,Autocuration,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,144,H
3471,,16117,,,,,,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,144,H
3472,,17200,,,,,,,Autocuration,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,144,H
3473,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,144,H
3474,,16700,,,,,,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,144,H
3475,,1980,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,144,H
3476,,1980,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,144,H
3477,,12409,,,,,,,Autocuration,,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,104714,H
3478,,4365,,,,,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,144,H
3479,,4365,,,,,,,Autocuration,,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,144,H
3480,,4365,,,,,,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,144,H
3481,,6769,,Rattus norvegicus,,,10116.0,,Expert,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,Oocytes,12020,D
3482,,6769,,Rattus norvegicus,,,10116.0,,Expert,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,Oocytes,12020,D
3483,,6769,,Rattus norvegicus,,,10116.0,,Expert,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,Oocytes,12020,D
3484,Ileum,809,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,20033,D
3485,Ileum,809,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,20033,D
3486,,14290,,Cavia porcellus,,,10141.0,,Intermediate,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,20033,D
3487,Ileum,17358,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,20033,D
3488,,17358,,Cavia porcellus,,,10141.0,,Intermediate,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,20033,D
3489,Ileum,17358,2116.0,Cavia porcellus,,,10141.0,,Intermediate,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,20033,D
3490,Ileum,17386,2116.0,,,,,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,10209,H
3491,,3269,,,,,,,Autocuration,,Affinity against 5-hydroxytryptamine 7 receptor,B,,,10209,H
3492,,7721,,Cavia porcellus,,,10141.0,,Autocuration,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,104841,H
3493,,7721,,Cavia porcellus,,,10141.0,,Autocuration,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,104841,H
3494,Ileum,9117,2116.0,Cavia porcellus,,,10141.0,,Autocuration,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,104841,H
3495,,7721,,Cavia porcellus,,,10141.0,,Autocuration,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,104841,H
3496,,7721,,Cavia porcellus,,,10141.0,,Autocuration,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,104841,H
3497,,15796,,Cavia porcellus,,,10141.0,,Autocuration,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,104841,H
3498,,15796,,Cavia porcellus,,,10141.0,,Autocuration,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,104841,H
3499,Cardiac atrium,15650,2081.0,Homo sapiens,,,9606.0,,Expert,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,168,D
3500,Cardiac atrium,15650,2081.0,Homo sapiens,,,9606.0,,Expert,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,168,D
3501,,6866,,Homo sapiens,,,9606.0,,Autocuration,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,104841,D
3502,Cardiac atrium,15650,2081.0,Homo sapiens,,,9606.0,,Expert,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,168,D
3503,,10063,,Mus musculus,,,10090.0,,Autocuration,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,22226,U
3504,,12665,,Mus musculus,,,10090.0,,Autocuration,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,22226,U
3505,,7504,,,,,,,Autocuration,,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,104705,H
3506,,7504,,,,,,,Autocuration,,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,104705,H
3507,,7038,,,,,,,Autocuration,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,104705,H
3508,,7626,,,,,,,Autocuration,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,104705,H
3509,,7626,,,,,,,Autocuration,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,104705,H
3510,Stomach,7185,945.0,,,,,,Autocuration,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,104705,H
3511,Stomach,7185,945.0,,,,,,Autocuration,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,104705,H
3512,,7185,,,,,,,Autocuration,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,104705,H
3513,,6960,,,,,,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,104705,H
3514,,6960,,,,,,,Autocuration,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,104705,H
3515,Hippocampus,12416,10000000.0,,,,,,Autocuration,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,10576,H
3516,,15753,,,,,,,Expert,,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,12198,H
3517,,8062,,,,,,,Autocuration,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,104705,H
3518,,9036,,Rattus norvegicus,,,10116.0,,Autocuration,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,104705,D
3519,,15067,,Rattus norvegicus,,,10116.0,,Autocuration,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,104705,D
3520,Brain,15753,955.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,12198,D
3521,Cerebellum,15753,2037.0,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,12198,D
3522,,15295,,Rattus norvegicus,,,10116.0,,Autocuration,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,104705,D
3523,,6347,,Rattus norvegicus,,,10116.0,,Autocuration,,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,104705,D
3524,,6763,,,,,,,Autocuration,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,22226,U
3525,,12092,,Rattus norvegicus,,,10116.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,104705,D
3526,,1579,,Rattus norvegicus,,,10116.0,,Autocuration,,Affinity against 5-hydroxytryptamine receptor was determined,B,,,104705,D
3527,Stomach,1579,945.0,Rattus norvegicus,,,10116.0,,Autocuration,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,104705,D
3528,,5963,,Homo sapiens,,,9606.0,,Expert,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,121,D
3529,,5963,,Homo sapiens,,,9606.0,,Expert,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,121,D
3530,,5030,,,,,,,Autocuration,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,18065,H
3531,,15796,,,,,,,Expert,,Inhibition of 5-hydroxytryptamine reuptake,B,,,121,H
3532,,15413,,,,,,,Autocuration,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,18065,H
3533,,15413,,,,,,,Autocuration,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,18065,H
3534,,15413,,,,,,,Autocuration,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,18065,H
3535,,12409,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine receptor uptake,F,,,18065,H
3536,,16909,,Homo sapiens,,449.0,9606.0,,Expert,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,CHO,51,D
3537,,16909,,Homo sapiens,,,9606.0,,Expert,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,51,D
3538,,15629,,Homo sapiens,,,9606.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,10576,H
3539,,15629,,,,,,,Autocuration,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,10576,H
3540,,15629,,,,,,,Expert,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,10576,H
3541,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,10825,H
3542,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,10825,H
3543,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,10825,H
3544,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,10825,H
3545,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,10825,H
3546,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,10825,H
3547,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,10825,H
3548,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,10825,H
3549,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,10825,H
3550,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,10825,H
3551,Striatum,10034,2435.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,10825,H
3552,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,10825,H
3553,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,10825,H
3554,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,10825,H
3555,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,10825,H
3556,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,10825,H
3557,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,10825,H
3558,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,10825,H
3559,,1274,,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,168,H
3560,,17358,,,,,,,Autocuration,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,168,H
3561,,14532,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,168,H
3562,,16989,,,,,,,Expert,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,168,H
3563,,17200,,,,,,,Autocuration,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,168,H
3564,,15779,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,168,H
3565,,15779,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,168,H
3566,,15779,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,168,H
3567,,15650,,,,643.0,,,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,COS-7,168,H
3568,,15650,,,,643.0,,,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,COS-7,168,H
3569,,15650,,,,643.0,,,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,COS-7,168,H
3570,,15650,,,,643.0,,,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,COS-7,168,H
3571,,17046,,,,673.0,,,Autocuration,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,C6,168,H
3572,,17046,,,,673.0,,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,C6,168,H
3573,,15650,,,,673.0,,,Expert,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,C6,168,H
3574,,17046,,,,673.0,,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,C6,168,H
3575,,17066,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,10624,H
3576,,17200,,,,,,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,105,H
3577,,16146,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,10624,D
3578,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,CHO,10624,H
3579,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,10624,D
3580,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,10624,D
3581,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,10624,D
3582,,4234,,Homo sapiens,,,9606.0,,Expert,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,10624,D
3583,,6013,,,,,,,Autocuration,,Binding affinity towards 5-HT5A receptor,B,,,10624,H
3584,,17175,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,10624,H
3585,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,10624,H
3586,,6166,,,,,,,Autocuration,,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,10624,H
3587,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,10624,H
3588,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,HEK293,10624,H
3589,,5213,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,HEK293,10624,H
3590,,17066,,Mus musculus,,,10090.0,,Expert,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,10625,D
3591,,17066,,Mus musculus,,,10090.0,,Expert,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,10625,D
3592,,17066,,Mus musculus,,,10090.0,,Expert,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,10625,D
3593,,17066,,Mus musculus,,,10090.0,,Expert,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,10625,D
3594,,17066,,Mus musculus,,,10090.0,,Expert,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,10625,D
3595,,17175,,,,,,,Expert,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,10625,H
3596,,16190,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,HEK293,10576,H
3597,,16190,,,,722.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,HEK293,10626,H
3598,,4820,,,,,,,Expert,,Binding affinity towards 5-HT5a receptor,B,,,10624,H
3599,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,10624,D
3600,,17066,,,,,,,Expert,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,10624,H
3601,,17175,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,10624,H
3602,,16633,,,,,,,Autocuration,,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,10624,H
3603,,16633,,,,,,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,10624,H
3604,,16700,,,,,,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,10624,H
3605,,4639,,Cavia porcellus,,,10141.0,,Autocuration,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,104714,H
3606,,5486,,,,,,,Autocuration,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,104714,H
3607,,16146,,Homo sapiens,,,9606.0,,Expert,,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,10627,D
3608,,17273,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,10627,D
3609,,17687,,,,,,,Autocuration,,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3610,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,10627,D
3611,,16190,,,,308.0,,,Expert,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,HeLa,10627,H
3612,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,10627,D
3613,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,10627,D
3614,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,10627,D
3615,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,10627,D
3616,,3555,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,10627,D
3617,,5808,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3618,,6013,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3619,,15818,,,,722.0,,,Expert,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,HEK293,10627,H
3620,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,10627,H
3621,,3935,,,,722.0,,,Expert,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,HEK293,10627,H
3622,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3623,,3805,,Homo sapiens,,722.0,9606.0,,Expert,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,HEK293,10627,D
3624,,16441,,,,,,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,10627,H
3625,,16441,,,,,,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,10627,H
3626,,6786,,,,643.0,,,Expert,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,COS-7,10627,H
3627,,4234,,Homo sapiens,,,9606.0,,Expert,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,10627,D
3628,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3629,,17200,,,,,,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,10627,H
3630,,17451,,,,722.0,,,Autocuration,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,HEK293,10627,H
3631,,3935,,,,,,,Autocuration,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,10627,H
3632,,5033,,,,,,,Autocuration,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3633,,4540,,,,,,,Expert,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3634,,4540,,Homo sapiens,,308.0,9606.0,,Expert,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,HeLa,10627,D
3635,,4540,,Homo sapiens,,308.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,HeLa,10627,D
3636,,17296,,,,308.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,HeLa,10627,H
3637,,17296,,,,308.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,HeLa,10627,H
3638,,17296,,,,308.0,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,HeLa,10627,H
3639,,15779,,,,449.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,CHO,10627,H
3640,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,HEK293,10627,H
3641,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,HEK293,10627,H
3642,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,HEK293,10627,H
3643,,15779,,,,308.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,HeLa,10627,H
3644,,6166,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3645,,17451,,,,308.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,HeLa,10627,H
3646,,15316,,,,,,,Autocuration,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,10627,H
3647,,4199,,,,,,,Expert,,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3648,,15146,,,,308.0,,,Expert,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,HeLa,10627,H
3649,,5213,,,,,,,Autocuration,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,10627,H
3650,,16429,,,,,,,Autocuration,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,10627,H
3651,,14818,,,,308.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,HeLa,10627,H
3652,,4829,,,,308.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,HeLa,10627,H
3653,,4829,,,,308.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,HeLa,10627,H
3654,,4829,,,,308.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,HeLa,10627,H
3655,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,CHO,10628,H
3656,,14423,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,10628,H
3657,,15086,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,10628,H
3658,,4342,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,10628,H
3659,,16190,,Homo sapiens,,308.0,9606.0,,Autocuration,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,HeLa,10627,D
3660,,4820,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3661,,4639,,,,,,,Autocuration,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,10627,H
3662,,17066,,Homo sapiens,,,9606.0,,Expert,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,10627,D
3663,,6011,,,,,,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,10627,H
3664,,17066,,,,,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,10627,H
3665,,17515,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,10627,H
3666,,5014,,,,,,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,10627,H
3667,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,10627,H
3668,,17066,,,,,,,Expert,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,10627,H
3669,,17066,,,,,,,Expert,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,10627,H
3670,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,10627,H
3671,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,10627,H
3672,,16946,,,,,,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,10627,H
3673,,16946,,,,,,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,10627,H
3674,,16633,,,,,,,Autocuration,,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,10627,H
3675,,16633,,,,,,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,10627,H
3676,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,10627,D
3677,,16700,,,,,,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,10627,H
3678,,3269,,,,,,,Autocuration,,Affinity against 5-hydroxytryptamine 6 receptor,B,,,10627,H
3679,,5486,,,,,,,Autocuration,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,10627,H
3680,,16146,,Homo sapiens,,,9606.0,,Expert,,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,10209,D
3681,,5014,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,HEK293,10209,H
3682,,15463,,,,,,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,10209,H
3683,,3805,,,,,,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,10209,H
3684,,5014,,,,722.0,,,Expert,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,HEK293,10209,H
3685,,6491,,Homo sapiens,,,9606.0,,Expert,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,10209,D
3686,,16190,,,,449.0,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,CHO,10209,H
3687,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,10209,D
3688,,17066,,Homo sapiens,,,9606.0,,Expert,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,10209,D
3689,,3555,,Homo sapiens,,,9606.0,,Expert,,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,10209,D
3690,,6588,,,,449.0,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,CHO,10209,H
3691,,15463,,,,,,,Autocuration,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,10209,H
3692,,6013,,,,,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,10209,H
3693,,16209,,,,,,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,10209,H
3694,,3935,,,,,,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,10209,H
3695,,15818,,,,,,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,10209,H
3696,,5014,,,,722.0,,,Expert,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,HEK293,10209,H
3697,,16441,,,,,,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,10209,H
3698,,16441,,,,,,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,10209,H
3699,,4234,,Homo sapiens,,,9606.0,,Expert,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,10209,D
3700,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,10209,H
3701,,17200,,,,,,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,10209,H
3702,,17451,,,,449.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,CHO,10209,H
3703,,17085,,,,,,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,10209,H
3704,,5104,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,10209,H
3705,,5104,,,,,,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,10209,H
3706,,5033,,Homo sapiens,,643.0,9606.0,,Expert,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,COS-7,10209,D
3707,,5486,,,,643.0,,,Autocuration,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,COS-7,10209,H
3708,,4540,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,HEK293,10209,D
3709,,6166,,,,,,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,10209,H
3710,,17342,,,,722.0,,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,HEK293,10209,H
3711,,17342,,,,,,,Expert,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,10209,H
3712,,17296,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,10209,H
3713,,16429,,,,,,,Expert,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,10209,H
3714,,15779,,,,722.0,,,Autocuration,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,HEK293,10209,H
3715,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,10209,H
3716,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,10209,H
3717,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,10209,H
3718,,15779,,,,722.0,,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,HEK293,10209,H
3719,,17451,,,,449.0,,,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,CHO,10209,H
3720,,4199,,,,722.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,HEK293,10209,H
3721,,4199,,,,722.0,,,Expert,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,HEK293,10209,D
3722,,4199,,,,722.0,,,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,HEK293,10209,H
3723,,3680,,,,722.0,,,Intermediate,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,HEK293,10209,D
3724,,3680,,,,,,,Intermediate,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,10209,D
3725,,15316,,,,643.0,,,Autocuration,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,COS-7,10209,H
3726,,15146,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,HEK293,10209,H
3727,,5213,,,,722.0,,,Expert,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,HEK293,10209,H
3728,,5213,,,,722.0,,,Autocuration,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,HEK293,10209,H
3729,,14818,,Homo sapiens,,722.0,9606.0,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,HEK293,10209,D
3730,,14818,,,,722.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,HEK293,10209,H
3731,,14818,,,,722.0,,,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,HEK293,10209,H
3732,,4829,,,,722.0,,,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,HEK293,10209,H
3733,,17200,,Homo sapiens,,,9606.0,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,10209,D
3734,,17066,,Mus musculus,,,10090.0,,Expert,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,10022,D
3735,,14025,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,10209,H
3736,,15250,,,,449.0,,,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,CHO,11923,H
3737,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,CHO,11923,H
3738,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,CHO,11923,H
3739,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,CHO,11923,H
3740,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,CHO,11923,H
3741,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,CHO,11923,H
3742,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,CHO,11923,H
3743,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,CHO,11923,H
3744,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,CHO,11923,H
3745,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,CHO,11923,H
3746,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,CHO,11923,H
3747,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,CHO,11923,H
3748,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,CHO,11923,H
3749,,17066,,,,,,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,11923,H
3750,,17066,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,11923,D
3751,,17386,,,,,,,Expert,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,11923,H
3752,,14423,,,,,,,Autocuration,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,11923,H
3753,,15874,,Rattus norvegicus,,,10116.0,,Expert,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,11923,D
3754,,15874,,Rattus norvegicus,,,10116.0,,Expert,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,11923,D
3755,,16372,,Rattus norvegicus,,449.0,10116.0,,Expert,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,CHO,11923,D
3756,,4622,,,,,,,Autocuration,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,11923,H
3757,,15086,,,,,,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,11923,H
3758,,16372,,,,449.0,,,Autocuration,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,CHO,11923,H
3759,,16372,,,,449.0,,,Autocuration,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,CHO,11923,H
3760,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,CHO,11923,H
3761,,16372,,,,449.0,,,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,CHO,11923,H
3762,Ileum,17386,2116.0,,,,,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,11923,H
3763,Ileum,17386,2116.0,,,,,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,11923,H
3764,Ileum,17386,2116.0,,,,,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,11923,H
3765,,5831,,Rattus norvegicus,,,10116.0,Membranes,Expert,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,11923,D
3766,,4342,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,11923,H
3767,,17319,,,,,,,Expert,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,11923,H
3768,Hypothalamus,17342,1898.0,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,11923,H
3769,,17342,,,,,,,Autocuration,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,11923,H
3770,Hypothalamus,3680,1898.0,,,,,,Expert,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,11923,H
3771,,3680,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,11923,H
3772,,17319,,Rattus norvegicus,,722.0,10116.0,,Expert,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,HEK293,11923,D
3773,,17319,,Rattus norvegicus,,722.0,10116.0,,Expert,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,HEK293,11923,D
3774,,17319,,Rattus norvegicus,,722.0,10116.0,,Autocuration,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,HEK293,11923,D
3775,,4820,,,,,,,Expert,,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,10209,H
3776,,4639,,,,,,,Autocuration,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,10209,H
3777,,6011,,,,,,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,10209,H
3778,,17066,,Homo sapiens,,,9606.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,10209,D
3779,,17066,,,,,,,Expert,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,10209,H
3780,,17515,,,,,,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,10209,H
3781,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,10209,H
3782,,17066,,,,,,,Expert,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,10209,H
3783,,4373,,,,,,,Autocuration,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,10209,H
3784,,4373,,,,,,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,10209,H
3785,,4687,,,,,,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,10209,H
3786,,17342,,,,,,,Expert,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,10209,H
3787,,16946,,,,,,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,10209,H
3788,,16946,,,,,,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,10209,H
3789,,16633,,,,,,,Autocuration,,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,10209,H
3790,,16633,,,,,,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,10209,H
3791,,17066,,,,,,,Expert,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,10209,H
3792,,16700,,,,,,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,10209,H
3793,Ileum,17386,2116.0,,,,,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,10209,H
3794,,14080,,,,,,,Autocuration,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,55,H
3795,,14080,,Homo sapiens,,,9606.0,,Expert,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,55,D
3796,,409,,,,,,,Autocuration,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,55,H
3797,,409,,,,,,,Autocuration,,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,55,H
3798,,409,,,,,,,Autocuration,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,55,H
3799,Blood,11090,178.0,,,,,,Expert,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,55,H
3800,Blood,11090,178.0,,,,,,Expert,,Inhibition of 5-lipoxygenase in human whole blood.,B,,,55,H
3801,,948,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,55,H
3802,,948,,,,,,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,55,H
3803,,13622,,,,,,,Expert,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,55,H
3804,Blood,13622,178.0,,,,,,Autocuration,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,55,H
3805,,9637,,,,,,,Autocuration,,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,55,H
3806,,11320,,,,,,,Autocuration,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,55,H
3807,,11320,,,,,,,Expert,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,55,H
3808,,6838,,,,,,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,55,H
3809,Blood,17667,178.0,Homo sapiens,,,9606.0,,Expert,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,55,D
3810,,12703,,,,,,,Autocuration,,In vitro potency against human 5-Lipoxygenase,B,,,55,H
3811,,14312,,Homo sapiens,,,9606.0,,Expert,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,55,D
3812,Blood,14312,178.0,,,,,,Autocuration,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,55,H
3813,,5364,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,55,H
3814,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,55,H
3815,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,55,H
3816,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,55,H
3817,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,55,H
3818,,12365,,,,,,,Autocuration,,Inhibition of human 5-lipoxygenase in human cells,B,,,55,H
3819,,10603,,,,,,,Expert,,Inhibition of human neutrophil 5-lipoxygenase,B,,,55,H
3820,,10501,,,,,,,Autocuration,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,55,H
3821,Blood,12281,178.0,,,,,,Expert,,Inhibition of 5-lipoxygenase from human whole blood,B,,,55,H
3822,,2567,,,,,,,Autocuration,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,55,H
3823,,2567,,,,,,,Autocuration,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,55,H
3824,,10193,,,,,,,Expert,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,55,H
3825,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,55,H
3826,,13623,,,,,,,Expert,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,55,H
3827,,12780,,,,,,,Autocuration,,Tested against 5-lipoxygenase,B,,,55,H
3828,,12780,,,,,,,Autocuration,,Tested for activity against 5-Lipoxygenase (5-LO),B,,,55,H
3829,,12780,,,,,,,Autocuration,,Tested for activity against 5-lipoxygenase,B,,,55,H
3830,,11966,,,,,,,Autocuration,,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,55,H
3831,,5364,,,,,,,Autocuration,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,55,H
3832,,13165,,,,,,,Expert,,Inhibition of Human 5-lipoxygenase,B,,,55,H
3833,,5364,,,,,,,Autocuration,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,55,H
3834,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,55,H
3835,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,55,H
3836,,14863,,,,,,,Autocuration,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,55,H
3837,,14863,,,,,,,Autocuration,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,55,H
3838,Blood,11087,178.0,,,,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,55,H
3839,,455,,,,,,,Autocuration,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,55,H
3840,,13183,,,,,,,Autocuration,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,55,H
3841,,10319,,,,,,,Expert,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,55,H
3842,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,55,H
3843,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,55,H
3844,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,55,H
3845,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,55,H
3846,,951,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,55,H
3847,,9859,,,,,,,Expert,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,55,H
3848,,9859,,,,,,,Expert,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,55,H
3849,,9859,,,,,,,Autocuration,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,55,H
3850,,2567,,,,,,,Autocuration,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,55,H
3851,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,55,H
3852,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,55,H
3853,,949,,,,,,,Autocuration,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,55,H
3854,,949,,,,,,,Autocuration,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,55,H
3855,,10603,,,,,,,Expert,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,55,H
3856,,10603,,,,,,,Expert,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,55,H
3857,,10603,,,,,,,Autocuration,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,55,H
3858,,10603,,,,,,,Expert,,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,55,H
3859,,10603,,,,,,,Expert,,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,55,H
3860,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,55,H
3861,,14580,,Homo sapiens,,,9606.0,,Expert,,Inhibition of 5-Lipoxygenase (5-LOX),B,,,55,D
3862,,11090,,,,,,,Expert,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,17087,H
3863,,11090,,,,,,,Expert,,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,17087,H
3864,,6339,,,,,,,Autocuration,,Inhibitory activity against lipoxygenase-2 in mice,B,,,17087,H
3865,,6339,,,,,,,Expert,,Inhibitory activity against murine lipoxygenase-2.,B,,,17087,H
3866,,12281,,Mus musculus,,,10090.0,,Expert,,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,17087,D
3867,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,17087,H
3868,,11089,,Sus scrofa,,,9823.0,,Autocuration,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,55,H
3869,,10091,,Sus scrofa,,,9823.0,,Autocuration,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,55,H
3870,,14352,,Oryctolagus cuniculus,,,9986.0,,Autocuration,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,55,H
3871,,13329,,Rattus norvegicus,,,10116.0,,Expert,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,12166,D
3872,,13329,,,,,,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,12166,H
3873,,13329,,,,,,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,12166,H
3874,,13329,,,,,,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,12166,H
3875,,13329,,,,,,,Expert,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,12166,H
3876,,13329,,,,,,,Expert,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,12166,H
3877,,13329,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,12166,H
3878,,11311,,,,,,,Autocuration,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,12166,H
3879,,11311,,,,,,,Autocuration,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,12166,H
3880,,105,,,,702.0,,,Autocuration,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,RBL-1,12166,H
3881,,105,,,,702.0,,,Autocuration,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,RBL-1,12166,H
3882,,9138,,,,,,,Autocuration,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,12166,H
3883,,9138,,,,,,,Autocuration,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,12166,H
3884,,9138,,,,,,,Autocuration,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,12166,H
3885,,14427,,,,,,,Autocuration,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,12166,H
3886,,13329,,,,,,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,12166,H
3887,,13329,,,,,,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,12166,H
3888,,14427,,Rattus norvegicus,,663.0,10116.0,,Expert,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,RBL-2H3,12166,D
3889,,14427,,,,,,,Autocuration,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,12166,H
3890,,14427,,,,,,,Autocuration,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,12166,H
3891,,10293,,,,702.0,,,Expert,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,RBL-1,12166,H
3892,,338,,Rattus norvegicus,,702.0,10116.0,,Expert,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,RBL-1,12166,D
3893,,303,,,,,,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,12166,H
3894,,303,,,,702.0,,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,RBL-1,12166,H
3895,,9247,,,,702.0,,,Expert,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,RBL-1,12166,H
3896,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,RBL-1,12166,H
3897,,137,,,,702.0,,,Autocuration,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,RBL-1,12166,H
3898,,11481,,,,,,,Expert,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,12166,H
3899,,11481,,,,,,,Expert,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,12166,H
3900,,9029,,,,,,,Expert,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,12166,H
3901,,1701,,,,,,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,12166,H
3902,,1701,,,,,,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,12166,H
3903,,1701,,,,,,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,12166,H
3904,,1701,,,,,,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,12166,H
3905,,13358,,,,702.0,,,Expert,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,RBL-1,12166,H
3906,,1175,,,,702.0,,,Expert,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,RBL-1,12166,H
3907,,8797,,,,702.0,,,Expert,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,RBL-1,12166,H
3908,,8797,,,,,,,Autocuration,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,12166,H
3909,,577,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,12166,D
3910,,9295,,,,702.0,,,Expert,,In vitro inhibitory activity against RBL-1 5-LO,B,,RBL-1,12166,H
3911,,9295,,,,702.0,,,Autocuration,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,RBL-1,12166,H
3912,,9295,,,,702.0,,,Autocuration,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,RBL-1,12166,H
3913,,9295,,,,,,,Autocuration,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,12166,H
3914,,9295,,,,,,,Autocuration,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,12166,H
3915,,216,,,,,,,Autocuration,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,12166,H
3916,,11090,,,,702.0,,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,RBL-1,12166,H
3917,Blood,11090,178.0,,,,,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,12166,H
3918,,10091,,,,,,,Expert,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,12166,H
3919,,10274,,,,,,,Autocuration,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,12166,H
3920,,13622,,,,,,,Autocuration,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,12166,H
3921,,12118,,,,702.0,,,Expert,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,RBL-1,12166,H
3922,,12576,,,,,,,Expert,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,12166,H
3923,,9546,,,,702.0,,,Expert,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,RBL-1,12166,H
3924,,9521,,,,702.0,,,Autocuration,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,RBL-1,12166,H
3925,,10626,,,,702.0,,,Expert,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,RBL-1,12166,H
3926,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase,B,,RBL-1,12166,H
3927,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,RBL-1,12166,H
3928,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,RBL-1,12166,H
3929,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,RBL-1,12166,H
3930,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,RBL-1,12166,H
3931,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,RBL-1,12166,H
3932,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,RBL-1,12166,H
3933,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,RBL-1,12166,H
3934,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,RBL-1,12166,H
3935,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,RBL-1,12166,H
3936,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,RBL-1,12166,H
3937,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,RBL-1,12166,H
3938,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,RBL-1,12166,H
3939,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,RBL-1,12166,H
3940,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,RBL-1,12166,H
3941,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,RBL-1,12166,H
3942,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,RBL-1,12166,H
3943,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,RBL-1,12166,H
3944,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,RBL-1,12166,H
3945,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,RBL-1,12166,H
3946,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,RBL-1,12166,H
3947,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,RBL-1,12166,H
3948,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,RBL-1,12166,H
3949,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,RBL-1,12166,H
3950,,9401,,,,,,,Expert,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,12166,H
3951,,10325,,,,,,,Autocuration,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,12166,H
3952,,1556,,,,663.0,,,Expert,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,RBL-2H3,12166,H
3953,,1556,,,,663.0,,,Expert,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,RBL-2H3,12166,H
3954,,961,,Rattus norvegicus,,702.0,10116.0,,Expert,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,RBL-1,12166,D
3955,,6838,,,,,,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,12166,H
3956,,10325,,,,,,,Expert,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,12166,H
3957,,9209,,Rattus norvegicus,,702.0,10116.0,,Expert,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,12166,D
3958,,11520,,,,702.0,,,Expert,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,RBL-1,12166,H
3959,,137,,,,,,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,12166,H
3960,,4717,,,,702.0,,,Autocuration,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,RBL-1,12166,H
3961,,10636,,,,702.0,,,Expert,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,RBL-1,12166,H
3962,,14312,,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,12166,D
3963,,1203,,,,702.0,,,Autocuration,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,RBL-1,12166,H
3964,,1203,,,,,,,Autocuration,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,12166,H
3965,,13622,,,,702.0,,,Expert,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,RBL-1,12166,H
3966,,9793,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,12166,H
3967,,1143,,Rattus norvegicus,,702.0,10116.0,,Expert,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,RBL-1,12166,D
3968,,11854,,Rattus norvegicus,,702.0,10116.0,,Expert,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,RBL-1,12166,D
3969,,3595,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,RBL-1,12166,H
3970,,3595,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,RBL-1,12166,H
3971,,10501,,Rattus norvegicus,,702.0,10116.0,,Expert,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,12166,D
3972,,12526,,,,702.0,,,Expert,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,12166,H
3973,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,10825,H
3974,Limbic system,10034,349.0,,,,,,Autocuration,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,10825,H
3975,,10034,,,,,,,Autocuration,,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,10825,H
3976,Hippocampus,10046,10000000.0,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,10576,H
3977,Hippocampus,10046,10000000.0,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,10576,H
3978,,10046,,,,,,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,10577,H
3979,Blood,12079,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,55,H
3980,Blood,12079,178.0,,,,,,Autocuration,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,55,H
3981,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,12166,H
3982,,12338,,,,,,,Expert,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,17140,H
3983,,12143,,,,,,,Expert,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,17140,H
3984,,12143,,,,,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,17140,H
3985,,12143,,,,,,,Expert,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,17140,H
3986,,12143,,,,,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,17140,H
3987,,12365,,,,,,,Expert,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,17140,H
3988,,13500,,,,,,,Expert,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,17140,H
3989,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3990,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3991,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3992,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3993,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3994,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3995,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3996,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3997,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3998,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
3999,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,55,H
4000,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4001,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,55,H
4002,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4003,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,55,H
4004,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4005,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,55,H
4006,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4007,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,55,H
4008,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4009,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,55,H
4010,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4011,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,55,H
4012,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4013,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,55,H
4014,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4015,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,55,H
4016,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4017,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,55,H
4018,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4019,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,55,H
4020,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4021,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,55,H
4022,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4023,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,55,H
4024,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4025,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,55,H
4026,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4027,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4028,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4029,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4030,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4031,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4032,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4033,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4034,Blood,12832,178.0,Canis lupus familiaris,,,9615.0,,Autocuration,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,55,H
4035,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,55,H
4036,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,55,H
4037,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,55,H
4038,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,55,H
4039,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,55,H
4040,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,55,H
4041,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,55,H
4042,,3595,,Canis lupus familiaris,,,9615.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,55,H
4043,,9203,,Cavia porcellus,,,10141.0,,Autocuration,,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,55,H
4044,,82,,Cavia porcellus,,,10141.0,,Expert,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,55,H
4045,,11090,,Cavia porcellus,,,10141.0,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,55,H
4046,Blood,12832,178.0,Cavia porcellus,,,10141.0,,Autocuration,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,55,H
4047,,1065,,Cavia porcellus,,,10141.0,,Autocuration,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,55,H
4048,,1065,,Cavia porcellus,,,10141.0,,Autocuration,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,55,H
4049,,12832,,Cavia porcellus,,,10141.0,,Expert,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,55,H
4050,,12832,,Cavia porcellus,,,10141.0,,Expert,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,55,H
4051,,12832,,Cavia porcellus,,,10141.0,,Autocuration,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,55,H
4052,,10504,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,55,H
4053,,7788,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase,B,,,55,H
4054,,10001,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,55,H
4055,,10193,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,55,H
4056,,13243,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,55,H
4057,,13243,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity uM,B,,,55,H
4058,,969,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,55,H
4059,,10001,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,55,H
4060,,7788,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,55,H
4061,,10001,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,55,H
4062,,10193,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,55,H
4063,,13243,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity uM,B,,,55,H
4064,,13243,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,55,H
4065,,13243,,Cavia porcellus,,,10141.0,,Expert,,Inhibitory activity uM,B,,,55,H
4066,,13243,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity uM,F,,,55,H
4067,,10504,,Cavia porcellus,,,10141.0,,Autocuration,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,55,H
4068,,7788,,Cavia porcellus,,,10141.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,55,H
4069,Ileum,10546,2116.0,Cavia porcellus,,,10141.0,,Expert,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,55,H
4070,,13183,,,,,,,Autocuration,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,55,H
4071,,13183,,,,,,,Autocuration,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,55,H
4072,,2578,,,,,,,Autocuration,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,55,H
4073,,12780,,,,,,,Expert,,In vitro inhibition of human 5-Lipoxygenase.,B,,,55,H
4074,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,22226,U
4075,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,22226,U
4076,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,22226,U
4077,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,22226,U
4078,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,22226,U
4079,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,22226,U
4080,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,22226,U
4081,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,22226,U
4082,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,22226,U
4083,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,22226,U
4084,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,22226,U
4085,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,22226,U
4086,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,22226,U
4087,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,22226,U
4088,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,22226,U
4089,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,22226,U
4090,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,22226,U
4091,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,22226,U
4092,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,22226,U
4093,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,22226,U
4094,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,22226,U
4095,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,22226,U
4096,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,22226,U
4097,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,22226,U
4098,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,22226,U
4099,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,22226,U
4100,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,22226,U
4101,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,22226,U
4102,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,22226,U
4103,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,22226,U
4104,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,22226,U
4105,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,22226,U
4106,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,22226,U
4107,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,22226,U
4108,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,22226,U
4109,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,22226,U
4110,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,22226,U
4111,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,22226,U
4112,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,22226,U
4113,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,22226,U
4114,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,22226,U
4115,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,22226,U
4116,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,22226,U
4117,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,22226,U
4118,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,22226,U
4119,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,22226,U
4120,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,22226,U
4121,,7411,,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,22226,U
4122,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,22226,U
4123,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,22226,U
4124,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,22226,U
4125,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,22226,U
4126,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,22226,U
4127,,10797,,Homo sapiens,,741.0,9606.0,,Intermediate,,In vitro inhibition of 7226/S myeloma cancer cell line,F,,RPMI-8226,80433,N
4128,,6881,,Homo sapiens,,993.0,9606.0,,Intermediate,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,BEL-7404 tumor cell line,80698,N
4129,,3838,,Homo sapiens,,391.0,9606.0,,Intermediate,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,786-0,80640,N
4130,,3838,,Homo sapiens,,391.0,9606.0,,Intermediate,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,786-0,80640,N
4131,,12981,,Cricetulus griseus,,505.0,10029.0,,Expert,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,V79,81264,N
4132,,12981,,Cricetulus griseus,,505.0,10029.0,,Expert,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,V79,81264,N
4133,,7653,,Rattus norvegicus,,1119.0,10116.0,,Intermediate,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,7800C1 cell line,80635,N
4134,,7653,,Rattus norvegicus,,1119.0,10116.0,,Intermediate,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,7800C1 cell line,80635,N
4135,,7653,,Rattus norvegicus,,1119.0,10116.0,,Intermediate,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,7800C1 cell line,80635,N
4136,,7653,,Rattus norvegicus,,1119.0,10116.0,,Intermediate,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,7800C1 cell line,80635,N
4137,,7653,,Rattus norvegicus,,1119.0,10116.0,,Intermediate,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,7800C1 cell line,80635,N
4138,,7653,,Rattus norvegicus,,1119.0,10116.0,,Intermediate,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,7800C1 cell line,80635,N
4139,,17229,,Homo sapiens,,391.0,9606.0,,Intermediate,,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,786-0,80640,N
4140,,12858,,Homo sapiens,,391.0,9606.0,,Intermediate,,Cytotoxic activity against 786-0 Renal cancer cell line,F,,786-0,80640,N
4141,,16325,,Homo sapiens,,391.0,9606.0,,Intermediate,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,786-0,80640,N
4142,,16325,,Homo sapiens,,391.0,9606.0,,Intermediate,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,786-0,80640,N
4143,,5858,,Homo sapiens,,391.0,9606.0,,Intermediate,,In vitro antitumor activity against human renal 786-0 cell line,F,,786-0,80640,N
4144,,16325,,Homo sapiens,,391.0,9606.0,,Intermediate,,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,786-0,80640,N
4145,,14696,,Homo sapiens,,391.0,9606.0,,Intermediate,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,786-0,80640,N
4146,,3786,,Homo sapiens,,391.0,9606.0,,Intermediate,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,786-0,80640,N
4147,,14696,,Homo sapiens,,391.0,9606.0,,Intermediate,,inhibition of the growth of renal cancer(786-0) cell line,F,,786-0,80640,N
4148,,14769,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,786-0,80640,N
4149,,15354,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,786-0,80640,N
4150,,14255,,Homo sapiens,,391.0,9606.0,,Intermediate,,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,786-0,80640,N
4151,,14255,,Homo sapiens,,391.0,9606.0,,Intermediate,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,786-0,80640,N
4152,,14255,,Homo sapiens,,391.0,9606.0,,Intermediate,,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,786-0,80640,N
4153,,14696,,Homo sapiens,,391.0,9606.0,,Intermediate,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,786-0,80640,N
4154,,12016,,Homo sapiens,,391.0,9606.0,,Intermediate,,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,786-0,80640,N
4155,,2597,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,786-0,80640,N
4156,,12526,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,RBL-1,12166,H
4157,,12526,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,RBL-1,12166,H
4158,,14799,,,,,,,Autocuration,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,12166,H
4159,,3595,,,,702.0,,,Expert,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,RBL-1,12166,H
4160,,3595,,,,702.0,,,Expert,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,RBL-1,12166,H
4161,,12767,,,,,,,Autocuration,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,12166,H
4162,,10997,,,,,,,Autocuration,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,12166,H
4163,,11388,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,RBL-1,12166,H
4164,,167,,,,,,,Autocuration,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,12166,H
4165,,167,,,,,,,Autocuration,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,12166,H
4166,,13744,,,,,,,Expert,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,12166,H
4167,,1630,,,,,,,Autocuration,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,12166,H
4168,,1630,,,,,,,Autocuration,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,12166,H
4169,,969,,Rattus norvegicus,,,10116.0,,Expert,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,12166,D
4170,,13621,,,,702.0,,,Autocuration,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,12166,H
4171,,10089,,,,,,,Autocuration,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,12166,H
4172,,10193,,,,,,,Expert,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,12166,H
4173,,11966,,,,,,,Autocuration,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,12166,H
4174,,12251,,,,,,,Autocuration,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,12166,H
4175,,211,,,,702.0,,,Autocuration,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,RBL-1,12166,H
4176,,12251,,,,,,,Expert,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,12166,H
4177,,12495,,,,702.0,,,Autocuration,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,RBL-1,12166,H
4178,,414,,,,,,,Autocuration,,Tested for its inhibitory activity against 5-lipoxygenase,B,,,12166,H
4179,,414,,,,,,,Autocuration,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,12166,H
4180,,10325,,,,,,,Expert,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,12166,H
4181,,11966,,,,,,,Expert,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,12166,H
4182,,165,,,,702.0,,,Expert,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,RBL-1,12166,H
4183,,165,,,,702.0,,,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,RBL-1,12166,H
4184,,165,,,,702.0,,,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,RBL-1,12166,H
4185,,165,,,,702.0,,,Expert,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,RBL-1,12166,H
4186,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,12166,H
4187,,11311,,,,702.0,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,RBL-1,12166,H
4188,,11311,,,,702.0,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,RBL-1,12166,H
4189,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,12166,H
4190,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,12166,H
4191,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,12166,H
4192,,11311,,,,663.0,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,RBL-2H3,12166,H
4193,,11311,,,,663.0,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,RBL-2H3,12166,H
4194,,11311,,,,,,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,12166,H
4195,,11732,,,,,,,Autocuration,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,12166,H
4196,,11732,,,,,,,Expert,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,12166,H
4197,,11087,,,,,,,Expert,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,12166,H
4198,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,12166,H
4199,,11087,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,RBL-1,12166,H
4200,,11087,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,12166,D
4201,,496,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,RBL-1,12166,H
4202,,13986,,,,702.0,,,Expert,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,RBL-1,12166,H
4203,,11520,,,,,,,Autocuration,,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,12166,H
4204,,10293,,,,702.0,,,Autocuration,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,RBL-1,12166,H
4205,,303,,,,702.0,,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,RBL-1,12166,H
4206,,303,,,,702.0,,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,RBL-1,12166,H
4207,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,RBL-1,12166,H
4208,,9247,,Rattus norvegicus,,702.0,10116.0,,Expert,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,RBL-1,12166,D
4209,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,RBL-1,12166,H
4210,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,RBL-1,12166,H
4211,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,RBL-1,12166,H
4212,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,RBL-1,12166,H
4213,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,RBL-1,12166,H
4214,,9247,,,,702.0,,,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,RBL-1,12166,H
4215,,11481,,Rattus norvegicus,,,10116.0,,Expert,,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,12166,D
4216,,105,,,,,,,Autocuration,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,12166,H
4217,,9029,,,,,,,Expert,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,12166,H
4218,,1175,,,,702.0,,,Expert,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,RBL-1,12166,H
4219,,12118,,,,702.0,,,Autocuration,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,RBL-1,12166,H
4220,,12118,,,,702.0,,,Autocuration,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,RBL-1,12166,H
4221,,12118,,,,702.0,,,Autocuration,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,RBL-1,12166,H
4222,,9225,,,,702.0,,,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,RBL-1,12166,H
4223,,9401,,,,,,,Autocuration,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,12166,H
4224,,137,,,,,,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,12166,H
4225,,137,,,,,,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,12166,H
4226,,4717,,,,702.0,,,Autocuration,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,RBL-1,12166,H
4227,,3595,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,RBL-1,12166,H
4228,,10501,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,RBL-1,12166,H
4229,,10501,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,RBL-1,12166,H
4230,,10501,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,RBL-1,12166,H
4231,,12526,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,12166,H
4232,,14799,,Rattus norvegicus,,702.0,10116.0,,Expert,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,RBL-1,12166,D
4233,,14799,,,,,,,Autocuration,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,12166,H
4234,,3595,,,,702.0,,,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,RBL-1,12166,H
4235,,3595,,,,702.0,,,Expert,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,RBL-1,12166,H
4236,,12526,,,,702.0,,,Autocuration,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,12166,H
4237,,12526,,,,702.0,,,Autocuration,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,RBL-1,12166,H
4238,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,12166,H
4239,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,12166,H
4240,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,12166,H
4241,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,12166,H
4242,,9138,,,,,,,Expert,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,12166,H
4243,,9138,,,,,,,Autocuration,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,12166,H
4244,,11966,,,,,,,Autocuration,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,12166,H
4245,,165,,,,702.0,,,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,RBL-1,12166,H
4246,,165,,,,702.0,,,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,RBL-1,12166,H
4247,,11311,,,,663.0,,,Autocuration,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,RBL-2H3,12166,H
4248,,11311,,,,663.0,,,Autocuration,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,RBL-2H3,12166,H
4249,,11311,,,,663.0,,,Autocuration,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,RBL-2H3,12166,H
4250,,11311,,,,,,,Autocuration,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,12166,H
4251,,11311,,,,,,,Autocuration,,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,12166,H
4252,,11311,,,,663.0,,,Autocuration,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,RBL-2H3,12166,H
4253,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,12166,H
4254,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,12166,H
4255,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,12166,H
4256,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,12166,H
4257,,11087,,,,,,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,12166,H
4258,,496,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,RBL-1,12166,H
4259,,496,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,RBL-1,12166,H
4260,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,RBL-1,12166,H
4261,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,RBL-1,12166,H
4262,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,RBL-1,12166,H
4263,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,RBL-1,12166,H
4264,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,RBL-1,12166,H
4265,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,RBL-1,12166,H
4266,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,RBL-1,12166,H
4267,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,RBL-1,12166,H
4268,,13986,,,,702.0,,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,RBL-1,12166,H
4269,,13986,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,12166,D
4270,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,12166,H
4271,,9295,,,,,,,Autocuration,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,12166,H
4272,,4717,,,,702.0,,,Autocuration,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,RBL-1,12166,H
4273,,4717,,,,702.0,,,Autocuration,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,RBL-1,12166,H
4274,,11854,,,,702.0,,,Autocuration,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,RBL-1,12166,H
4275,,11854,,,,702.0,,,Autocuration,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,RBL-1,12166,H
4276,,11854,,,,702.0,,,Autocuration,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,RBL-1,12166,H
4277,,10193,,,,,,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,12166,H
4278,,9295,,,,702.0,,,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,RBL-1,12166,H
4279,,9295,,,,702.0,,,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,RBL-1,12166,H
4280,,9295,,,,702.0,,,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,RBL-1,12166,H
4281,,9295,,,,702.0,,,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,RBL-1,12166,H
4282,,165,,,,702.0,,,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,RBL-1,12166,H
4283,,11311,,,,,,,Autocuration,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,12166,H
4284,,10489,,Homo sapiens,,702.0,9606.0,,Expert,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,RBL-1,12166,H
4285,,10489,,Rattus norvegicus,,702.0,10116.0,,Expert,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,RBL-1,12166,D
4286,,10489,,Rattus norvegicus,,702.0,10116.0,,Expert,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,RBL-1,12166,D
4287,,14799,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,12166,D
4288,,9295,,Glycine max,,,3847.0,,Autocuration,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,12054,H
4289,,16811,,,,,,,Autocuration,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,22226,U
4290,,168,,,,,,,Expert,,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,55,H
4291,,6309,,,,,,,Autocuration,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,55,H
4292,,6309,,,,,,,Autocuration,,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,55,H
4293,,3092,,,,702.0,,,Autocuration,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,RBL-1,55,H
4294,,168,,,,,,,Expert,,Inhibitory activity against 5-lipoxygenase.,B,,,55,H
4295,,168,,,,,,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,55,H
4296,,168,,,,,,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,55,H
4297,,168,,,,,,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,55,H
4298,,12338,,,,,,,Expert,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,55,H
4299,,4501,,,,,,,Autocuration,,Tested for the inhibitory activity against 5-lipoxygenase,B,,,55,H
4300,,1132,,,,,,,Autocuration,,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,55,H
4301,,2117,,,,,,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,55,H
4302,,168,,,,,,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,55,H
4303,,168,,,,,,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,55,H
4304,,13575,,,,702.0,,,Autocuration,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,RBL-1,12166,H
4305,,11089,,,,,,,Autocuration,,,B,,,12166,H
4306,,216,,,,,,,Autocuration,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,10102,H
4307,,13165,,,,,,,Autocuration,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,10102,H
4308,,3278,,,,,,,Autocuration,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,10102,H
4309,,3278,,,,,,,Expert,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,10102,H
4310,,11966,,,,,,,Autocuration,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,10102,H
4311,,175,,,,,,,Autocuration,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,10102,H
4312,,175,,,,,,,Autocuration,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,10102,H
4313,,13449,,,,,,,Autocuration,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,10102,H
4314,,12014,,,,,,,Autocuration,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,11238,H
4315,,12014,,,,,,,Autocuration,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,11238,H
4316,,12014,,,,,,,Autocuration,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,11238,H
4317,,99,,,,,,,Intermediate,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,100284,S
4318,,4349,,Homo sapiens,,,9606.0,,Autocuration,,The dark toxicity against 543 human galactophore carcinoma cells,F,,,22226,U
4319,,4071,,Homo sapiens,,390.0,9606.0,,Expert,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,Panel (56 tumour cell lines),80623,N
4320,,17589,,Homo sapiens,,345.0,9606.0,,Expert,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,5637,80008,N
4321,,15002,,Homo sapiens,,345.0,9606.0,,Intermediate,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,5637,80008,N
4322,,13958,,Homo sapiens,,345.0,9606.0,,Intermediate,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,5637,80008,N
4323,,17589,,Homo sapiens,,345.0,9606.0,,Expert,,Growth inhibition against human 5637 cell lines,F,,5637,80008,N
4324,,16748,,Homo sapiens,,345.0,9606.0,,Expert,,Antitumor activity against human bladder carcinoma 5637 cells.,F,,5637,80008,N
4325,,16747,,Homo sapiens,,345.0,9606.0,,Intermediate,,Antitumor activity against human bladder carcinoma 5637 cells,F,,5637,80008,N
4326,,16747,,Homo sapiens,,345.0,9606.0,,Intermediate,,Antitumor activity against human bladder carcinoma 5637 cells,F,,5637,80008,N
4327,,15285,,Bos taurus,,,9913.0,,Expert,,In vitro inhibition of bovine trypsin(Trp).,B,,,10443,D
4328,,3726,,Cercopithecidae,,407.0,9527.0,,Expert,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,CV-1,240,H
4329,,5033,,,,,,,Autocuration,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,10577,H
4330,,11756,,,,,,,Autocuration,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,104698,H
4331,,11953,,,,,,,Autocuration,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,22226,U
4332,,5033,,Cavia porcellus,,,10141.0,,Intermediate,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,20033,D
4333,,11347,,Rattus norvegicus,,,10116.0,Microsomes,Expert,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,17045,H
4334,,11347,,Rattus norvegicus,,,10116.0,Microsomes,Expert,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,17045,H
4335,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,22226,U
4336,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,22226,U
4337,,17588,,Trypanosoma brucei,,,5691.0,,Expert,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,11938,H
4338,,17588,,Trypanosoma brucei,,,5691.0,,Autocuration,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,11938,H
4339,,17588,,Ovis aries,,,9940.0,,Expert,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,11938,H
4340,,17588,,Ovis aries,,,9940.0,,Autocuration,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,11938,H
4341,,16485,,,,,,,Autocuration,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,11938,H
4342,,4337,,Homo sapiens,,,9606.0,,Intermediate,,Average inhibitory concentration against 60 human cell lines was reported,F,,,22226,U
4343,,4112,,Homo sapiens,,,9606.0,,Expert,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,22226,U
4344,,16160,,Homo sapiens,,542.0,9606.0,,Intermediate,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,Panel NCI-60 (60 carcinoma cell lines),80315,N
4345,,16160,,Homo sapiens,,542.0,9606.0,,Intermediate,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,Panel NCI-60 (60 carcinoma cell lines),80315,N
4346,,17376,,,,542.0,,,Expert,,In vitro mean growth inhibitory activity against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),80315,N
4347,,17376,,,,542.0,,,Expert,,In vitro mean growth lethal concentration against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),80315,N
4348,,17376,,,,542.0,,,Expert,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),80315,N
4349,,17376,,,,542.0,,,Expert,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,Panel NCI-60 (60 carcinoma cell lines),80315,N
4350,,3241,,,,,,,Autocuration,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,104775,H
4351,,3241,,,,,,,Autocuration,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,104775,H
4352,,3725,,,,,,,Expert,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,275,H
4353,,10805,,Plasmodium falciparum,,,5833.0,,Expert,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,50425,N
4354,,10805,,Plasmodium falciparum,,,5833.0,,Expert,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,50425,N
4355,,10805,,Plasmodium falciparum,,,5833.0,,Expert,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,50425,N
4356,,10805,,Plasmodium falciparum,,,5833.0,,Expert,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,50425,N
4357,,10805,,Plasmodium falciparum,,,5833.0,,Intermediate,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,50425,N
4358,,10144,,Mus musculus,,850.0,10090.0,,Intermediate,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,6C3HED,80628,N
4359,,10144,,Mus musculus,,850.0,10090.0,,Intermediate,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,6C3HED,80628,N
4360,,10144,,Mus musculus,,850.0,10090.0,,Intermediate,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,6C3HED,80628,N
4361,,10144,,Mus musculus,,850.0,10090.0,,Intermediate,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,6C3HED,80628,N
4362,,10144,,Mus musculus,,850.0,10090.0,,Intermediate,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,6C3HED,80628,N
4363,,10144,,Mus musculus,,850.0,10090.0,,Intermediate,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,6C3HED,80628,N
4364,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,22224,U
4365,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,22224,U
4366,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,22224,U
4367,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,22224,U
4368,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,22224,U
4369,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,22224,U
4370,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,22224,U
4371,,10685,,Mus musculus,,,10090.0,,Autocuration,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,22224,U
4372,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,22224,U
4373,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,22224,U
4374,,10685,,Mus musculus,,,10090.0,,Autocuration,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,22224,U
4375,,10144,,Mus musculus,,,10090.0,,Autocuration,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,22224,U
4376,,10144,,Mus musculus,,,10090.0,,Autocuration,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,22224,U
4377,,10144,,Mus musculus,,,10090.0,,Autocuration,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,22224,U
4378,,10144,,Mus musculus,,,10090.0,,Autocuration,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,22224,U
4379,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,22224,U
4380,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,22224,U
4381,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,22224,U
4382,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,22224,U
4383,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,22224,U
4384,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,22224,U
4385,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,22224,U
4386,,10685,,Mus musculus,,,10090.0,,Autocuration,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,22224,U
4387,,8831,,Mus musculus,,850.0,10090.0,,Intermediate,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,6C3HED,80628,N
4388,,11704,,,,,,,Autocuration,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,22224,U
4389,,11704,,Mus musculus,,,10090.0,,Intermediate,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,50594,N
4390,,10685,,Mus musculus,,850.0,10090.0,,Intermediate,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,6C3HED,80628,N
4391,,10685,,Mus musculus,,850.0,10090.0,,Intermediate,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,6C3HED,80628,N
4392,,11368,,Mus musculus,,850.0,10090.0,,Expert,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,6C3HED,80628,N
4393,,11368,,Mus musculus,,850.0,10090.0,,Intermediate,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,6C3HED,80628,N
4394,,11368,,Mus musculus,,850.0,10090.0,,Expert,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,6C3HED,80628,N
4395,,17763,,Staphylococcus aureus,,,1280.0,,Autocuration,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,22226,U
4396,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,22226,U
4397,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,22226,U
4398,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,22226,U
4399,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,22226,U
4400,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,22226,U
4401,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,22226,U
4402,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,22226,U
4403,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,22226,U
4404,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,22226,U
4405,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,22226,U
4406,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,22226,U
4407,Liver,7411,2107.0,Rattus norvegicus,,,10116.0,Microsomes,Autocuration,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,22226,U
4408,Plasma,347,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,The apparent total plasma clearance in monkey,A,In vivo,,22224,U
4409,,3341,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,22224,U
4410,,17853,,Cercopithecidae,,,9527.0,,Autocuration,,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,22224,U
4411,,4514,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance in rhesus monkey,A,In vivo,,22224,U
4412,,6062,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,22224,U
4413,,6821,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance of compound was determined in monkey,A,In vivo,,22224,U
4414,,6057,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance was calculated in rhesus monkey,A,In vivo,,22224,U
4415,,5145,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance in rhesus monkey,A,In vivo,,22224,U
4416,,6641,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,22224,U
4417,,5472,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance was evaluated in rhesus,A,In vivo,,22224,U
4418,,4257,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,22224,U
4419,,5546,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,22224,U
4420,,5334,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
4421,,5334,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
4422,,17509,,Cercopithecidae,,,9527.0,,Autocuration,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,22224,U
4423,,6535,,Cercopithecidae,,,9527.0,,Autocuration,,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,22224,U
4424,,5668,,Cercopithecidae,,,9527.0,,Autocuration,,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,22224,U
4425,,5922,,Cercopithecidae,,,9527.0,,Autocuration,,Cmax in cynomolgus monkey by iv administration,A,In vivo,,22224,U
4426,,5922,,Cercopithecidae,,,9527.0,,Autocuration,,Cmax in cynomolgus monkey by po administration,A,In vivo,,22224,U
4427,,6078,,Cercopithecidae,,,9527.0,,Autocuration,,Cmax value evaluated in monkey,A,In vivo,,22224,U
4428,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,22224,U
4429,Plasma,3249,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,22224,U
4430,Plasma,3249,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,22224,U
4431,Plasma,5553,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Maximal plasma concentration in squirrel monkeys,A,In vivo,,22224,U
4432,,1916,,Cercopithecidae,,,9527.0,,Autocuration,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,22224,U
4433,Plasma,6227,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,22224,U
4434,,4809,,Cercopithecidae,,,9527.0,,Autocuration,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,22224,U
4435,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,22224,U
4436,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,22224,U
4437,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,22224,U
4438,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,22224,U
4439,Plasma,6221,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,22224,U
4440,,167,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,22224,U
4441,,167,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,22224,U
4442,,4257,,monkey,,,9443.0,,Autocuration,,Absolute bioavailability was evaluated in monkey,A,In vivo,,22224,U
4443,,6221,,monkey,,,9443.0,,Autocuration,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,22224,U
4444,,17667,,monkey,,,9443.0,,Autocuration,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,22224,U
4445,,17267,,Macaca mulatta,,,9544.0,,Autocuration,,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,22224,U
4446,,4256,,marmosets,,,38020.0,,Autocuration,,Bioavailability determined after oral administration in marmoset,A,In vivo,,22224,U
4447,,4256,,Macaca fascicularis,,,9541.0,,Autocuration,,Oral bioavailability in cynomolgus monkey,A,In vivo,,22224,U
4448,,17853,,monkey,,,9443.0,,Autocuration,,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,22224,U
4449,,16365,,monkey,,,9443.0,,Autocuration,,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,22224,U
4450,,1916,,Macaca fascicularis,,,9541.0,,Autocuration,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,22224,U
4451,,5334,,Macaca mulatta,,,9544.0,,Autocuration,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
4452,,5334,,Macaca mulatta,,,9544.0,,Autocuration,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
4453,,17592,,monkey,,,9443.0,,Autocuration,,Bioavailability of the compound was determined in monkey,A,In vivo,,22224,U
4454,,1399,,Saimiri sciureus,,,9521.0,,Autocuration,,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,22224,U
4455,,4809,,monkey,,,9443.0,,Autocuration,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,22224,U
4456,,3341,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey,A,In vivo,,22224,U
4457,,64,,Saimiri sciureus,,,9521.0,,Autocuration,,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,22224,U
4458,,5005,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability in Rhesus monkey,A,In vivo,,22224,U
4459,,5005,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,22224,U
4460,,5237,,Macaca fascicularis,,,9541.0,,Autocuration,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,22224,U
4461,,5237,,Macaca fascicularis,,,9541.0,,Autocuration,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,22224,U
4462,,5302,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,22224,U
4463,,17667,,monkey,,,9443.0,,Autocuration,,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,22224,U
4464,,6161,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,50588,N
4465,,6161,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,50588,N
4466,Plasma,3854,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half life determined,A,,,50588,N
4467,Plasma,993,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half life in dog,A,,,50588,N
4468,Plasma,4514,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half-life in Beagle dogs,A,,,50588,N
4469,Plasma,5334,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,50588,N
4470,Plasma,5334,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,50588,N
4471,,1466,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,50588,N
4472,,1466,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,50588,N
4473,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for the half life period in dog,A,,,50588,N
4474,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,50588,N
4475,,3880,,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for half life in dog,A,,,50588,N
4476,Plasma,3639,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,50588,N
4477,,3880,,Canis lupus familiaris,,,9615.0,,Intermediate,,The half life was determined,A,,,50588,N
4478,Plasma,3918,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,The plasma half-life in dogs,A,,,50588,N
4479,Plasma,16452,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,50588,N
4480,,17796,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog,A,,,50588,N
4481,,5983,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,50588,N
4482,,1466,,Canis lupus familiaris,,,9615.0,,Intermediate,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,50588,N
4483,,16456,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,50588,N
4484,,6113,,Mustela putorius furo,,,9669.0,,Expert,,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,50506,N
4485,,6113,,Mustela putorius furo,,,9669.0,,Expert,,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,50506,N
4486,,17796,,Macaca fascicularis,,,9541.0,,Autocuration,,Bioavailability in cynomolgus monkey,A,In vivo,,22224,U
4487,,17796,,Macaca fascicularis,,,9541.0,,Intermediate,,Volume of distribution in cynomolgus,A,In vivo,,100710,N
4488,Plasma,5308,1969.0,Cavia porcellus,,,10141.0,,Autocuration,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,22224,U
4489,,4877,,Cavia porcellus,,,10141.0,,Autocuration,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,22224,U
4490,,4876,,Cavia porcellus,,,10141.0,,Autocuration,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,22224,U
4491,Plasma,4878,1969.0,Cavia porcellus,,,10141.0,,Autocuration,,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,22224,U
4492,,5308,,Cavia porcellus,,,10141.0,,Autocuration,,Bioavailability in guinea pig was tested,A,In vivo,,22224,U
4493,,4877,,Cavia porcellus,,,10141.0,,Autocuration,,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,22224,U
4494,,4876,,Cavia porcellus,,,10141.0,,Autocuration,,Tested for the oral bioavailability of the compound,A,In vivo,,22224,U
4495,,4876,,Cavia porcellus,,,10141.0,,Autocuration,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,22224,U
4496,,5308,,Cavia porcellus,,,10141.0,,Autocuration,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,22224,U
4497,Lung,4877,2048.0,Cavia porcellus,,,10141.0,,Autocuration,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,22224,U
4498,,4878,,Cavia porcellus,,,10141.0,,Autocuration,,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,22224,U
4499,Blood,5689,178.0,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4500,Brain,5689,955.0,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4501,,5689,,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4502,Intestine,5689,160.0,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4503,Kidney,5689,2113.0,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4504,Liver,5689,2107.0,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4505,,5689,,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4506,Spleen,5689,2106.0,Cavia porcellus,,,10141.0,,Autocuration,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,22224,U
4507,,14465,,Cavia porcellus,,,10141.0,,Autocuration,,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,22224,U
4508,,5689,,Cavia porcellus,,,10141.0,,Autocuration,,Partition coefficient was measured as -log (counts per min ),A,,,22224,U
4509,,611,,Cavia porcellus,,,10141.0,,Autocuration,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,22224,U
4510,,611,,Cavia porcellus,,,10141.0,,Autocuration,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,22224,U
4511,,14465,,Cavia porcellus,,,10141.0,,Autocuration,,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,22224,U
4512,,4876,,Cavia porcellus,,,10141.0,,Autocuration,,"Tested for the half life period of the compound, intravenously",A,In vivo,,22224,U
4513,,5689,,Cavia porcellus,,,10141.0,,Autocuration,,Half-life was measured,A,,,22224,U
4514,,7515,,Cavia porcellus,,,10141.0,,Autocuration,,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,22224,U
4515,,17667,,Cavia porcellus,,,10141.0,,Autocuration,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,22224,U
4516,,17667,,Cavia porcellus,,,10141.0,,Autocuration,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,22224,U
4517,,4727,,Cricetulus griseus,,,10029.0,,Autocuration,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,22224,U
4518,,10107,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
4519,,10107,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
4520,,10107,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
4521,,10107,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
4522,,10107,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,50594,N
4523,,10107,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
4524,,10107,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
4525,Blood,3655,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4526,Blood,3655,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4527,Blood,3655,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4528,Bone,3655,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4529,Bone,3655,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4530,Bone,3655,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4531,Brain,3655,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4532,Brain,3655,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4533,Brain,3655,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4534,Heart,3655,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4535,Heart,3655,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4536,Heart,3655,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4537,Intestine,3655,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4538,Intestine,3655,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4539,Intestine,3655,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4540,Kidney,3655,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4541,Kidney,3655,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4542,Kidney,3655,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4543,Liver,3655,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4544,Liver,3655,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4545,Liver,3655,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4546,Lung,3655,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4547,Lung,3655,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4548,Lung,3655,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4549,Muscle tissue,3655,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4550,Muscle tissue,3655,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4551,Muscle tissue,3655,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4552,Spleen,3655,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4553,Spleen,3655,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4554,Spleen,3655,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4555,Stomach,3655,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,50594,N
4556,Stomach,3655,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,50594,N
4557,Stomach,3655,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,50594,N
4558,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,50594,N
4559,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,50594,N
4560,,16597,,Mus musculus,,,10090.0,,Intermediate,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,50594,N
4561,,16597,,Mus musculus,,,10090.0,,Intermediate,,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,50594,N
4562,,17764,,Mus musculus,,,10090.0,,Intermediate,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,50594,N
4563,,17764,,Mus musculus,,,10090.0,,Intermediate,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,50594,N
4564,,3830,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,A2780,81034,N
4565,,3829,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,A2780,81034,N
4566,,2040,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,A2780,81034,N
4567,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,A2780,81034,N
4568,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,A2780,81034,N
4569,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,A2780,81034,N
4570,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,A2780,81034,N
4571,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,A2780,81034,N
4572,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,A2780,81034,N
4573,,2859,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxicity against A2780 cell line,F,,A2780,81034,N
4574,,5618,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro inhibitory activity against human tumor cell line A2780,F,,A2780,81034,N
4575,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,A2780,81034,N
4576,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,A2780,81034,N
4577,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,A2780,81034,N
4578,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,A2780,81034,N
4579,,2113,,Homo sapiens,,478.0,9606.0,,Intermediate,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,A2780,81034,N
4580,,2113,,Homo sapiens,,478.0,9606.0,,Intermediate,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,A2780,81034,N
4581,,16745,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,A2780,81034,N
4582,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,A2780,81034,N
4583,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,A2780,81034,N
4584,,15684,,Homo sapiens,,478.0,9606.0,,Intermediate,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,A2780,81034,N
4585,,2040,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,A2780,81034,N
4586,,2040,,Homo sapiens,,478.0,9606.0,,Intermediate,,Relative resistance factor in A2780 cisplatin-resistant line,F,,A2780,81034,N
4587,,16165,,Homo sapiens,,478.0,9606.0,,Intermediate,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,A2780,81034,N
4588,,16165,,Homo sapiens,,478.0,9606.0,,Intermediate,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,A2780,81034,N
4589,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,A2780,81034,N
4590,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,A2780,81034,N
4591,,3992,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,A2780,81034,N
4592,,10553,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,A2780,81034,N
4593,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,A2780,81034,N
4594,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,A2780,81034,N
4595,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,A2780,81034,N
4596,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,A2780,81034,N
4597,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,A2780,81034,N
4598,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,A2780,81034,N
4599,,15569,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,A2780,81034,N
4600,,17420,,Homo sapiens,,478.0,9606.0,,Intermediate,,Antiproliferative effect of compound on A2780/DX cell line,F,,A2780,81034,N
4601,,17420,,Homo sapiens,,478.0,9606.0,,Intermediate,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,A2780,81034,N
4602,,15099,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,A2780,81034,N
4603,,15099,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,A2780,81034,N
4604,,17672,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,A2780,81034,N
4605,,17672,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,A2780,81034,N
4606,,17270,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against A2780ADR cell line,F,,A2780,81034,N
4607,,17270,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against A2780CIS cell line,F,,A2780,81034,N
4608,,5574,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,A2780,81034,N
4609,,2113,,Homo sapiens,,478.0,9606.0,,Intermediate,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,A2780,81034,N
4610,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,81034,N
4611,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,81034,N
4612,,17839,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability of compound in rhesus macaques,A,In vivo,,22224,U
4613,,6821,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey,A,In vivo,,22224,U
4614,,6078,,monkey,,,9443.0,,Autocuration,,Oral bioavailability evaluated in monkey,A,In vivo,,22224,U
4615,,6535,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,22224,U
4616,,4449,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability in Rhesus monkey,A,In vivo,,22224,U
4617,,6057,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,22224,U
4618,,5922,,Macaca fascicularis,,,9541.0,,Autocuration,,Oral bioavailability in cynomolgus monkey,A,In vivo,,22224,U
4619,,5940,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey,A,In vivo,,22224,U
4620,,6265,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey,A,In vivo,,22224,U
4621,,6265,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,22224,U
4622,,6265,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,22224,U
4623,,5940,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey,A,In vivo,,22224,U
4624,,5940,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey,A,In vivo,,22224,U
4625,,4514,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability in rhesus monkey,A,In vivo,,22224,U
4626,,5546,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,22224,U
4627,,5553,,Saimiri sciureus,,,9521.0,,Autocuration,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,22224,U
4628,,6641,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,22224,U
4629,,5472,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability in Rhesus monkey,A,In vivo,,22224,U
4630,,5668,,Macaca mulatta,,,9544.0,,Autocuration,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,22224,U
4631,,5711,,monkey,,,9443.0,,Autocuration,,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,22224,U
4632,,5145,,Macaca mulatta,,,9544.0,,Autocuration,,Bioavailability in Rhesus monkey,A,In vivo,,22224,U
4633,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
4634,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
4635,,3249,,Cercopithecidae,,,9527.0,,Autocuration,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,22224,U
4636,,3249,,Cercopithecidae,,,9527.0,,Autocuration,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,22224,U
4637,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,22224,U
4638,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,22224,U
4639,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,22224,U
4640,,4809,,Cercopithecidae,,,9527.0,,Autocuration,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,22224,U
4641,,4809,,Cercopithecidae,,,9527.0,,Autocuration,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,22224,U
4642,,14294,,Cercopithecidae,,,9527.0,Microsomes,Autocuration,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,22224,U
4643,,14294,,Cercopithecidae,,,9527.0,Microsomes,Autocuration,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,22224,U
4644,,14294,,Cercopithecidae,,,9527.0,Microsomes,Autocuration,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,22224,U
4645,,14294,,Cercopithecidae,,,9527.0,Microsomes,Autocuration,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,22224,U
4646,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,22224,U
4647,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,22224,U
4648,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,22224,U
4649,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
4650,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
4651,,6821,,Cercopithecidae,,,9527.0,,Autocuration,,Elimination Half-life of compound was determined in monkey,A,,,22224,U
4652,,17267,,Cercopithecidae,,,9527.0,,Autocuration,,Half life of compound was determined in rhesus monkey,A,,,22224,U
4653,Plasma,5819,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Half life in monkey plasma,A,,,22224,U
4654,Plasma,5819,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Half life in monkey plasma; Not detected,A,,,22224,U
4655,,1916,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,22224,U
4656,,17509,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,22224,U
4657,,1399,,Cercopithecidae,,,9527.0,,Autocuration,,Terminal half life of the compound.,A,,,22224,U
4658,,1916,,Cercopithecidae,,,9527.0,,Autocuration,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,22224,U
4659,,4809,,Cercopithecidae,,,9527.0,,Autocuration,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,22224,U
4660,,5546,,Cercopithecidae,,,9527.0,,Autocuration,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,22224,U
4661,Urine,3443,1088.0,Cercopithecidae,,,9527.0,,Autocuration,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
4662,Urine,3443,1088.0,Cercopithecidae,,,9527.0,,Autocuration,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
4663,,4257,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,22224,U
4664,,6221,,Cercopithecidae,,,9527.0,,Autocuration,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,22224,U
4665,,5472,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution was evaluated in rhesus,A,In vivo,,22224,U
4666,,4727,,Cricetulus griseus,,,10029.0,,Autocuration,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,22224,U
4667,,4727,,Cricetulus griseus,,,10029.0,,Autocuration,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,22224,U
4668,,4727,,Cricetulus griseus,,,10029.0,,Autocuration,,Bioavailability in hamster was determined,A,In vivo,,22224,U
4669,,4727,,Cricetulus griseus,,,10029.0,,Autocuration,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,22224,U
4670,,4727,,Cricetulus griseus,,,10029.0,,Autocuration,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,22224,U
4671,Blood,4727,178.0,Cricetulus griseus,,,10029.0,,Autocuration,,Half life of compound was determined in hamster blood,A,,,22224,U
4672,,1452,,Sus scrofa,,,9823.0,,Autocuration,,Michaelis-Menten constant of the compound.,A,,,22224,U
4673,,1452,,Sus scrofa,,,9823.0,,Autocuration,,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,22224,U
4674,,1452,,Sus scrofa,,,9823.0,,Autocuration,,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,22224,U
4675,,1452,,Sus scrofa,,,9823.0,,Autocuration,,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,22224,U
4676,,11706,,Homo sapiens,,,9606.0,,Expert,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,235,D
4677,,1916,,Homo sapiens,,,9606.0,,Autocuration,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,22224,U
4678,,17791,,Homo sapiens,,,9606.0,,Autocuration,,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,22224,U
4679,,7766,,Homo sapiens,,,9606.0,,Autocuration,,Active metabolite of ifosfamide determined in humans; A-Active,A,,,22224,U
4680,,6567,,Homo sapiens,,,9606.0,,Autocuration,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,22224,U
4681,,6567,,Homo sapiens,,,9606.0,,Autocuration,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,22224,U
4682,,6567,,Homo sapiens,,,9606.0,,Autocuration,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,22224,U
4683,,6567,,Homo sapiens,,,9606.0,,Autocuration,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,22224,U
4684,,17791,,Homo sapiens,,,9606.0,,Autocuration,,Compound was evaluated for oral bioavailability in human,A,,,22224,U
4685,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,22224,U
4686,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,22224,U
4687,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,22224,U
4688,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,22224,U
4689,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,22224,U
4690,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,22224,U
4691,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,22224,U
4692,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent of compound in healthy individuals (Group D),A,,,22224,U
4693,Liver,4397,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,22224,U
4694,,17409,,Homo sapiens,,,9606.0,,Autocuration,,Binding towards human plasma protein at 10 uM,A,,,22224,U
4695,,17409,,Homo sapiens,,,9606.0,,Autocuration,,Binding towards human plasma protein at 100 uM,A,,,22224,U
4696,,17176,,Homo sapiens,,,9606.0,,Autocuration,,Human plasma protein binding activity was determined,A,,,22224,U
4697,,15444,,Homo sapiens,,,9606.0,,Autocuration,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,22224,U
4698,,17267,,Homo sapiens,,,9606.0,,Autocuration,,Percent binding of compound towards human plasma protein was determined,A,,,22224,U
4699,Liver,5944,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Plasma clearance in human liver microsomes,A,In vitro,,22224,U
4700,Liver,5668,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro intrinsic clearance in human liver microsome,A,In vitro,,22224,U
4701,Liver,5669,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro intrinsic clearance in human liver microsome,A,In vitro,,22224,U
4702,,5041,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro microsome metabolism clearance in human was determined,A,In vitro,,22224,U
4703,,5041,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,22224,U
4704,,5041,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,22224,U
4705,Liver,5676,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,22224,U
4706,Liver,5944,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Plasma clearance in human liver microsomes,A,In vitro,,22224,U
4707,Liver,17538,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro clearance in human liver microsomes,A,In vitro,,22224,U
4708,Liver,6331,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,22224,U
4709,Liver,5948,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,22224,U
4710,,5965,,Homo sapiens,,,9606.0,,Autocuration,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,22224,U
4711,,1916,,Homo sapiens,,,9606.0,,Autocuration,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,22224,U
4712,,5965,,Homo sapiens,,,9606.0,,Autocuration,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,22224,U
4713,,1299,,Homo sapiens,,,9606.0,,Autocuration,,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,22224,U
4714,,1299,,Homo sapiens,,,9606.0,,Autocuration,,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,22224,U
4715,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4716,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4717,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4718,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4719,,17764,,Mus musculus,,,10090.0,,Intermediate,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,50594,N
4720,,17764,,Mus musculus,,,10090.0,,Intermediate,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,50594,N
4721,,17764,,Mus musculus,,,10090.0,,Intermediate,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,50594,N
4722,,17764,,Mus musculus,,,10090.0,,Intermediate,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,50594,N
4723,,14294,,Mus musculus,,,10090.0,,Intermediate,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,50594,N
4724,,14294,,Mus musculus,,,10090.0,,Intermediate,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,50594,N
4725,,14294,,Mus musculus,,,10090.0,,Intermediate,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,50594,N
4726,Liver,6251,2107.0,Mus musculus,,,10090.0,,Intermediate,,In vitro metabolic potential in mouse liver microsomes,A,,,50594,N
4727,,17582,,Mus musculus,,,10090.0,,Intermediate,,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,50594,N
4728,Adrenal gland,17811,2369.0,Mus musculus,,,10090.0,,Intermediate,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,50594,N
4729,Brain,17811,955.0,Mus musculus,,,10090.0,,Intermediate,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,50594,N
4730,Brain,17811,955.0,Mus musculus,,,10090.0,,Intermediate,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,50594,N
4731,,17811,,Mus musculus,,,10090.0,,Intermediate,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,50594,N
4732,Kidney,17811,2113.0,Mus musculus,,,10090.0,,Intermediate,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,50594,N
4733,,17811,,Mus musculus,,,10090.0,,Intermediate,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,50594,N
4734,,5288,,Mus musculus,,,10090.0,,Intermediate,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,50594,N
4735,Serum,2717,1977.0,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,50594,N
4736,Serum,2717,1977.0,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,50594,N
4737,Serum,2717,1977.0,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,50594,N
4738,Plasma,17753,1969.0,Mus musculus,,,10090.0,,Intermediate,,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,50594,N
4739,Plasma,17753,1969.0,Mus musculus,,,10090.0,,Intermediate,,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,50594,N
4740,Plasma,17753,1969.0,Mus musculus,,,10090.0,,Intermediate,,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,50594,N
4741,,17764,,Mus musculus,,,10090.0,,Intermediate,,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,50594,N
4742,,17764,,Mus musculus,,,10090.0,,Intermediate,,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,50594,N
4743,,17764,,Mus musculus,,,10090.0,,Intermediate,,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,50594,N
4744,,17764,,Mus musculus,,,10090.0,,Intermediate,,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,50594,N
4745,,17764,,Mus musculus,,,10090.0,,Intermediate,,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,50594,N
4746,,17764,,Mus musculus,,,10090.0,,Intermediate,,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,50594,N
4747,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,50594,N
4748,,2675,,Mus musculus,,,10090.0,,Intermediate,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,50594,N
4749,,2675,,Mus musculus,,,10090.0,,Intermediate,,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,50594,N
4750,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,50594,N
4751,,4890,,Mus musculus,,,10090.0,,Intermediate,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,50594,N
4752,,429,,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,50594,N
4753,Blood,17837,178.0,Mus musculus,,,10090.0,,Intermediate,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,50594,N
4754,,16597,,Mus musculus,,,10090.0,,Intermediate,,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,50594,N
4755,,16597,,Mus musculus,,,10090.0,,Intermediate,,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,50594,N
4756,,6619,,Mus musculus,,,10090.0,,Intermediate,,Half life in ob/ob mice,A,,,50594,N
4757,,4066,,Mus musculus,,,10090.0,,Intermediate,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,50594,N
4758,,4239,,Mus musculus,,,10090.0,,Intermediate,,Half-life was measured in mouse,A,,,50594,N
4759,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,50594,N
4760,,8999,,Mus musculus,,,10090.0,,Intermediate,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,50594,N
4761,,8999,,Mus musculus,,,10090.0,,Intermediate,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,50594,N
4762,Brain,17641,955.0,Mus musculus,,,10090.0,,Intermediate,,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,50594,N
4763,Kidney,17641,2113.0,Mus musculus,,,10090.0,,Intermediate,,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,50594,N
4764,Liver,17641,2107.0,Mus musculus,,,10090.0,,Intermediate,,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,50594,N
4765,Lung,17641,2048.0,Mus musculus,,,10090.0,,Intermediate,,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,50594,N
4766,Spleen,17641,2106.0,Mus musculus,,,10090.0,,Intermediate,,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,50594,N
4767,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,50594,N
4768,,4890,,Mus musculus,,,10090.0,,Intermediate,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,50594,N
4769,,429,,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,50594,N
4770,,429,,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,50594,N
4771,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,50594,N
4772,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,81034,N
4773,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,A2780,81034,N
4774,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,81034,N
4775,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,81034,N
4776,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,81034,N
4777,,16913,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,A2780,81034,N
4778,,17270,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against A2780TAX cell line,F,,A2780,81034,N
4779,,5618,,Homo sapiens,,481.0,9606.0,,Intermediate,,In vitro inhibitory activity against human tumor cell line A2780cis,F,,A2780cisR,80017,N
4780,,17777,,Homo sapiens,,478.0,9606.0,,Expert,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,A2780,81034,N
4781,,16112,,Homo sapiens,,481.0,9606.0,,Intermediate,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,A2780cisR,80017,N
4782,,15748,,Homo sapiens,,481.0,9606.0,,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,A2780cisR,80017,N
4783,,6633,,Homo sapiens,,478.0,9606.0,,Intermediate,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,A2780,81034,N
4784,,16930,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,A2780,81034,N
4785,,17496,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,A2780,81034,N
4786,,12989,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro antitumor activity against A2780cisR cell line.,F,,A2780,81034,N
4787,,4840,,Homo sapiens,,478.0,9606.0,,Intermediate,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,A2780,81034,N
4788,,12989,,Homo sapiens,,478.0,9606.0,,Expert,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,A2780,81034,N
4789,,16745,,Homo sapiens,,481.0,9606.0,,Intermediate,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,A2780cisR,80017,N
4790,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,A2780,81034,N
4791,,16547,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,11736,D
4792,,16547,,,,,,,Expert,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,11736,H
4793,,16547,,Rattus norvegicus,,,10116.0,,Expert,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,11736,D
4794,,15856,,Homo sapiens,,722.0,9606.0,,Expert,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,HEK293,278,D
4795,,15856,,Homo sapiens,,722.0,9606.0,,Expert,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,HEK293,278,D
4796,,16547,,Mus musculus,,,10090.0,,Expert,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,11831,D
4797,,16547,,,,,,,Expert,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,11831,H
4798,,16547,,Mus musculus,,,10090.0,,Expert,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,11831,D
4799,,17402,,,,,,,Expert,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,280,H
4800,,11746,,Homo sapiens,,574.0,9606.0,,Autocuration,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,T-cells,22226,U
4801,,11746,,Homo sapiens,,574.0,9606.0,,Autocuration,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,T-cells,22226,U
4802,,5455,,Homo sapiens,,455.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,A-375,80018,N
4803,,2068,,Homo sapiens,,455.0,9606.0,,Intermediate,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,A-375,80018,N
4804,,2683,,Homo sapiens,,455.0,9606.0,,Intermediate,,In vitro antitumor activity against A375cell line extracted form melanoma,F,,A-375,80018,N
4805,,15313,,Homo sapiens,,455.0,9606.0,,Expert,,Inhibition of cell growth in (A375) melan cell line,F,,A-375,80018,N
4806,,13739,,Homo sapiens,,455.0,9606.0,,Intermediate,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,A-375,80018,N
4807,,13739,,Homo sapiens,,455.0,9606.0,,Intermediate,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,A-375,80018,N
4808,,14750,,Homo sapiens,,455.0,9606.0,,Intermediate,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,A-375,80018,N
4809,,14777,,Homo sapiens,,797.0,9606.0,,Intermediate,,Antiproliferative activity measured against A427 human lung carcinoma,F,,A-427,80019,N
4810,,14777,,Homo sapiens,,797.0,9606.0,,Intermediate,,Antiproliferative activity measured against A427 human lung carcinoma,F,,A-427,80019,N
4811,,17672,,Homo sapiens,,797.0,9606.0,,Intermediate,,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,A-427,80019,N
4812,,14368,,Homo sapiens,,797.0,9606.0,,Intermediate,,Inhibition of large cell lung carcinoma (A427),F,,A-427,80019,N
4813,,14368,,Homo sapiens,,797.0,9606.0,,Intermediate,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,A-427,80019,N
4814,,13866,,Homo sapiens,,797.0,9606.0,,Intermediate,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,A-427,80019,N
4815,,2545,,Homo sapiens,,797.0,9606.0,,Intermediate,,Inhibitory concentration in human lung carcinoma A427 cell line,F,,A-427,80019,N
4816,,2545,,Homo sapiens,,797.0,9606.0,,Intermediate,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,A-427,80019,N
4817,,6062,,Cercopithecidae,,,9527.0,,Autocuration,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,22224,U
4818,,4578,,Cercopithecidae,,,9527.0,,Autocuration,,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,22224,U
4819,,17592,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution in monkey,A,In vivo,,22224,U
4820,,5005,,Macaca mulatta,,,9544.0,,Autocuration,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,22224,U
4821,,5005,,Macaca mulatta,,,9544.0,,Autocuration,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,22224,U
4822,,5922,,Cercopithecidae,,,9527.0,,Autocuration,,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,22224,U
4823,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,22224,U
4824,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,22224,U
4825,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,22224,U
4826,,6057,,Cercopithecidae,,,9527.0,,Autocuration,,Volume displacement was calculated in rhesus monkey,A,In vivo,,22224,U
4827,,5145,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,22224,U
4828,,6821,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution of compound was determined in monkey,A,In vivo,,22224,U
4829,,5334,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
4830,,5334,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
4831,,6641,,Cercopithecidae,,,9527.0,,Autocuration,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,22224,U
4832,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,22224,U
4833,,6535,,Cercopithecidae,,,9527.0,,Autocuration,,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,22224,U
4834,,4809,,Cercopithecidae,,,9527.0,,Autocuration,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,22224,U
4835,,6062,,Cercopithecidae,,,9527.0,,Autocuration,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,22224,U
4836,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,22224,U
4837,,4578,,Cercopithecidae,,,9527.0,,Autocuration,,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,22224,U
4838,,4809,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,22224,U
4839,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Baboon plasma free fraction. ,A,,,22224,U
4840,,6057,,Cercopithecidae,,,9527.0,,Autocuration,,Area under the curve was calculated in rhesus monkey after iv administration,A,,,22224,U
4841,,6057,,Cercopithecidae,,,9527.0,,Autocuration,,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,22224,U
4842,,17853,,Cercopithecidae,,,9527.0,,Autocuration,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,22224,U
4843,,5302,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period in monkey after 5 mg/kg dose,A,In vivo,,22224,U
4844,,4257,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,22224,U
4845,,4257,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,22224,U
4846,Plasma,13501,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,22224,U
4847,,5394,,Cercopithecidae,,,9527.0,,Autocuration,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,22224,U
4848,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,22224,U
4849,,3341,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for terminal half life in monkey,A,,,22224,U
4850,,3045,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,22224,U
4851,Plasma,5005,1969.0,Macaca mulatta,,,9544.0,,Autocuration,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,22224,U
4852,,4847,,Cercopithecidae,,,9527.0,,Autocuration,,Half life of compound was determined in squirrel monkey,A,,,22224,U
4853,,4256,,Macaca fascicularis,,,9541.0,,Autocuration,,Half life after iv administration in cynomolgus monkey,A,In vivo,,22224,U
4854,Plasma,6535,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,22224,U
4855,,6057,,Cercopithecidae,,,9527.0,,Autocuration,,Half life was calculated in rhesus monkey,A,,,22224,U
4856,,17592,,Cercopithecidae,,,9527.0,,Autocuration,,Half life in monkey,A,,,22224,U
4857,,6641,,Cercopithecidae,,,9527.0,,Autocuration,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,22224,U
4858,,5472,,Cercopithecidae,,,9527.0,,Autocuration,,Half life was evaluated in rhesus,A,,,22224,U
4859,,6221,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,22224,U
4860,,5668,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,22224,U
4861,,4809,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,22224,U
4862,,5546,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,22224,U
4863,,5553,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,22224,U
4864,,6078,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life was calculated in monkey,A,,,22224,U
4865,,5147,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life in Squirrel monkey,A,,,22224,U
4866,,5145,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life in rhesus monkey,A,,,22224,U
4867,,6062,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,22224,U
4868,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,22224,U
4869,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,22224,U
4870,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,22224,U
4871,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4872,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4873,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4874,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,22224,U
4875,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,22224,U
4876,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,22224,U
4877,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,22224,U
4878,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,22224,U
4879,,1916,,Homo sapiens,,,9606.0,,Autocuration,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,22224,U
4880,,16643,,Homo sapiens,,,9606.0,,Autocuration,,Oral bioavailability in human,A,In vivo,,22224,U
4881,,17248,,Homo sapiens,,,9606.0,,Autocuration,,Compound was tested for human plasma protein binding,A,,,22224,U
4882,,17248,,Homo sapiens,,,9606.0,,Autocuration,,Compound was tested for human plasma protein binding; Not determined,A,,,22224,U
4883,,6241,,Homo sapiens,,,9606.0,,Autocuration,,Protein binding activity of compound in human plasma; % Free,A,,,22224,U
4884,,17716,,Homo sapiens,,,9606.0,,Autocuration,,Unbound fraction (plasma),A,,,22224,U
4885,Plasma,17605,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life for the hydrolysis of compound in human blood serum,A,,,22224,U
4886,Plasma,17625,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life period in human plasma using phosphate buffer (0.08 M),A,,,22224,U
4887,Plasma,17625,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life period in human plasma using phosphate buffer (0.1 M),A,,,22224,U
4888,Plasma,17747,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life in human plasma was determined,A,,,22224,U
4889,,15613,,Homo sapiens,,,9606.0,,Autocuration,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,22224,U
4890,,354,,Homo sapiens,,,9606.0,,Autocuration,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,22224,U
4891,,3741,,Homo sapiens,,,9606.0,,Autocuration,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,22224,U
4892,,3741,,Homo sapiens,,,9606.0,,Autocuration,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,22224,U
4893,,3741,,Homo sapiens,,,9606.0,,Autocuration,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,22224,U
4894,,17599,,Homo sapiens,,,9606.0,,Autocuration,,Partition coefficient (logP),A,,,22224,U
4895,,5486,,Homo sapiens,,,9606.0,,Autocuration,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,22224,U
4896,,5600,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,22224,U
4897,,14294,,Homo sapiens,,,9606.0,,Autocuration,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,22224,U
4898,,14294,,Homo sapiens,,,9606.0,,Autocuration,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,22224,U
4899,,14294,,Homo sapiens,,,9606.0,,Autocuration,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,22224,U
4900,,14294,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,22224,U
4901,,14294,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,22224,U
4902,,14294,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Metabolism of compound in human microsomes; Trace,A,,,22224,U
4903,Liver,6260,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,22224,U
4904,,6187,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,22224,U
4905,Liver,6251,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro metabolic potential in human liver microsomes,A,,,22224,U
4906,,3246,,Homo sapiens,,,9606.0,,Autocuration,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,22224,U
4907,,17313,,Homo sapiens,,,9606.0,,Autocuration,,Tested for human plasma protein binding of the compound; Not tested,A,,,22224,U
4908,,6227,,Homo sapiens,,,9606.0,,Autocuration,,Compound was tested for percent protein binding (PB) in human,A,,,22224,U
4909,Plasma,5530,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Protein binding in human plasma,A,,,22224,U
4910,,6108,,Homo sapiens,,,9606.0,,Autocuration,,Permeability coefficient (B to A) in Caco-2 cell,A,,,22224,U
4911,,6108,,Homo sapiens,,,9606.0,,Autocuration,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,22224,U
4912,,2774,,Homo sapiens,,,9606.0,,Autocuration,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,22224,U
4913,,16643,,Homo sapiens,,,9606.0,,Autocuration,,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,22224,U
4914,,17582,,Homo sapiens,,495.0,9606.0,,Autocuration,,Cellular permeability of compound was determined in Caco-2 cells; High,A,,Caco-2,22224,U
4915,,6838,,Homo sapiens,,495.0,9606.0,,Autocuration,,Permeability in Caco-2 cells of compound,A,,Caco-2,22224,U
4916,,6108,,Homo sapiens,,,9606.0,,Autocuration,,Permeability coefficient (A to B) in Caco-2 cell,A,,,22224,U
4917,,6108,,Homo sapiens,,,9606.0,,Autocuration,,Permeability coefficient (B to A) in Caco-2 cell,A,,,22224,U
4918,,6108,,Homo sapiens,,,9606.0,,Autocuration,,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,22224,U
4919,,2146,,Homo sapiens,,,9606.0,,Autocuration,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,22224,U
4920,,4514,,Homo sapiens,,,9606.0,,Autocuration,,Compound was tested for protein binding in human plasma,A,,,22224,U
4921,,6108,,Homo sapiens,,,9606.0,,Autocuration,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,22224,U
4922,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,22224,U
4923,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,50594,N
4924,,3277,,Mus musculus,,,10090.0,,Intermediate,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,50594,N
4925,,3802,,Mus musculus,,,10090.0,,Intermediate,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,50594,N
4926,Plasma,2862,1969.0,Mus musculus,,,10090.0,,Intermediate,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,50594,N
4927,Plasma,6348,1969.0,Mus musculus,,,10090.0,,Intermediate,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,50594,N
4928,,17764,,Mus musculus,,,10090.0,,Intermediate,,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,50594,N
4929,,5781,,Mus musculus,,,10090.0,,Intermediate,,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,50594,N
4930,,17764,,Mus musculus,,,10090.0,,Intermediate,,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,50594,N
4931,,4066,,Mus musculus,,,10090.0,,Intermediate,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,50594,N
4932,Brain,17641,955.0,Mus musculus,,,10090.0,,Intermediate,,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
4933,Kidney,17641,2113.0,Mus musculus,,,10090.0,,Intermediate,,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
4934,Liver,17641,2107.0,Mus musculus,,,10090.0,,Intermediate,,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
4935,Lung,17641,2048.0,Mus musculus,,,10090.0,,Intermediate,,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
4936,,17764,,Mus musculus,,,10090.0,,Intermediate,,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,50594,N
4937,,17764,,Mus musculus,,,10090.0,,Intermediate,,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,50594,N
4938,,17764,,Mus musculus,,,10090.0,,Intermediate,,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,50594,N
4939,,17764,,Mus musculus,,,10090.0,,Intermediate,,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,50594,N
4940,Spleen,17641,2106.0,Mus musculus,,,10090.0,,Intermediate,,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
4941,,16597,,Mus musculus,,,10090.0,,Intermediate,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,50594,N
4942,,16597,,Mus musculus,,,10090.0,,Intermediate,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,50594,N
4943,,5951,,Mus musculus,,,10090.0,,Intermediate,,Tmax value in IRC mice,A,,,50594,N
4944,,5506,,Mus musculus,,,10090.0,,Intermediate,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,50594,N
4945,,5506,,Mus musculus,,,10090.0,,Intermediate,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,50594,N
4946,Urine,429,1088.0,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,50594,N
4947,Urine,429,1088.0,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,50594,N
4948,Urine,4066,1088.0,Mus musculus,,,10090.0,,Intermediate,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,50594,N
4949,,17734,,Mus musculus,,,10090.0,,Intermediate,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,50594,N
4950,,17734,,Mus musculus,,,10090.0,,Intermediate,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,50594,N
4951,,6062,,Mus musculus,,,10090.0,,Intermediate,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,50594,N
4952,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,50594,N
4953,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,50594,N
4954,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,50594,N
4955,,5980,,Mus musculus,,,10090.0,,Intermediate,,Vd in mice,A,In vivo,,50594,N
4956,,17592,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution in mouse,A,In vivo,,50594,N
4957,,6348,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,50594,N
4958,,17753,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,50594,N
4959,,17753,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,50594,N
4960,,17753,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,50594,N
4961,,4239,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,50594,N
4962,,2862,,Mus musculus,,,10090.0,,Intermediate,,Value distribution upon iv administration in mouse,A,In vivo,,50594,N
4963,,17734,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,50594,N
4964,,2675,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,50594,N
4965,,2675,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,50594,N
4966,,17837,,Mus musculus,,,10090.0,,Intermediate,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,50594,N
4967,,5727,,Mus musculus,,,10090.0,,Intermediate,,Steady state volume of distribution was determined in mice,A,In vivo,,50594,N
4968,,17852,,Mus musculus,,,10090.0,,Intermediate,,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,50594,N
4969,,17764,,Mus musculus,,,10090.0,,Intermediate,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,50594,N
4970,,16597,,Mus musculus,,,10090.0,,Intermediate,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,50594,N
4971,,6062,,Mus musculus,,,10090.0,,Intermediate,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,50594,N
4972,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,50594,N
4973,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,50594,N
4974,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,50594,N
4975,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
4976,,10708,,Homo sapiens,,797.0,9606.0,,Intermediate,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,A-427,80019,N
4977,,16597,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,A-431,80852,N
4978,,16062,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,A-431,80852,N
4979,,16062,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,A-431,80852,N
4980,,16958,,Homo sapiens,,500.0,9606.0,,Expert,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,A-431,80852,N
4981,,6700,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of A431 human carcinoma cell proliferation,F,,A-431,80852,N
4982,,17226,,Homo sapiens,,500.0,9606.0,,Expert,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,A-431,80852,N
4983,,6828,,Homo sapiens,,500.0,9606.0,,Intermediate,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,A-431,80852,N
4984,,12314,,Homo sapiens,,500.0,9606.0,,Intermediate,,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,A-431,80852,N
4985,,13412,,Homo sapiens,,500.0,9606.0,,Expert,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,A-431,9,D
4986,,13299,,Homo sapiens,,500.0,9606.0,,Intermediate,,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,A-431,80852,N
4987,,17420,,Homo sapiens,,500.0,9606.0,,Intermediate,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,A-431,80852,N
4988,,13678,,Homo sapiens,,500.0,9606.0,,Intermediate,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,A-431,80852,N
4989,,14171,,,,500.0,,,Expert,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,A-431,9,H
4990,,6333,,Homo sapiens,,500.0,9606.0,,Expert,,Tested for antiproliferative activity against human A431 cells,F,,A-431,80852,N
4991,,2356,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,A-431,9,D
4992,,15578,,Homo sapiens,,500.0,9606.0,,Expert,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,A-431,80852,N
4993,,5126,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of A431 cell proliferation,F,,A-431,80852,N
4994,,6844,,Homo sapiens,,500.0,9606.0,,Expert,,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,A-431,80852,N
4995,,6844,,Homo sapiens,,500.0,9606.0,,Expert,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,A-431,80852,N
4996,,4925,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,A-431,80852,N
4997,,4925,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,A-431,80852,N
4998,,13978,,Homo sapiens,,500.0,9606.0,,Intermediate,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,A-431,80852,N
4999,,16786,,Homo sapiens,,500.0,9606.0,,Intermediate,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,A-431,80852,N
5000,,13412,,,,500.0,,,Expert,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,A-431,9,H
5001,,17824,,Homo sapiens,,500.0,9606.0,,Intermediate,,In vivo antiproliferative activity against A431 cell line,F,,A-431,80852,N
5002,,12751,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,A-431,9,D
5003,,12380,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,A-431,80852,N
5004,,4959,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,A-431,9,D
5005,,6333,,Homo sapiens,,500.0,9606.0,,Intermediate,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,A-431,80852,N
5006,,6333,,Homo sapiens,,500.0,9606.0,,Intermediate,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,A-431,80852,N
5007,,6333,,Homo sapiens,,500.0,9606.0,,Intermediate,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,A-431,80852,N
5008,,5296,,Homo sapiens,,,9606.0,,Expert,,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,9,D
5009,,12624,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of A431 cell proliferation,F,,A-431,80852,N
5010,,14926,,Homo sapiens,,500.0,9606.0,,Expert,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,A-431,9,D
5011,,14926,,Homo sapiens,,500.0,9606.0,,Expert,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,A-431,9,D
5012,,14926,,,,500.0,,,Expert,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,A-431,9,H
5013,,15144,,Homo sapiens,,500.0,9606.0,,Intermediate,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,A-431,80852,N
5014,,15144,,Homo sapiens,,500.0,9606.0,,Intermediate,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,A-431,80852,N
5015,,5245,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,A-431,80852,N
5016,,5245,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,A-431,80852,N
5017,,5245,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,A-431,80852,N
5018,,5245,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,A-431,80852,N
5019,,5245,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,A-431,80852,N
5020,,5922,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life period in cynomolgus monkey,A,,,22224,U
5021,Plasma,1116,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,22224,U
5022,,17853,,Cercopithecidae,,,9527.0,,Autocuration,,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,22224,U
5023,Plasma,993,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Plasma half life in monkey,A,,,22224,U
5024,Plasma,4514,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Plasma half-life in rhesus monkey,A,,,22224,U
5025,Plasma,5334,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
5026,Plasma,5334,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,22224,U
5027,,4578,,Cercopithecidae,,,9527.0,,Autocuration,,Tested for half life upon iv administration to african green monkey,A,In vivo,,22224,U
5028,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,22224,U
5029,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,22224,U
5030,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,22224,U
5031,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,22224,U
5032,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,22224,U
5033,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,22224,U
5034,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,22224,U
5035,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,22224,U
5036,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,22224,U
5037,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,22224,U
5038,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,22224,U
5039,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,22224,U
5040,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,22224,U
5041,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,22224,U
5042,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,22224,U
5043,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,22224,U
5044,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,22224,U
5045,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,22224,U
5046,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,22224,U
5047,,11271,,Cercopithecidae,,,9527.0,,Autocuration,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,22224,U
5048,,5809,,Rattus norvegicus,,,10116.0,,Intermediate,,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,50597,N
5049,Plasma,17720,1969.0,Rattus norvegicus,,,10116.0,,Intermediate,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,50597,N
5050,Plasma,3546,1969.0,Rattus norvegicus,,,10116.0,,Intermediate,,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,50597,N
5051,Plasma,3546,1969.0,Rattus norvegicus,,,10116.0,,Intermediate,,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,50597,N
5052,,3546,,Rattus norvegicus,,,10116.0,,Intermediate,,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,50597,N
5053,,3546,,Rattus norvegicus,,,10116.0,,Intermediate,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,50597,N
5054,,3546,,Rattus norvegicus,,,10116.0,,Intermediate,,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,50597,N
5055,,3546,,Rattus norvegicus,,,10116.0,,Intermediate,,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,50597,N
5056,,3546,,Rattus norvegicus,,,10116.0,,Intermediate,,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,50597,N
5057,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,22224,U
5058,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,22224,U
5059,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,22224,U
5060,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,22224,U
5061,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,22224,U
5062,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,22224,U
5063,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,22224,U
5064,,10625,,Papio hamadryas,,,9557.0,,Autocuration,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,22224,U
5065,,3510,,beagle,,,9615.0,,Autocuration,,Area under curve after 1 mpk peroral administration to beagles,A,,,22224,U
5066,,3510,,beagle,,,9615.0,,Autocuration,,Area under curve after 2 mpk peroral administration to beagles,A,,,22224,U
5067,,3510,,beagle,,,9615.0,,Autocuration,,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,22224,U
5068,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,22224,U
5069,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,22224,U
5070,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,22224,U
5071,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,22224,U
5072,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,22224,U
5073,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,22224,U
5074,Urine,7766,1088.0,Homo sapiens,,,9606.0,,Autocuration,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,22224,U
5075,Liver,16643,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,22224,U
5076,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,22224,U
5077,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,22224,U
5078,,6852,,Homo sapiens,,,9606.0,,Autocuration,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,22224,U
5079,Liver,6567,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,22224,U
5080,,6570,,Homo sapiens,,,9606.0,,Autocuration,,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,22224,U
5081,,6570,,Homo sapiens,,,9606.0,,Autocuration,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,22224,U
5082,Liver,5237,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,22224,U
5083,Liver,5237,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,22224,U
5084,Liver,5237,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,22224,U
5085,,5202,,Homo sapiens,,,9606.0,,Autocuration,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,22224,U
5086,,5481,,Homo sapiens,,,9606.0,,Autocuration,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,22224,U
5087,,5481,,Homo sapiens,,,9606.0,,Autocuration,,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,22224,U
5088,,3956,,Homo sapiens,,,9606.0,,Autocuration,,The percent remaining in human plasma after 30 min was determined,A,,,22224,U
5089,Plasma,5074,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Conversion rate of the prodrug in human plasma,A,,,22224,U
5090,Plasma,5074,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Conversion rate of the prodrug in human plasma; ND means no data,A,,,22224,U
5091,Blood,4727,178.0,Homo sapiens,,,9606.0,,Autocuration,,Half life of compound was determined in human blood,A,,,22224,U
5092,,5965,,Homo sapiens,,,9606.0,,Autocuration,,Half life of compound was determined in man with once daily dosing,A,,,22224,U
5093,,5732,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Half life in human microsomes,A,In vitro,,22224,U
5094,Plasma,5819,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life in human plasma,A,,,22224,U
5095,Plasma,5819,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life in human plasma; Not detected,A,,,22224,U
5096,,1916,,Homo sapiens,,,9606.0,,Autocuration,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,22224,U
5097,Liver,6597,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,22224,U
5098,Plasma,5229,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life in human plasma,A,,,22224,U
5099,Plasma,5229,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life of the parent prodrug in plasma,A,,,22224,U
5100,Plasma,2192,1969.0,Homo sapiens,,,9606.0,,Autocuration,,In vitro half life in human plasma was determined,A,In vitro,,22224,U
5101,Liver,3032,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,22224,U
5102,,1916,,Homo sapiens,,,9606.0,,Autocuration,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,22224,U
5103,,17716,,Homo sapiens,,,9606.0,,Autocuration,,Observed volume of distribution,A,In vivo,,22224,U
5104,,15778,,Homo sapiens,,,9606.0,,Autocuration,,Oral bioavailability in human,A,In vivo,,22224,U
5105,,17313,,Homo sapiens,,,9606.0,,Autocuration,,Tested for human plasma protein binding of the compound,A,,,22224,U
5106,,4231,,Homo sapiens,,,9606.0,,Autocuration,,"First order rate constant, k was determined in human plasma",A,,,22224,U
5107,,4755,,Homo sapiens,,,9606.0,,Autocuration,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,22224,U
5108,,4755,,Homo sapiens,,,9606.0,,Autocuration,,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,22224,U
5109,Liver,16907,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,22224,U
5110,,10839,,Homo sapiens,,,9606.0,,Autocuration,,The compound was tested for the plasma binding in human,A,,,22224,U
5111,,10839,,Homo sapiens,,,9606.0,,Autocuration,,Plasma protein binding (human),A,,,22224,U
5112,Liver,3199,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,22224,U
5113,Blood,1345,178.0,Homo sapiens,,,9606.0,,Autocuration,,Half life measured in vitro for its stability in human blood,A,In vitro,,22224,U
5114,Serum,4297,1977.0,Homo sapiens,,,9606.0,,Autocuration,,Half life in human serum,A,,,22224,U
5115,Serum,4297,1977.0,Homo sapiens,,,9606.0,,Autocuration,,Half life in human serum; ND=not determined,A,,,22224,U
5116,,4297,,Homo sapiens,,,9606.0,,Autocuration,,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,22224,U
5117,,4297,,Homo sapiens,,,9606.0,,Autocuration,,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,22224,U
5118,Plasma,4231,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life of the in human plasma,A,,,22224,U
5119,,5633,,Homo sapiens,,,9606.0,S9,Autocuration,,Half life period in human hepatic S9 fraction was determined,A,In vitro,,22224,U
5120,Liver,5633,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Half life period in human liver microsome was determined,A,In vitro,,22224,U
5121,,17791,,Homo sapiens,,,9606.0,,Autocuration,,Half life period was determined; 6-7,A,,,22224,U
5122,,17791,,Homo sapiens,,,9606.0,,Autocuration,,Half life period was evaluated in human,A,,,22224,U
5123,Plasma,3160,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life time in human plasma,A,,,22224,U
5124,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5125,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5126,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5127,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5128,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,50594,N
5129,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5130,Liver,16438,2107.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5131,Liver,16438,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,50594,N
5132,Liver,16438,2107.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5133,Spleen,16438,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,50594,N
5134,Spleen,16438,2106.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,50594,N
5135,Spleen,16438,2106.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5136,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,50594,N
5137,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,50594,N
5138,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5139,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,50594,N
5140,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,50594,N
5141,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5142,Blood,16438,178.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,50594,N
5143,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,50594,N
5144,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5145,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,50594,N
5146,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5147,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,50594,N
5148,Brain,16438,955.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,50594,N
5149,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,50594,N
5150,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5151,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5152,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,50594,N
5153,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5154,Heart,16438,948.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,50594,N
5155,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5156,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,50594,N
5157,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,50594,N
5158,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5159,Kidney,16438,2113.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,50594,N
5160,Liver,16438,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,50594,N
5161,Liver,16438,2107.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,50594,N
5162,Liver,16438,2107.0,Mus musculus,,,10090.0,,Intermediate,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,50594,N
5163,,5245,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,A-431,80852,N
5164,,5245,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,A-431,80852,N
5165,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,A-431,80852,N
5166,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,A-431,80852,N
5167,,16093,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,A-431,9,D
5168,,16825,,Homo sapiens,,500.0,9606.0,,Intermediate,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,A-431,80852,N
5169,,4848,,Homo sapiens,,500.0,9606.0,,Intermediate,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,A-431,80852,N
5170,,14827,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,A-431,9,D
5171,,14827,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,A-431,9,D
5172,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,A-431,80852,N
5173,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,A-431,80852,N
5174,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,A-431,80852,N
5175,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,A-431,80852,N
5176,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,A-431,80852,N
5177,,16289,,Homo sapiens,,500.0,9606.0,,Expert,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,A-431,9,D
5178,,16289,,,,500.0,,,Expert,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,A-431,9,H
5179,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,A-431,80852,N
5180,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,A-431,80852,N
5181,,16289,,,,500.0,,,Expert,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,A-431,80852,N
5182,,14555,,Mus musculus,,500.0,10090.0,,Expert,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,80852,N
5183,,14555,,Mus musculus,,500.0,10090.0,,Expert,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,80852,N
5184,,14555,,Mus musculus,,500.0,10090.0,,Expert,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,80852,N
5185,,14555,,Mus musculus,,500.0,10090.0,,Expert,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,A-431,80852,N
5186,,1937,,Homo sapiens,,500.0,9606.0,,Expert,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,A-431,80852,N
5187,,13739,,Homo sapiens,,500.0,9606.0,,Intermediate,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,A-431,80852,N
5188,,3558,,Homo sapiens,,500.0,9606.0,,Intermediate,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,A-431,80852,N
5189,,3558,,Homo sapiens,,500.0,9606.0,,Intermediate,,Dose giving a 50% decrease in the living cell number (A437 cells),F,,A-431,80852,N
5190,,17686,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,A549,80682,N
5191,,5305,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,A549,80682,N
5192,,3614,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,A549,80682,N
5193,,17229,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro antitumor activity against renal A498 tumor cell lines,F,,A498,80021,N
5194,,15935,,Homo sapiens,,624.0,9606.0,,Intermediate,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,A498,80021,N
5195,,15935,,Homo sapiens,,624.0,9606.0,,Intermediate,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,A498,80021,N
5196,,15560,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,A498,80021,N
5197,,13891,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,A498,80021,N
5198,,13891,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,A498,80021,N
5199,,13788,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,A498,80021,N
5200,,15403,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was evaluated against Human cell line renal A498,F,,A498,80021,N
5201,,1009,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was tested for inhibition of A498 human renal cancer cell line,F,,A498,80021,N
5202,,1043,,Homo sapiens,,624.0,9606.0,,Intermediate,,Growth inhibitory activity against A498 human cancer cell line,F,,A498,80021,N
5203,,5858,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro antitumor activity against human renal A498 cell line,F,,A498,80021,N
5204,,5958,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxic activity against renal (A498) cell line,F,,A498,80021,N
5205,,5506,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,A498,80021,N
5206,,12781,,Homo sapiens,,624.0,9606.0,,Intermediate,,Tested for cytostatic activity against renal A498 cell line,F,,A498,80021,N
5207,,14399,,Homo sapiens,,624.0,9606.0,,Intermediate,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,A498,80021,N
5208,,5958,,Homo sapiens,,624.0,9606.0,,Expert,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,A498,80021,N
5209,,3510,,beagle,,,9615.0,,Autocuration,,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,22224,U
5210,,3510,,Canis lupus familiaris,,,9615.0,,Autocuration,beagle,Bioavailability,A,In vivo,,22224,U
5211,,3510,,Canis lupus familiaris,,,9615.0,,Autocuration,beagle,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,22224,U
5212,,3510,,Canis lupus familiaris,,,9615.0,,Autocuration,beagle,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,22224,U
5213,,3085,,Bos taurus,,,9913.0,,Autocuration,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,22224,U
5214,,3085,,Bos taurus,,,9913.0,,Autocuration,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,22224,U
5215,,3085,,Bos taurus,,,9913.0,,Autocuration,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,22224,U
5216,,9372,,Bos taurus,,,9913.0,,Autocuration,,Solubility against bovine alpha-chymotrypsin,A,,,22224,U
5217,,3085,,Bos taurus,,,9913.0,,Autocuration,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,22224,U
5218,,3085,,Bos taurus,,,9913.0,,Autocuration,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,22224,U
5219,Spleen,1469,2106.0,Bos taurus,,,9913.0,,Autocuration,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,22224,U
5220,,4297,,Bos taurus,,,9913.0,,Autocuration,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,22224,U
5221,,4297,,Bos taurus,,,9913.0,,Autocuration,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,22224,U
5222,,17585,,Bos taurus,,,9913.0,,Autocuration,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,22224,U
5223,Spleen,1336,2106.0,Bos taurus,,,9913.0,,Autocuration,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,22224,U
5224,,3085,,Bos taurus,,,9913.0,,Autocuration,,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,22224,U
5225,,2857,,Bos taurus,,,9913.0,,Autocuration,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,22224,U
5226,,2857,,Bos taurus,,,9913.0,,Autocuration,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,22224,U
5227,,2857,,Bos taurus,,,9913.0,,Autocuration,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,22224,U
5228,,1540,,Bos taurus,,,9913.0,,Autocuration,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,22224,U
5229,Plasma,6316,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,50588,N
5230,Plasma,17594,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC after administration at 100 mg/kg/day in dogs,A,,,50588,N
5231,Plasma,4953,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,50588,N
5232,Plasma,16907,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC value after 15 mg/kg iv dose in Dogs,A,,,50588,N
5233,Plasma,16907,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC value after 30 mg/kg po dose in Dogs,A,,,50588,N
5234,Plasma,2959,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,50588,N
5235,Plasma,17594,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,50588,N
5236,,5356,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,50588,N
5237,,16807,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,50588,N
5238,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,50588,N
5239,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,50588,N
5240,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,50588,N
5241,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,50588,N
5242,,5802,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,50588,N
5243,,3598,,Canis lupus familiaris,,,9615.0,,Expert,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,50588,N
5244,,3598,,Canis lupus familiaris,,,9615.0,,Expert,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,50588,N
5245,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,50588,N
5246,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,50588,N
5247,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,50588,N
5248,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,50588,N
5249,,4186,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,50588,N
5250,,5007,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,50588,N
5251,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,50588,N
5252,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,50588,N
5253,,5006,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined,A,,,50588,N
5254,,5006,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve in dogs,A,,,50588,N
5255,,3771,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,50588,N
5256,,3771,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,50588,N
5257,,3771,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,50588,N
5258,,1916,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,50588,N
5259,,5302,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve value in dog at a dose of 5 mg/kg,A,,,50588,N
5260,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,50588,N
5261,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,50588,N
5262,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,50588,N
5263,,4368,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,50588,N
5264,,5318,,Homo sapiens,,,9606.0,,Autocuration,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,22224,U
5265,,5318,,Homo sapiens,,,9606.0,,Autocuration,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,22224,U
5266,,5318,,Homo sapiens,,,9606.0,,Autocuration,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,22224,U
5267,,5318,,Homo sapiens,,,9606.0,,Autocuration,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,22224,U
5268,Blood,14518,178.0,Homo sapiens,,,9606.0,,Autocuration,,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,22224,U
5269,Plasma,2209,1969.0,Homo sapiens,,,9606.0,,Autocuration,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,22224,U
5270,Plasma,6787,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life in human plasma,A,,,22224,U
5271,Plasma,4898,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life in human plasma was reported,A,,,22224,U
5272,Serum,6072,1977.0,Homo sapiens,,,9606.0,,Autocuration,,Half life in human serum,A,,,22224,U
5273,Plasma,16907,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life upon exposure to human plasma,A,,,22224,U
5274,,5656,,Homo sapiens,,,9606.0,Microsomes,Autocuration,,t1/2 in human microsomes,A,In vitro,,22224,U
5275,Plasma,4755,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half life period in 80% human plasma at 37 degree Centigrade,A,,,22224,U
5276,Zone of skin,17503,14.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,22224,U
5277,Plasma,12357,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,22224,U
5278,,3076,,Homo sapiens,,,9606.0,,Autocuration,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,22224,U
5279,Liver,6410,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,22224,U
5280,Plasma,3741,1969.0,Homo sapiens,,,9606.0,,Autocuration,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,22224,U
5281,Plasma,3741,1969.0,Homo sapiens,,,9606.0,,Autocuration,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,22224,U
5282,Plasma,3741,1969.0,Homo sapiens,,,9606.0,,Autocuration,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,22224,U
5283,,1540,,Homo sapiens,,,9606.0,,Autocuration,,Half-life in the CEM cell extracts,A,,,22224,U
5284,Plasma,2905,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,22224,U
5285,Plasma,2905,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,22224,U
5286,,5523,,Homo sapiens,,,9606.0,,Autocuration,,Half-life was determined,A,,,22224,U
5287,Blood,1499,178.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life (human blood stability),A,,,22224,U
5288,Blood,1499,178.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life (human blood stability); no data,A,,,22224,U
5289,Plasma,17065,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life in human plasma,A,,,22224,U
5290,,6861,,Homo sapiens,,,9606.0,,Autocuration,,CYP3A4 metabolism half-life (t1/2),A,,,22224,U
5291,Blood,1499,178.0,Homo sapiens,,,9606.0,,Autocuration,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,22224,U
5292,Plasma,530,1969.0,Homo sapiens,,,9606.0,,Autocuration,,In vitro half life in human plasma,A,In vitro,,22224,U
5293,Plasma,1116,1969.0,Homo sapiens,,,9606.0,,Autocuration,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,22224,U
5294,Plasma,6695,1969.0,Homo sapiens,,,9606.0,,Autocuration,,In vitro hydrolysis in human plasma,A,In vitro,,22224,U
5295,Plasma,6695,1969.0,Homo sapiens,,,9606.0,,Autocuration,,In vitro hydrolysis in human plasma; no data,A,In vitro,,22224,U
5296,Liver,10,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,22224,U
5297,Plasma,993,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Plasma half life in human,A,,,22224,U
5298,Plasma,15429,1969.0,Homo sapiens,,,9606.0,,Autocuration,,Stability after incubation with human plasma (at 37 degree C),A,,,22224,U
5299,Plasma,1675,1969.0,Homo sapiens,,,9606.0,,Autocuration,,T1/2 was evaluated in human plasma,A,,,22224,U
5300,Plasma,2209,1969.0,Homo sapiens,,,9606.0,,Autocuration,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,22224,U
5301,Plasma,2209,1969.0,Homo sapiens,,,9606.0,,Autocuration,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,22224,U
5302,,5318,,Homo sapiens,,,9606.0,,Autocuration,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,22224,U
5303,,2412,,Homo sapiens,,,9606.0,,Autocuration,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,22224,U
5304,,2412,,Homo sapiens,,,9606.0,,Autocuration,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,22224,U
5305,Plasma,2906,1969.0,Homo sapiens,,,9606.0,,Autocuration,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,22224,U
5306,Plasma,2906,1969.0,Homo sapiens,,,9606.0,,Autocuration,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,22224,U
5307,,5495,,Homo sapiens,,,9606.0,,Autocuration,,Time taken for 50% to be consumed by serum PON1 was determined,A,,,22224,U
5308,,5495,,Homo sapiens,,,9606.0,,Autocuration,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,22224,U
5309,Liver,4397,2107.0,Homo sapiens,,,9606.0,Microsomes,Autocuration,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,22224,U
5310,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5311,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5312,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5313,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5314,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5315,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,22224,U
5316,,6058,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,786-0,80640,N
5317,,17708,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,786-0,80640,N
5318,,14017,,Homo sapiens,,391.0,9606.0,,Expert,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,786-0,80640,N
5319,,16818,,Homo sapiens,,391.0,9606.0,,Intermediate,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,786-0,80640,N
5320,,16818,,Homo sapiens,,391.0,9606.0,,Intermediate,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,786-0,80640,N
5321,,16818,,Homo sapiens,,391.0,9606.0,,Intermediate,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,786-0,80640,N
5322,,11970,,Homo sapiens,,391.0,9606.0,,Intermediate,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,786-0,80640,N
5323,,12400,,Homo sapiens,,391.0,9606.0,,Intermediate,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,786-0,80640,N
5324,,12888,,Homo sapiens,,391.0,9606.0,,Expert,,Cytotoxic effect on renal cancer line 786-0,F,,786-0,80640,N
5325,,15300,,Homo sapiens,,391.0,9606.0,,Intermediate,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,786-0,80640,N
5326,,14769,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,786-0,80640,N
5327,,15895,,Homo sapiens,,391.0,9606.0,,Intermediate,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,786-0,80640,N
5328,,17376,,Homo sapiens,,391.0,9606.0,,Intermediate,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,786-0,80640,N
5329,,14882,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,786-0,80640,N
5330,,14882,,Homo sapiens,,391.0,9606.0,,Intermediate,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,786-0,80640,N
5331,,15176,,Homo sapiens,,391.0,9606.0,,Intermediate,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,786-0,80640,N
5332,,12696,,Homo sapiens,,391.0,9606.0,,Intermediate,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,786-0,80640,N
5333,,2496,,Homo sapiens,,391.0,9606.0,,Intermediate,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,786-0,80640,N
5334,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,791T cell line,80641,N
5335,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,791T cell line,80641,N
5336,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,791T cell line,80641,N
5337,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,791T cell line,80641,N
5338,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,791T cell line,80641,N
5339,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,791T cell line,80641,N
5340,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,791T cell line,80641,N
5341,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,791T cell line,80641,N
5342,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,791T cell line,80641,N
5343,,11831,,Homo sapiens,,972.0,9606.0,,Intermediate,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,791T cell line,80641,N
5344,,12782,,Homo sapiens,,391.0,9606.0,,Intermediate,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,786-0,80640,N
5345,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,22226,U
5346,,15313,,Homo sapiens,,741.0,9606.0,,Expert,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,RPMI-8226,80433,N
5347,,15313,,Homo sapiens,,741.0,9606.0,,Expert,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,RPMI-8226,80433,N
5348,,11544,,Homo sapiens,,741.0,9606.0,,Intermediate,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,RPMI-8226,80433,N
5349,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,RPMI-8226,80433,N
5350,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,RPMI-8226,80433,N
5351,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,RPMI-8226,80433,N
5352,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,RPMI-8226,80433,N
5353,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,80433,N
5354,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,80433,N
5355,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,80433,N
5356,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,RPMI-8226,80433,N
5357,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,80433,N
5358,,14769,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,A498,80021,N
5359,,15354,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,A498,80021,N
5360,,17445,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,A498,80021,N
5361,,4337,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro inhibitory concentration against renal cancer cell line A498,F,,A498,80021,N
5362,,15277,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxicity against A 498 tumor cell line,F,,A498,80021,N
5363,,4812,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro antitumor activity against A498 human cancer cell line,F,,A498,80021,N
5364,,4812,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,A498,80021,N
5365,,4995,,Homo sapiens,,624.0,9606.0,,Intermediate,,Inhibitory dose required against A498 human tumor cell lines,F,,A498,80021,N
5366,,5847,,Homo sapiens,,624.0,9606.0,,Intermediate,,Anticancer activity against one renal cancer (A498 cell line),F,,A498,80021,N
5367,,6557,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxicity against melanoma A498 cell line,F,,A498,80021,N
5368,,2597,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was tested for growth inhibitory activity against A498 cell line,F,,A498,80021,N
5369,,6058,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound tested for growth inhibition of renal cancer cell line A498,F,,A498,80021,N
5370,,17708,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,A498,80021,N
5371,,15176,,Homo sapiens,,624.0,9606.0,,Intermediate,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,A498,80021,N
5372,,15300,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,A498,80021,N
5373,,11970,,Homo sapiens,,624.0,9606.0,,Intermediate,,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,A498,80021,N
5374,,12400,,Homo sapiens,,624.0,9606.0,,Intermediate,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,A498,80021,N
5375,,12888,,Homo sapiens,,624.0,9606.0,,Expert,,Cytotoxic effect on renal cancer lines A498,F,,A498,80021,N
5376,,3030,,Homo sapiens,,624.0,9606.0,,Intermediate,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,A498,80021,N
5377,,14769,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,A498,80021,N
5378,,17376,,Homo sapiens,,624.0,9606.0,,Intermediate,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,A498,80021,N
5379,,16558,,Homo sapiens,,624.0,9606.0,,Intermediate,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,A498,80021,N
5380,,5194,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,A498,80021,N
5381,,10708,,Homo sapiens,,624.0,9606.0,,Intermediate,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,A498,80021,N
5382,,16880,,Homo sapiens,,646.0,9606.0,,Expert,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,A549,80682,N
5383,,10196,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumor activity against A549 human lung carcinoma cell line,F,,A549,80682,N
5384,,10196,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,A549,80682,N
5385,,10196,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,A549,80682,N
5386,,12083,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,A549,80682,N
5387,,16464,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,A549,80682,N
5388,,16464,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A549,80682,N
5389,,16470,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxic activity against human lung A549 cell line,F,,A549,80682,N
5390,,16470,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,A549,80682,N
5391,,16470,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against human lung A549 cell line),F,,A549,80682,N
5392,,16470,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,A549,80682,N
5393,,16582,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,A549,80682,N
5394,,15935,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,A549,80682,N
5395,,15935,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,A549,80682,N
5396,,16597,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of A549 human lung carcinoma cell proliferation,F,,A549,80682,N
5397,,17376,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,A549,80682,N
5398,,16496,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,A549,80682,N
5399,,16152,,Homo sapiens,,646.0,9606.0,,Intermediate,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,A549,80682,N
5400,,16152,,Homo sapiens,,646.0,9606.0,,Intermediate,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,A549,80682,N
5401,,16464,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A549,80682,N
5402,,2288,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,A549,80682,N
5403,,17350,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,A549,80682,N
5404,,4090,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of A549 cancer cell proliferation,F,,A549,80682,N
5405,,4090,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of A549 cancer cell proliferation (Not tested),F,,A549,80682,N
5406,,17350,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,A549,80682,N
5407,,4197,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,A549,80682,N
5408,,17072,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,A549,80682,N
5409,,17072,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,A549,80682,N
5410,,5194,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against Renal cell lines A549 was determined,F,,A549,80682,N
5411,,4257,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,50588,N
5412,,6123,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,50588,N
5413,,1337,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,50588,N
5414,,1337,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,50588,N
5415,,8833,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,50588,N
5416,,8833,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,50588,N
5417,,8833,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,50588,N
5418,,8833,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,50588,N
5419,Plasma,17657,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under plasma concentration time curve in dog upon oral administration,A,,,50588,N
5420,Plasma,17650,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,50588,N
5421,,1977,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,50588,N
5422,,1977,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,50588,N
5423,,3132,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve for the compound was obtained when tested in dog,A,,,50588,N
5424,,5473,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve at a dose of 1 mg/kg,A,,,50588,N
5425,,5474,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve at a dose of 1 mg/kg (oral),A,,,50588,N
5426,,5474,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,50588,N
5427,,6062,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,50588,N
5428,,4709,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,50588,N
5429,,2652,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,50588,N
5430,,2652,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,50588,N
5431,,2877,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for area under the curve in dog blood.,A,,,50588,N
5432,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,50588,N
5433,Plasma,5130,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC in dog after oral dose (1 mg/kg),A,,,50588,N
5434,,6265,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,50588,N
5435,,4657,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,50588,N
5436,,16367,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,50588,N
5437,,16367,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,50588,N
5438,,9579,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,50588,N
5439,,9579,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,50588,N
5440,,5983,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,50588,N
5441,,6241,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,50588,N
5442,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,50588,N
5443,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,50588,N
5444,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,50588,N
5445,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,50588,N
5446,,6641,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,50588,N
5447,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,50588,N
5448,,17791,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,50588,N
5449,,17655,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,50588,N
5450,,17655,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,50588,N
5451,,6596,,Canis lupus familiaris,,,9615.0,,Intermediate,,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,50588,N
5452,,3880,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,,,50588,N
5453,,16367,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,50588,N
5454,Plasma,17409,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma protein binding towards dog plasma at 10 uM,A,,,50588,N
5455,Plasma,17409,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma protein binding towards dog plasma at 100 uM,A,,,50588,N
5456,,2959,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,50588,N
5457,,13501,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,50588,N
5458,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,50588,N
5459,,15145,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dogs,A,In vivo,,50588,N
5460,,4219,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability,A,In vivo,,50588,N
5461,,17538,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,50588,N
5462,,17538,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,50588,N
5463,,1466,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,50588,N
5464,,17650,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,50588,N
5465,,3132,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,50588,N
5466,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5467,Liver,2413,2107.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5468,Liver,2413,2107.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,22224,U
5469,Liver,2413,2107.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5470,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5471,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5472,Muscle tissue,2413,2385.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5473,Muscle tissue,2413,2385.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,22224,U
5474,Muscle tissue,2413,2385.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5475,Spleen,2413,2106.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5476,Spleen,2413,2106.0,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5477,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,22224,U
5478,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,22224,U
5479,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5480,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,22224,U
5481,,2413,,Mus sp.,,,10095.0,,Autocuration,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,22224,U
5482,,17827,,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,22224,U
5483,Cerebellum,17827,2037.0,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,22224,U
5484,Frontal cortex,17827,1870.0,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,22224,U
5485,,17827,,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,22224,U
5486,Striatum,17827,2435.0,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,22224,U
5487,,17827,,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,22224,U
5488,Cerebellum,17827,2037.0,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,22224,U
5489,Frontal cortex,17827,1870.0,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,22224,U
5490,,17827,,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,22224,U
5491,Striatum,17827,2435.0,Cercopithecidae,,,9527.0,,Autocuration,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,22224,U
5492,,17791,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for oral bioavailability in rats,A,,,22224,U
5493,Plasma,17667,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,22224,U
5494,,17791,,Cercopithecidae,,,9527.0,,Autocuration,,Half life period was evaluated in monkey,A,,,22224,U
5495,,110,,Cercopithecidae,,,9527.0,,Autocuration,,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,22224,U
5496,Plasma,5781,1969.0,Mus musculus,,,10090.0,,Intermediate,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,50594,N
5497,Plasma,17734,1969.0,Mus musculus,,,10090.0,,Intermediate,,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,50594,N
5498,Plasma,17718,1969.0,Mus musculus,,,10090.0,,Intermediate,,AUC value was determined after oral administration,A,,,50594,N
5499,,4573,,Mus musculus,,,10090.0,,Intermediate,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,50594,N
5500,,3277,,Mus musculus,,,10090.0,,Intermediate,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,50594,N
5501,,2862,,Mus musculus,,,10090.0,,Intermediate,,Area under curve by ioral administration in mouse,A,,,50594,N
5502,,2862,,Mus musculus,,,10090.0,,Intermediate,,Area under curve by iv administration in mouse,A,,,50594,N
5503,,5951,,Mus musculus,,,10090.0,,Intermediate,,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,50594,N
5504,,17729,,Mus musculus,,,10090.0,,Intermediate,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,50594,N
5505,,17728,,Mus musculus,,,10090.0,,Intermediate,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,50594,N
5506,,17728,,Mus musculus,,,10090.0,,Intermediate,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,50594,N
5507,,17729,,Mus musculus,,,10090.0,,Intermediate,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,50594,N
5508,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,RPMI-8226,80433,N
5509,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,RPMI-8226,80433,N
5510,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,RPMI-8226,80433,N
5511,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,RPMI-8226,80433,N
5512,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,80433,N
5513,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,80433,N
5514,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,RPMI-8226,80433,N
5515,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,80433,N
5516,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,RPMI-8226,80433,N
5517,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,RPMI-8226,80433,N
5518,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,RPMI-8226,80433,N
5519,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,RPMI-8226,80433,N
5520,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,80433,N
5521,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,RPMI-8226,80433,N
5522,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,RPMI-8226,80433,N
5523,,9424,,Homo sapiens,,741.0,9606.0,,Intermediate,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,RPMI-8226,80433,N
5524,,9424,,Homo sapiens,,741.0,9606.0,,Expert,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,RPMI-8226,80433,N
5525,,11544,,Homo sapiens,,741.0,9606.0,,Intermediate,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,RPMI-8226,80433,N
5526,,17378,,Homo sapiens,,741.0,9606.0,,Intermediate,,Cytotoxicity of compound against 8226/DOX1V cells,F,,RPMI-8226,80433,N
5527,,17378,,Homo sapiens,,741.0,9606.0,,Intermediate,,Cytotoxicity of compound against 8226/S cells,F,,RPMI-8226,80433,N
5528,,17079,,Homo sapiens,,741.0,9606.0,,Intermediate,,Inhibitory concentration against 8226 myeloma cancer cell line,F,,RPMI-8226,80433,N
5529,,17079,,Homo sapiens,,741.0,9606.0,,Intermediate,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,RPMI-8226,80433,N
5530,,13466,,Homo sapiens,,854.0,9606.0,,Intermediate,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,833K,80647,N
5531,,13466,,Homo sapiens,,854.0,9606.0,,Intermediate,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,833K,80647,N
5532,,2392,,Homo sapiens,,854.0,9606.0,,Expert,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,833K,80647,N
5533,,2392,,Homo sapiens,,854.0,9606.0,,Intermediate,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,833K,80647,N
5534,,6608,,,,,,,Autocuration,,Inhibitory activity against caspase-1,B,,,22226,U
5535,,10199,,Enterococcus faecalis,,,1351.0,,Autocuration,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,45,H
5536,,17749,,Homo sapiens,,705.0,9606.0,,Intermediate,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,8701-BC,80648,N
5537,,17749,,Homo sapiens,,705.0,9606.0,,Intermediate,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,8701-BC,80648,N
5538,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,22226,U
5539,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,22226,U
5540,,1229,,,,,,,Intermediate,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,22226,U
5541,,6390,,,,,,,Autocuration,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,22226,U
5542,,16219,,Streptococcus pyogenes,,,1314.0,,Autocuration,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,22226,U
5543,,16219,,Streptococcus pyogenes,,,1314.0,,Autocuration,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,22226,U
5544,,17043,,,,,,,Autocuration,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,11922,H
5545,,6929,,Homo sapiens,,324.0,9606.0,,Intermediate,,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,KB ,81115,N
5546,,6929,,Homo sapiens,,324.0,9606.0,,Intermediate,,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,KB ,81115,N
5547,,7083,,Homo sapiens,,,9606.0,,Autocuration,,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,22226,U
5548,,12446,,Rattus norvegicus,,392.0,10116.0,,Intermediate,,Cytotoxic concentration against 9L cells was determined on day 3,F,,9L,80653,N
5549,,15345,,Rattus norvegicus,,392.0,10116.0,,Expert,,Tested in vitro for anticancer activity against 9L cells,F,,9L,80653,N
5550,,15345,,Rattus norvegicus,,392.0,10116.0,,Expert,,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,9L,80653,N
5551,,6301,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,A549,80682,N
5552,,4833,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,A549,80682,N
5553,,4833,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,A549,80682,N
5554,,4833,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,A549,80682,N
5555,,13330,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against human lung carcinoma A549 cell line,F,,A549,80682,N
5556,,17517,,Homo sapiens,,646.0,9606.0,,Expert,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,A549,25,D
5557,,17517,,Homo sapiens,,646.0,9606.0,,Expert,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,A549,25,D
5558,,14425,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro growth inhibition of A549, lung carcinoma",F,,A549,80682,N
5559,,14425,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro growth inhibition of A549, lung carcinoma.",F,,A549,80682,N
5560,,5228,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,A549,80682,N
5561,,5351,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,A549,80682,N
5562,,12198,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,A549,80682,N
5563,,13891,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,A549,80682,N
5564,,5677,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity in A549 (human carcinoma) cell line.,F,,A549,80682,N
5565,,13788,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity on lung carcinoma (A-549) cell line,F,,A549,80682,N
5566,,13384,,Homo sapiens,,646.0,9606.0,,Expert,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,A549,80682,N
5567,,6726,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effective dose of compound against replication of A549 cell line was evaluated,F,,A549,80682,N
5568,,3455,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,A549,80682,N
5569,,5726,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,A549,80682,N
5570,,5726,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,A549,80682,N
5571,,3936,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was evaluated for antiproliferative activity against A549 cell line,F,,A549,80682,N
5572,,14991,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,A549,80682,N
5573,,5243,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,A549,80682,N
5574,,12858,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,A549,80682,N
5575,,6776,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibition against A549 cell line was evaluated,F,,A549,80682,N
5576,,16558,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,A549,80682,N
5577,,4583,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,A549,80682,N
5578,,13514,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,A549,80682,N
5579,,15166,,Homo sapiens,,646.0,9606.0,,Expert,,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,A549,80682,N
5580,,13873,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,A549,80682,N
5581,,6447,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,A549,80682,N
5582,,2068,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,A549,80682,N
5583,,1863,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,A549,80682,N
5584,,13873,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,A549,80682,N
5585,,13873,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,A549,80682,N
5586,,13873,,Homo sapiens,,646.0,9606.0,,Expert,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,A549,80682,N
5587,,579,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,A549,80682,N
5588,,579,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,A549,80682,N
5589,,4584,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,A549,80682,N
5590,,5421,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,A549,80682,N
5591,,5421,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,A549,80682,N
5592,,5421,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,A549,80682,N
5593,,5421,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,A549,80682,N
5594,,14188,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,A549,80682,N
5595,,14188,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,A549,80682,N
5596,,15354,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,A549,80682,N
5597,,14253,,Homo sapiens,,646.0,9606.0,,Expert,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,A549,80682,N
5598,,13873,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,A549,80682,N
5599,,3043,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (conscious),A,In vivo,,50588,N
5600,,3045,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,50588,N
5601,,3022,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,50588,N
5602,,4453,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
5603,,1696,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
5604,,5045,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
5605,,5356,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (fasted),A,In vivo,,50588,N
5606,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,50588,N
5607,,6448,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
5608,,1475,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
5609,,3788,,Canis lupus familiaris,,,9615.0,,Intermediate,,Percent bioavailability in dog,A,In vivo,,50588,N
5610,,3639,,Canis lupus familiaris,,,9615.0,,Intermediate,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,50588,N
5611,,13397,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
5612,,2137,,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,50588,N
5613,,2959,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,50588,N
5614,,6448,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
5615,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,8 hour trough Blood level in dog was measured after administration of compound,A,,,50588,N
5616,Plasma,3639,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,50588,N
5617,,6316,,Canis lupus familiaris,,,9615.0,,Intermediate,,C24 after oral administration at 5 mg/kg,A,,,50588,N
5618,,5238,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance after oral and iv dosing in dogs,A,,,50588,N
5619,Plasma,17796,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance of the drug was measured in the plasma of dog,A,,,50588,N
5620,,2652,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,50588,N
5621,,5654,,Canis lupus familiaris,,,9615.0,,Intermediate,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,50588,N
5622,,6621,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance of compound was determined in dogs,A,In vivo,,50588,N
5623,,6505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,50588,N
5624,,5802,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,50588,N
5625,,17267,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog was determined,A,In vivo,,50588,N
5626,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,50588,N
5627,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,50588,N
5628,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,50588,N
5629,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dogs,A,In vivo,,50588,N
5630,,5542,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,50588,N
5631,,5199,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,50588,N
5632,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,50588,N
5633,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,50588,N
5634,,16367,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma administration to dogs,A,In vivo,,50588,N
5635,,5505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was determined,A,In vivo,,50588,N
5636,,6215,,Canis lupus familiaris,,,9615.0,,Intermediate,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,50588,N
5637,,1466,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,50588,N
5638,Liver,5007,2107.0,Homo sapiens,,,9606.0,Microsomes,Intermediate,,Intrinsic clearance in human liver microsomes,A,In vitro,,102164,S
5639,Liver,5007,2107.0,Homo sapiens,,,9606.0,Microsomes,Intermediate,,Intrinsic clearance in human liver microsomes,A,In vitro,,102164,S
5640,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,50588,N
5641,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,50588,N
5642,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,50588,N
5643,,6221,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,50588,N
5644,,5007,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,50588,N
5645,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,50588,N
5646,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,50588,N
5647,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,50588,N
5648,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was measured in dog,A,In vivo,,50588,N
5649,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was measured in dog,A,In vivo,,50588,N
5650,,5983,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,50588,N
5651,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,50588,N
5652,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,50588,N
5653,,6039,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,50588,N
5654,,6039,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,50588,N
5655,,6039,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,50588,N
5656,,4368,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,50588,N
5657,,4305,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,50588,N
5658,Plasma,1918,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance value was evaluated in dog plasma,A,In vivo,,50588,N
5659,,6005,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,50588,N
5660,Plasma,4839,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for plasma clearance in dog,A,In vivo,,50588,N
5661,,4239,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,50588,N
5662,,17729,,Mus musculus,,,10090.0,,Intermediate,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,50594,N
5663,,17728,,Mus musculus,,,10090.0,,Intermediate,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,50594,N
5664,,5302,,Mus musculus,,,10090.0,,Intermediate,,Area under curve value in mouse at a dose of 10 mg/kg,A,,,50594,N
5665,,5506,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,50594,N
5666,,5506,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,50594,N
5667,,17764,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,50594,N
5668,,17764,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,50594,N
5669,,17764,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,50594,N
5670,,17764,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,50594,N
5671,,17764,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,50594,N
5672,,17753,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for the compound at 24 mg/Kg,A,,,50594,N
5673,,17753,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for the compound at 40 mg/Kg,A,,,50594,N
5674,,17753,,Mus musculus,,,10090.0,,Intermediate,,Area under curve was determined for the compound at 5 mg/Kg,A,,,50594,N
5675,,3132,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,50594,N
5676,,3132,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve for the compound was obtained when tested in mouse,A,,,50594,N
5677,,17837,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,50594,N
5678,,17837,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,50594,N
5679,,6062,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,50594,N
5680,,4066,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,50594,N
5681,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,50594,N
5682,,14239,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,50594,N
5683,,14239,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,50594,N
5684,,4890,,Mus musculus,,,10090.0,,Intermediate,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,50594,N
5685,,429,,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,50594,N
5686,,429,,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,50594,N
5687,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,50594,N
5688,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,50594,N
5689,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,50594,N
5690,,6091,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,50594,N
5691,,6091,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,50594,N
5692,,6091,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,50594,N
5693,,6091,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,50594,N
5694,,6178,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,50594,N
5695,,6178,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,50594,N
5696,,6619,,Mus musculus,,,10090.0,,Intermediate,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,50594,N
5697,,6619,,Mus musculus,,,10090.0,,Intermediate,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,50594,N
5698,,3760,,Mus musculus,,,10090.0,,Intermediate,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,50594,N
5699,,3760,,Mus musculus,,,10090.0,,Intermediate,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,50594,N
5700,,3760,,Mus musculus,,,10090.0,,Intermediate,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,50594,N
5701,,3760,,Mus musculus,,,10090.0,,Intermediate,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,50594,N
5702,,3192,,Mus musculus,,,10090.0,,Intermediate,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,50594,N
5703,,3192,,Mus musculus,,,10090.0,,Intermediate,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,50594,N
5704,,2675,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve was evaluated in mice after intravenous administration,A,,,50594,N
5705,,2675,,Mus musculus,,,10090.0,,Intermediate,,Area under the curve was evaluated in mice after oral administration,A,,,50594,N
5706,Plasma,16597,1969.0,Mus musculus,,,10090.0,,Intermediate,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,50594,N
5707,Plasma,16597,1969.0,Mus musculus,,,10090.0,,Intermediate,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,50594,N
5708,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,50594,N
5709,,17734,,Mus musculus,,,10090.0,,Intermediate,,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,50594,N
5710,Blood,7767,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5711,,15345,,,,392.0,,,Intermediate,,The compound was tested in vitro for anticancer activity against 9L cells,F,,9L,80653,N
5712,,2181,,Rattus norvegicus,,,10116.0,,Autocuration,,Anti proliferation activity determined; Weak effect,F,,,22226,U
5713,,2181,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,22226,U
5714,,2181,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,22226,U
5715,,2181,,Rattus norvegicus,,,10116.0,,Autocuration,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,22226,U
5716,,10486,,Mus musculus,,,10090.0,,Autocuration,,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,22226,U
5717,,10486,,Mus musculus,,,10090.0,,Autocuration,,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,22226,U
5718,,15508,,,,,,,Autocuration,,Partition coefficient (logD6.5),A,,,22224,U
5719,,5242,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,A2780,81034,N
5720,,16167,,Homo sapiens,,455.0,9606.0,,Intermediate,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,A-375,80018,N
5721,,4782,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,A-431,80852,N
5722,,16093,,Homo sapiens,,500.0,9606.0,,Expert,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,A-431,9,D
5723,,2596,,Homo sapiens,,624.0,9606.0,,Intermediate,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,A498,80021,N
5724,,2596,,Homo sapiens,,624.0,9606.0,,Intermediate,,in vitro cytotoxicity against A 498 cancer cell line,F,,A498,80021,N
5725,,3239,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,A498,80021,N
5726,,1847,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxic activity against A 498 renal cancer cell lines.,F,,A498,80021,N
5727,,10553,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,A498,80021,N
5728,,16219,,Staphylococcus aureus,,,1280.0,,Autocuration,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,22226,U
5729,,16219,,Staphylococcus aureus,,,1280.0,,Autocuration,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,22226,U
5730,,16219,,Staphylococcus aureus,,,1280.0,,Autocuration,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,22226,U
5731,,16219,,Staphylococcus aureus,,,1280.0,,Autocuration,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,22226,U
5732,,4782,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration required against A 549 lung cancer cell line,F,,A549,80682,N
5733,,11805,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,A549,80682,N
5734,,11805,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,A549,80682,N
5735,,2007,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,A549,80682,N
5736,,4594,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for its cytotoxicity against A 549 cell line,F,,A549,80682,N
5737,,6018,,Homo sapiens,,646.0,9606.0,,Expert,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,A549,80682,N
5738,,6018,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,A549,80682,N
5739,,3599,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,A549,80682,N
5740,,2551,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,A549,80682,N
5741,,16132,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,A549,80682,N
5742,,16132,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,A549,80682,N
5743,,2551,,Homo sapiens,,646.0,9606.0,,Expert,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,A549,80682,N
5744,,2551,,Homo sapiens,,646.0,9606.0,,Expert,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,A549,80682,N
5745,,11913,,,,,,,Autocuration,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,22226,U
5746,,12621,,,,,,,Autocuration,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,104694,H
5747,,12621,,,,,,,Autocuration,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,104694,H
5748,,12621,,,,,,,Autocuration,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,104694,H
5749,,12621,,,,,,,Autocuration,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,104694,H
5750,,12621,,,,,,,Autocuration,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,104694,H
5751,,3600,,Homo sapiens,,624.0,9606.0,,Expert,,Inhibition of A-498 human Renal cell proliferation,F,,A498,80021,N
5752,,1796,,Rattus norvegicus,,,10116.0,,Autocuration,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,22226,U
5753,,1796,,Rattus norvegicus,,,10116.0,,Autocuration,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,22226,U
5754,,1796,,Rattus norvegicus,,,10116.0,,Autocuration,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,22226,U
5755,,16464,,Homo sapiens,,622.0,9606.0,,Expert,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,A 172,80012,N
5756,,16464,,Homo sapiens,,622.0,9606.0,,Intermediate,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A 172,80012,N
5757,,16464,,Homo sapiens,,622.0,9606.0,,Intermediate,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A 172,80012,N
5758,,13617,,Homo sapiens,,646.0,9606.0,,Expert,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,A549,80682,N
5759,,4584,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,A549,80682,N
5760,,13799,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxic activity evaluated against A549 tumor cells,F,,A549,80682,N
5761,,16726,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,A549,80682,N
5762,,16109,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,A549,80682,N
5763,,16109,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,A549,80682,N
5764,,15474,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,A549,80682,N
5765,,6851,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity of compound against A549 cell line,F,,A549,80682,N
5766,,17534,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,A549,80682,N
5767,,2621,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,A549,80682,N
5768,,830,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,A549,80682,N
5769,,14255,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,A549,80682,N
5770,,14255,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,A549,80682,N
5771,,1590,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,A549,80682,N
5772,,6146,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,A549,80682,N
5773,,17427,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,A549,80682,N
5774,,5280,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,A549,80682,N
5775,,16786,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,A549,80682,N
5776,,5895,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against A549 (human lung cancer),F,,A549,80682,N
5777,,14297,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,A549,80682,N
5778,,17824,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vivo antiproliferative activity against A549 cell line,F,,A549,80682,N
5779,,14368,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,A549,80682,N
5780,,14368,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,A549,80682,N
5781,,14254,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,A549,80682,N
5782,,15897,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,A549,80682,N
5783,,13866,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,A549,80682,N
5784,,13370,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,A549,80682,N
5785,,4862,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 lung cancer cell line,F,,A549,80682,N
5786,,4862,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,A549,80682,N
5787,,4862,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,A549,80682,N
5788,,15970,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration against A549 (lung cancer) cell line,F,,A549,80682,N
5789,,17713,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,A549,80682,N
5790,,4833,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,A549,80682,N
5791,,13736,,Homo sapiens,,646.0,9606.0,,Expert,,Activity against A549 cancer cell line.,F,,A549,80682,N
5792,,4312,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was evaluated for cytotoxicity against A549 cell line,F,,A549,80682,N
5793,,5421,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,A549,80682,N
5794,,5421,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,A549,80682,N
5795,,14717,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,A549,80682,N
5796,,4634,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 lung cancer cell line,F,,A549,80682,N
5797,,1149,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 cell line; inactive,F,,A549,80682,N
5798,,5421,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,A549,80682,N
5799,,5421,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,A549,80682,N
5800,,5421,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,A549,80682,N
5801,,3320,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,A549,80682,N
5802,,3320,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,A549,80682,N
5803,,3320,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,A549,80682,N
5804,,3320,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,A549,80682,N
5805,,3320,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,A549,80682,N
5806,,5726,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,A549,80682,N
5807,,17800,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,50588,N
5808,,5985,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was measured in dog,A,In vivo,,50588,N
5809,,5530,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,50588,N
5810,,5530,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,50588,N
5811,Plasma,4839,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for plasma clearance in dog,A,In vivo,,50588,N
5812,,3639,,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for clearance in dog plasma.,A,In vivo,,50588,N
5813,,4838,,Canis lupus familiaris,,,9615.0,,Intermediate,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,50588,N
5814,,4137,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,50588,N
5815,Plasma,5017,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,50588,N
5816,Liver,17538,2107.0,Canis lupus familiaris,,,9615.0,Microsomes,Intermediate,,In vitro clearance in dog liver microsomes,A,In vitro,,50588,N
5817,,6161,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,50588,N
5818,,6161,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,50588,N
5819,,1696,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog,A,In vivo,,50588,N
5820,,6762,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance rate in dog,A,In vivo,,50588,N
5821,Plasma,5932,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,50588,N
5822,,6305,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance in dogs,A,In vivo,,50588,N
5823,,4942,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dogs,A,In vivo,,50588,N
5824,,4219,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was determined,A,In vivo,,50588,N
5825,,17853,,Canis lupus familiaris,,,9615.0,,Intermediate,,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,50588,N
5826,,4514,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in Beagle dogs,A,In vivo,,50588,N
5827,,6448,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance (Clp) in dog,A,In vivo,,50588,N
5828,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,50588,N
5829,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,50588,N
5830,,6062,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,50588,N
5831,,6821,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance of compound was determined in dog,A,In vivo,,50588,N
5832,,4709,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,50588,N
5833,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,50588,N
5834,,5374,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog was determined,A,In vivo,,50588,N
5835,,6057,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was calculated in dog,A,In vivo,,50588,N
5836,,4727,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,50588,N
5837,,5145,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog,A,In vivo,,50588,N
5838,,17657,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog,A,In vivo,,50588,N
5839,,17657,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog; Unable to calculate,A,In vivo,,50588,N
5840,,5145,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in rhesus monkey,A,In vivo,,50588,N
5841,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,50588,N
5842,,6641,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,50588,N
5843,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,50588,N
5844,,5472,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was evaluated in dog,A,In vivo,,50588,N
5845,,5472,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,50588,N
5846,,5472,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was evaluated in rhesus,A,In vivo,,50588,N
5847,,5472,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,50588,N
5848,,4257,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,50588,N
5849,,6679,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,50588,N
5850,,5546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,50588,N
5851,,6348,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,50588,N
5852,,5474,,Canis lupus familiaris,,,9615.0,,Intermediate,,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,50588,N
5853,Plasma,6316,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,50588,N
5854,,17594,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,50588,N
5855,,17594,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,50588,N
5856,,5802,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,50588,N
5857,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,50588,N
5858,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,50588,N
5859,Plasma,1466,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,50588,N
5860,,6505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,50588,N
5861,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,50588,N
5862,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,50588,N
5863,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,50588,N
5864,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,50588,N
5865,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,50588,N
5866,,6123,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,50588,N
5867,,6123,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,50588,N
5868,,6757,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,50588,N
5869,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,50588,N
5870,Blood,7767,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5871,Blood,7767,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5872,Bone,7767,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5873,Bone,7767,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5874,Bone,7767,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5875,,7767,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5876,,7767,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5877,,7767,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5878,Heart,7767,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5879,Heart,7767,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5880,Heart,7767,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5881,Kidney,7767,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5882,Kidney,7767,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5883,Kidney,7767,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5884,Intestine,7767,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5885,Intestine,7767,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5886,Intestine,7767,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5887,Liver,7767,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5888,Liver,7767,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5889,Liver,7767,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5890,Lung,7767,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5891,Lung,7767,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5892,Lung,7767,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5893,Muscle tissue,7767,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5894,Muscle tissue,7767,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5895,Muscle tissue,7767,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5896,,7767,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5897,,7767,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5898,,7767,,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5899,Intestine,7767,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5900,Intestine,7767,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5901,Intestine,7767,160.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5902,Spleen,7767,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5903,Spleen,7767,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5904,Spleen,7767,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5905,Stomach,7767,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5906,Stomach,7767,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
5907,,2036,,Homo sapiens,,622.0,9606.0,,Expert,,Cytotoxicity against A-172 human tumor cell lines,F,,A 172,80012,N
5908,,2357,,Homo sapiens,,622.0,9606.0,,Intermediate,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,A 172,80012,N
5909,,1457,,Homo sapiens,,623.0,9606.0,,Intermediate,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,A204,80014,N
5910,,4379,,Homo sapiens,,478.0,9606.0,,Intermediate,,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,A2780,81034,N
5911,,1093,,Homo sapiens,,455.0,9606.0,,Intermediate,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,A-375,80018,N
5912,,12152,,Homo sapiens,,455.0,9606.0,,Intermediate,,Tested in vitro against A-375 cell line human melanoma,F,,A-375,80018,N
5913,,16464,,Homo sapiens,,797.0,9606.0,,Expert,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,A-427,80019,N
5914,,16464,,Homo sapiens,,797.0,9606.0,,Intermediate,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A-427,80019,N
5915,,16582,,Homo sapiens,,797.0,9606.0,,Expert,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,A-427,80019,N
5916,,16464,,Homo sapiens,,797.0,9606.0,,Intermediate,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,A-427,80019,N
5917,,10413,,Homo sapiens,,797.0,9606.0,,Intermediate,,Antitumor activity on A-427 lung carcinoma cell lines,F,,A-427,80019,N
5918,,6418,,Homo sapiens,,797.0,9606.0,,Intermediate,,Cytotoxic activity against human A-427 lung tumor cell line,F,,A-427,80019,N
5919,,17134,,Homo sapiens,,797.0,9606.0,,Expert,,In vitro antitumor effects against human A-427 cell lines.,F,,A-427,80019,N
5920,,16132,,Homo sapiens,,797.0,9606.0,,Expert,,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,A-427,80019,N
5921,,16132,,Homo sapiens,,797.0,9606.0,,Intermediate,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,A-427,80019,N
5922,,16780,,Homo sapiens,,797.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,A-427,80019,N
5923,,4085,,Homo sapiens,,500.0,9606.0,,Expert,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,A-431,80852,N
5924,,1276,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,A498,80021,N
5925,,3498,,Homo sapiens,,624.0,9606.0,,Expert,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,A498,80021,N
5926,,1169,,Homo sapiens,,624.0,9606.0,,Intermediate,,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,A498,80021,N
5927,,4450,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,A498,80021,N
5928,,3311,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,A498,80021,N
5929,,4461,,Homo sapiens,,624.0,9606.0,,Intermediate,,Antitumor cytotoxic activity against A-498 cell line was determined,F,,A498,80021,N
5930,,3311,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,A498,80021,N
5931,,3311,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,A498,80021,N
5932,,1457,,Homo sapiens,,624.0,9606.0,,Intermediate,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,A498,80021,N
5933,,3664,,Homo sapiens,,624.0,9606.0,,Intermediate,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,A498,80021,N
5934,,15895,,Homo sapiens,,624.0,9606.0,,Intermediate,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,A498,80021,N
5935,,11843,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,A549,80682,N
5936,,11843,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,A549,80682,N
5937,,17705,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,A549,80682,N
5938,,17705,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,A549,80682,N
5939,,4369,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,A549,80682,N
5940,,4369,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,A549,80682,N
5941,,4369,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,A549,80682,N
5942,,4369,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,A549,80682,N
5943,,4369,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,A549,80682,N
5944,,4369,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,A549,80682,N
5945,,4369,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,A549,80682,N
5946,,4787,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,A549,80682,N
5947,,4787,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,A549,80682,N
5948,,6513,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity against A-549 cell line,F,,A549,80682,N
5949,,6690,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,A549,80682,N
5950,,6690,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,A549,80682,N
5951,,12263,,Homo sapiens,,646.0,9606.0,,Expert,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,A549,80682,N
5952,,1054,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,A549,80682,N
5953,,1359,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,A549,80682,N
5954,,3547,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,A549,80682,N
5955,,5771,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxic activity towards A-549 cells,F,,A549,80682,N
5956,,14425,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro percent inhibition of A549, lung carcinoma.",F,,A549,80682,N
5957,,14425,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro percent inhibition of A549, lung carcinoma",F,,A549,80682,N
5958,,14425,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro percent inhibition of A549, lung carcinoma.",F,,A549,80682,N
5959,,14425,,Homo sapiens,,646.0,9606.0,,Intermediate,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,A549,80682,N
5960,,5280,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,A549,80682,N
5961,,15176,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,A549,80682,N
5962,,15300,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,A549,80682,N
5963,,17824,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,80682,N
5964,,17824,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,80682,N
5965,,17824,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,80682,N
5966,,17824,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,80682,N
5967,,17824,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,A549,80682,N
5968,,17824,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,A549,80682,N
5969,,17528,,Homo sapiens,,646.0,9606.0,,Intermediate,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,A549,80682,N
5970,,6870,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,A549,80682,N
5971,,6870,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,A549,80682,N
5972,,6870,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,A549,80682,N
5973,,6870,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,A549,80682,N
5974,,16726,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,A549,80682,N
5975,,6170,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,A549,80682,N
5976,,6583,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,A549,80682,N
5977,,6583,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,A549,80682,N
5978,,6583,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,A549,80682,N
5979,,6583,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,A549,80682,N
5980,,6583,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,A549,80682,N
5981,,17321,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,A549,80682,N
5982,,17528,,Homo sapiens,,646.0,9606.0,,Expert,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,A549,80682,N
5983,,12888,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,A549,80682,N
5984,,4312,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,A549,80682,N
5985,,4312,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,A549,80682,N
5986,,4312,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,A549,80682,N
5987,,17737,,Mus musculus,,646.0,10090.0,,Intermediate,,In vitro antiproliferative activity against A549 cell line,F,,A549,80682,N
5988,,6630,,,,646.0,,,Intermediate,,Synergism with indomethacin in A549 cells,F,,A549,80682,N
5989,,6630,,,,646.0,,,Intermediate,,Synergism with tolmetin in A549 cells,F,,A549,80682,N
5990,,6630,,,,646.0,,,Intermediate,,Synergism with sulindac in A549 cells,F,,A549,80682,N
5991,,6630,,,,646.0,,,Intermediate,,Antagonism of indomethacin in A549 cells,F,,A549,80682,N
5992,,6630,,,,646.0,,,Intermediate,,Antagonism of sulindac in A549 cells,F,,A549,80682,N
5993,,6630,,,,646.0,,,Intermediate,,Antagonism of tolmetin in A549 cells,F,,A549,80682,N
5994,,6630,,,,646.0,,,Intermediate,,Synergism with indomethacin in A549 cells,F,,A549,80682,N
5995,,6630,,,,646.0,,,Intermediate,,Synergism with sulindac in A549 cells,F,,A549,80682,N
5996,,6630,,,,646.0,,,Intermediate,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,A549,80682,N
5997,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,50588,N
5998,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,50588,N
5999,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,50588,N
6000,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,50588,N
6001,,5944,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,50588,N
6002,,2959,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,50588,N
6003,,6241,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value in dog,A,In vivo,,50588,N
6004,,6241,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,50588,N
6005,,2652,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,50588,N
6006,Plasma,1806,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,50588,N
6007,Plasma,1806,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,50588,N
6008,,1021,,Canis lupus familiaris,,,9615.0,,Intermediate,,Concentration maxima after oral dosing in dogs,A,In vivo,,50588,N
6009,,1021,,Canis lupus familiaris,,,9615.0,,Intermediate,,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,50588,N
6010,,1021,,Canis lupus familiaris,,,9615.0,,Intermediate,,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,50588,N
6011,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,50588,N
6012,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,50588,N
6013,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,50588,N
6014,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,50588,N
6015,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,50588,N
6016,Plasma,5130,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,50588,N
6017,Plasma,3249,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,50588,N
6018,Plasma,5473,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,50588,N
6019,Plasma,5474,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,50588,N
6020,Plasma,4657,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,50588,N
6021,,3031,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration of compound in dog was evaluated.,A,In vivo,,50588,N
6022,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,50588,N
6023,,4186,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,50588,N
6024,,5007,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,50588,N
6025,Plasma,3132,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration obtained in dog plasma was determined,A,In vivo,,50588,N
6026,,5006,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration was determined,A,In vivo,,50588,N
6027,,4727,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,50588,N
6028,,1916,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,50588,N
6029,Plasma,1918,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration was evaluated in dog plasma,A,In vivo,,50588,N
6030,,3045,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,50588,N
6031,Plasma,9579,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,50588,N
6032,Plasma,9579,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,50588,N
6033,Plasma,933,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration in dog,A,In vivo,,50588,N
6034,Plasma,17839,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,50588,N
6035,Plasma,17839,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,50588,N
6036,Plasma,17839,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,50588,N
6037,Plasma,17839,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,50588,N
6038,Plasma,6348,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,50588,N
6039,Plasma,16367,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,50588,N
6040,Plasma,1337,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,50588,N
6041,Plasma,1337,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,50588,N
6042,Plasma,5199,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,50588,N
6043,Plasma,17650,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,50588,N
6044,Plasma,6679,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,50588,N
6045,Plasma,5356,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,50588,N
6046,Plasma,5356,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,50588,N
6047,Plasma,6227,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,50588,N
6048,Plasma,6227,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,50588,N
6049,Plasma,6227,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,50588,N
6050,Plasma,6227,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,50588,N
6051,Plasma,3598,1969.0,Canis lupus familiaris,,,9615.0,,Expert,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,50588,N
6052,,4368,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,50588,N
6053,,6265,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,50588,N
6054,Stomach,7767,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
6055,Urine,7767,1088.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,50594,N
6056,Urine,7767,1088.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,50594,N
6057,Urine,7767,1088.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,50594,N
6058,,17811,,Mus musculus,,,10090.0,,Intermediate,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,50594,N
6059,,17811,,Mus musculus,,,10090.0,,Intermediate,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,50594,N
6060,,17827,,Mus musculus,,,10090.0,,Intermediate,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,50594,N
6061,Blood,17827,178.0,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,50594,N
6062,,17827,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,50594,N
6063,,17827,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,50594,N
6064,,17827,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,50594,N
6065,Blood,17827,178.0,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,50594,N
6066,Blood,17827,178.0,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,50594,N
6067,,17827,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,50594,N
6068,,17827,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,50594,N
6069,,17827,,Mus musculus,,,10090.0,,Intermediate,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,50594,N
6070,,17827,,Mus musculus,,,10090.0,,Intermediate,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,50594,N
6071,,17827,,Mus musculus,,,10090.0,,Intermediate,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,50594,N
6072,,17257,,Mus musculus,,,10090.0,,Intermediate,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,50594,N
6073,,17257,,Mus musculus,,,10090.0,,Intermediate,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,50594,N
6074,,17257,,Mus musculus,,,10090.0,,Intermediate,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,50594,N
6075,,17257,,Mus musculus,,,10090.0,,Intermediate,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,50594,N
6076,,17827,,Mus musculus,,,10090.0,,Intermediate,,Time at maximum activity in mice (Radiolabeled compound),A,,,50594,N
6077,,3760,,Mus musculus,,,10090.0,,Intermediate,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,50594,N
6078,,3760,,Mus musculus,,,10090.0,,Intermediate,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,50594,N
6079,,17409,,Mus musculus,,,10090.0,,Intermediate,,Binding towards mouse plasma protein at 10 uM,A,,,50594,N
6080,,17409,,Mus musculus,,,10090.0,,Intermediate,,Binding towards mouse plasma protein at 100 uM,A,,,50594,N
6081,,2675,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,50594,N
6082,,2675,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability was evaluated in mice after oral administration,A,In vivo,,50594,N
6083,,3132,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,50594,N
6084,,3132,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,50594,N
6085,,16597,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,50594,N
6086,,2862,,Mus musculus,,,10090.0,,Intermediate,,Oral bioavailability in mouse,A,In vivo,,50594,N
6087,,17764,,Mus musculus,,,10090.0,,Intermediate,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,50594,N
6088,Brain,846,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6089,Brain,846,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6090,Brain,846,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6091,Brain,846,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6092,Brain,846,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6093,Brain,846,955.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6094,Heart,846,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6095,Heart,846,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6096,Heart,846,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6097,Heart,846,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6098,,1276,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,A549,80682,N
6099,,3498,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,A549,80682,N
6100,,1169,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,A549,80682,N
6101,,4450,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,A549,80682,N
6102,,358,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,A549,80682,N
6103,,358,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,A549,80682,N
6104,,358,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,A549,80682,N
6105,,358,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,A549,80682,N
6106,,358,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,A549,80682,N
6107,,358,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,A549,80682,N
6108,,358,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,A549,80682,N
6109,,15167,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against A-549 human lung cancer cells,F,,A549,80682,N
6110,,4139,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,A549,80682,N
6111,,833,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,A549,80682,N
6112,,15718,,Homo sapiens,,646.0,9606.0,,Expert,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,A549,80682,N
6113,,12373,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,A549,80682,N
6114,,637,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,A549,80682,N
6115,,14867,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,A549,80682,N
6116,,4461,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumor cytotoxic activity against A-549 cell line was determined,F,,A549,80682,N
6117,,5406,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,A549,80682,N
6118,,4457,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,A549,80682,N
6119,,1386,,Homo sapiens,,646.0,9606.0,,Expert,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,A549,80682,N
6120,,3265,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumoral activity was assayed against A-549 cell line,F,,A549,80682,N
6121,,2359,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,A549,80682,N
6122,,4457,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,A549,80682,N
6123,,12454,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,A549,80682,N
6124,,1481,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for inhibition of cell growth of A-549 cells,F,,A549,80682,N
6125,,1750,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,A549,80682,N
6126,,5065,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,A549,80682,N
6127,,808,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,A549,80682,N
6128,,16364,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,A549,80682,N
6129,,1847,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity against A-549 cell lines.,F,,A549,80682,N
6130,,1747,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,A549,80682,N
6131,,1003,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against human A549 non small cell lung cell lines,F,,A549,80682,N
6132,,15313,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of cell growth in (A-549) lung cell line,F,,A549,80682,N
6133,,3122,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,A549,80682,N
6134,,16049,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antitumor activity against A-549 tumor cells.,F,,A549,80682,N
6135,,17134,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro antitumor effects against human A-549 cell lines.,F,,A549,80682,N
6136,,6406,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxic activity of compound against A-549 cell line,F,,A549,80682,N
6137,,627,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,A549,80682,N
6138,,12307,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,A549,80682,N
6139,,17861,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,A549,80682,N
6140,,6682,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,A549,80682,N
6141,,6663,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration of compound against A-549 cell line,F,,A549,80682,N
6142,,2454,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,A549,80682,N
6143,,14709,,Homo sapiens,,646.0,9606.0,,Intermediate,,cytotoxic activity against leukemia (A-549) cancer cell line,F,,A549,80682,N
6144,,15718,,Homo sapiens,,646.0,9606.0,,Expert,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,A549,80682,N
6145,,15718,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,A549,80682,N
6146,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,A549,80682,N
6147,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,A549,80682,N
6148,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,A549,80682,N
6149,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,A549,80682,N
6150,,6630,,,,646.0,,,Intermediate,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,A549,80682,N
6151,,16726,,Homo sapiens,,646.0,9606.0,,Intermediate,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,A549,80682,N
6152,,17846,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against A549 cells; No cytotoxicity,F,,A549,80682,N
6153,,3415,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,A549,80682,N
6154,,3415,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,A549,80682,N
6155,,5609,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro anticancer activity against human lung (A549) cell line,F,,A549,80682,N
6156,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,A549,80682,N
6157,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,A549,80682,N
6158,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,A549,80682,N
6159,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,A549,80682,N
6160,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,A549,80682,N
6161,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,A549,80682,N
6162,,16295,,Homo sapiens,,646.0,9606.0,,Expert,,Inhibition of A549 human lung tumor cell proliferation,F,,A549,80682,N
6163,,16825,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,A549,80682,N
6164,,3439,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against human tumor cell line A549,F,,A549,80682,N
6165,,10870,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,A549,80682,N
6166,,4845,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,A549,80682,N
6167,,5822,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,A549,80682,N
6168,,5822,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,A549,80682,N
6169,,5822,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,A549,80682,N
6170,,16381,,Homo sapiens,,646.0,9606.0,,Intermediate,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,A549,80682,N
6171,,16381,,Homo sapiens,,646.0,9606.0,,Intermediate,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,A549,80682,N
6172,,16381,,Homo sapiens,,646.0,9606.0,,Intermediate,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,A549,80682,N
6173,,5609,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro anticancer activity against human lung (A549) cell line,F,,A549,80682,N
6174,,4644,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,A549,80682,N
6175,,4644,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,A549,80682,N
6176,,4644,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,A549,80682,N
6177,,4644,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,A549,80682,N
6178,,5822,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,A549,80682,N
6179,,3415,,Homo sapiens,,646.0,9606.0,,Expert,,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,A549,80682,N
6180,,16726,,Homo sapiens,,646.0,9606.0,,Intermediate,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,A549,80682,N
6181,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,A549,80682,N
6182,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,A549,80682,N
6183,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,A549,80682,N
6184,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,A549,80682,N
6185,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,A549,80682,N
6186,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,A549,80682,N
6187,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,A549,80682,N
6188,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,A549,80682,N
6189,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,A549,80682,N
6190,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,A549,80682,N
6191,,16726,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,A549,80682,N
6192,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,A549,80682,N
6193,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,A549,80682,N
6194,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,A549,80682,N
6195,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,A549,80682,N
6196,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,50588,N
6197,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,50588,N
6198,,4809,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,50588,N
6199,,5983,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,50588,N
6200,,6251,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,50588,N
6201,Plasma,5932,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,50588,N
6202,Blood,4273,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for the peak blood level in dog,A,In vivo,,50588,N
6203,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,50588,N
6204,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,50588,N
6205,Blood,6221,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,50588,N
6206,,4709,,Canis lupus familiaris,,,9615.0,,Intermediate,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,50588,N
6207,,167,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,50588,N
6208,Plasma,6241,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,50588,N
6209,,344,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,50588,N
6210,,344,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,50588,N
6211,,344,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,50588,N
6212,,2189,,Canis lupus familiaris,,,9615.0,,Intermediate,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,50588,N
6213,Urine,2189,1088.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,50588,N
6214,Urine,2189,1088.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,50588,N
6215,Urine,2189,1088.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,50588,N
6216,,4257,,Canis lupus familiaris,,,9615.0,,Intermediate,,Absolute bioavailability was evaluated in dog,A,In vivo,,50588,N
6217,,6221,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,50588,N
6218,,6215,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,50588,N
6219,,17267,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6220,,6621,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6221,,3854,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability after intravenous administration in dogs,A,In vivo,,50588,N
6222,,3854,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability after peroral administration in dogs,A,In vivo,,50588,N
6223,,5007,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,50588,N
6224,,4333,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,50588,N
6225,Plasma,4333,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,50588,N
6226,,5006,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability,A,In vivo,,50588,N
6227,,5199,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability,A,In vivo,,50588,N
6228,,4368,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,50588,N
6229,,3771,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6230,,4953,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6231,,5064,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6232,,17657,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6233,,17796,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6234,,17853,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,50588,N
6235,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,50588,N
6236,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,50588,N
6237,,5006,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6238,,16365,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was evaluated after oral administration in dog,A,In vivo,,50588,N
6239,,1916,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,50588,N
6240,,1918,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was evaluated in dog,A,In vivo,,50588,N
6241,,4239,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6242,,6505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6243,,5334,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,50588,N
6244,,5334,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,50588,N
6245,,4809,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,50588,N
6246,,6348,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,50588,N
6247,,6005,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,50588,N
6248,,17804,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,50588,N
6249,,3184,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6250,,1806,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,50588,N
6251,,1806,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,50588,N
6252,,1806,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,50588,N
6253,,4839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6254,,5017,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,50588,N
6255,Heart,846,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6256,Heart,846,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6257,Kidney,846,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6258,Kidney,846,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6259,Kidney,846,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6260,Kidney,846,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6261,Kidney,846,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6262,Kidney,846,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6263,Liver,846,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6264,Liver,846,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6265,Liver,846,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6266,Liver,846,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6267,Liver,846,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6268,Liver,846,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6269,Lung,846,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6270,Lung,846,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6271,Lung,846,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6272,Lung,846,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6273,Lung,846,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6274,Lung,846,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,50594,N
6275,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6276,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6277,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6278,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6279,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6280,Brain,6599,955.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6281,Brain,6599,955.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6282,Brain,6599,955.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6283,Brain,6599,955.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6284,Brain,6599,955.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6285,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6286,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6287,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6288,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6289,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6290,Kidney,6599,2113.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6291,Kidney,6599,2113.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6292,Kidney,6599,2113.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6293,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,A549,80682,N
6294,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,A549,80682,N
6295,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,A549,80682,N
6296,,17130,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,A549,80682,N
6297,,3263,,Homo sapiens,,646.0,9606.0,,Expert,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,A549,80682,N
6298,,6663,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,A549,80682,N
6299,,6663,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,A549,80682,N
6300,,6663,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,A549,80682,N
6301,,6663,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,A549,80682,N
6302,,6663,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,A549,80682,N
6303,,6663,,Homo sapiens,,646.0,9606.0,,Intermediate,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,A549,80682,N
6304,,6663,,Homo sapiens,,646.0,9606.0,,Intermediate,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,A549,80682,N
6305,,6663,,Homo sapiens,,646.0,9606.0,,Intermediate,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,A549,80682,N
6306,,6663,,Homo sapiens,,646.0,9606.0,,Intermediate,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,A549,80682,N
6307,,6663,,Homo sapiens,,646.0,9606.0,,Intermediate,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,A549,80682,N
6308,,3983,,Homo sapiens,,646.0,9606.0,,Intermediate,,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,A549,80682,N
6309,,11141,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,A549,80682,N
6310,,5076,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 tumor cell line.,F,,A549,80682,N
6311,,3311,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,A549,80682,N
6312,,3311,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,A549,80682,N
6313,,3311,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,A549,80682,N
6314,,5076,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,A549,80682,N
6315,,4150,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,A549,80682,N
6316,,2150,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,A549,80682,N
6317,,4644,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,A549,80682,N
6318,,263,,Homo sapiens,,646.0,9606.0,,Intermediate,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,A549,80682,N
6319,,11333,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic concentration against A-549 tumor cells.,F,,A549,80682,N
6320,,11333,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,A549,80682,N
6321,,15895,,Homo sapiens,,646.0,9606.0,,Intermediate,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,A549,80682,N
6322,,16677,,Acinetobacter baumannii,,,470.0,,Expert,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,50191,N
6323,,10624,,Acinetobacter calcoaceticus,,,471.0,,Intermediate,,Activity against Acinetobacter calcoaceticus (AC54),F,,,50192,N
6324,,16717,,Aspergillus flavus,,,5059.0,,Expert,,In vitro antifungal activity against Aspergillus flavus CM74,F,,,50274,N
6325,,16717,,Aspergillus flavus,,,5059.0,,Expert,,In vitro antifungal activity against Aspergillus flavus CM74,F,,,50274,N
6326,,5513,,Aspergillus fumigatus,,,746128.0,,Intermediate,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,50416,N
6327,,15962,,Aspergillus fumigatus,,,746128.0,,Intermediate,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,50416,N
6328,,15962,,Aspergillus fumigatus,,,746128.0,,Intermediate,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,50416,N
6329,,15962,,Aspergillus fumigatus,,,746128.0,,Intermediate,,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,50416,N
6330,,15962,,Aspergillus fumigatus,,,746128.0,,Intermediate,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,50416,N
6331,,16717,,Aspergillus fumigatus,,,746128.0,,Expert,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,50416,N
6332,,16717,,Aspergillus fumigatus,,,746128.0,,Expert,,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,50416,N
6333,,8117,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,50296,N
6334,,8117,,Actinomyces viscosus,,,1656.0,,Intermediate,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,50366,N
6335,,15472,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,50535,N
6336,,15472,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,50535,N
6337,,16443,,Aggregatibacter actinomycetemcomitans,,,714.0,,Intermediate,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,50169,N
6338,,16443,,Aggregatibacter actinomycetemcomitans,,,714.0,,Intermediate,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,50169,N
6339,,16443,,Aggregatibacter actinomycetemcomitans,,,714.0,,Intermediate,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,50169,N
6340,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,A549,80682,N
6341,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,A549,80682,N
6342,,16381,,Homo sapiens,,646.0,9606.0,,Intermediate,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,A549,80682,N
6343,,16381,,Homo sapiens,,646.0,9606.0,,Intermediate,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,A549,80682,N
6344,,16381,,Homo sapiens,,646.0,9606.0,,Intermediate,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,A549,80682,N
6345,,16381,,Homo sapiens,,646.0,9606.0,,Intermediate,,GI values against A549 cells (lung cancer),F,,A549,80682,N
6346,,17206,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,A549,80682,N
6347,,16325,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 human adenocarcinoma,F,,A549,80682,N
6348,,10708,,Homo sapiens,,646.0,9606.0,,Intermediate,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,A549,80682,N
6349,,10708,,Homo sapiens,,646.0,9606.0,,Intermediate,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,A549,80682,N
6350,,17376,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,A549,80682,N
6351,,17376,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,A549,80682,N
6352,,17488,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity against human A549 lung cells,F,,A549,80682,N
6353,,17404,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,A549,80682,N
6354,,10958,,Homo sapiens,,646.0,9606.0,,Expert,,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,A549,80682,N
6355,,17099,,Homo sapiens,,646.0,9606.0,,Expert,,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,A549,80682,N
6356,,17099,,Homo sapiens,,646.0,9606.0,,Intermediate,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,A549,80682,N
6357,,4096,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,A549,80682,N
6358,,4096,,Homo sapiens,,646.0,9606.0,,Expert,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,A549,80682,N
6359,,4096,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,A549,80682,N
6360,,2525,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro inhibitory activity against A549 tumor cell culture,F,,A549,80682,N
6361,,2525,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,A549,80682,N
6362,,5302,,Homo sapiens,,646.0,9606.0,,Intermediate,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,A549,80682,N
6363,,16325,,Homo sapiens,,646.0,9606.0,,Intermediate,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,A549,80682,N
6364,,16939,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,A549,80682,N
6365,,17229,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,A549,80682,N
6366,,17380,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,A549,80682,N
6367,,17380,,Homo sapiens,,646.0,9606.0,,Intermediate,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,A549,80682,N
6368,,1903,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,A549,80682,N
6369,,3838,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,A549,80682,N
6370,,14696,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,A549,80682,N
6371,,3838,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,A549,80682,N
6372,,1522,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,A549,80682,N
6373,,12400,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,A549,80682,N
6374,,14696,,Homo sapiens,,646.0,9606.0,,Intermediate,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,A549,80682,N
6375,,14769,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,A549,80682,N
6376,,14696,,Homo sapiens,,646.0,9606.0,,Intermediate,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,A549,80682,N
6377,,1888,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,A549,80682,N
6378,,12016,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,A549,80682,N
6379,,6058,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,A549,80682,N
6380,,17708,,Homo sapiens,,646.0,9606.0,,Intermediate,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,A549,80682,N
6381,,12301,,Homo sapiens,,646.0,9606.0,,Intermediate,,Antitumor activity against A549/ATCC cell line,F,,A549,80682,N
6382,,11970,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,A549,80682,N
6383,,11818,,Homo sapiens,,646.0,9606.0,,Expert,,In vitro cytotoxicity against A549/ATCC cell line.,F,,A549,80682,N
6384,,12400,,Homo sapiens,,646.0,9606.0,,Intermediate,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,A549,80682,N
6385,,3381,,Homo sapiens,,646.0,9606.0,,Intermediate,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,A549,80682,N
6386,,17376,,Homo sapiens,,646.0,9606.0,,Intermediate,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,A549,80682,N
6387,,10708,,Homo sapiens,,646.0,9606.0,,Intermediate,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,A549,80682,N
6388,,2964,,Homo sapiens,,,9606.0,,Autocuration,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,22226,U
6389,,5005,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for oral bioavailability in dogs,A,In vivo,,22224,U
6390,,6229,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,50588,N
6391,,6229,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,50588,N
6392,,5374,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6393,,5374,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,50588,N
6394,,6265,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,50588,N
6395,,5654,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,50588,N
6396,,5654,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,50588,N
6397,,16456,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,50588,N
6398,,5302,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,50588,N
6399,,3624,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,50588,N
6400,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability of active FTIs in dogs,A,In vivo,,50588,N
6401,,5802,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,50588,N
6402,,3598,,Canis lupus familiaris,,,9615.0,,Expert,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,50588,N
6403,,17839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6404,,6762,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6405,,6821,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6406,,6821,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,50588,N
6407,,5210,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6408,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,50588,N
6409,,761,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability,A,In vivo,,50588,N
6410,,761,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,50588,N
6411,,761,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability administered in solution in rats,A,In vivo,,50588,N
6412,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,50588,N
6413,,5474,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,50588,N
6414,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,50588,N
6415,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in Dog; ND = not determined,A,In vivo,,50588,N
6416,,3352,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6417,,6168,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6418,,5988,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6419,,4942,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6420,,4942,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dogs; No data,A,In vivo,,50588,N
6421,,14541,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability measured in dogs,A,In vivo,,50588,N
6422,,4449,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6423,,6057,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability was calculated in dog,A,In vivo,,50588,N
6424,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,50588,N
6425,,5542,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (i.v. dosing),A,In vivo,,50588,N
6426,,5542,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6427,,5546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,50588,N
6428,,4514,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in Beagle dogs,A,In vivo,,50588,N
6429,,3624,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6430,,3854,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6431,,5836,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6432,,5940,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6433,,6168,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6434,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6435,,6251,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6436,,6448,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6437,,6647,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6438,,5940,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6439,,933,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6440,,5210,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6441,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,50588,N
6442,,6641,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,50588,N
6443,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,50588,N
6444,,5472,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6445,,5985,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6446,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6447,,5530,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,50588,N
6448,,5530,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,50588,N
6449,,6305,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability (F) in dogs,A,In vivo,,50588,N
6450,,5210,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6451,,5238,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6452,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,50588,N
6453,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,50588,N
6454,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,50588,N
6455,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,50588,N
6456,Kidney,6599,2113.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6457,Kidney,6599,2113.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6458,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6459,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6460,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6461,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6462,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6463,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6464,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6465,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6466,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6467,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6468,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6469,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6470,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6471,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6472,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6473,Spleen,6599,2106.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6474,Spleen,6599,2106.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6475,Spleen,6599,2106.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6476,Spleen,6599,2106.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6477,Spleen,6599,2106.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6478,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6479,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6480,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6481,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6482,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6483,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6484,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6485,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6486,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6487,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6488,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6489,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6490,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6491,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6492,Heart,6599,948.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6493,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6494,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6495,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6496,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6497,Liver,6599,2107.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6498,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6499,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6500,,12269,,aeinetobacter anitrotap,,,107673.0,,Intermediate,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,50067,N
6501,,12269,,Acinetobacter calcoaceticus subsp. anitratus,,,107673.0,,Intermediate,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,50067,N
6502,,12269,,Acinetobacter calcoaceticus subsp. anitratus,,,107673.0,,Intermediate,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,50067,N
6503,,12269,,aeinetobacter anitrotap,,,107673.0,,Intermediate,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,50067,N
6504,,10624,,Acinetobacter calcoaceticus,,,471.0,,Intermediate,,Activity against Acinetobacter calcoaceticus (AC54),F,,,50192,N
6505,,17216,,Anolis carolinensis,,,28377.0,,Intermediate,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,50714,N
6506,,17216,,Anolis carolinensis,,,28377.0,,Intermediate,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,50714,N
6507,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,50296,N
6508,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,50296,N
6509,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,50296,N
6510,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,50296,N
6511,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,50296,N
6512,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,50296,N
6513,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,50296,N
6514,,9560,,Actinomyces naeslundii,,,1655.0,,Intermediate,,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,50296,N
6515,,114,,Artemia salina,,,85549.0,,Intermediate,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,50056,N
6516,,114,,Artemia salina,,,85549.0,,Intermediate,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,50056,N
6517,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,50532,N
6518,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,50532,N
6519,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,50532,N
6520,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,50532,N
6521,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,50532,N
6522,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,50532,N
6523,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,50532,N
6524,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,50532,N
6525,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,50532,N
6526,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,50532,N
6527,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,50532,N
6528,,10841,,Ascaris suum,,,6253.0,,Intermediate,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,50532,N
6529,,8117,,Actinomyces viscosus,,,1656.0,,Intermediate,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,50366,N
6530,,8117,,Actinomyces viscosus,,,1656.0,,Intermediate,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,50366,N
6531,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,50366,N
6532,,9560,,Actinomyces viscosus,,,1656.0,,Expert,,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,50366,N
6533,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,50366,N
6534,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,50366,N
6535,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,50366,N
6536,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,50366,N
6537,,9560,,Actinomyces viscosus,,,1656.0,,Expert,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,50366,N
6538,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,50366,N
6539,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,50366,N
6540,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,Plaque bactericidal index against Actinomyces viscosus 626,F,,,50366,N
6541,,9560,,Actinomyces viscosus,,,1656.0,,Intermediate,,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,50366,N
6542,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,50535,N
6543,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,50535,N
6544,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,50535,N
6545,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,50535,N
6546,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,50535,N
6547,,10708,,Homo sapiens,,165.0,9606.0,,Intermediate,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,A673,80023,N
6548,,10708,,Homo sapiens,,645.0,9606.0,,Intermediate,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,A704,80661,N
6549,,416,,Rattus norvegicus,,,10116.0,,Autocuration,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,22226,U
6550,,14354,,Mus musculus,,625.0,10090.0,,Intermediate,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,A9,80024,N
6551,,14354,,Mus musculus,,625.0,10090.0,,Intermediate,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,A9,80024,N
6552,,5116,,Homo sapiens,,625.0,9606.0,,Intermediate,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,A9,80024,N
6553,,5116,,Homo sapiens,,625.0,9606.0,,Intermediate,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,A9,80024,N
6554,,15694,,Homo sapiens,,874.0,9606.0,,Expert,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,Human ovarian carcinoma cell line,81037,N
6555,,13038,,Mus musculus,,625.0,10090.0,,Expert,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,A9,80024,N
6556,,13038,,Mus musculus,,625.0,10090.0,,Expert,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,A9,80024,N
6557,,10923,,Mus musculus,,625.0,10090.0,,Expert,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,A9,80024,N
6558,,10923,,Mus musculus,,625.0,10090.0,,Intermediate,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,A9,80024,N
6559,,10923,,Mus musculus,,625.0,10090.0,,Intermediate,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,A9,80024,N
6560,,10923,,,,,,,Expert,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,10649,H
6561,,10923,,Mus musculus,,625.0,10090.0,,Intermediate,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,A9,80024,N
6562,,10923,,Mus musculus,,625.0,10090.0,,Intermediate,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,A9,80024,N
6563,,8158,,Cricetulus griseus,,975.0,10029.0,,Intermediate,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,AA6,80663,N
6564,,15494,,Homo sapiens,,,9606.0,,Autocuration,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,22226,U
6565,,15494,,Homo sapiens,,,9606.0,,Autocuration,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,22226,U
6566,,12348,,Homo sapiens,,974.0,9606.0,,Intermediate,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,AA5,80662,N
6567,,12348,,Homo sapiens,,974.0,9606.0,,Intermediate,,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,AA5,80662,N
6568,,2726,,Homo sapiens,,974.0,9606.0,,Intermediate,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,AA5,80662,N
6569,,2726,,Homo sapiens,,379.0,9606.0,,Intermediate,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,U-937,80566,N
6570,,10747,,Cricetulus griseus,,274.0,10029.0,,Intermediate,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,UV4,80578,N
6571,,11005,,Cricetulus griseus,,185.0,10029.0,,Expert,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,CHO-AA8,80089,N
6572,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Average intracellular compound concentration when the hypoxic SER=1.6,F,,CHO-AA8,80089,N
6573,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,CHO-AA8,80089,N
6574,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,CHO-AA8,80089,N
6575,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,CHO-AA8,80089,N
6576,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,CHO-AA8,80089,N
6577,,13436,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,CHO-AA8,80089,N
6578,,13435,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,CHO-AA8,80089,N
6579,,13302,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,CHO-AA8,80089,N
6580,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,CHO-AA8,80089,N
6581,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,CHO-AA8,80089,N
6582,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,CHO-AA8,80089,N
6583,,12878,,Cricetulus griseus,,185.0,10029.0,,Expert,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,CHO-AA8,80089,N
6584,,12878,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,CHO-AA8,80089,N
6585,,14367,,Cricetulus griseus,,185.0,10029.0,,Expert,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,CHO-AA8,80089,N
6586,,14367,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,CHO-AA8,80089,N
6587,,12398,,hampster,,185.0,36483.0,,Expert,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,CHO-AA8,80089,N
6588,,12878,,Cricetulus griseus,,185.0,10029.0,,Expert,,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,CHO-AA8,80089,N
6589,,13820,,Cricetulus griseus,,185.0,10029.0,,Expert,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,CHO-AA8,80089,N
6590,,13436,,Cricetulus griseus,,185.0,10029.0,,Expert,,Inhibition of growth under aerobic conditions in AA8 cells,F,,CHO-AA8,80089,N
6591,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,50588,N
6592,,5711,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,50588,N
6593,,4353,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,50588,N
6594,,4353,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,50588,N
6595,,17800,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (mongrel),A,In vivo,,50588,N
6596,,3994,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,50588,N
6597,,3994,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,50588,N
6598,,5145,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6599,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,50588,N
6600,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,50588,N
6601,,5983,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,50588,N
6602,,4273,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6603,,12500,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,50588,N
6604,Plasma,12500,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,50588,N
6605,,3639,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6606,,3880,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6607,,4838,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog,A,In vivo,,50588,N
6608,,15600,,Canis lupus familiaris,,,9615.0,,Intermediate,,oral bioavailability was measured in dogs,A,In vivo,,50588,N
6609,,17248,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for plasma protein binding in dog; Not determined,A,,,50588,N
6610,,17248,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for plasma protein binding of dog,A,,,50588,N
6611,,17248,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for plasma protein binding of dog; Not determined,A,,,50588,N
6612,,17443,,Canis lupus familiaris,,,9615.0,,Intermediate,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,50588,N
6613,,4186,,Canis lupus familiaris,,,9615.0,,Intermediate,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,50588,N
6614,,3749,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was determined,A,,,50588,N
6615,,3249,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,50588,N
6616,,3022,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was evaluated in dog,A,,,50588,N
6617,,3749,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was determined,A,,,50588,N
6618,,2517,,Canis lupus familiaris,,,9615.0,,Intermediate,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,50588,N
6619,Heart,2517,948.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,50588,N
6620,Kidney,2517,2113.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,50588,N
6621,Liver,2517,2107.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,50588,N
6622,Lung,2517,2048.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,50588,N
6623,Spleen,2517,2106.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,50588,N
6624,,3639,,Canis lupus familiaris,,,9615.0,,Intermediate,,LogP in dog,A,,,50588,N
6625,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Partition coefficient (logP),A,,,50588,N
6626,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Partition coefficient in dog,A,,,50588,N
6627,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,50588,N
6628,,4809,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,50588,N
6629,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,50588,N
6630,,14294,,Canis lupus familiaris,,,9615.0,,Intermediate,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,50588,N
6631,,14294,,Canis lupus familiaris,,,9615.0,,Intermediate,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,50588,N
6632,,14294,,Canis lupus familiaris,,,9615.0,,Intermediate,,Metabolism of compound in dog S9 microsomes; Trace,A,,,50588,N
6633,Liver,6251,2107.0,Canis lupus familiaris,,,9615.0,,Intermediate,,In vitro metabolic potential in dog liver microsomes,A,,,50588,N
6634,,3748,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,50588,N
6635,,2713,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6636,,6512,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6637,,6679,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,50588,N
6638,,3749,,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for bioavailability in dogs,A,In vivo,,50588,N
6639,,3749,,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for oral bioavailability in dogs,A,In vivo,,50588,N
6640,,6742,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog,A,In vivo,,50588,N
6641,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for percent protein binding (PB) in dog,A,,,50588,N
6642,,6874,,Canis lupus familiaris,,,9615.0,,Intermediate,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,50588,N
6643,Plasma,2877,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for plasma clearance.,A,In vivo,,50588,N
6644,Plasma,12500,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for plasma clearance in dog,A,In vivo,,50588,N
6645,Plasma,12500,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,50588,N
6646,,4709,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,50588,N
6647,Liver,5542,2107.0,Canis lupus familiaris,,,9615.0,,Intermediate,,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,50588,N
6648,,17594,,Canis lupus familiaris,,,9615.0,,Intermediate,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,50588,N
6649,,2652,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,50588,N
6650,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,50588,N
6651,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6652,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6653,Lung,6599,2048.0,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6654,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,CCRF S-180,50594,N
6655,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,CCRF S-180,50594,N
6656,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,CCRF S-180,50594,N
6657,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,CCRF S-180,50594,N
6658,,6599,,Mus musculus,,42.0,10090.0,,Intermediate,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,CCRF S-180,50594,N
6659,Brain,17641,955.0,Mus musculus,,,10090.0,,Intermediate,,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,50594,N
6660,Kidney,17641,2113.0,Mus musculus,,,10090.0,,Intermediate,,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,50594,N
6661,Liver,17641,2107.0,Mus musculus,,,10090.0,,Intermediate,,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,50594,N
6662,Lung,17641,2048.0,Mus musculus,,,10090.0,,Intermediate,,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,50594,N
6663,Spleen,17641,2106.0,Mus musculus,,,10090.0,,Intermediate,,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,50594,N
6664,,17852,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance in mouse,A,In vivo,,50594,N
6665,,17764,,Mus musculus,,,10090.0,,Intermediate,,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,50594,N
6666,,17837,,Mus musculus,,,10090.0,,Intermediate,,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,50594,N
6667,,2675,,Mus musculus,,,10090.0,,Intermediate,,Clearance was evaluated in mice after intravenous administration,A,In vivo,,50594,N
6668,,2675,,Mus musculus,,,10090.0,,Intermediate,,Clearance was evaluated in mice after oral administration,A,In vivo,,50594,N
6669,,4239,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,50594,N
6670,,17753,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,50594,N
6671,,17753,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance of at 24 mg/Kg,A,In vivo,,50594,N
6672,,17753,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance at 24 mg/Kg,A,In vivo,,50594,N
6673,,17753,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance at 5 mg/Kg,A,In vivo,,50594,N
6674,,5727,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance in mice,A,In vivo,,50594,N
6675,,2862,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance value upon iv administration in mouse,A,In vivo,,50594,N
6676,Plasma,5980,1969.0,Mus musculus,,,10090.0,,Intermediate,,Total plasma clearance in mice,A,In vivo,,50594,N
6677,,17592,,Mus musculus,,,10090.0,,Intermediate,,Clearance in mouse,A,In vivo,,50594,N
6678,,17718,,Mus musculus,,,10090.0,,Intermediate,,Clearance value was determined,A,In vivo,,50594,N
6679,,16597,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,50594,N
6680,,17384,,,,,,,Intermediate,,Calculated partition coefficient (clogP),P,,,22229,U
6681,,6062,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,50594,N
6682,,17734,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,50594,N
6683,,6348,,Mus musculus,,,10090.0,,Intermediate,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,50594,N
6684,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,50594,N
6685,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,50594,N
6686,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,50594,N
6687,,16597,,Mus musculus,,,10090.0,,Intermediate,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,50594,N
6688,,5781,,Mus musculus,,,10090.0,,Intermediate,,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,50594,N
6689,,17764,,Mus musculus,,,10090.0,,Intermediate,,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,50594,N
6690,Brain,17641,955.0,Mus musculus,,,10090.0,,Intermediate,,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
6691,Kidney,17641,2113.0,Mus musculus,,,10090.0,,Intermediate,,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
6692,Liver,17641,2107.0,Mus musculus,,,10090.0,,Intermediate,,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
6693,Lung,17641,2048.0,Mus musculus,,,10090.0,,Intermediate,,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
6694,,17764,,Mus musculus,,,10090.0,,Intermediate,,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,50594,N
6695,,17764,,Mus musculus,,,10090.0,,Intermediate,,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,50594,N
6696,,17764,,Mus musculus,,,10090.0,,Intermediate,,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,50594,N
6697,,17764,,Mus musculus,,,10090.0,,Intermediate,,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,50594,N
6698,,17764,,Mus musculus,,,10090.0,,Intermediate,,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,50594,N
6699,Spleen,17641,2106.0,Mus musculus,,,10090.0,,Intermediate,,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,50594,N
6700,,16597,,Mus musculus,,,10090.0,,Intermediate,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,50594,N
6701,,16597,,Mus musculus,,,10090.0,,Intermediate,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,50594,N
6702,,5727,,Mus musculus,,,10090.0,,Intermediate,,Cmax value was determined,A,In vivo,,50594,N
6703,,5951,,Mus musculus,,,10090.0,,Intermediate,,Cmax value in IRC mice,A,In vivo,,50594,N
6704,,5506,,Mus musculus,,,10090.0,,Intermediate,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,50594,N
6705,,5506,,Mus musculus,,,10090.0,,Intermediate,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,50594,N
6706,Plasma,14239,1969.0,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,50594,N
6707,Plasma,4890,1969.0,Mus musculus,,,10090.0,,Intermediate,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,50594,N
6708,,429,,Mus musculus,,,10090.0,,Intermediate,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,50594,N
6709,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,50535,N
6710,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,50535,N
6711,,10986,,Acanthocheilonema viteae,,,6277.0,,Intermediate,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,50535,N
6712,,13227,,Homo sapiens,,455.0,9606.0,,Intermediate,,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,A-375,80018,N
6713,,4481,,Rattus norvegicus,,,10116.0,Brain membranes,Expert,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,12512,D
6714,,16931,,Homo sapiens,,,9606.0,,Expert,,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,114,D
6715,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,CHO,114,H
6716,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,CHO,114,H
6717,,3850,,,,449.0,,,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,CHO,114,H
6718,,3850,,,,449.0,,,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,CHO,114,H
6719,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,CHO,114,H
6720,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,CHO,114,H
6721,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,CHO,114,H
6722,,3850,,Homo sapiens,,449.0,9606.0,,Expert,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,CHO,114,D
6723,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,CHO,114,H
6724,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,CHO,114,H
6725,,3850,,,,449.0,,,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,CHO,114,H
6726,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,CHO,114,H
6727,,3850,,,,449.0,,,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,CHO,114,H
6728,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,CHO,114,H
6729,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,CHO,114,H
6730,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,CHO,114,H
6731,,3850,,,,449.0,,,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,CHO,114,H
6732,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,CHO,114,H
6733,,3850,,,,449.0,,,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,CHO,114,H
6734,,3850,,,,449.0,,,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,CHO,114,H
6735,,12680,,Oryctolagus cuniculus,,164.0,9986.0,,Intermediate,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,A10,80013,N
6736,,1313,,Rattus norvegicus,,164.0,10116.0,,Autocuration,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,A10,22226,U
6737,,1313,,Rattus norvegicus,,164.0,10116.0,,Autocuration,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,A10,22226,U
6738,,17567,,Rattus norvegicus,,164.0,10116.0,,Intermediate,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,A10,80013,N
6739,,17567,,Rattus norvegicus,,164.0,10116.0,,Intermediate,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,A10,80013,N
6740,,11819,,Rattus norvegicus,,164.0,10116.0,,Intermediate,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,A10,80013,N
6741,,13436,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,CHO-AA8,80089,N
6742,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,CHO-AA8,80089,N
6743,,12651,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,CHO-AA8,80089,N
6744,,13300,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,CHO-AA8,80089,N
6745,,15296,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,CHO-AA8,80089,N
6746,,15328,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,CHO-AA8,80089,N
6747,,13302,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,CHO-AA8,80089,N
6748,,14367,,Cricetulus griseus,,185.0,10029.0,,Expert,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,CHO-AA8,80089,N
6749,,17002,,Cricetulus griseus,,185.0,10029.0,,Expert,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,CHO-AA8,80089,N
6750,,13436,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,CHO-AA8,80089,N
6751,,13435,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Inhibitory activity against aerobic growth of AA8 cells.,F,,CHO-AA8,80089,N
6752,,10503,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,CHO-AA8,80089,N
6753,,10503,,Cricetulus griseus,,185.0,10029.0,,Expert,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,CHO-AA8,80089,N
6754,,10503,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,CHO-AA8,80089,N
6755,,15090,,Cricetulus griseus,,185.0,10029.0,,Expert,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,CHO-AA8,80089,N
6756,,10368,,Cricetulus griseus,,185.0,10029.0,,Expert,,Cytotoxicity against AA8 cell line,F,,CHO-AA8,80089,N
6757,,12651,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,CHO-AA8,80089,N
6758,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,CHO-AA8,80089,N
6759,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,CHO-AA8,80089,N
6760,,12687,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,CHO-AA8,80089,N
6761,,1890,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,CHO-AA8,80089,N
6762,,10747,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,CHO-AA8,80089,N
6763,,10747,,Cricetulus griseus,,185.0,10029.0,,Intermediate,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,CHO-AA8,80089,N
6764,,11616,,Cricetulus griseus,,,10029.0,,Autocuration,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,22224,U
6765,,11616,,Cricetulus griseus,,185.0,10029.0,,Expert,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,CHO-AA8,80089,N
6766,,3471,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,CHO-AA8,22224,U
6767,,3471,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,CHO-AA8,22224,U
6768,,3471,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,CHO-AA8,22224,U
6769,,3471,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,CHO-AA8,22224,U
6770,,3471,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,CHO-AA8,22224,U
6771,,3471,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,CHO-AA8,22224,U
6772,,3471,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,CHO-AA8,22224,U
6773,,11616,,Cricetulus griseus,,185.0,10029.0,,Expert,,Concentration required to reduce AA8 cell survival by 10%,F,,CHO-AA8,80089,N
6774,,2656,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,CHO-AA8,22224,U
6775,,10518,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,CHO-AA8,22224,U
6776,,10518,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,CHO-AA8,22224,U
6777,,10518,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,CHO-AA8,22224,U
6778,,10518,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,CHO-AA8,22224,U
6779,,16156,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,CHO-AA8,22224,U
6780,,2656,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,CHO-AA8,22224,U
6781,,11005,,Cricetulus griseus,,,10029.0,,Autocuration,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,22224,U
6782,,11942,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,CHO-AA8,22224,U
6783,,2128,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,CHO-AA8,22224,U
6784,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,50588,N
6785,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,50588,N
6786,,9579,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,50588,N
6787,,9579,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was measured in dog after oral 17b administration,A,In vivo,,50588,N
6788,,9579,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,50588,N
6789,,9579,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,50588,N
6790,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,50588,N
6791,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,50588,N
6792,,3184,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,50588,N
6793,Plasma,5017,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,50588,N
6794,,6821,,Canis lupus familiaris,,,9615.0,,Intermediate,,Elimination Half-life of compound was determined in dog,A,,,50588,N
6795,,17839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life of compound in dog following oral administration,A,In vivo,,50588,N
6796,,17267,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life of compound was determined in dog,A,,,50588,N
6797,Blood,4727,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life of compound was determined in dog blood,A,,,50588,N
6798,,5238,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life after oral and iv dosing in dogs,A,In vivo,,50588,N
6799,,4942,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dogs in hours,A,,,50588,N
6800,,6505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,50588,N
6801,,5130,,Canis lupus familiaris,,,9615.0,,Intermediate,,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,50588,N
6802,,1475,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was evaluated in dog,A,,,50588,N
6803,,17804,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,50588,N
6804,,17804,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,50588,N
6805,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period (10 mg/kg) was determined in dog,A,In vivo,,50588,N
6806,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period (10 mg/kg) was determined in dog,A,In vivo,,50588,N
6807,,5542,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,50588,N
6808,,5542,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,50588,N
6809,,6084,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period in dog,A,,,50588,N
6810,,6241,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,50588,N
6811,,1916,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,50588,N
6812,,6621,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of compound was determined in dogs,A,,,50588,N
6813,Plasma,1696,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dog plasma,A,,,50588,N
6814,,17800,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in mongrel dogs was determined,A,,,50588,N
6815,,17657,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dog upon oral administration,A,In vivo,,50588,N
6816,,17657,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,50588,N
6817,,4239,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life was measured in dog,A,,,50588,N
6818,,5985,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life was measured in dog,A,,,50588,N
6819,,9932,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,50588,N
6820,,5199,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral half life was determined,A,In vivo,,50588,N
6821,Plasma,5199,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,50588,N
6822,Plasma,1475,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half life was evaluated,A,,,50588,N
6823,Plasma,1475,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half life was evaluated in Dog,A,,,50588,N
6824,Plasma,1475,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma half life was evaluated in dog,A,,,50588,N
6825,,6316,,Canis lupus familiaris,,,9615.0,,Intermediate,,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,50588,N
6826,,4883,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for the half life value in dog,A,,,50588,N
6827,,4727,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,50588,N
6828,,1916,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,50588,N
6829,Blood,1337,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,50588,N
6830,Blood,1337,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,50588,N
6831,,6265,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,50588,N
6832,,4809,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,50588,N
6833,,5983,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,50588,N
6834,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,50588,N
6835,,5313,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,50588,N
6836,Plasma,17650,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,50588,N
6837,Plasma,5199,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,50588,N
6838,Plasma,933,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Time taken for maximum plasma concentration in dog,A,,,50588,N
6839,,16367,,Canis lupus familiaris,,,9615.0,,Intermediate,,Time to reach Cmax after oral administration to dogs,A,In vivo,,50588,N
6840,Plasma,6348,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,50588,N
6841,,6316,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,50588,N
6842,,6215,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,50588,N
6843,,3598,,Canis lupus familiaris,,,9615.0,,Expert,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,50588,N
6844,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,50588,N
6845,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,50588,N
6846,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,50594,N
6847,,5969,,Mus musculus,,,10090.0,,Intermediate,,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,50594,N
6848,,4573,,Mus musculus,,,10090.0,,Intermediate,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,50594,N
6849,Plasma,3277,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,50594,N
6850,Plasma,17734,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,50594,N
6851,Plasma,3132,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,50594,N
6852,Plasma,3132,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,50594,N
6853,Plasma,6348,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,50594,N
6854,Plasma,17729,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,50594,N
6855,Plasma,17729,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,50594,N
6856,Plasma,17729,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,50594,N
6857,Plasma,17728,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,50594,N
6858,Plasma,17728,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,50594,N
6859,Plasma,17728,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,50594,N
6860,,4066,,Mus musculus,,,10090.0,,Intermediate,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,50594,N
6861,,6178,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,50594,N
6862,,6178,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,50594,N
6863,,3760,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,50594,N
6864,,3760,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,50594,N
6865,,3760,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,50594,N
6866,,3760,,Mus musculus,,,10090.0,,Intermediate,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,50594,N
6868,,5961,,Mus musculus,,,10090.0,,Intermediate,,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,50594,N
6869,,6137,,Mus musculus,,,10090.0,,Intermediate,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,50594,N
6870,,3802,,Mus musculus,,,10090.0,,Intermediate,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,50594,N
6871,,3535,,Mus musculus,,,10090.0,,Intermediate,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,50594,N
6872,,3535,,Mus musculus,,,10090.0,,Intermediate,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,50594,N
6873,,3535,,Mus musculus,,,10090.0,,Intermediate,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,50594,N
6874,,3535,,Mus musculus,,,10090.0,,Intermediate,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,50594,N
6875,,3535,,Mus musculus,,,10090.0,,Intermediate,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,50594,N
6876,,3535,,Mus musculus,,,10090.0,,Intermediate,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,50594,N
6877,Plasma,2862,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum concentration in plasma upon oral administration in mouse,A,,,50594,N
6878,Plasma,2675,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum plasma concentration was evaluated in mice after oral administration,A,,,50594,N
6879,Plasma,2675,1969.0,Mus musculus,,,10090.0,,Intermediate,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,50594,N
6880,,5399,,Mus musculus,,,10090.0,,Intermediate,,Dose at which the compound induced fecal excretion in mice,A,,,50594,N
6893,,11819,,Rattus norvegicus,,164.0,10116.0,,Expert,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,A10,80013,N
6894,,11819,,Rattus norvegicus,,164.0,10116.0,,Expert,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,A10,80013,N
6895,,11819,,Rattus norvegicus,,164.0,10116.0,,Expert,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,A10,80013,N
6896,,11819,,Rattus norvegicus,,164.0,10116.0,,Expert,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,A10,80013,N
6897,,16361,,Rattus norvegicus,,164.0,10116.0,,Intermediate,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,A10,80013,N
6898,,2288,,Homo sapiens,,393.0,9606.0,,Intermediate,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,A121,80655,N
6899,,10404,,Homo sapiens,,393.0,9606.0,,Intermediate,,Anticancer activity against human ovarian carcinoma A121 cells,F,,A121,80655,N
6900,,14790,,Homo sapiens,,393.0,9606.0,,Intermediate,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,A121,80655,N
6901,,14790,,Homo sapiens,,393.0,9606.0,,Intermediate,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,A121,80655,N
6902,,14253,,Homo sapiens,,393.0,9606.0,,Expert,,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,A121,80655,N
6903,,13617,,Homo sapiens,,393.0,9606.0,,Expert,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,A121,80655,N
6904,,1003,,Homo sapiens,,393.0,9606.0,,Intermediate,,Cytotoxicity against human A121 ovarian cells,F,,A121,80655,N
6905,,830,,Homo sapiens,,393.0,9606.0,,Intermediate,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,A121,80655,N
6906,,12307,,Homo sapiens,,393.0,9606.0,,Intermediate,,In vitro cytotoxicity against human ovarian carcinoma A21,F,,A121,80655,N
6907,,14254,,Homo sapiens,,393.0,9606.0,,Intermediate,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,A121,80655,N
6908,,13370,,Homo sapiens,,393.0,9606.0,,Intermediate,,Inhibitory activity of compound against human A121 ovarian cell line.,F,,A121,80655,N
6909,,14790,,Homo sapiens,,393.0,9606.0,,Intermediate,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,A121,80655,N
6910,,3614,,Homo sapiens,,393.0,9606.0,,Intermediate,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,A121,80655,N
6911,,2664,,Homo sapiens,,622.0,9606.0,,Intermediate,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,A 172,80012,N
6912,,2037,,Homo sapiens,,622.0,9606.0,,Expert,,In vitro cytotoxicity against A172 human tumor cell lines.,F,,A 172,80012,N
6913,,14539,,Homo sapiens,,622.0,9606.0,,Intermediate,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,A 172,80012,N
6914,,2836,,Homo sapiens,,622.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,A 172,80012,N
6915,,10708,,Homo sapiens,,622.0,9606.0,,Intermediate,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,A 172,80012,N
6916,,8975,,Canis lupus familiaris,,,9615.0,,Autocuration,,Association constant against A2 adenosine receptor,B,,,104729,H
6917,,7645,,fish,,1085.0,,,Intermediate,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,A2,80656,N
6918,,11377,,Rattus norvegicus,,,10116.0,,Autocuration,,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,104713,D
6919,,13528,,Homo sapiens,,623.0,9606.0,,Expert,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,A204,80014,N
6920,,10160,,Homo sapiens,,623.0,9606.0,,Expert,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,A204,80014,N
6921,,15144,,Homo sapiens,,404.0,9606.0,,Intermediate,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,A2058,80015,N
6922,,13160,,Homo sapiens,,973.0,9606.0,,Intermediate,,Growth inhibition against Human squamous cell line(A 253),F,,A253 cell line,80657,N
6923,,12898,,Homo sapiens,,973.0,9606.0,,Intermediate,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,A253 cell line,80657,N
6924,,13069,,Homo sapiens,,973.0,9606.0,,Intermediate,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,A253 cell line,80657,N
6925,,15984,,Homo sapiens,,973.0,9606.0,,Intermediate,,Growth inhibition of A253 cell lines.,F,,A253 cell line,80657,N
6926,,15564,,Homo sapiens,,973.0,9606.0,,Intermediate,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,A253 cell line,80657,N
6927,,15564,,Homo sapiens,,973.0,9606.0,,Intermediate,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,A253 cell line,80657,N
6928,,15564,,Homo sapiens,,973.0,9606.0,,Intermediate,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,A253 cell line,80657,N
6929,,4720,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,A2780,81034,N
6930,,16112,,Homo sapiens,,478.0,9606.0,,Intermediate,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,A2780,81034,N
6931,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,A2780,81034,N
6932,,16378,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,A2780,81034,N
6933,,16085,,Homo sapiens,,478.0,9606.0,,Expert,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,A2780,81034,N
6934,,16317,,Homo sapiens,,478.0,9606.0,,Intermediate,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,A2780,81034,N
6935,,15748,,Homo sapiens,,478.0,9606.0,,Intermediate,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,A2780,81034,N
6936,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,A2780,81034,N
6937,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,A2780,81034,N
6938,,16597,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,A2780,81034,N
6939,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,A2780,81034,N
6940,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,A2780,81034,N
6941,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,A2780,81034,N
6942,,15296,,Cricetulus griseus,,,10029.0,,Autocuration,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,22224,U
6943,,10251,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,CHO-AA8,22224,U
6944,,10251,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,CHO-AA8,22224,U
6945,,10251,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,CHO-AA8,22224,U
6946,,10251,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,CHO-AA8,22224,U
6947,,11858,,Cricetulus griseus,,,10029.0,,Autocuration,,Growth inhibition against CHO-derived cell line AA8,F,,,22224,U
6948,,11858,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,CHO-AA8,22224,U
6949,,11616,,hampster,,185.0,36483.0,,Expert,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,CHO-AA8,80089,N
6950,,11616,,Cricetulus griseus,,185.0,10029.0,,Expert,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,CHO-AA8,80089,N
6951,,10518,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,CHO-AA8,22224,U
6952,,11396,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,CHO-AA8,22224,U
6953,,10518,,Cricetulus griseus,,185.0,10029.0,,Autocuration,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,CHO-AA8,22224,U
6954,,11616,,Cricetulus griseus,,185.0,10029.0,,Expert,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,CHO-AA8,80089,N
6955,,14837,,,,,,,Autocuration,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,12675,H
6956,,14837,,,,,,,Autocuration,,Number of binding sites (n) of isolated serum protein AAG,F,,,12675,H
6957,,16037,,,,,,,Intermediate,,Association constant for binding to AATT duplex,B,,,22222,M
6958,,16597,,Homo sapiens,,416.0,9606.0,,Expert,,Inhibition of ABAE human fibroblast cell proliferation,F,,ABAE,100090,N
6959,,8831,,Mus musculus,,1064.0,10090.0,,Intermediate,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,AC755,80668,N
6960,,13419,,Oryctolagus cuniculus,,,9986.0,,Expert,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,102444,D
6961,,13419,,Oryctolagus cuniculus,,,9986.0,,Expert,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,102444,D
6962,,15778,,,,,,,Autocuration,,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,69,H
6963,,15778,,,,,,,Autocuration,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,69,H
6964,,12988,,Homo sapiens,,978.0,9606.0,,Intermediate,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,ACH-2 cell line,80669,N
6965,,12988,,Homo sapiens,,978.0,9606.0,,Intermediate,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,ACH-2 cell line,80669,N
6966,,12988,,Human immunodeficiency virus 1,,998.0,11676.0,,Autocuration,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,T cell line,22224,U
6967,,12988,,Human immunodeficiency virus 1,,998.0,11676.0,,Autocuration,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,T cell line,22224,U
6968,,12988,,Human immunodeficiency virus 1,,998.0,11676.0,,Autocuration,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,T cell line,22224,U
6969,,11843,,Homo sapiens,,626.0,9606.0,,Intermediate,,Inhibition of growth of renal cancer ACHN cell line,F,,ACHN,80025,N
6970,,16939,,Homo sapiens,,626.0,9606.0,,Intermediate,,Inhibition of growth of ACHN renal cancer cell line,F,,ACHN,80025,N
6971,,4782,,Homo sapiens,,626.0,9606.0,,Intermediate,,Inhibitory concentration required against ACHN renal cancer cell line,F,,ACHN,80025,N
6972,,6310,,Homo sapiens,,626.0,9606.0,,Expert,,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,ACHN,80025,N
6973,,6310,,Homo sapiens,,626.0,9606.0,,Intermediate,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,ACHN,80025,N
6974,,12858,,Homo sapiens,,626.0,9606.0,,Intermediate,,Cytotoxic activity against ACHN Renal cancer cell line,F,,ACHN,80025,N
6975,,17380,,Homo sapiens,,626.0,9606.0,,Intermediate,,Cytotoxicity evaluation against ACHN renal cancer cells,F,,ACHN,80025,N
6976,,5858,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro antitumor activity against human renal ACHN cell line,F,,ACHN,80025,N
6977,,3838,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,ACHN,80025,N
6978,,3838,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,ACHN,80025,N
6979,,5406,,Homo sapiens,,626.0,9606.0,,Intermediate,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,ACHN,80025,N
6980,,4071,,Homo sapiens,,626.0,9606.0,,Intermediate,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,ACHN,80025,N
6981,,4071,,Homo sapiens,,626.0,9606.0,,Expert,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,ACHN,80025,N
6982,,4071,,Homo sapiens,,626.0,9606.0,,Intermediate,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,ACHN,80025,N
6983,,15002,,Homo sapiens,,626.0,9606.0,,Intermediate,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,ACHN,80025,N
6984,,14769,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,ACHN,80025,N
6985,,13958,,Homo sapiens,,626.0,9606.0,,Intermediate,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,ACHN,80025,N
6986,,1665,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,ACHN,80025,N
6987,,15354,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,ACHN,80025,N
6988,,15354,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,ACHN,80025,N
6989,,13978,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,ACHN,80025,N
6990,,6798,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,ACHN,80025,N
6991,,2959,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,50588,N
6992,,9932,,Canis lupus familiaris,,,9615.0,,Intermediate,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,50588,N
6993,,5546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,50588,N
6994,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,50588,N
6995,,16907,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,50588,N
6996,,4257,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,50588,N
6997,,4305,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,50588,N
6998,,5472,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution was evaluated in dog,A,In vivo,,50588,N
6999,,6062,,Canis lupus familiaris,,,9615.0,,Intermediate,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,50588,N
7000,,3598,,Canis lupus familiaris,,,9615.0,,Expert,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,50588,N
7001,,12500,,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for volume of distribution in dog,A,In vivo,,50588,N
7002,,12500,,Canis lupus familiaris,,,9615.0,,Intermediate,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,50588,N
7003,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,50588,N
7004,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vd in dog,A,In vivo,,50588,N
7005,,4219,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution was determined,A,In vivo,,50588,N
7006,,1696,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution in dog,A,In vivo,,50588,N
7007,,5542,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,50588,N
7008,,5199,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,50588,N
7009,,6348,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,50588,N
7010,,4727,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,50588,N
7011,,16367,,Canis lupus familiaris,,,9615.0,,Intermediate,,Steady state volume of distribution was determined,A,In vivo,,50588,N
7012,,2652,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,50588,N
7013,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,50588,N
7014,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,50588,N
7015,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,50588,N
7016,,5334,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,50588,N
7017,,4239,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,50588,N
7018,,4709,,Canis lupus familiaris,,,9615.0,,Intermediate,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,50588,N
7019,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,50588,N
7020,,6057,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume displacement was calculated in dog,A,In vivo,,50588,N
7021,,5654,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,50588,N
7022,,5505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution constant was determined,A,In vivo,,50588,N
7023,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,50588,N
7024,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,50588,N
7025,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,50588,N
7026,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution (Vdss) was measured in dog,A,In vivo,,50588,N
7027,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution (Vdss) was measured in dog,A,In vivo,,50588,N
7028,,6679,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,50588,N
7029,,5145,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution in steady state was determined in dog,A,In vivo,,50588,N
7030,,6821,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution of compound was determined in dog,A,In vivo,,50588,N
7031,,4137,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,50588,N
7032,,5334,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,50588,N
7033,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution (Vdss) was measured in dog,A,In vivo,,50588,N
7034,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,50588,N
7035,,6641,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,50588,N
7036,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,50588,N
7037,,11659,,Canis lupus familiaris,,,9615.0,,Intermediate,,Maximum rate of depolarization of the upstroke of the action potential,A,,,50588,N
7038,,6448,,Canis lupus familiaris,,,9615.0,,Intermediate,,Steady state volume distribution in dog,A,In vivo,,50588,N
7039,,5474,,Canis lupus familiaris,,,9615.0,,Intermediate,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,50588,N
7040,,1466,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,50588,N
7041,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,50588,N
7042,,6535,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,50588,N
7043,,17764,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,50588,N
7044,,6215,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,50588,N
7045,,6505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,50588,N
7046,,3639,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vss was determined,A,,,50588,N
7047,,3639,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vss in dog,A,,,50588,N
7048,,6062,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,50588,N
7049,,4942,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume distribution in dogs,A,In vivo,,50588,N
7050,,17796,,Canis lupus familiaris,,,9615.0,,Intermediate,,Volume of distribution in dog,A,In vivo,,50588,N
7051,,4883,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tested for the oral bioavailability in dog,A,In vivo,,50588,N
7060,,17837,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,50594,N
7061,,17729,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,50594,N
7062,,17729,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,50594,N
7063,,4239,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability was measured in mouse,A,In vivo,,50594,N
7064,,17592,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability in mouse,A,In vivo,,50594,N
7065,,6348,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,50594,N
7066,,2801,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability in mouse,A,In vivo,,50594,N
7067,,2801,,Mus musculus,,,10090.0,,Intermediate,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,50594,N
7068,,17718,,Mus musculus,,,10090.0,,Intermediate,,Oral bioavailability in mouse,A,In vivo,,50594,N
7069,,5727,,Mus musculus,,,10090.0,,Intermediate,,Oral availability at 50 mg/kg po in male mice,A,In vivo,,50594,N
7070,,5302,,Mus musculus,,,10090.0,,Intermediate,,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,50594,N
7071,,3598,,Mus musculus,,,10090.0,,Expert,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,50594,N
7072,,5961,,Mus musculus,,,10090.0,,Intermediate,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,50594,N
7074,,6091,,Mus musculus,,,10090.0,,Intermediate,,Oral bioavailability in mouse,A,In vivo,,50594,N
7075,,6091,,Mus musculus,,,10090.0,,Intermediate,,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,50594,N
7076,,5711,,Mus musculus,,,10090.0,,Intermediate,,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,50594,N
7077,,17728,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,50594,N
7078,,17728,,Mus musculus,,,10090.0,,Intermediate,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,50594,N
7079,,3802,,Mus musculus,,,10090.0,,Intermediate,,Tested for bioavailability of the compound,A,In vivo,,50594,N
7080,,3802,,Mus musculus,,,10090.0,,Intermediate,,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,50594,N
7081,Plasma,14029,1969.0,Mus musculus,,,10090.0,,Intermediate,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,50594,N
7082,Plasma,14029,1969.0,Mus musculus,,,10090.0,,Intermediate,,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,50594,N
7083,Plasma,14029,1969.0,Mus musculus,,,10090.0,,Intermediate,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,50594,N
7084,Plasma,14029,1969.0,Mus musculus,,,10090.0,,Intermediate,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,50594,N
7085,Plasma,14029,1969.0,Mus musculus,,,10090.0,,Intermediate,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,50594,N
7086,,17753,,Mus musculus,,,10090.0,,Intermediate,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,50594,N
7087,,17753,,Mus musculus,,,10090.0,,Intermediate,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,50594,N
7088,,17753,,Mus musculus,,,10090.0,,Intermediate,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,50594,N
7089,Blood,10107,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7090,Blood,10107,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
7091,Blood,10107,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7092,Blood,10107,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7093,Blood,10107,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7094,Blood,10107,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7095,Blood,10107,178.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7096,Bone,10107,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7097,Bone,10107,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,50594,N
7098,,15608,,Homo sapiens,,478.0,9606.0,,Intermediate,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,A2780,81034,N
7099,,3290,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,A2780,81034,N
7100,,2859,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was evaluated for cytotoxicity against A2780 cell line,F,,A2780,81034,N
7101,,15688,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibition of A2780 cell clonogenic assay,F,,A2780,81034,N
7102,,5642,,Homo sapiens,,478.0,9606.0,,Expert,,Cytotoxic effect on ovarian cancer cell line (A2780),F,,A2780,81034,N
7103,,6633,,Homo sapiens,,478.0,9606.0,,Intermediate,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,A2780,81034,N
7104,,3906,,Homo sapiens,,478.0,9606.0,,Intermediate,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,A2780,81034,N
7105,,6788,,Homo sapiens,,478.0,9606.0,,Expert,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,A2780,81034,N
7106,,17582,,Homo sapiens,,478.0,9606.0,,Expert,,Antiproliferative activity against human A2780 cells,F,,A2780,81034,N
7107,,17764,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibition of human A2780 cell proliferation,F,,A2780,81034,N
7108,,17764,,Homo sapiens,,478.0,9606.0,,Expert,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,A2780,81034,N
7109,,17764,,Homo sapiens,,478.0,9606.0,,Expert,,Inhibition of human A2780 cell proliferation (No data),F,,A2780,81034,N
7110,,2815,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,A2780,81034,N
7111,,16930,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,A2780,81034,N
7112,,17777,,Homo sapiens,,478.0,9606.0,,Expert,,Growth inhibition against A2780 wild-type ovarian cell lines,F,,A2780,81034,N
7113,,17777,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,A2780,81034,N
7114,,16936,,Homo sapiens,,,9606.0,,Autocuration,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,104766,D
7115,,13759,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,A2780,81034,N
7116,,13759,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,A2780,81034,N
7117,,13759,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,A2780,81034,N
7118,,13759,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,A2780,81034,N
7119,,15292,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,A2780,81034,N
7120,,15292,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,A2780,81034,N
7121,,15069,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro inhibition of human ovarian cell line A2780,F,,A2780,81034,N
7122,,15069,,Homo sapiens,,478.0,9606.0,,Expert,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,A2780,81034,N
7123,,14073,,Homo sapiens,,478.0,9606.0,,Intermediate,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,A2780,81034,N
7124,,14553,,Homo sapiens,,478.0,9606.0,,Expert,,Concentration required to inhibit A2780-cell growth by 50%,F,,A2780,81034,N
7125,,13040,,Homo sapiens,,478.0,9606.0,,Expert,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,A2780,81034,N
7126,,6891,,Homo sapiens,,478.0,9606.0,,Expert,,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,A2780,81034,N
7127,,15569,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,A2780,81034,N
7128,,14190,,Homo sapiens,,478.0,9606.0,,Expert,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,A2780,81034,N
7129,,15014,,Homo sapiens,,478.0,9606.0,,Expert,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,A2780,81034,N
7130,,15014,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,A2780,81034,N
7131,,17496,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,A2780,81034,N
7132,,13617,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,A2780,81034,N
7133,,13617,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,A2780,81034,N
7134,,13617,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,A2780,81034,N
7135,,13617,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,A2780,81034,N
7136,,17672,,Homo sapiens,,478.0,9606.0,,Intermediate,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,A2780,81034,N
7137,,4544,,Homo sapiens,,478.0,9606.0,,Intermediate,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,A2780,81034,N
7138,,4544,,Homo sapiens,,478.0,9606.0,,Intermediate,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,A2780,81034,N
7139,,16317,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,A2780,81034,N
7140,,15099,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,A2780,81034,N
7141,,13978,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,A2780,81034,N
7142,,12989,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro antitumor activity against A2780 cell line.,F,,A2780,81034,N
7143,,5574,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,A2780,81034,N
7144,,13528,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,A2780,81034,N
7145,,12782,,Homo sapiens,,626.0,9606.0,,Intermediate,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,ACHN,80025,N
7146,,14255,,Homo sapiens,,626.0,9606.0,,Intermediate,,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,ACHN,80025,N
7147,,16364,,Homo sapiens,,626.0,9606.0,,Intermediate,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,ACHN,80025,N
7148,,17376,,Homo sapiens,,626.0,9606.0,,Expert,,In vitro lethal concentration against most sensitive ACHN cell line,F,,ACHN,80025,N
7149,,12016,,Homo sapiens,,626.0,9606.0,,Intermediate,,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,ACHN,80025,N
7150,,6058,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,ACHN,80025,N
7151,,17708,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,ACHN,80025,N
7152,,15176,,Homo sapiens,,626.0,9606.0,,Intermediate,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,ACHN,80025,N
7153,,2806,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro anticancer activity against ACHN renal cancer cell line,F,,ACHN,80025,N
7154,,15300,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,ACHN,80025,N
7155,,16364,,Homo sapiens,,626.0,9606.0,,Intermediate,,Percent selectivity was evaluated in renal ACHN cell lines,F,,ACHN,80025,N
7156,,13859,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro inhibitory activity against renal ACHN cancer cell line,F,,ACHN,80025,N
7157,,11970,,Homo sapiens,,626.0,9606.0,,Intermediate,,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,ACHN,80025,N
7158,,2450,,Homo sapiens,,626.0,9606.0,,Intermediate,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,ACHN,80025,N
7159,,12696,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,ACHN,80025,N
7160,,12400,,Homo sapiens,,626.0,9606.0,,Intermediate,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,ACHN,80025,N
7161,,12888,,Homo sapiens,,626.0,9606.0,,Expert,,Cytotoxic effect on renal cancer line ACHN,F,,ACHN,80025,N
7162,,3156,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,ACHN,80025,N
7163,,3381,,Homo sapiens,,626.0,9606.0,,Intermediate,,In vitro inhibition of Renal Cancer ACHN cell lines,F,,ACHN,80025,N
7164,,16747,,Homo sapiens,,626.0,9606.0,,Intermediate,,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,ACHN,80025,N
7165,,16748,,Homo sapiens,,626.0,9606.0,,Expert,,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,ACHN,80025,N
7166,,12062,,Homo sapiens,,626.0,9606.0,,Intermediate,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,ACHN,80025,N
7167,,14769,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,ACHN,80025,N
7168,,15895,,Homo sapiens,,626.0,9606.0,,Intermediate,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,ACHN,80025,N
7169,,17376,,Homo sapiens,,626.0,9606.0,,Intermediate,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,ACHN,80025,N
7170,,14882,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,ACHN,80025,N
7171,,14882,,Homo sapiens,,626.0,9606.0,,Intermediate,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,ACHN,80025,N
7172,,15661,,Homo sapiens,,626.0,9606.0,,Intermediate,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,ACHN,80025,N
7173,,9680,,,,,,,Autocuration,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,22224,U
7174,,14579,,,,,,,Autocuration,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,10647,H
7175,,17290,,Cytomegalovirus,,468.0,10358.0,,Expert,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,HEL,50529,N
7176,,17290,,Cytomegalovirus,,,10358.0,,Intermediate,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,50529,N
7177,,15891,,,,,,,Autocuration,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,12159,H
7178,,15890,,,,,,,Autocuration,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,12159,H
7179,,3801,,Bos taurus,,979.0,9913.0,,Intermediate,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,ADDP cell line,80670,N
7180,,9222,,Mus musculus,,980.0,10090.0,,Intermediate,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,ADJ/PC6,80671,N
7181,,9222,,Mus musculus,,980.0,10090.0,,Intermediate,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,ADJ/PC6,80671,N
7182,,7257,,Mus musculus,,980.0,10090.0,,Intermediate,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,ADJ/PC6,80671,N
7183,,7257,,Mus musculus,,980.0,10090.0,,Intermediate,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,ADJ/PC6,80671,N
7184,,7257,,Mus musculus,,980.0,10090.0,,Intermediate,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,ADJ/PC6,80671,N
7185,,8084,,Mus musculus,,980.0,10090.0,,Intermediate,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,ADJ/PC6,80671,N
7186,,14943,,Mus musculus,,,10090.0,,Autocuration,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,22224,U
7187,,14943,,Mus musculus,,,10090.0,,Autocuration,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,22224,U
7188,,14943,,Mus musculus,,,10090.0,,Autocuration,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,22224,U
7189,,10524,,Bacillus subtilis,,,1423.0,,Autocuration,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,22224,U
7190,Plasma,3546,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,50588,N
7191,Plasma,3546,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,50588,N
7192,,3546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,50588,N
7193,,3546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,50588,N
7194,,3546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,50588,N
7195,,3184,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,50588,N
7196,,16456,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,50588,N
7197,,4809,,Canis lupus familiaris,,,9615.0,,Intermediate,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,50588,N
7198,,4219,,,,,,,Intermediate,,Calculated partition coefficient (clogP),P,,,22229,U
7199,,3748,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog,A,,,50588,N
7200,,3132,,Canis lupus familiaris,,,9615.0,,Intermediate,,Time taken for EC90 was determined when tested in dog,A,,,50588,N
7201,,4219,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life (iv) was determined,A,,,50588,N
7202,Liver,16907,2107.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,50588,N
7203,,6057,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve was calculated in dog after iv administration,A,,,50588,N
7204,,6057,,Canis lupus familiaris,,,9615.0,,Intermediate,,Area under the curve was calculated in dog after peroral administration,A,,,50588,N
7205,,17853,,Canis lupus familiaris,,,9615.0,,Intermediate,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,50588,N
7206,,3639,,Canis lupus familiaris,,,9615.0,,Intermediate,,pKa was evaluated in dog,A,,,50588,N
7207,,14541,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,50588,N
7208,,16456,,Canis lupus familiaris,,,9615.0,,Intermediate,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,50588,N
7209,,16456,,Canis lupus familiaris,,,9615.0,,Intermediate,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,50588,N
7210,,2652,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,50588,N
7211,,3624,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for the half-life (t 1/2) in hours,A,,,50588,N
7212,Blood,1337,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,50588,N
7213,Blood,1337,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,50588,N
7214,,4709,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,50588,N
7215,,15660,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was measured in dog,A,,,50588,N
7216,,5302,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period in dog after 5 mg/kg dose,A,In vivo,,50588,N
7217,,17791,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was evaluated in dog; 4-4.8,A,,,50588,N
7218,,6348,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,50588,N
7219,,4257,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,50588,N
7220,,3771,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life was determined,A,,,50588,N
7221,,6305,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dogs,A,,,50588,N
7222,Plasma,13501,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,50588,N
7223,,17594,,Canis lupus familiaris,,,9615.0,,Intermediate,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,50588,N
7224,,3045,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,50588,N
7225,,3043,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,50588,N
7226,,4839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for half life in dog,A,,,50588,N
7227,,4839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Compound was tested for its half life in dog,A,,,50588,N
7228,,5802,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,50588,N
7229,,17839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life of compound in dog was determined,A,,,50588,N
7230,,4219,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life (iv) was determined,A,In vivo,,50588,N
7231,Blood,13966,178.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,50588,N
7232,Plasma,3994,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,50588,N
7233,Plasma,3994,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,50588,N
7234,,4453,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog,A,,,50588,N
7235,Plasma,6535,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog plasma,A,,,50588,N
7236,Plasma,6535,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,50588,N
7237,Plasma,6535,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,50588,N
7238,Plasma,3132,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,50588,N
7239,,5374,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog was determined,A,,,50588,N
7240,,5007,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,50588,N
7241,Plasma,16907,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life upon exposure to human plasma,A,,,50588,N
7242,,6057,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was calculated in dog,A,,,50588,N
7243,,5006,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was determined,A,,,50588,N
7244,,5473,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was determined,A,,,50588,N
7245,,4368,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,50588,N
7246,,6448,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog,A,,,50588,N
7247,,4353,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog after intra venous administration of the compound,A,,,50588,N
7248,,4353,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,50588,N
7249,,4353,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog after po administration of the compound,A,In vivo,,50588,N
7250,,4353,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,50588,N
7251,,6265,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,50588,N
7252,,5006,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dogs,A,,,50588,N
7253,,5356,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,50588,N
7254,,405,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in rat,A,,,50588,N
7255,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,50588,N
7256,Bone,10107,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7257,Bone,10107,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7258,Bone,10107,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7259,Bone,10107,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7260,Bone,10107,10000001.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7261,Gut,10107,10000004.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7262,Gut,10107,10000004.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
7263,Gut,10107,10000004.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7264,Gut,10107,10000004.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7265,Gut,10107,10000004.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7266,Gut,10107,10000004.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7267,Gut,10107,10000004.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7268,Heart,10107,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7269,Heart,10107,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
7270,Heart,10107,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7271,Heart,10107,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7272,Heart,10107,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7273,Heart,10107,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7274,Heart,10107,948.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7275,Kidney,10107,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7276,Kidney,10107,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,50594,N
7277,Kidney,10107,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7278,Kidney,10107,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7279,Kidney,10107,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7280,Kidney,10107,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7281,Kidney,10107,2113.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7282,Liver,10107,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7283,Liver,10107,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
7284,Liver,10107,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7285,Liver,10107,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7286,Liver,10107,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7287,Liver,10107,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7288,Liver,10107,2107.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7289,Lung,10107,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7290,,5895,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,A2780,81034,N
7291,,6338,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,A2780,81034,N
7292,,15163,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,A2780,81034,N
7293,,15163,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,A2780,81034,N
7294,,15000,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,A2780,81034,N
7295,,15000,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,A2780,81034,N
7296,,14729,,Homo sapiens,,478.0,9606.0,,Expert,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,A2780,81034,N
7297,,17270,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity against A2780 cell line,F,,A2780,81034,N
7298,,5685,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,A2780,81034,N
7299,,3563,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,A2780,81034,N
7300,,17753,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,A2780,81034,N
7301,,16317,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,A2780,81034,N
7302,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Inhibition of tubulin polymerization in analogy of ca.,F,,A2780,81034,N
7303,,3801,,Homo sapiens,,478.0,9606.0,,Intermediate,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,A2780,81034,N
7304,,6181,,Homo sapiens,,478.0,9606.0,,Expert,,Cytotoxic effect in ovarian cancer cell line (A2780),F,,A2780,81034,N
7305,,5318,,Homo sapiens,,478.0,9606.0,,Intermediate,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,A2780,81034,N
7306,,4840,,Homo sapiens,,478.0,9606.0,,Intermediate,,Tested for the cytotoxicity in A2780 ovarian cell line,F,,A2780,81034,N
7307,,15748,,Homo sapiens,,478.0,9606.0,,Intermediate,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,A2780,81034,N
7308,,15748,,Homo sapiens,,478.0,9606.0,,Intermediate,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,A2780,81034,N
7309,,15748,,,,481.0,,,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,A2780cisR,80017,N
7310,,15748,,,,481.0,,,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,A2780cisR,80017,N
7311,,15748,,,,481.0,,,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,A2780cisR,80017,N
7312,,15748,,,,481.0,,,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,A2780cisR,80017,N
7313,,17753,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vivo log of cells killed after administration of compound in A2780 cell line,F,,A2780,81034,N
7314,,17753,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,A2780,81034,N
7315,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,A2780,81034,N
7316,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,A2780,81034,N
7317,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,A2780,81034,N
7318,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,A2780,81034,N
7319,,17528,,Homo sapiens,,478.0,9606.0,,Intermediate,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,A2780,81034,N
7320,,6633,,Homo sapiens,,478.0,9606.0,,Intermediate,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,A2780,81034,N
7321,,15000,,Homo sapiens,,478.0,9606.0,,Expert,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,A2780,81034,N
7322,,17528,,Homo sapiens,,478.0,9606.0,,Expert,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,A2780,81034,N
7323,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,A2780,81034,N
7324,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,A2780,81034,N
7325,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,A2780,81034,N
7326,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,A2780,81034,N
7327,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,A2780,81034,N
7328,,16936,,Homo sapiens,,478.0,9606.0,,Expert,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,A2780,81034,N
7329,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,A2780,81034,N
7330,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,A2780,81034,N
7331,,16936,,Homo sapiens,,478.0,9606.0,,Intermediate,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,A2780,81034,N
7332,,17737,,Mus musculus,,478.0,10090.0,,Intermediate,,In vitro antiproliferative activity against A2780 cell line,F,,A2780,81034,N
7333,,17764,,Mus musculus,,478.0,10090.0,,Expert,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,A2780,81034,N
7334,,3830,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,A2780,81034,N
7335,,3829,,Homo sapiens,,478.0,9606.0,,Intermediate,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,A2780,81034,N
7336,,3546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,50588,N
7337,,3546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,50588,N
7338,,5668,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,22224,U
7339,Plasma,3443,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
7340,Plasma,3443,1969.0,Cercopithecidae,,,9527.0,,Autocuration,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,22224,U
7341,,4256,,Macaca fascicularis,,,9541.0,,Autocuration,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,22224,U
7342,,4256,,Macaca fascicularis,,,9541.0,,Autocuration,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,22224,U
7343,,4256,,Macaca fascicularis,,,9541.0,,Autocuration,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,22224,U
7344,,4256,,Rattus norvegicus,,,10116.0,,Autocuration,,Oral Bioavailability in rat,A,In vivo,,22224,U
7345,,1916,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,22224,U
7346,,5302,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve value in monkey at a dose of 5 mg/kg,A,,,22224,U
7347,,4257,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,22224,U
7348,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,22224,U
7349,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,22224,U
7350,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,22224,U
7351,,6078,,Cercopithecidae,,,9527.0,,Autocuration,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,22224,U
7352,,6078,,Cercopithecidae,,,9527.0,,Autocuration,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,22224,U
7353,,6062,,Cercopithecidae,,,9527.0,,Autocuration,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,22224,U
7354,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,22224,U
7355,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,22224,U
7356,,5394,,Cercopithecidae,,,9527.0,,Autocuration,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,22224,U
7357,,4397,,Cercopithecidae,,,9527.0,,Autocuration,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,22224,U
7358,,17509,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,22224,U
7359,,17509,,Cercopithecidae,,,9527.0,,Autocuration,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,22224,U
7360,,6641,,Cercopithecidae,,,9527.0,,Autocuration,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,22224,U
7361,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,22224,U
7362,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,22224,U
7363,,3443,,Cercopithecidae,,,9527.0,,Autocuration,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,22224,U
7364,,17409,,Cercopithecidae,,,9527.0,,Autocuration,,Binding towards monkey plasma protein at 10 uM,A,,,22224,U
7365,,17409,,Cercopithecidae,,,9527.0,,Autocuration,,Binding towards monkey plasma protein at 100 uM,A,,,22224,U
7366,,1052,,Cercopithecidae,,,9527.0,,Autocuration,,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,22224,U
7367,,13501,,Cercopithecidae,,,9527.0,,Autocuration,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,22224,U
7368,,17509,,monkey,,,9443.0,,Autocuration,,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,22224,U
7369,,5394,,Cercopithecidae,,,9527.0,,Autocuration,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,22224,U
7370,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,22224,U
7371,,11219,,monkey,,,9443.0,,Autocuration,,Bioavailability in monkey (i.d. dosing),A,In vivo,,22224,U
7372,,3045,,Cercopithecidae,,,9527.0,,Autocuration,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,22224,U
7373,,17796,,Cercopithecidae,,,9527.0,,Autocuration,,Clearance of the drug was measured in cynomolgus,A,,,22224,U
7374,,1399,,Cercopithecidae,,,9527.0,,Autocuration,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,22224,U
7375,,2661,,Cercopithecidae,,,9527.0,,Autocuration,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,22224,U
7376,Plasma,5005,1969.0,Macaca mulatta,,,9544.0,,Autocuration,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,22224,U
7377,,17267,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance in rhesus monkey was determined,A,In vivo,,22224,U
7378,,6535,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,22224,U
7379,,5922,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance in cynomolgus monkey,A,In vivo,,22224,U
7380,,6221,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,22224,U
7381,,5668,,Cercopithecidae,,,9527.0,,Autocuration,,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,22224,U
7382,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,22224,U
7383,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,22224,U
7384,,5355,,Cercopithecidae,,,9527.0,,Autocuration,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,22224,U
7385,,4578,,Cercopithecidae,,,9527.0,,Autocuration,,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,22224,U
7386,,17592,,Cercopithecidae,,,9527.0,,Autocuration,,Clearance in monkey,A,In vivo,,22224,U
7387,,6641,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,50588,N
7388,,6642,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,50588,N
7389,,16367,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was evaluated after intravenous administration to dogs,A,In vivo,,50588,N
7390,,5472,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was evaluated in dog,A,,,50588,N
7391,,5474,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life was evaluated in dog,A,,,50588,N
7392,,5654,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,50588,N
7393,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,50588,N
7394,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period after intravenous administration in dog,A,In vivo,,50588,N
7395,,6221,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,50588,N
7396,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period at a dose of 1 uM/kg in dog was determined,A,,,50588,N
7397,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,50588,N
7398,,5668,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,50588,N
7399,,3854,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was determined,A,,,50588,N
7400,,5505,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was determined,A,,,50588,N
7401,,6251,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,50588,N
7402,,1918,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was evaluated in dog,A,,,50588,N
7403,,5546,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,50588,N
7404,,4809,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,50588,N
7405,,6215,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,50588,N
7406,,4527,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,50588,N
7407,,17594,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,50588,N
7408,,17839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,50588,N
7409,,17839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,50588,N
7410,,17839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,50588,N
7411,,17839,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,50588,N
7412,Plasma,5210,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of compound in plasma of dog was determined,A,,,50588,N
7413,,5210,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of compound was determined in dogs,A,,,50588,N
7414,,2959,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,50588,N
7415,,4137,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,50588,N
7416,,5064,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in Dog,A,,,50588,N
7417,,5147,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in Dog,A,,,50588,N
7418,,5145,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dog,A,,,50588,N
7419,,6123,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,50588,N
7420,,6123,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,50588,N
7421,,4333,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dogs,A,,,50588,N
7422,,4333,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in dogs; ND indicates not determined,A,,,50588,N
7423,Plasma,12500,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in plasma of dog,A,,,50588,N
7424,Plasma,12500,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,50588,N
7425,,6005,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,50588,N
7426,,6062,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,50588,N
7427,,17650,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,50588,N
7428,,5530,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,50588,N
7429,,5530,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,50588,N
7430,,5600,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,50588,N
7431,,6039,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,50588,N
7432,,6039,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,50588,N
7433,,6039,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,50588,N
7434,,6227,,Canis lupus familiaris,,,9615.0,,Intermediate,,t1/2 in dog,A,,,50588,N
7435,,14541,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period measured in dogs,A,,,50588,N
7436,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,50588,N
7437,,4521,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,50588,N
7438,,6679,,Canis lupus familiaris,,,9615.0,,Intermediate,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,50588,N
7439,Plasma,1116,1969.0,Canis lupus familiaris,,,9615.0,,Intermediate,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,50588,N
7440,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,50588,N
7441,,5444,,Canis lupus familiaris,,,9615.0,,Intermediate,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,50588,N
7442,,17853,,Canis lupus familiaris,,,9615.0,,Intermediate,,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,50588,N
7443,,4353,,Canis lupus familiaris,,,9615.0,,Intermediate,,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,50588,N
7444,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,50588,N
7445,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,50588,N
7446,,16452,,Canis lupus familiaris,,,9615.0,,Intermediate,,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,50588,N
7447,Lung,10107,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,50594,N
7448,Lung,10107,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7449,Lung,10107,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7450,Lung,10107,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7451,Lung,10107,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7452,Lung,10107,2048.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7453,Muscle tissue,10107,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7454,Muscle tissue,10107,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,50594,N
7455,Muscle tissue,10107,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7456,Muscle tissue,10107,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7457,Muscle tissue,10107,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7458,Muscle tissue,10107,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7459,Muscle tissue,10107,2385.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7460,Zone of skin,10107,14.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7461,Zone of skin,10107,14.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
7462,Zone of skin,10107,14.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7463,Zone of skin,10107,14.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7464,Zone of skin,10107,14.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7465,Zone of skin,10107,14.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7466,Zone of skin,10107,14.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7467,Spleen,10107,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7468,Spleen,10107,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
7469,Spleen,10107,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7470,Spleen,10107,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7471,Spleen,10107,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7472,Spleen,10107,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7473,Spleen,10107,2106.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7474,Stomach,10107,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,50594,N
7475,Stomach,10107,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,50594,N
7476,Stomach,10107,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,50594,N
7477,Stomach,10107,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,50594,N
7478,Stomach,10107,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,50594,N
7479,Stomach,10107,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,50594,N
7480,Stomach,10107,945.0,Mus musculus,,,10090.0,,Intermediate,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,50594,N
7481,,4689,,Rattus norvegicus,,,10116.0,,Intermediate,,Oral bioavailability in rat,A,In vivo,,50597,N
7482,,4950,,Rattus norvegicus,,,10116.0,,Intermediate,,Tested for the bioavailability in rat,A,In vivo,,50597,N
7483,,5328,,Rattus norvegicus,,,10116.0,,Intermediate,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,50597,N
7484,,406,,Rattus norvegicus,,,10116.0,,Intermediate,,Bioavailability in rat,A,In vivo,,50597,N
7485,,12500,,Rattus norvegicus,,,10116.0,,Intermediate,,Bioavailability in rat,A,In vivo,,50597,N
7486,,12500,,Rattus norvegicus,,,10116.0,,Intermediate,,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,50597,N
7487,,5247,,Rattus norvegicus,,,10116.0,,Intermediate,,Bioavailability in rat,A,In vivo,,50597,N
7488,Plasma,4186,1969.0,Rattus norvegicus,,,10116.0,,Intermediate,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,50597,N
7489,Plasma,4186,1969.0,Rattus norvegicus,,,10116.0,,Intermediate,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,50597,N
7490,,6647,,Rattus norvegicus,,,10116.0,,Intermediate,,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,50597,N
7491,,6484,,Rattus norvegicus,,,10116.0,,Intermediate,,Half life was determined,A,,,50597,N
7492,,3249,,Rattus norvegicus,,,10116.0,,Intermediate,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,50597,N
7493,Plasma,6281,1969.0,Rattus norvegicus,,,10116.0,,Intermediate,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,50597,N
7494,,3307,,Rattus norvegicus,,,10116.0,,Intermediate,,Half life in rats,A,,,50597,N
7495,Blood,12058,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,50597,N
7496,,8833,,Rattus norvegicus,,,10116.0,,Intermediate,,Hill coefficient of the compound,A,,,50597,N
7497,Blood,3193,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,50597,N
7498,Blood,3193,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,50597,N
7499,Blood,3193,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,50597,N
7500,Blood,3193,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,50597,N
7501,Blood,3193,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,50597,N
7502,Blood,3193,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,50597,N
7503,Blood,3193,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,50597,N
7504,,5960,,Rattus norvegicus,,,10116.0,,Intermediate,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,50597,N
7505,Brain,13950,955.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7506,Brain,13950,955.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7507,Brain,13950,955.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7508,Brain,13950,955.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7509,Brain,13950,955.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7510,Thyroid gland,13950,2046.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7511,Thyroid gland,13950,2046.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7512,Thyroid gland,13950,2046.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7513,Thyroid gland,13950,2046.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7514,Thyroid gland,13950,2046.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,50597,N
7515,Blood,9866,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,50597,N
7516,Blood,9866,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,50597,N
7517,Blood,9866,178.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,50597,N
7518,Bone,9866,10000001.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,50597,N
7519,Bone,9866,10000001.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,50597,N
7520,Bone,9866,10000001.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,50597,N
7521,Heart,9866,948.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,50597,N
7522,Heart,9866,948.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,50597,N
7523,Heart,9866,948.0,Rattus norvegicus,,,10116.0,,Intermediate,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,50597,N
